# Dossier zur Nutzenbewertung gemäß § 35a SGB V

*Alectinib (Alecensa®)*

Roche Pharma AG

**Modul 4 A, Anhang 4-G**

*Monotherapie zur adjuvanten Behandlung nach vollständiger Tumorresektion bei erwachsenen Patienten mit ALK-positivem NSCLC mit hohem Risiko für ein Rezidiv (siehe Abschnitt 5.1 zu den Auswahlkriterien)*

Vollständige Darstellung der für das vorliegende Dossier relevanten Ergebnisse in unveränderter Form

Stand: 02.07.2024

# Inhaltsverzeichnis

**Seite**

**Seite**

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**1 Mortalität**

**1.1 Gesamtüberleben (OS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Overall Survival**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 2 | 1,5 | 128 | 98,5 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 4 | 3,1 | 123 | 96,9 | NE | NE | NE | NE | NE | NE | 0,3603 | 0,46 | 0,08 | 2,52 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_OS_IT_26JUN2023_40336.xls
26JAN2024 18:09

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Overall Survival**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 128 | 128 | 128 | 127 | 111 | 91 | 63 | 58 | 43 | 30 | 26 | 16 | 4 |
| Platinum-Based Chemotherapy | 127 | 118 | 117 | 115 | 114 | 104 | 80 | 64 | 59 | 45 | 34 | 28 | 17 | 3 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 2 | 2 | 2 | 2 | 17 | 37 | 65 | 70 | 85 | 98 | 102 | 112 | 124 |
| Platinum-Based Chemotherapy | 0 | 9 | 9 | 11 | 12 | 22 | 45 | 61 | 66 | 79 | 89 | 95 | 106 | 120 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..7/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_OS_IT_26JUN2023_40336.pdf
26JAN2024 19:01

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**1 Mortalität**

**1.1 Gesamtüberleben (OS)**

**1.1.1 Subgruppenanalysen Gesamtüberleben (OS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Overall Survival**
**MODEL: Unstratified Analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 130 | 100,0 | 2 | 1,5 | 128 | 98,5 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 4 | 3,1 | 123 | 96,9 | NE | NE | NE | NE | NE | NE | 0,3663 | 0,47 | 0,09 | 2,54 | | |
| Sex | Male | 55 | 42,3 | 1 | 1,8 | 54 | 98,2 | NE | NE | NE | NE | NE | NE | 68 | 53,5 | 3 | 4,4 | 65 | 95,6 | NE | NE | NE | NE | NE | NE | 0,4061 | 0,40 | 0,04 | 3,81 | | 0,7341 |
| | Female | 75 | 57,7 | 1 | 1,3 | 74 | 98,7 | NE | NE | NE | NE | NE | NE | 59 | 46,5 | 1 | 1,7 | 58 | 98,3 | NE | NE | NE | NE | NE | NE | 0,8182 | 0,72 | 0,05 | 11,57 | | |
| Age | < 65 | 103 | 79,2 | 1 | 1,0 | 102 | 99,0 | NE | NE | NE | NE | NE | NE | 93 | 73,2 | 1 | 1,1 | 92 | 98,9 | NE | NE | NE | NE | NE | NE | 0,9253 | 0,88 | 0,05 | 14,02 | | 0,6752 |
| | >= 65 | 27 | 20,8 | 1 | 3,7 | 26 | 96,3 | NE | NE | NE | NE | NE | NE | 34 | 26,8 | 3 | 8,8 | 31 | 91,2 | NE | 37,4 | NE | NE | NE | NE | 0,4006 | 0,39 | 0,04 | 3,77 | | |
| Geographic region | Asia Pacific | 75 | 57,7 | 0 | 0,0 | 75 | 100,0 | NE | NE | NE | NE | NE | NE | 72 | 56,7 | 0 | 0,0 | 72 | 100,0 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | | 1,0000 |
| | Europe | 53 | 40,8 | 2 | 3,8 | 51 | 96,2 | NE | NE | NE | NE | NE | NE | 51 | 40,2 | 4 | 7,8 | 47 | 92,2 | NE | 37,4 | NE | NE | NE | NE | 0,3727 | 0,47 | 0,09 | 2,57 | | |
| | Rest of World | 2 | 1,5 | 0 | 0,0 | 2 | 100,0 | NE | NE | NE | NE | NE | NE | 4 | 3,1 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | | |
| Race/ethnicity (eCRF) | Asian | 72 | 55,4 | 0 | 0,0 | 72 | 100,0 | NE | NE | NE | NE | NE | NE | 71 | 55,9 | 0 | 0,0 | 71 | 100,0 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | | 0,9978 |
| | Non-Asian | 56 | 43,1 | 2 | 3,6 | 54 | 96,4 | NE | NE | NE | NE | NE | NE | 52 | 40,9 | 4 | 7,7 | 48 | 92,3 | NE | 37,4 | NE | NE | NE | NE | 0,3386 | 0,45 | 0,08 | 2,44 | | |
| | Unknown | 2 | 1,5 | 0 | 0,0 | 2 | 100,0 | NE | NE | NE | NE | NE | NE | 4 | 3,1 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | | |
| Baseline ECOG | 0 | 72 | 55,4 | 0 | 0,0 | 72 | 100,0 | NE | NE | NE | NE | NE | NE | 65 | 51,2 | 0 | 0,0 | 65 | 100,0 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | | 0,9978 |
| | 1 | 58 | 44,6 | 2 | 3,4 | 56 | 96,6 | NE | NE | NE | NE | NE | NE | 62 | 48,8 | 4 | 6,5 | 58 | 93,5 | NE | 37,4 | NE | NE | NE | NE | 0,4853 | 0,55 | 0,10 | 3,01 | | |
| Extent of disease (eCRF) | Stage IB | 17 | 13,1 | 0 | 0,0 | 17 | 100,0 | NE | NE | NE | NE | NE | NE | 9 | 7,1 | 1 | 11,1 | 8 | 88,9 | NE | 32,6 | NE | NE | NE | NE | 0,3545 | 0,00 | 0,00 | NE | | 0,3108 |
| | Stage II | 43 | 33,1 | 0 | 0,0 | 43 | 100,0 | NE | NE | NE | NE | NE | NE | 47 | 37,0 | 1 | 2,1 | 46 | 97,9 | NE | NE | NE | NE | NE | NE | 0,2705 | 0,00 | 0,00 | NE | | |
| | Stage IIIA | 70 | 53,8 | 2 | 2,9 | 68 | 97,1 | NE | NE | NE | NE | NE | NE | 71 | 55,9 | 2 | 2,8 | 69 | 97,2 | NE | NE | NE | NE | NE | NE | 0,9192 | 0,90 | 0,13 | 6,41 | | |
| Smoking history | Never | 84 | 64,6 | 2 | 2,4 | 82 | 97,6 | NE | NE | NE | NE | NE | NE | 70 | 55,1 | 2 | 2,9 | 68 | 97,1 | NE | NE | NE | NE | NE | NE | 0,8166 | 0,79 | 0,11 | 5,64 | | 0,1953 |
| | Previous/Current | 46 | 35,4 | 0 | 0,0 | 46 | 100,0 | NE | NE | NE | NE | NE | NE | 57 | 44,9 | 2 | 3,5 | 55 | 96,5 | NE | NE | NE | NE | NE | NE | 0,1894 | 0,00 | 0,00 | NE | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_sg_OS_IT_26JUN2023_40336.xls
26JAN2024 18:22

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.1 DFS Ereigniszeitanalyse (Prüfarzt-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Disease Free Survival**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 15 | 11,5 | 115 | 88,5 | NE | 38,7 | NE | NE | NE | NE | 127 | 100,0 | 50 | 39,4 | 77 | 60,6 | 19,4 | 14,1 | 22,9 | 41,3 | 28,5 | NE | <.0001 | 0,24 | 0,13 | 0,43 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFS_IT_26JUN2023_40336.xls
26JAN2024 18:04

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Disease Free Survival**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 125 | 123 | 123 | 120 | 101 | 74 | 58 | 54 | 39 | 22 | 18 | 10 | 4 |
| Platinum-Based Chemotherapy | 127 | 113 | 110 | 98 | 93 | 80 | 55 | 43 | 37 | 27 | 21 | 17 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 4 | 4 | 4 | 4 | 21 | 48 | 62 | 66 | 80 | 94 | 97 | 105 | 111 |
| Platinum-Based Chemotherapy | 0 | 9 | 9 | 10 | 11 | 17 | 32 | 42 | 44 | 53 | 58 | 61 | 66 | 75 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ../BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFS_IT_26JUN2023_40336.pdf
26JAN2024 18:57

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.1 DFS Ereigniszeitanalyse (Prüfarzt-Bewertung)**

**2.1.1.1 Subgruppenanalyse DFS Ereigniszeitanalyse (Prüfarzt-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Disease Free Survival**
**MODEL: Unstratified Analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 130 | 100,0 | 15 | 11,5 | 115 | 88,5 | NE | 38,7 | NE | NE | NE | NE | 127 | 100,0 | 50 | 39,4 | 77 | 60,6 | 19,4 | 14,1 | 22,9 | 41,3 | 28,5 | NE | <.0001 | 0,24 | 0,14 | 0,43 | | |
| Sex | Male | 55 | 42,3 | 7 | 12,7 | 48 | 87,3 | NE | 33,7 | NE | NE | NE | NE | 68 | 53,5 | 28 | 41,2 | 40 | 58,8 | 20,1 | 11,3 | 23,5 | 33,1 | 22,9 | NE | 0,0007 | 0,26 | 0,11 | 0,60 | | 0,8225 |
| | Female | 75 | 57,7 | 8 | 10,7 | 67 | 89,3 | NE | 38,7 | NE | NE | NE | NE | 59 | 46,5 | 22 | 37,3 | 37 | 62,7 | 19,3 | 14,1 | 37,4 | 41,3 | 27,8 | NE | <.0001 | 0,22 | 0,10 | 0,50 | | |
| Age | < 65 | 103 | 79,2 | 11 | 10,7 | 92 | 89,3 | NE | 38,7 | NE | NE | NE | NE | 93 | 73,2 | 32 | 34,4 | 61 | 65,6 | 22,4 | 17,5 | 28,5 | 44,4 | 30,6 | NE | <.0001 | 0,26 | 0,13 | 0,52 | | 0,7858 |
| | >= 65 | 27 | 20,8 | 4 | 14,8 | 23 | 85,2 | 42,3 | 42,3 | NE | NE | 42,3 | NE | 34 | 26,8 | 18 | 52,9 | 16 | 47,1 | 13,9 | 8,1 | 20,3 | 23,1 | 16,1 | NE | 0,0051 | 0,24 | 0,08 | 0,71 | | |
| Geographic region | Asia Pacific | 75 | 57,7 | 9 | 12,0 | 66 | 88,0 | 42,3 | 38,4 | NE | NE | NE | NE | 72 | 56,7 | 23 | 31,9 | 49 | 68,1 | 22,4 | 13,9 | 33,1 | NE | 33,1 | NE | 0,0028 | 0,33 | 0,15 | 0,71 | | 0,4080 |
| | Europe | 53 | 40,8 | 6 | 11,3 | 47 | 88,7 | NE | NE | NE | NE | NE | NE | 51 | 40,2 | 25 | 49,0 | 26 | 51,0 | 16,6 | 10,4 | 22,8 | 30,6 | 20,3 | NE | <.0001 | 0,18 | 0,08 | 0,45 | | |
| | Rest of World | 2 | 1,5 | 0 | 0,0 | 2 | 100,0 | NE | NE | NE | NE | NE | NE | 4 | 3,1 | 2 | 50,0 | 2 | 50,0 | 19,8 | 11,1 | NE | 28,5 | 11,1 | NE | 0,1336 | 0,00 | 0,00 | NE | | |
| Race/ethnicity (eCRF) | Asian | 72 | 55,4 | 9 | 12,5 | 63 | 87,5 | 38,8 | 38,4 | NE | NE | 42,3 | NE | 71 | 55,9 | 22 | 31,0 | 49 | 69,0 | 22,4 | 14,1 | 44,4 | NE | 33,1 | NE | 0,0079 | 0,36 | 0,17 | 0,79 | | 0,1776 |
| | Non-Asian | 56 | 43,1 | 6 | 10,7 | 50 | 89,3 | NE | NE | NE | NE | NE | NE | 52 | 40,9 | 26 | 50,0 | 26 | 50,0 | 16,6 | 11,1 | 20,4 | 28,5 | 20,3 | NE | <.0001 | 0,17 | 0,07 | 0,40 | | |
| | Unknown | 2 | 1,5 | 0 | 0,0 | 2 | 100,0 | NE | NE | NE | NE | NE | NE | 4 | 3,1 | 2 | 50,0 | 2 | 50,0 | 5,7 | 5,7 | NE | 23,5 | 5,7 | NE | 0,2807 | 0,00 | 0,00 | NE | | |
| Baseline ECOG | 0 | 72 | 55,4 | 7 | 9,7 | 65 | 90,3 | NE | 38,4 | NE | NE | NE | NE | 65 | 51,2 | 25 | 38,5 | 40 | 61,5 | 16,9 | 11,3 | 27,8 | NE | 27,8 | NE | <.0001 | 0,20 | 0,09 | 0,46 | | 0,4413 |
| | 1 | 58 | 44,6 | 8 | 13,8 | 50 | 86,2 | 42,3 | 38,7 | NE | NE | 42,3 | NE | 62 | 48,8 | 25 | 40,3 | 37 | 59,7 | 20,4 | 16,1 | 28,5 | 37,4 | 24,9 | NE | 0,0023 | 0,31 | 0,14 | 0,69 | | |
| Extent of disease (eCRF) | Stage IB | 17 | 13,1 | 1 | 5,9 | 16 | 94,1 | NE | NE | NE | NE | NE | NE | 9 | 7,1 | 3 | 33,3 | 6 | 66,7 | 41,3 | 2,8 | NE | 41,3 | 22,9 | NE | 0,2504 | 0,28 | 0,03 | 2,81 | | 0,9985 |
| | Stage II | 43 | 33,1 | 5 | 11,6 | 38 | 88,4 | NE | 33,7 | NE | NE | NE | NE | 47 | 37,0 | 18 | 38,3 | 29 | 61,7 | 20,4 | 10,4 | 30,6 | NE | 24,9 | NE | 0,0024 | 0,24 | 0,09 | 0,65 | | |
| | Stage IIIA | 70 | 53,8 | 9 | 12,9 | 61 | 87,1 | 38,8 | 38,4 | NE | NE | NE | NE | 71 | 55,9 | 29 | 40,8 | 42 | 59,2 | 17,5 | 14,1 | 22,4 | 33,1 | 22,4 | NE | <.0001 | 0,24 | 0,11 | 0,51 | | |
| Smoking history | Never | 84 | 64,6 | 10 | 11,9 | 74 | 88,1 | NE | 33,7 | NE | NE | NE | NE | 70 | 55,1 | 27 | 38,6 | 43 | 61,4 | 19,4 | 16,1 | 24,9 | 44,4 | 24,9 | NE | 0,0001 | 0,27 | 0,13 | 0,55 | | 0,5978 |
| | Previous/Current | 46 | 35,4 | 5 | 10,9 | 41 | 89,1 | NE | 38,7 | NE | NE | NE | NE | 57 | 44,9 | 23 | 40,4 | 34 | 59,6 | 19,3 | 8,5 | 28,1 | 41,3 | 28,1 | NE | 0,0004 | 0,21 | 0,08 | 0,54 | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_sg_DFS_IT_26JUN2023_40336.xls
26JAN2024 18:16

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.1 DFS Ereigniszeitanalyse (Prüfarzt-Bewertung) – Einzelkomponenten**

**2.1.2.1.1 DFS Ereigniszeitanalyse (Prüfarzt-Bewertung) – Einzelkomponenten Rezidiv und neues primäres NSCLC**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to first Recurrence (DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 15 | 11,5 | 115 | 88,5 | NE | 38,7 | NE | NE | NE | NE | 127 | 100,0 | 49 | 38,6 | 78 | 61,4 | 19,4 | 14,1 | 22,9 | 44,4 | 28,5 | NE | <.0001 | 0,25 | 0,14 | 0,44 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSREC_IT_26JUN2023_40336.xls
26JAN2024 18:05

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to first Recurrence (DFS)**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 125 | 123 | 123 | 120 | 101 | 74 | 58 | 54 | 39 | 22 | 18 | 10 | 4 |
| Platinum-Based Chemotherapy | 127 | 113 | 110 | 98 | 93 | 80 | 55 | 43 | 37 | 27 | 21 | 17 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 4 | 4 | 4 | 4 | 21 | 48 | 62 | 66 | 80 | 94 | 97 | 105 | 111 |
| Platinum-Based Chemotherapy | 0 | 9 | 9 | 10 | 11 | 17 | 32 | 42 | 44 | 53 | 59 | 62 | 67 | 76 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSREC_IT_26JUN2023_40336.pdf
26JAN2024 18:58

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.1 DFS Ereigniszeitanalyse (Prüfarzt-Bewertung) – Einzelkomponenten**

**2.1.2.1.2 DFS Ereigniszeitanalyse (Prüfarzt-Bewertung) – Einzelkomponente Tod ohne Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to Death (DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 0 | 0 | 130 | 100,0 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 1 | 0,8 | 126 | 99,2 | NE | NE | NE | NE | NE | NE | 0,1859 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSDTH_IT_26JUN2023_40336.xls
26JAN2024 18:07

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to Death (DFS)**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 125 | 123 | 123 | 120 | 101 | 74 | 58 | 54 | 39 | 22 | 18 | 10 | 4 |
| Platinum-Based Chemotherapy | 127 | 113 | 110 | 98 | 93 | 80 | 55 | 43 | 37 | 27 | 21 | 17 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 5 | 7 | 7 | 10 | 29 | 56 | 72 | 76 | 91 | 108 | 112 | 120 | 126 |
| Platinum-Based Chemotherapy | 0 | 14 | 17 | 29 | 34 | 47 | 72 | 84 | 90 | 100 | 105 | 109 | 115 | 124 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSDTH_IT_26JUN2023_40336.pdf
26JAN2024 18:59

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.2 DFS Ereignisrate (Prüfarzt-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: DFS Rate**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 15 | 11,5 | 127 | 100,0 | 50 | 39,4 | 0,20 | | 0,11 | 0,39 | -0,272 | | -0,375 | -0,168 | 0,29 | | 0,17 | 0,49 | <.0001 | | 3,45 | | 2,05 | 5,80 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFS_IT_26JUN2023_40336.xls
07MAR2024 12:06

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.2 DFS Ereignisrate (Prüfarzt-Bewertung)**

**2.1.2.2.1 DFS Ereignisrate (Prüfarzt-Bewertung) – Einzelkomponenten Rezidiv und neues primäres NSCLC**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Recurrence Rate (DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 15 | 11,5 | 127 | 100,0 | 49 | 38,6 | 0,21 | | 0,11 | 0,40 | -0,264 | | -0,367 | -0,162 | 0,30 | | 0,18 | 0,50 | <.0001 | 3,37 | | 2,00 | 5,69 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSREC_IT_26JUN2023_40336.xls
07MAR2024 12:09

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.2 DFS Ereignisrate (Prüfarzt-Bewertung)**

**2.1.2.2.2 DFS Ereignisrate (Prüfarzt-Bewertung) – Einzelkomponente Tod ohne Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Death Rate (DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 0 | 0 | 127 | 100,0 | 1 | 0,8 | 0,00 | | 0,00 | NE | | * | | | | * | | | | | * | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSDTH_IT_26JUN2023_40336.xls
07MAR2024 12:11

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.3 Deskriptive Darstellung der Art der Rezidive**

Location of First Documented Recurrence or New Primary NSCLC, Intent-to-Treat Patients
Protocol: BO40336
Snapshot Date: 03AUG2023, Clinical Data Cut-off Date: 26JUN2023.

| | Alectinib (N=130) | Chemotherapy (N=127) |
|---|---|---|
| Patients with event | 15 (11.5%) | 49 (38.6%) |
| Local recurrence of Lung Cancer | 8 ( 6.2% | 20 (15.7%) |
| Regional recurrence of Lung Cancer | 5 ( 3.8% | 12 ( 9.4%) |
| Distant recurrence of Lung Cancer | 5 ( 3.8% | 27 (21.3%) |
| New Primary Lung Cancer | 1 ( 0.8% | 0 |
| Sites of Distant recurrence | | |
| Adrenal gland | 0 | 3 ( 2.4%) |
| Bone | 1 ( 0.8% | 8 ( 6.3%) |
| Brain | 4 ( 3.1% | 14 (11.0%) |
| Kidney | 0 | 1 ( 0.8%) |
| Lymph Node | 0 | 2 ( 1.6%) |
| Other | 1 ( 0.8% | 0 |
| Peritoneum | 0 | 1 ( 0.8%) |
| Site of New Primary Lung Cancer | | |
| Not Applicable | 1 ( 0.8% | 0 |

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/INTERIM_2023/prod/program/t_ef_pdloc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/INTERIM_2023/prod/output/t_ef_pdloc_IT_26JUN2023_40336.out
29AUG2023 18:16 Page 1 of 1

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.4 ZNS-DFS Ereigniszeitanalyse (Prüfarzt-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: CNS Disease Free Survival**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 5 | 3,8 | 125 | 96,2 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 18 | 14,2 | 109 | 85,8 | NE | 30,6 | NE | NE | NE | NE | 0,0009 | 0,22 | 0,08 | 0,58 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSCNS_IT_26JUN2023_40336.xls
26JAN2024 18:11

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: CNS Disease Free Survival**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 125 | 124 | 124 | 121 | 102 | 74 | 58 | 54 | 39 | 22 | 18 | 10 | 4 |
| Platinum-Based Chemotherapy | 127 | 115 | 111 | 98 | 93 | 82 | 57 | 45 | 39 | 27 | 21 | 17 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 5 | 6 | 6 | 8 | 26 | 54 | 68 | 72 | 87 | 103 | 107 | 115 | 121 |
| Platinum-Based Chemotherapy | 0 | 10 | 13 | 24 | 26 | 35 | 56 | 68 | 72 | 83 | 88 | 92 | 98 | 107 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSCNS_IT_26JUN2023_40336.pdf
26JAN2024 19:02

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.4 ZNS-DFS Ereigniszeitanalyse (Prüfarzt-Bewertung)**

**2.1.2.4.1 ZNS-DFS Ereigniszeitanalyse (Prüfarzt-Bewertung) – Einzelkomponente ZNS-Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to first CNS Recurrence (CNS-DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 4 | 3,1 | 126 | 96,9 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 14 | 11,0 | 113 | 89,0 | NE | NE | NE | NE | NE | NE | 0,0045 | 0,23 | 0,07 | 0,69 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSCNSR_IT_26JUN2023_40336.xls
26JAN2024 18:13

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to first CNS Recurrence (CNS-DFS)**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 125 | 124 | 124 | 121 | 102 | 74 | 58 | 54 | 39 | 22 | 18 | 10 | 4 |
| Platinum-Based Chemotherapy | 127 | 115 | 111 | 98 | 93 | 82 | 57 | 45 | 39 | 27 | 21 | 17 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 5 | 6 | 6 | 8 | 27 | 55 | 69 | 73 | 88 | 104 | 108 | 116 | 122 |
| Platinum-Based Chemotherapy | 0 | 10 | 14 | 25 | 27 | 36 | 58 | 70 | 74 | 86 | 92 | 96 | 102 | 111 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSCNSR_IT_26JUN2023_40336.pdf
26JAN2024 19:03

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.4 ZNS-DFS Ereigniszeitanalyse (Prüfarzt-Bewertung)**

**2.1.2.4.2 ZNS-DFS Ereigniszeitanalyse (Prüfarzt-Bewertung) – Einzelkomponente Tod ohne ZNS Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to Death (CNS-DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 1 | 0,8 | 129 | 99,2 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 4 | 3,1 | 123 | 96,9 | NE | NE | NE | NE | NE | NE | 0,0828 | 0,18 | 0,02 | 1,60 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSCNSD_IT_26JUN2023_40336.xls
26JAN2024 18:15

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to Death (CNS-DFS)**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 125 | 124 | 124 | 121 | 102 | 74 | 58 | 54 | 39 | 22 | 18 | 10 | 4 |
| Platinum-Based Chemotherapy | 127 | 115 | 111 | 98 | 93 | 82 | 57 | 45 | 39 | 27 | 21 | 17 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 5 | 6 | 6 | 9 | 27 | 55 | 71 | 75 | 90 | 107 | 111 | 119 | 125 |
| Platinum-Based Chemotherapy | 0 | 12 | 15 | 28 | 33 | 44 | 68 | 80 | 86 | 97 | 102 | 106 | 112 | 121 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSCNSD_IT_26JUN2023_40336.pdf
26JAN2024 19:05

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.5 ZNS-DFS Ereignisrate (Prüfarzt-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: DFS Rate (CNS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 5 | 3,8 | 127 | 100,0 | 18 | 14,2 | 0,25 | | 0,09 | 0,68 | | * | | | 0,27 | | 0,10 | 0,71 | 0,0076 | 3,69 | | 1,41 | 9,62 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSCNS_IT_26JUN2023_40336.xls
07MAR2024 12:14

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.5 ZNS-DFS Ereignisrate (Prüfarzt-Bewertung)**

**2.1.2.5.1 ZNS-DFS Ereignisrate (Prüfarzt-Bewertung) – Einzelkomponente ZNS-Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Recurrence Rate (CNS-DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 4 | 3,1 | 127 | 100,0 | 14 | 11,0 | 0,26 | | 0,08 | 0,81 | | * | | | 0,28 | | 0,10 | 0,83 | 0,0214 | 3,55 | | 1,21 | 10,47 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSCNSR_IT_26JUN2023_40336.xls
07MAR2024 12:16

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.2 Ergänzende Analysen Krankheitsfreies Überleben (DFS)**

**2.1.2.5 ZNS-DFS Ereignisrate (Prüfarzt-Bewertung)**

**2.1.2.5.2 ZNS-DFS Ereignisrate (Prüfarzt-Bewertung) – Einzelkomponente Tod ohne ZNS-Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Death Rate (CNS-DFS)**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 1 | 0,8 | 127 | 100,0 | 4 | 3,1 | 0,23 | | 0,02 | 2,09 | | * | | | 0,23 | | 0,03 | 1,98 | 0,1814 | 4,32 | | 0,51 | 36,89 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSCNSD_IT_26JUN2023_40336.xls
07MAR2024 12:18

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.3 Sensitivitätsanalysen Krankheitsfreies Überleben (DFS)**

**2.1.3.1 DFS Ereigniszeitanalyse (BICR-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Disease Free Survival according to BICR**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 16 | 12,3 | 114 | 87,7 | NE | 38,7 | NE | NE | NE | NE | 127 | 100,0 | 39 | 30,7 | 88 | 69,3 | 20,6 | 14,0 | 28,4 | NE | 37,4 | NE | <.0001 | 0,30 | 0,17 | 0,54 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSO_IT_26JUN2023_40336.xls
26APR2024 7:14

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Disease Free Survival according to BICR**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 122 | 122 | 119 | 119 | 101 | 72 | 55 | 52 | 38 | 21 | 18 | 9 | 3 |
| Platinum-Based Chemotherapy | 127 | 111 | 104 | 92 | 85 | 74 | 51 | 39 | 34 | 24 | 17 | 15 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 3 | 3 | 3 | 3 | 19 | 48 | 64 | 67 | 80 | 94 | 97 | 105 | 111 |
| Platinum-Based Chemotherapy | 0 | 13 | 14 | 19 | 22 | 29 | 46 | 55 | 58 | 67 | 72 | 74 | 77 | 86 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSO_IT_26JUN2023_40336.pdf
26APR2024 7:29

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.3 Sensitivitätsanalysen Krankheitsfreies Überleben (DFS)**

**2.1.3.1 DFS Ereigniszeitanalyse (BICR-Bewertung)**

**2.1.3.1.1 DFS Ereigniszeitanalyse (BICR-Bewertung) – Einzelkomponente Rezidiv und neues primäres NSCLC**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to first Recurrence (DFS) according to BICR**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 16 | 12,3 | 114 | 87,7 | NE | 38,7 | NE | NE | NE | NE | 127 | 100,0 | 37 | 29,1 | 90 | 70,9 | 20,6 | 14,0 | 28,4 | NE | 38,8 | NE | <.0001 | 0,32 | 0,18 | 0,58 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSOREC_IT_26JUN2023_40336.xls
26APR2024 7:16

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to first Recurrence (DFS) according to BICR**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 122 | 122 | 119 | 119 | 101 | 72 | 55 | 52 | 38 | 21 | 18 | 9 | 3 |
| Platinum-Based Chemotherapy | 127 | 111 | 104 | 92 | 85 | 74 | 51 | 39 | 34 | 24 | 17 | 15 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 3 | 3 | 3 | 3 | 19 | 48 | 64 | 67 | 80 | 94 | 97 | 105 | 111 |
| Platinum-Based Chemotherapy | 0 | 13 | 14 | 19 | 22 | 29 | 46 | 55 | 58 | 68 | 74 | 76 | 79 | 88 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSOREC_IT_26JUN2023_40336.pdf
26APR2024 7:31

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.3 Sensitivitätsanalysen Krankheitsfreies Überleben (DFS)**

**2.1.3.1 DFS Ereigniszeitanalyse (BICR-Bewertung)**

**2.1.3.1.2 DFS Ereigniszeitanalyse (BICR-Bewertung) – Einzelkomponente Tod ohne Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to Death (DFS) according to BICR**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Time to Event Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | | | | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | | | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | Patients | | Patients with Event | | Censored | | Time to event | | | | | | log-rank | Hazard Ratio | | | |
| Name | Level | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | n | % | n | % | n | % | Q1 (months) | 95% Lower CL for Q1 | 95% Upper CL for Q1 | Median (months) | 95% Lower CL for Median | 95% Upper CL for Median | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | |
| All | n/a | 130 | 100,0 | 0 | 0 | 130 | 100,0 | NE | NE | NE | NE | NE | NE | 127 | 100,0 | 2 | 1,6 | 125 | 98,4 | NE | NE | NE | NE | NE | NE | 0,0624 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_tte_str_DFSODTH_IT_26JUN2023_40336.xls
26APR2024 7:19

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Time to Death (DFS) according to BICR**
**STUDY: BO40336**




| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | | | | | | | | |
| Alectinib | 130 | 122 | 122 | 119 | 119 | 101 | 72 | 55 | 52 | 38 | 21 | 18 | 9 | 3 |
| Platinum-Based Chemotherapy | 127 | 111 | 104 | 92 | 85 | 74 | 51 | 39 | 34 | 24 | 17 | 15 | 11 | 2 |
| Patients censored | | | | | | | | | | | | | | |
| Alectinib | 0 | 8 | 8 | 11 | 11 | 29 | 58 | 75 | 78 | 92 | 109 | 112 | 121 | 127 |
| Platinum-Based Chemotherapy | 0 | 16 | 23 | 35 | 42 | 53 | 76 | 88 | 93 | 102 | 108 | 110 | 114 | 123 |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_DFSODTH_IT_26JUN2023_40336.pdf
26APR2024 7:32

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023 2**

**Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.4 Sensitivitätsanalysen Krankheitsfreies Überleben (DFS)**

**2.1.3.2 DFS Ereignisrate (BICR-Bewertung)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: DFS Rate according to BICR**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 16 | 12,3 | 127 | 100,0 | 39 | 30,7 | 0,32 | | 0,17 | 0,60 | -0,178 | | -0,276 | -0,081 | 0,40 | | 0,24 | 0,67 | 0,0006 | 2,51 | | 1,49 | 4,23 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSO_IT_26JUN2023_40336.xls
26APR2024 9:16

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.4 Sensitivitätsanalysen Krankheitsfreies Überleben (DFS)**

**2.1.4.2 DFS Ereignisrate (BICR-Bewertung)**

**2.1.3.2.1 DFS Ereignisrate (BICR-Bewertung) – Einzelkomponente ZNS-Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Recurrence Rate (DFS) according to BICR**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 16 | 12,3 | 127 | 100,0 | 37 | 29,1 | 0,34 | | 0,18 | 0,65 | -0,164 | | -0,260 | -0,068 | 0,42 | | 0,25 | 0,72 | 0,0014 | 2,36 | | 1,39 | 4,01 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSOREC_IT_26JUN2023_40336.xls
26APR2024 9:18

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.1 Krankheitsfreies Überleben (DFS)**

**2.1.4 Sensitivitätsanalysen Krankheitsfreies Überleben (DFS)**

**2.1.4.2 DFS Ereignisrate (BICR-Bewertung)**

**2.1.3.2.2 DFS Ereignisrate (BICR-Bewertung) – Einzelkomponente Tod ohne ZNS-Rezidiv**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Death Rate (DFS) according to BICR**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=130) | | | | Platinum-Based Chemotherapy (N=127) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 130 | 100,0 | 0 | 0 | 127 | 100,0 | 2 | 1,6 | 0,00 | | 0,00 | NE | | * | | | | * | | | | | * | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RDFSODTH_IT_26JUN2023_40336.xls
26APR2024 9:20

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.2 Subjektiver Gesundheitszustand anhand der EQ-5D VAS**

**2.2.1 Rücklaufquoten und Mittelwertsverlauf der EQ-5D VAS**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: EQ-5D-5L: EQ5D02-EQ VAS Score until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 127 | 97,7 | 81,05 | 16,42 | 127 | 100,0 | 120 | 94,5 | 76,10 | 15,18 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 78,84 | 16,61 | 119 | 93,7 | 117 | 98,3 | 76,52 | 15,08 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 80,83 | 15,62 | 117 | 92,1 | 116 | 99,1 | 75,53 | 16,55 |
| WEEK 9 | n/a | 123 | 94,6 | 120 | 97,6 | 81,32 | 14,76 | 112 | 88,2 | 110 | 98,2 | 77,24 | 15,41 |
| WEEK 12 | n/a | 122 | 93,8 | 120 | 98,4 | 81,02 | 16,38 | 106 | 83,5 | 96 | 90,6 | 77,64 | 15,86 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_VAS_IT_26JUN2023_40336.xls
03JUN2024 13:36

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: EQ-5D-5L: EQ5D02-EQ VAS Score until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_VAS_IT_26JUN2023_40336.pdf
24MAY2024 11:51

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: EQ-5D-5L: EQ5D02-EQ VAS Score**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 127 | 97,7 | 81,05 | 16,42 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 78,84 | 16,61 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 80,83 | 15,62 |
| WEEK 9 | n/a | 123 | 94,6 | 120 | 97,6 | 81,32 | 14,76 |
| WEEK 12 | n/a | 122 | 93,8 | 120 | 98,4 | 81,02 | 16,38 |
| WEEK 24 | n/a | 119 | 91,5 | 117 | 98,3 | 83,07 | 15,72 |
| WEEK 36 | n/a | 116 | 89,2 | 113 | 97,4 | 82,23 | 14,85 |
| WEEK 48 | n/a | 116 | 89,2 | 114 | 98,3 | 82,90 | 14,23 |
| WEEK 60 | n/a | 116 | 89,2 | 111 | 95,7 | 83,10 | 14,29 |
| WEEK 72 | n/a | 113 | 86,9 | 108 | 95,6 | 83,01 | 14,93 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 83,06 | 13,66 |
| WEEK 96 | n/a | 96 | 73,8 | 95 | 99,0 | 83,39 | 13,58 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_VAS_IT_26JUN2023_40336.xls
03JUN2024 13:52

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: EQ-5D-5L: EQ5D02-EQ VAS Score**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 76,10 | 15,18 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 76,52 | 15,08 |
| WEEK 6 | n/a | 117 | 92,1 | 116 | 99,1 | 75,53 | 16,55 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 77,24 | 15,41 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 77,64 | 15,86 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 97 | 87,4 | 83,05 | 13,06 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 83,68 | 12,37 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 84,65 | 11,83 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 84,19 | 12,83 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 85 | 96,6 | 83,98 | 12,68 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 81 | 94,2 | 84,21 | 13,19 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 73 | 98,6 | 83,25 | 13,61 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_VAS_IT_26JUN2023_40336.xls
03JUN2024 13:52

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: EQ-5D-5L: EQ5D02-EQ VAS Score**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: .._analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_VAS_IT_26JUN2023_40336.pdf
24MAY2024 12:06

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.2 Subjektiver Gesundheitszustand anhand der EQ-5D VAS**

**2.2.2 Verschlechterung des subjektiven Gesundheitszustands anhand der EQ-5D VAS, MID =15**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for EQ-5D-5L (VAS)**
**ENDPOINT: Deterioration of 15 Points Health State (VAS)[EQ-5D-5L] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=119) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 119 | 100,0 | 16 | 13,4 | 96 | 100,0 | 12 | 12,5 | 1,07 | | 0,47 | 2,43 | -0,002 | | -0,087 | 0,084 | 1,15 | | 0,58 | 2,28 | 0,6917 | 0,87 | | 0,44 | 1,73 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_VASD15_VASEV12_IT_26JUN2023_40336.xls
26JAN2024 17:33

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.2 Subjektiver Gesundheitszustand anhand der EQ-5D VAS**

**2.2.2 Verschlechterung des subjektiven Gesundheitszustands anhand der EQ-5D VAS, MID =15**

**2.2.2.1 Subgruppenanalysen Verschlechterung des subjektiven Gesundheitszustands anhand der EQ-5D VAS, MID =15**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for EQ-5D-5L (VAS)**
**ENDPOINT: Deterioration of 15 Points Health State (VAS)[EQ-5D-5L] at Week 12**
**MODEL: Unstratified Analysis**
**STUDY: BO40336**
**Dichotomous Analysis by Subgroups (Efficacy)**

| | | Alectinib (N=119) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Interaction Test p-value (likelihood ratio) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 119 | 100,0 | 16 | 13,4 | 96 | 100,0 | 12 | 12,5 | 1,09 | | 0,49 | 2,42 | 0,009 | | -0,081 | 0,100 | 1,08 | | 0,53 | 2,16 | 0,8379 | | 0,93 | | 0,46 | 1,87 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 52 | 43,7 | 6 | 11,5 | 49 | 51,0 | 2 | 4,1 | 3,06 | | 0,59 | 15,98 | 0,075 | | -0,028 | 0,178 | 2,83 | | 0,60 | 13,35 | 0,1894 | 0,0958 | 0,35 | | 0,07 | 1,67 |
| | Female | 67 | 56,3 | 10 | 14,9 | 47 | 49,0 | 10 | 21,3 | 0,65 | | 0,25 | 1,71 | -0,064 | | -0,208 | 0,081 | 0,70 | | 0,32 | 1,55 | 0,3810 | | 1,43 | | 0,64 | 3,15 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 96 | 80,7 | 13 | 13,5 | 73 | 76,0 | 9 | 12,3 | 1,11 | | 0,45 | 2,77 | 0,012 | | -0,090 | 0,114 | 1,10 | | 0,50 | 2,43 | 0,8167 | 0,9133 | 0,91 | | 0,41 | 2,01 |
| | >= 65 | 23 | 19,3 | 3 | 13,0 | 23 | 24,0 | 3 | 13,0 | 1,00 | | 0,18 | 5,56 | 0,000 | | -0,195 | 0,195 | 1,00 | | 0,22 | 4,45 | 1,0000 | | 1,00 | | 0,22 | 4,45 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 69 | 58,0 | 8 | 11,6 | 60 | 62,5 | 6 | 10,0 | 1,18 | | 0,39 | 3,62 | 0,016 | | -0,091 | 0,123 | 1,16 | | 0,43 | 3,15 | 0,7720 | 0,3837 | 0,86 | | 0,32 | 2,35 |
| | Europe | 48 | 40,3 | 7 | 14,6 | 34 | 35,4 | 6 | 17,6 | 0,80 | | 0,24 | 2,62 | -0,031 | | -0,193 | 0,132 | 0,83 | | 0,30 | 2,24 | 0,7080 | | 1,21 | | 0,45 | 3,28 |
| | Rest of World | 2 | 1,7 | 1 | 50,0 | 2 | 2,1 | 0 | 0,0 | | * | | | | * | | | NE | | NE | NE | NE | | NE | | NE | NE |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Race/ethnicity (eCRF) | Asian | 66 | 55,5 | 8 | 12,1 | 60 | 62,5 | 6 | 10,0 | 1,24 | | 0,40 | 3,81 | 0,021 | | -0,088 | 0,131 | 1,21 | | 0,45 | 3,29 | 0,7059 | 0,6921 | 0,83 | | 0,30 | 2,24 |
| | Non-Asian | 51 | 42,9 | 8 | 15,7 | 35 | 36,5 | 6 | 17,1 | 0,90 | | 0,28 | 2,86 | -0,015 | | -0,174 | 0,145 | 0,92 | | 0,35 | 2,41 | 0,8572 | | 1,09 | | 0,42 | 2,87 |
| | Unknown | 2 | 1,7 | 0 | 0,0 | 1 | 1,0 | 0 | 0,0 | NE | | NE | NE | NE | | NE | NE | NE | | NE | NE | NE | | NE | | NE | NE |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 67 | 56,3 | 11 | 16,4 | 48 | 50,0 | 5 | 10,4 | 1,69 | | 0,55 | 5,23 | 0,060 | | -0,064 | 0,184 | 1,58 | | 0,59 | 4,24 | 0,3677 | 0,2348 | 0,63 | | 0,24 | 1,71 |
| | 1 | 52 | 43,7 | 5 | 9,6 | 48 | 50,0 | 7 | 14,6 | 0,62 | | 0,18 | 2,11 | -0,050 | | -0,178 | 0,078 | 0,66 | | 0,22 | 1,94 | 0,4491 | | 1,52 | | 0,52 | 4,46 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Extent of disease (eCRF) | Stage IB | 14 | 11,8 | 5 | 35,7 | 8 | 8,3 | 2 | 25,0 | 1,67 | | 0,24 | 11,57 | 0,107 | | -0,284 | 0,498 | 1,43 | | 0,36 | 5,74 | 0,6152 | 0,8583 | 0,70 | | 0,17 | 2,81 |
| | Stage II | 40 | 33,6 | 4 | 10,0 | 37 | 38,5 | 4 | 10,8 | 0,92 | | 0,21 | 3,96 | -0,008 | | -0,145 | 0,128 | 0,93 | | 0,25 | 3,43 | 0,9073 | | 1,08 | | 0,29 | 4,01 |
| | Stage IIIA | 65 | 54,6 | 7 | 10,8 | 51 | 53,1 | 6 | 11,8 | 0,91 | | 0,28 | 2,88 | -0,010 | | -0,126 | 0,106 | 0,92 | | 0,33 | 2,56 | 0,8660 | | 1,09 | | 0,39 | 3,05 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Smoking history | Never | 79 | 66,4 | 11 | 13,9 | 58 | 60,4 | 9 | 15,5 | 0,88 | | 0,34 | 2,29 | -0,016 | | -0,136 | 0,105 | 0,90 | | 0,40 | 2,02 | 0,7940 | 0,4778 | 1,11 | | 0,49 | 2,51 |
| | Previous/Current | 40 | 33,6 | 5 | 12,5 | 38 | 39,6 | 3 | 7,9 | 1,67 | | 0,37 | 7,52 | 0,046 | | -0,088 | 0,180 | 1,58 | | 0,41 | 6,17 | 0,5080 | | 0,63 | | 0,16 | 2,46 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_sg_VASD15_VASEV12_IT_26JUN2023_40336.xls
26JAN2024 17:35

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**2 Morbidität**

**2.2 Subjektiver Gesundheitszustand anhand der EQ-5D VAS**

**2.2.3 MMRM-Analysen des subjektiven Gesundheitszustands anhand der EQ-5D VAS**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)**
**ENDPOINT: EQ-5D-5L: EQ5D02-EQ VAS Score**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in EQ-5D-5L: EQ5D02-EQ VAS Score (Analysis of MMRM)**

| | | | Alectinib (N=126) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| EQ-5D-5L: EQ5D02-EQ VAS Score | All | n/a | 126 | 126 | 126 | -0,46 | 1,13 | 119 | 119 | 119 | -1,47 | 1,17 | 1,01 | 1,43 | -1,81 | 3,83 | Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS) | adjusted |
| | | | | | | | | | | | | | | | | | | |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_VAS_VASEVAL_IT_26JUN2023_40336.xls
26JAN2024 17:06

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.1 Rücklaufquoten und Mittelwertsverlauf des SF-36v2**

**3.1.1.1 Körperlicher Gesundheitszustand (PCS)**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Component Summary until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 122 | 93,8 | 46,65 | 7,93 | 127 | 100,0 | 113 | 89,0 | 46,21 | 7,87 |
| WEEK 3 | n/a | 127 | 97,7 | 124 | 97,6 | 44,85 | 7,93 | 119 | 93,7 | 109 | 91,6 | 46,17 | 6,88 |
| WEEK 6 | n/a | 123 | 94,6 | 118 | 95,9 | 46,13 | 7,68 | 117 | 92,1 | 108 | 92,3 | 45,67 | 7,63 |
| WEEK 9 | n/a | 123 | 94,6 | 116 | 94,3 | 46,76 | 7,79 | 112 | 88,2 | 109 | 97,3 | 45,47 | 7,36 |
| WEEK 12 | n/a | 122 | 93,8 | 114 | 93,4 | 47,85 | 8,08 | 106 | 83,5 | 95 | 89,6 | 45,97 | 7,32 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_PCS_IT_26JUN2023_40336.xls
03JUN2024 13:18

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Component Summary until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_PCS_IT_26JUN2023_40336.pdf
24MAY2024 11:37

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Component Summary**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 122 | 93,8 | 46,65 | 7,93 |
| WEEK 3 | n/a | 127 | 97,7 | 124 | 97,6 | 44,85 | 7,93 |
| WEEK 6 | n/a | 123 | 94,6 | 118 | 95,9 | 46,13 | 7,68 |
| WEEK 9 | n/a | 123 | 94,6 | 116 | 94,3 | 46,76 | 7,79 |
| WEEK 12 | n/a | 122 | 93,8 | 114 | 93,4 | 47,85 | 8,08 |
| WEEK 24 | n/a | 119 | 91,5 | 111 | 93,3 | 48,14 | 7,16 |
| WEEK 36 | n/a | 116 | 89,2 | 111 | 95,7 | 48,00 | 7,45 |
| WEEK 48 | n/a | 116 | 89,2 | 109 | 94,0 | 47,80 | 7,95 |
| WEEK 60 | n/a | 116 | 89,2 | 110 | 94,8 | 48,52 | 7,79 |
| WEEK 72 | n/a | 113 | 86,9 | 105 | 92,9 | 48,61 | 7,15 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 48,42 | 7,54 |
| WEEK 96 | n/a | 96 | 73,8 | 93 | 96,9 | 48,77 | 7,24 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_PCS_IT_26JUN2023_40336.xls
03JUN2024 13:37

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Component Summary**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 113 | 89,0 | 46,21 | 7,87 |
| WEEK 3 | n/a | 119 | 93,7 | 109 | 91,6 | 46,17 | 6,88 |
| WEEK 6 | n/a | 117 | 92,1 | 108 | 92,3 | 45,67 | 7,63 |
| WEEK 9 | n/a | 112 | 88,2 | 109 | 97,3 | 45,47 | 7,36 |
| WEEK 12 | n/a | 106 | 83,5 | 95 | 89,6 | 45,97 | 7,32 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 94 | 84,7 | 48,38 | 6,78 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 97 | 90,7 | 49,64 | 7,56 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 92 | 90,2 | 49,62 | 6,74 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 89 | 92,7 | 50,33 | 6,79 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 83 | 94,3 | 49,68 | 7,07 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 77 | 89,5 | 50,43 | 6,89 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 69 | 93,2 | 49,69 | 7,58 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_PCS_IT_26JUN2023_40336.xls
03JUN2024 13:37

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Component Summary**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: .._analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_PCS_IT_26JUN2023_40336.pdf
24MAY2024 11:53

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.1 Rücklaufquoten und Mittelwertsverlauf des SF-36v2**

**3.1.1.1 Körperlicher Gesundheitszustand (PCS)**

**3.1.1.1.1 Individuelle Domänen Körperlicher Gesundheitszustand (PCS)**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Bodily Pain until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 47,76 | 10,22 | 127 | 100,0 | 120 | 94,5 | 48,12 | 9,98 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 48,71 | 9,78 | 119 | 93,7 | 117 | 98,3 | 47,71 | 9,89 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 50,64 | 9,78 | 117 | 92,1 | 116 | 99,1 | 47,67 | 10,09 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 51,50 | 10,22 | 112 | 88,2 | 110 | 98,2 | 49,08 | 9,66 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 52,23 | 9,76 | 106 | 83,5 | 96 | 90,6 | 49,25 | 9,25 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_BP_IT_26JUN2023_40336.xls
03JUN2024 13:22

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Bodily Pain until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_BP_IT_26JUN2023_40336.pdf
24MAY2024 11:40

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Bodily Pain**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 47,76 | 10,22 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 48,71 | 9,78 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 50,64 | 9,78 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 51,50 | 10,22 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 52,23 | 9,76 |
| WEEK 24 | n/a | 119 | 91,5 | 116 | 97,5 | 53,07 | 9,43 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 52,41 | 9,27 |
| WEEK 48 | n/a | 116 | 89,2 | 112 | 96,6 | 52,69 | 9,61 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 53,47 | 8,97 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 53,11 | 8,71 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 53,05 | 9,51 |
| WEEK 96 | n/a | 96 | 73,8 | 95 | 99,0 | 53,36 | 8,60 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_BP_IT_26JUN2023_40336.xls
03JUN2024 13:40

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Bodily Pain**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 48,12 | 9,98 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 47,71 | 9,89 |
| WEEK 6 | n/a | 117 | 92,1 | 116 | 99,1 | 47,67 | 10,09 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 49,08 | 9,66 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 49,25 | 9,25 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 51,75 | 9,22 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 53,81 | 9,40 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 54,85 | 9,03 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 53,71 | 9,12 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 53,26 | 8,95 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 54,27 | 8,78 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 52,58 | 9,42 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_BP_IT_26JUN2023_40336.xls
03JUN2024 13:40

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Bodily Pain**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_BP_IT_26JUN2023_40336.pdf
24MAY2024 11:56

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: General Health until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 123 | 94,6 | 46,74 | 9,49 | 127 | 100,0 | 113 | 89,0 | 44,90 | 10,33 |
| WEEK 3 | n/a | 127 | 97,7 | 124 | 97,6 | 45,52 | 9,19 | 119 | 93,7 | 110 | 92,4 | 43,25 | 9,10 |
| WEEK 6 | n/a | 123 | 94,6 | 120 | 97,6 | 45,44 | 9,74 | 117 | 92,1 | 108 | 92,3 | 43,83 | 8,60 |
| WEEK 9 | n/a | 123 | 94,6 | 116 | 94,3 | 46,60 | 9,06 | 112 | 88,2 | 109 | 97,3 | 43,46 | 8,40 |
| WEEK 12 | n/a | 122 | 93,8 | 114 | 93,4 | 46,73 | 9,48 | 106 | 83,5 | 95 | 89,6 | 42,38 | 8,91 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_GH_IT_26JUN2023_40336.xls
03JUN2024 13:24

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: General Health until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_GH_IT_26JUN2023_40336.pdf
24MAY2024 11:42

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: General Health**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 123 | 94,6 | 46,74 | 9,49 |
| WEEK 3 | n/a | 127 | 97,7 | 124 | 97,6 | 45,52 | 9,19 |
| WEEK 6 | n/a | 123 | 94,6 | 120 | 97,6 | 45,44 | 9,74 |
| WEEK 9 | n/a | 123 | 94,6 | 116 | 94,3 | 46,60 | 9,06 |
| WEEK 12 | n/a | 122 | 93,8 | 114 | 93,4 | 46,73 | 9,48 |
| WEEK 24 | n/a | 119 | 91,5 | 112 | 94,1 | 46,47 | 9,23 |
| WEEK 36 | n/a | 116 | 89,2 | 111 | 95,7 | 46,71 | 9,68 |
| WEEK 48 | n/a | 116 | 89,2 | 111 | 95,7 | 45,88 | 10,07 |
| WEEK 60 | n/a | 116 | 89,2 | 110 | 94,8 | 46,88 | 9,84 |
| WEEK 72 | n/a | 113 | 86,9 | 105 | 92,9 | 47,12 | 9,98 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 46,28 | 9,63 |
| WEEK 96 | n/a | 96 | 73,8 | 94 | 97,9 | 47,31 | 10,24 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_GH_IT_26JUN2023_40336.xls
03JUN2024 13:42

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: General Health**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 113 | 89,0 | 44,90 | 10,33 |
| WEEK 3 | n/a | 119 | 93,7 | 110 | 92,4 | 43,25 | 9,10 |
| WEEK 6 | n/a | 117 | 92,1 | 108 | 92,3 | 43,83 | 8,60 |
| WEEK 9 | n/a | 112 | 88,2 | 109 | 97,3 | 43,46 | 8,40 |
| WEEK 12 | n/a | 106 | 83,5 | 95 | 89,6 | 42,38 | 8,91 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 94 | 84,7 | 45,95 | 8,04 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 97 | 90,7 | 45,56 | 8,79 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 92 | 90,2 | 45,59 | 8,03 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 89 | 92,7 | 46,06 | 8,58 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 83 | 94,3 | 46,45 | 9,43 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 77 | 89,5 | 46,11 | 8,61 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 69 | 93,2 | 46,77 | 8,99 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_GH_IT_26JUN2023_40336.xls
03JUN2024 13:42

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: General Health**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_GH_IT_26JUN2023_40336.pdf
24MAY2024 11:57

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Functioning until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 47,28 | 7,88 | 127 | 100,0 | 120 | 94,5 | 46,72 | 8,67 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 44,88 | 9,08 | 119 | 93,7 | 116 | 97,5 | 46,88 | 8,23 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 45,08 | 9,13 | 117 | 92,1 | 115 | 98,3 | 45,43 | 9,44 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 45,52 | 8,64 | 112 | 88,2 | 110 | 98,2 | 45,57 | 9,17 |
| WEEK 12 | n/a | 122 | 93,8 | 119 | 97,5 | 46,57 | 9,18 | 106 | 83,5 | 96 | 90,6 | 46,58 | 8,66 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_PF_IT_26JUN2023_40336.xls
03JUN2024 13:27

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Functioning until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_PF_IT_26JUN2023_40336.pdf
24MAY2024 11:44

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Functioning**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 47,28 | 7,88 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 44,88 | 9,08 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 45,08 | 9,13 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 45,52 | 8,64 |
| WEEK 12 | n/a | 122 | 93,8 | 119 | 97,5 | 46,57 | 9,18 |
| WEEK 24 | n/a | 119 | 91,5 | 115 | 96,6 | 47,22 | 8,15 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 46,71 | 9,51 |
| WEEK 48 | n/a | 116 | 89,2 | 112 | 96,6 | 46,97 | 8,58 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 47,16 | 8,22 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 47,65 | 7,97 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 47,16 | 8,88 |
| WEEK 96 | n/a | 96 | 73,8 | 95 | 99,0 | 47,07 | 8,57 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_PF_IT_26JUN2023_40336.xls
03JUN2024 13:44

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Functioning**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 46,72 | 8,67 |
| WEEK 3 | n/a | 119 | 93,7 | 116 | 97,5 | 46,88 | 8,23 |
| WEEK 6 | n/a | 117 | 92,1 | 115 | 98,3 | 45,43 | 9,44 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 45,57 | 9,17 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 46,58 | 8,66 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 48,46 | 8,13 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 49,48 | 8,52 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 49,24 | 8,70 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 49,74 | 8,09 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 49,07 | 8,49 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 49,35 | 9,38 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 48,91 | 8,76 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_PF_IT_26JUN2023_40336.xls
03JUN2024 13:44

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Physical Functioning**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_PF_IT_26JUN2023_40336.pdf
24MAY2024 12:00

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role-Physical until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 40,91 | 11,52 | 127 | 100,0 | 120 | 94,5 | 40,08 | 11,10 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 41,14 | 10,27 | 119 | 93,7 | 117 | 98,3 | 39,88 | 10,54 |
| WEEK 6 | n/a | 123 | 94,6 | 120 | 97,6 | 42,08 | 10,12 | 117 | 92,1 | 115 | 98,3 | 38,69 | 11,17 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 43,81 | 9,61 | 112 | 88,2 | 110 | 98,2 | 39,15 | 10,57 |
| WEEK 12 | n/a | 122 | 93,8 | 119 | 97,5 | 44,22 | 9,76 | 106 | 83,5 | 96 | 90,6 | 39,25 | 10,15 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_RP_IT_26JUN2023_40336.xls
03JUN2024 13:31

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role-Physical until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_RP_IT_26JUN2023_40336.pdf
24MAY2024 11:47

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role-Physical**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 40,91 | 11,52 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 41,14 | 10,27 |
| WEEK 6 | n/a | 123 | 94,6 | 120 | 97,6 | 42,08 | 10,12 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 43,81 | 9,61 |
| WEEK 12 | n/a | 122 | 93,8 | 119 | 97,5 | 44,22 | 9,76 |
| WEEK 24 | n/a | 119 | 91,5 | 115 | 96,6 | 44,76 | 9,95 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 45,33 | 9,17 |
| WEEK 48 | n/a | 116 | 89,2 | 113 | 97,4 | 45,37 | 9,71 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 45,85 | 9,72 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 45,87 | 9,12 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 45,99 | 9,58 |
| WEEK 96 | n/a | 96 | 73,8 | 95 | 99,0 | 46,13 | 9,83 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_RP_IT_26JUN2023_40336.xls
03JUN2024 13:47

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role-Physical**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 40,08 | 11,10 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 39,88 | 10,54 |
| WEEK 6 | n/a | 117 | 92,1 | 115 | 98,3 | 38,69 | 11,17 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 39,15 | 10,57 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 39,25 | 10,15 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 44,61 | 10,67 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 46,76 | 10,25 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 47,64 | 9,53 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 47,95 | 9,98 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 47,61 | 10,20 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 47,33 | 11,25 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 46,75 | 11,12 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_RP_IT_26JUN2023_40336.xls
03JUN2024 13:47

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role-Physical**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_RP_IT_26JUN2023_40336.pdf
24MAY2024 12:02

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.1 Rücklaufquoten und Mittelwertsverlauf des SF-36v2**

**3.1.1.2 Mentaler Gesundheitszustand (MCS)**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Component Summary until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 122 | 93,8 | 45,69 | 11,47 | 127 | 100,0 | 113 | 89,0 | 44,23 | 12,82 |
| WEEK 3 | n/a | 127 | 97,7 | 124 | 97,6 | 48,30 | 9,91 | 119 | 93,7 | 109 | 91,6 | 41,50 | 12,84 |
| WEEK 6 | n/a | 123 | 94,6 | 118 | 95,9 | 48,03 | 10,98 | 117 | 92,1 | 108 | 92,3 | 42,46 | 12,18 |
| WEEK 9 | n/a | 123 | 94,6 | 116 | 94,3 | 50,10 | 10,11 | 112 | 88,2 | 109 | 97,3 | 42,77 | 11,75 |
| WEEK 12 | n/a | 122 | 93,8 | 114 | 93,4 | 48,81 | 10,49 | 106 | 83,5 | 95 | 89,6 | 42,14 | 11,60 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_MCS_IT_26JUN2023_40336.xls
03JUN2024 13:20

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Component Summary until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_MCS_IT_26JUN2023_40336.pdf
24MAY2024 11:39

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Component Summary**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 122 | 93,8 | 45,69 | 11,47 |
| WEEK 3 | n/a | 127 | 97,7 | 124 | 97,6 | 48,30 | 9,91 |
| WEEK 6 | n/a | 123 | 94,6 | 118 | 95,9 | 48,03 | 10,98 |
| WEEK 9 | n/a | 123 | 94,6 | 116 | 94,3 | 50,10 | 10,11 |
| WEEK 12 | n/a | 122 | 93,8 | 114 | 93,4 | 48,81 | 10,49 |
| WEEK 24 | n/a | 119 | 91,5 | 111 | 93,3 | 49,81 | 10,14 |
| WEEK 36 | n/a | 116 | 89,2 | 111 | 95,7 | 49,17 | 10,41 |
| WEEK 48 | n/a | 116 | 89,2 | 109 | 94,0 | 49,58 | 9,71 |
| WEEK 60 | n/a | 116 | 89,2 | 110 | 94,8 | 49,38 | 9,88 |
| WEEK 72 | n/a | 113 | 86,9 | 105 | 92,9 | 49,98 | 9,20 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 49,30 | 9,80 |
| WEEK 96 | n/a | 96 | 73,8 | 93 | 96,9 | 49,88 | 10,37 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_MCS_IT_26JUN2023_40336.xls
03JUN2024 13:39

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Component Summary**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 113 | 89,0 | 44,23 | 12,82 |
| WEEK 3 | n/a | 119 | 93,7 | 109 | 91,6 | 41,50 | 12,84 |
| WEEK 6 | n/a | 117 | 92,1 | 108 | 92,3 | 42,46 | 12,18 |
| WEEK 9 | n/a | 112 | 88,2 | 109 | 97,3 | 42,77 | 11,75 |
| WEEK 12 | n/a | 106 | 83,5 | 95 | 89,6 | 42,14 | 11,60 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 94 | 84,7 | 48,67 | 11,37 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 97 | 90,7 | 48,98 | 11,07 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 92 | 90,2 | 50,04 | 10,99 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 89 | 92,7 | 49,17 | 11,34 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 83 | 94,3 | 49,34 | 11,22 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 77 | 89,5 | 48,61 | 12,37 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 69 | 93,2 | 48,90 | 11,53 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_MCS_IT_26JUN2023_40336.xls
03JUN2024 13:39

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Component Summary**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: .._analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_MCS_IT_26JUN2023_40336.pdf
24MAY2024 11:54

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.1 Rücklaufquoten und Mittelwertsverlauf des SF-36v2**

**3.1.1.2 Mentaler Gesundheitszustand (MCS)**

**3.1.1.2.1 Individuelle Domänen Mentaler Gesundheitszustand (MCS)**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Health until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 46,09 | 11,87 | 127 | 100,0 | 120 | 94,5 | 45,15 | 12,10 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 49,44 | 9,05 | 119 | 93,7 | 117 | 98,3 | 44,18 | 11,70 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 49,05 | 10,03 | 117 | 92,1 | 116 | 99,1 | 45,10 | 11,02 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 50,29 | 10,12 | 112 | 88,2 | 110 | 98,2 | 45,68 | 11,21 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 49,43 | 10,60 | 106 | 83,5 | 96 | 90,6 | 45,00 | 10,32 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_MH_IT_26JUN2023_40336.xls
03JUN2024 13:25

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Health until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_MH_IT_26JUN2023_40336.pdf
24MAY2024 11:43

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Health**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 46,09 | 11,87 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 49,44 | 9,05 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 49,05 | 10,03 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 50,29 | 10,12 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 49,43 | 10,60 |
| WEEK 24 | n/a | 119 | 91,5 | 115 | 96,6 | 50,99 | 9,50 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 49,55 | 10,80 |
| WEEK 48 | n/a | 116 | 89,2 | 111 | 95,7 | 50,95 | 9,29 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 49,86 | 9,64 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 50,51 | 9,47 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 49,96 | 9,97 |
| WEEK 96 | n/a | 96 | 73,8 | 94 | 97,9 | 50,41 | 10,44 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_MH_IT_26JUN2023_40336.xls
03JUN2024 13:43

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Health**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 45,15 | 12,10 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 44,18 | 11,70 |
| WEEK 6 | n/a | 117 | 92,1 | 116 | 99,1 | 45,10 | 11,02 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 45,68 | 11,21 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 45,00 | 10,32 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 49,13 | 11,17 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 49,67 | 11,14 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 50,48 | 10,47 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 49,57 | 10,63 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 49,74 | 10,97 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 49,44 | 11,60 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 49,41 | 11,37 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_MH_IT_26JUN2023_40336.xls
03JUN2024 13:43

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Mental Health**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_MH_IT_26JUN2023_40336.pdf
24MAY2024 11:58

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role Emotional until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 41,95 | 12,40 | 127 | 100,0 | 120 | 94,5 | 41,66 | 12,61 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 42,85 | 11,67 | 119 | 93,7 | 117 | 98,3 | 39,03 | 13,88 |
| WEEK 6 | n/a | 123 | 94,6 | 119 | 96,7 | 42,36 | 11,97 | 117 | 92,1 | 115 | 98,3 | 37,25 | 14,16 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 45,00 | 10,78 | 112 | 88,2 | 110 | 98,2 | 38,92 | 13,24 |
| WEEK 12 | n/a | 122 | 93,8 | 119 | 97,5 | 44,35 | 10,97 | 106 | 83,5 | 96 | 90,6 | 38,91 | 12,56 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_RE_IT_26JUN2023_40336.xls
03JUN2024 13:29

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role Emotional until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_RE_IT_26JUN2023_40336.pdf
24MAY2024 11:46

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role Emotional**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 41,95 | 12,40 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 42,85 | 11,67 |
| WEEK 6 | n/a | 123 | 94,6 | 119 | 96,7 | 42,36 | 11,97 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 45,00 | 10,78 |
| WEEK 12 | n/a | 122 | 93,8 | 119 | 97,5 | 44,35 | 10,97 |
| WEEK 24 | n/a | 119 | 91,5 | 115 | 96,6 | 44,59 | 11,51 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 45,19 | 11,09 |
| WEEK 48 | n/a | 116 | 89,2 | 113 | 97,4 | 45,28 | 10,76 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 46,20 | 10,33 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 46,00 | 10,92 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 45,48 | 10,56 |
| WEEK 96 | n/a | 96 | 73,8 | 95 | 99,0 | 46,26 | 10,08 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_RE_IT_26JUN2023_40336.xls
03JUN2024 13:46

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role Emotional**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 41,66 | 12,61 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 39,03 | 13,88 |
| WEEK 6 | n/a | 117 | 92,1 | 115 | 98,3 | 37,25 | 14,16 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 38,92 | 13,24 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 38,91 | 12,56 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 45,43 | 12,51 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 46,39 | 12,25 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 47,66 | 11,63 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 46,61 | 12,45 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 46,48 | 12,80 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 45,72 | 13,80 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 45,48 | 13,35 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_RE_IT_26JUN2023_40336.xls
03JUN2024 13:46

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Role Emotional**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_RE_IT_26JUN2023_40336.pdf
24MAY2024 12:01

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Social Functioning until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 126 | 96,9 | 44,08 | 10,98 | 127 | 100,0 | 120 | 94,5 | 41,85 | 12,29 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 45,50 | 10,22 | 119 | 93,7 | 117 | 98,3 | 40,35 | 11,80 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 46,53 | 10,27 | 117 | 92,1 | 116 | 99,1 | 40,39 | 12,21 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 47,68 | 9,76 | 112 | 88,2 | 110 | 98,2 | 40,34 | 11,09 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 47,42 | 10,15 | 106 | 83,5 | 96 | 90,6 | 40,49 | 10,94 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_SF_IT_26JUN2023_40336.xls
03JUN2024 13:32

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Social Functioning until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_SF_IT_26JUN2023_40336.pdf
24MAY2024 11:49

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Social Functioning**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 126 | 96,9 | 44,08 | 10,98 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 45,50 | 10,22 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 46,53 | 10,27 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 47,68 | 9,76 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 47,42 | 10,15 |
| WEEK 24 | n/a | 119 | 91,5 | 116 | 97,5 | 48,20 | 9,41 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 48,42 | 9,54 |
| WEEK 48 | n/a | 116 | 89,2 | 112 | 96,6 | 48,33 | 9,25 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 48,47 | 9,52 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 48,69 | 10,17 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 48,21 | 9,92 |
| WEEK 96 | n/a | 96 | 73,8 | 95 | 99,0 | 48,64 | 9,67 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_SF_IT_26JUN2023_40336.xls
03JUN2024 13:49

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Social Functioning**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 41,85 | 12,29 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 40,35 | 11,80 |
| WEEK 6 | n/a | 117 | 92,1 | 116 | 99,1 | 40,39 | 12,21 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 40,34 | 11,09 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 40,49 | 10,94 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 47,70 | 10,57 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 48,61 | 9,88 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 49,46 | 9,56 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 49,30 | 9,82 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 49,58 | 9,21 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 50,10 | 9,79 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 48,94 | 10,54 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_SF_IT_26JUN2023_40336.xls
03JUN2024 13:49

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Social Functioning**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_SF_IT_26JUN2023_40336.pdf
24MAY2024 12:04

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Vitality until Week 12**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

| | | Alectinib (N=130) | | | | | | Platinum-Based Chemotherapy (N=127) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | | | Statistics | | Patients | | | | Statistics | |
| Name Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 50,97 | 10,43 | 127 | 100,0 | 120 | 94,5 | 49,57 | 11,33 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 51,44 | 9,81 | 119 | 93,7 | 117 | 98,3 | 47,82 | 11,13 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 52,09 | 10,49 | 117 | 92,1 | 116 | 99,1 | 49,08 | 9,87 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 53,43 | 10,44 | 112 | 88,2 | 110 | 98,2 | 48,66 | 10,73 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 53,18 | 10,58 | 106 | 83,5 | 96 | 90,6 | 48,09 | 11,26 |
| | | | | | | | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_WK12_VT_IT_26JUN2023_40336.xls
03JUN2024 13:34

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Vitality until Week 12**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..ta_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_WK12_VT_IT_26JUN2023_40336.pdf
24MAY2024 11:50

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Vitality**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Alectinib (N=130)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 130 | 100,0 | 125 | 96,2 | 50,97 | 10,43 |
| WEEK 3 | n/a | 127 | 97,7 | 125 | 98,4 | 51,44 | 9,81 |
| WEEK 6 | n/a | 123 | 94,6 | 121 | 98,4 | 52,09 | 10,49 |
| WEEK 9 | n/a | 123 | 94,6 | 119 | 96,7 | 53,43 | 10,44 |
| WEEK 12 | n/a | 122 | 93,8 | 118 | 96,7 | 53,18 | 10,58 |
| WEEK 24 | n/a | 119 | 91,5 | 116 | 97,5 | 53,80 | 10,12 |
| WEEK 36 | n/a | 116 | 89,2 | 112 | 96,6 | 53,37 | 9,75 |
| WEEK 48 | n/a | 116 | 89,2 | 111 | 95,7 | 52,93 | 10,52 |
| WEEK 60 | n/a | 116 | 89,2 | 112 | 96,6 | 53,48 | 9,38 |
| WEEK 72 | n/a | 113 | 86,9 | 107 | 94,7 | 54,19 | 9,32 |
| WEEK 84 | n/a | 110 | 84,6 | 108 | 98,2 | 53,62 | 10,09 |
| WEEK 96 | n/a | 96 | 73,8 | 94 | 97,9 | 54,15 | 10,48 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_VT_IT_26JUN2023_40336.xls
03JUN2024 13:50

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Vitality**
**MODEL: --**
**STUDY: BO40336**
**Compliance and Mean**

Platinum-Based Chemotherapy (N=127)

| | | Patients | | | | Statistics | |
|---|---|---|---|---|---|---|---|
| Name<br>Visit | Level | in study[1] | % | with value[1] | % | Mean[2] | SD(Mean) |
| All | | | | | | | |
| BASELINE | n/a | 127 | 100,0 | 120 | 94,5 | 49,57 | 11,33 |
| WEEK 3 | n/a | 119 | 93,7 | 117 | 98,3 | 47,82 | 11,13 |
| WEEK 6 | n/a | 117 | 92,1 | 116 | 99,1 | 49,08 | 9,87 |
| WEEK 9 | n/a | 112 | 88,2 | 110 | 98,2 | 48,66 | 10,73 |
| WEEK 12 | n/a | 106 | 83,5 | 96 | 90,6 | 48,09 | 11,26 |
| DISEASE FOLLOW-UP VISIT 1 | n/a | 111 | 87,4 | 96 | 86,5 | 53,52 | 9,51 |
| DISEASE FOLLOW-UP VISIT 2 | n/a | 107 | 84,3 | 100 | 93,5 | 54,31 | 9,37 |
| DISEASE FOLLOW-UP VISIT 3 | n/a | 102 | 80,3 | 96 | 94,1 | 54,56 | 10,45 |
| DISEASE FOLLOW-UP VISIT 4 | n/a | 96 | 75,6 | 91 | 94,8 | 54,56 | 10,13 |
| DISEASE FOLLOW-UP VISIT 5 | n/a | 88 | 69,3 | 84 | 95,5 | 54,06 | 9,98 |
| DISEASE FOLLOW-UP VISIT 6 | n/a | 86 | 67,7 | 80 | 93,0 | 53,73 | 10,29 |
| DISEASE FOLLOW-UP VISIT 7 | n/a | 74 | 58,3 | 71 | 95,9 | 54,07 | 10,18 |
| | | | | | | | |

[1] in study: number of subjects in the population excluding subjects who had progressive disease, died or withdrew their ICF before the visit had happened; % based on the population
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mean_byarm_VT_IT_26JUN2023_40336.xls
03JUN2024 13:50

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: SF-36V2: Vitality**
**STUDY: BO40336**




Any assessments performed after recurrence of disease were not included.
Clinical cut-off: 26JUN2023

Program: ..ies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_mean_plot.sas
Output: ..a_analysis/ACE_INTERIM_2023/prod/output/g_mean_plot_byarm_VT_IT_26JUN2023_40336.pdf
24MAY2024 12:05

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.1 Verschlechterung des körperlichen Gesundheitszustands (PCS), MID = 9,4**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 9.4 Points Physical Component Summary [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 109 | 92,4 | 7 | 6,4 | 91 | 94,8 | 5 | 5,5 | 1,25 | | 0,38 | 4,15 | 0,010 | | -0,069 | 0,089 | 1,37 | | 0,45 | 4,17 | 0,5756 | 0,73 | | 0,24 | 2,21 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_PCSD94_SF36EV12_IT_26JUN2023_40336.xls
19MAR2024 7:51

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.1 Verschlechterung des körperlichen Gesundheitszustands (PCS), MID = 9,4**

**3.1.2.1.1 Subgruppenanalysen Verschlechterung des körperlichen Gesundheitszustands (PCS), MID = 9,4**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 9.4 Points Physical Component Summary [SF-36V2] at Week 12**
**MODEL: Unstratified Analysis**
**STUDY: BO40336**
**Dichotomous Analysis by Subgroups (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Interaction Test p-value (likelihood ratio) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 109 | 92,4 | 7 | 6,4 | 91 | 94,8 | 5 | 5,5 | 1,18 | | 0,36 | 3,85 | 0,009 | | -0,056 | 0,075 | 1,17 | | 0,38 | 3,56 | 0,7836 | | 0,86 | | 0,28 | 2,60 |
| Sex | Male | 48 | 40,7 | 3 | 6,3 | 47 | 49,0 | 3 | 6,4 | 0,98 | | 0,19 | 5,11 | -0,001 | | -0,099 | 0,097 | 0,98 | | 0,21 | 4,61 | 0,9787 | 0,7359 | 1,02 | | 0,22 | 4,81 |
| | Female | 61 | 51,7 | 4 | 6,6 | 44 | 45,8 | 2 | 4,5 | 1,47 | | 0,26 | 8,42 | 0,020 | | -0,067 | 0,108 | 1,44 | | 0,28 | 7,53 | 0,6638 | | 0,69 | | 0,13 | 3,62 |
| Age | < 65 | 87 | 73,7 | 4 | 4,6 | 71 | 74,0 | 5 | 7,0 | 0,64 | | 0,16 | 2,46 | -0,024 | | -0,098 | 0,050 | 0,65 | | 0,18 | 2,34 | 0,5128 | 0,0352 | 1,53 | | 0,43 | 5,49 |
| | >= 65 | 22 | 18,6 | 3 | 13,6 | 20 | 20,8 | 0 | 0,0 | | * | | | | * | | | NE | | NE | NE | NE | | NE | | NE | NE |
| Geographic region | Asia Pacific | 64 | 54,2 | 6 | 9,4 | 59 | 61,5 | 4 | 6,8 | 1,42 | | 0,38 | 5,31 | 0,026 | | -0,070 | 0,122 | 1,38 | | 0,41 | 4,66 | 0,6010 | NE | 0,72 | | 0,21 | 2,44 |
| | Europe | 43 | 36,4 | 0 | 0,0 | 30 | 31,3 | 1 | 3,3 | | * | | | | * | | | 0,00 | | 0,00 | NE | 0,9999 | | >999.99 | | 0,00 | NE |
| | Rest of World | 2 | 1,7 | 1 | 50,0 | 2 | 2,1 | 0 | 0,0 | | * | | | | * | | | NE | | NE | NE | NE | | NE | | NE | NE |
| Race/ethnicity (eCRF) | Asian | 62 | 52,5 | 6 | 9,7 | 59 | 61,5 | 4 | 6,8 | 1,47 | | 0,39 | 5,51 | 0,029 | | -0,069 | 0,127 | 1,43 | | 0,42 | 4,81 | 0,5656 | 0,6352 | 0,70 | | 0,21 | 2,36 |
| | Non-Asian | 45 | 38,1 | 1 | 2,2 | 31 | 32,3 | 1 | 3,2 | 0,68 | | 0,04 | 11,33 | -0,010 | | -0,086 | 0,066 | 0,69 | | 0,04 | 10,60 | 0,7893 | | 1,45 | | 0,09 | 22,34 |
| | Unknown | 2 | 1,7 | 0 | 0,0 | 1 | 1,0 | 0 | 0,0 | NE | | NE | NE | NE | | NE | NE | NE | | NE | NE | NE | | NE | | NE | NE |
| Baseline ECOG | 0 | 59 | 50,0 | 3 | 5,1 | 44 | 45,8 | 3 | 6,8 | 0,73 | | 0,14 | 3,81 | -0,017 | | -0,111 | 0,076 | 0,75 | | 0,16 | 3,52 | 0,7110 | 0,4188 | 1,34 | | 0,28 | 6,33 |
| | 1 | 50 | 42,4 | 4 | 8,0 | 47 | 49,0 | 2 | 4,3 | 1,96 | | 0,34 | 11,22 | 0,037 | | -0,057 | 0,132 | 1,88 | | 0,36 | 9,79 | 0,4533 | | 0,53 | | 0,10 | 2,77 |
| Extent of disease (eCRF) | Stage IB | 13 | 11,0 | 2 | 15,4 | 7 | 7,3 | 0 | 0,0 | | * | | | | * | | | NE | | NE | NE | NE | 0,2779 | NE | | NE | NE |
| | Stage II | 35 | 29,7 | 2 | 5,7 | 34 | 35,4 | 1 | 2,9 | 2,00 | | 0,17 | 23,14 | 0,028 | | -0,068 | 0,123 | 1,94 | | 0,18 | 20,45 | 0,5802 | | 0,51 | | 0,05 | 5,42 |
| | Stage IIIA | 61 | 51,7 | 3 | 4,9 | 50 | 52,1 | 4 | 8,0 | 0,59 | | 0,13 | 2,79 | -0,031 | | -0,124 | 0,062 | 0,61 | | 0,14 | 2,62 | 0,5106 | | 1,63 | | 0,38 | 6,93 |
| Smoking history | Never | 73 | 61,9 | 3 | 4,1 | 55 | 57,3 | 2 | 3,6 | 1,14 | | 0,18 | 7,04 | 0,005 | | -0,063 | 0,072 | 1,13 | | 0,20 | 6,53 | 0,8913 | 0,8861 | 0,88 | | 0,15 | 5,12 |
| | Previous/Current | 36 | 30,5 | 4 | 11,1 | 36 | 37,5 | 3 | 8,3 | 1,37 | | 0,28 | 6,63 | 0,028 | | -0,109 | 0,164 | 1,33 | | 0,32 | 5,54 | 0,6921 | | 0,75 | | 0,18 | 3,11 |

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_sg_PCSD94_SF36EV12_IT_26JUN2023_40336.xls
19MAR2024 7:55

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.1 Verschlechterung des körperlichen Gesundheitszustands (PCS)**

**3.1.2.1.2 Ergänzende Analysen PCS - Individuelle Domänen zu Verschlechterung des körperlichen Gesundheitszustands (PCS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 6 Points Bodily Pain [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 116 | 98,3 | 14 | 12,1 | 96 | 100,0 | 18 | 18,8 | 0,59 | | 0,28 | 1,26 | -0,075 | | -0,173 | 0,023 | 0,65 | | 0,34 | 1,24 | 0,1879 | 1,54 | | 0,81 | 2,93 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_BPD6_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 16:55

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 7 Points General Health [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 110 | 93,2 | 20 | 18,2 | 91 | 94,8 | 28 | 30,8 | 0,52 | | 0,27 | 1,01 | -0,117 | | -0,237 | 0,003 | 0,62 | | 0,38 | 1,03 | 0,0662 | 1,60 | | 0,97 | 2,66 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_GHD7_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:19

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 6 Points Physical Functioning [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 117 | 99,2 | 27 | 23,1 | 96 | 100,0 | 20 | 20,8 | 1,16 | | 0,60 | 2,22 | 0,025 | | -0,086 | 0,136 | 1,14 | | 0,69 | 1,91 | 0,6065 | 0,87 | | 0,52 | 1,46 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_PFD6_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:01

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 6 Points Role-Physical [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 117 | 99,2 | 19 | 16,2 | 96 | 100,0 | 26 | 27,1 | 0,52 | | 0,27 | 1,01 | -0,116 | | -0,228 | -0,005 | 0,59 | | 0,35 | 1,00 | 0,0516 | 1,69 | | 1,00 | 2,88 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RPD6_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:05

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.1 Verschlechterung des körperlichen Gesundheitszustands (PCS)**

**3.1.2.1.3 Sensitivitätsanalyse PCS - Verschlechterung des körperlichen Gesundheitszustands (PCS), MID = 10**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 10 Points Physical Component Summary [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 109 | 92,4 | 5 | 4,6 | 91 | 94,8 | 3 | 3,3 | 1,66 | | 0,37 | 7,34 | | * | | | 1,89 | | 0,50 | 7,11 | 0,3489 | 0,53 | | 0,14 | 2,00 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_PCSD10_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 16:51

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2 3.1.2.2 Verschlechterung des mentalen Gesundheitszustands (MCS), MID = 9,6**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 9.6 Points Mental Component Summary [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 109 | 92,4 | 8 | 7,3 | 91 | 94,8 | 22 | 24,2 | 0,24 | | 0,10 | 0,59 | -0,166 | | -0,264 | -0,068 | 0,30 | | 0,14 | 0,65 | 0,0019 | 3,30 | | 1,55 | 7,02 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_MCSD96_SF36EV12_IT_26JUN2023_40336.xls
19MAR2024 7:53

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.2 Verschlechterung des mentalen Gesundheitszustands (MCS)**

**3.1.2.2.1 Subgruppenanalysen Verschlechterung des mentalen Gesundheitszustands (MCS), MID = 9,6**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 9.6 Points Mental Component Summary [SF-36V2] at Week 12**
**MODEL: Unstratified Analysis**
**STUDY: BO40336**
**Dichotomous Analysis by Subgroups (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Interaction Test p-value (likelihood ratio) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 109 | 92,4 | 8 | 7,3 | 91 | 94,8 | 22 | 24,2 | 0,25 | | 0,10 | 0,59 | -0,168 | | -0,269 | -0,068 | 0,30 | | 0,14 | 0,65 | 0,0021 | | 3,29 | | 1,54 | 7,04 |
| Sex | Male | 48 | 40,7 | 4 | 8,3 | 47 | 49,0 | 14 | 29,8 | 0,21 | | 0,06 | 0,71 | -0,215 | | -0,367 | -0,062 | 0,28 | | 0,10 | 0,79 | 0,0159 | 0,7460 | 3,57 | | 1,27 | 10,07 |
| | Female | 61 | 51,7 | 4 | 6,6 | 44 | 45,8 | 8 | 18,2 | 0,32 | | 0,09 | 1,13 | -0,116 | | -0,246 | 0,014 | 0,36 | | 0,12 | 1,12 | 0,0785 | | 2,77 | | 0,89 | 8,63 |
| Age | < 65 | 87 | 73,7 | 6 | 6,9 | 71 | 74,0 | 19 | 26,8 | 0,20 | | 0,08 | 0,54 | -0,199 | | -0,315 | -0,083 | 0,26 | | 0,11 | 0,61 | 0,0021 | 0,3897 | 3,88 | | 1,64 | 9,19 |
| | >= 65 | 22 | 18,6 | 2 | 9,1 | 20 | 20,8 | 3 | 15,0 | 0,57 | | 0,08 | 3,80 | -0,059 | | -0,256 | 0,138 | 0,61 | | 0,11 | 3,26 | 0,5599 | | 1,65 | | 0,31 | 8,89 |
| Geographic region | Asia Pacific | 64 | 54,2 | 3 | 4,7 | 59 | 61,5 | 12 | 20,3 | 0,19 | | 0,05 | 0,72 | -0,157 | | -0,272 | -0,041 | 0,23 | | 0,07 | 0,78 | 0,0179 | 0,5977 | 4,34 | | 1,29 | 14,62 |
| | Europe | 43 | 36,4 | 5 | 11,6 | 30 | 31,3 | 9 | 30,0 | 0,31 | | 0,09 | 1,04 | -0,184 | | -0,374 | 0,006 | 0,39 | | 0,14 | 1,04 | 0,0603 | | 2,58 | | 0,96 | 6,94 |
| | Rest of World | 2 | 1,7 | 0 | 0,0 | 2 | 2,1 | 1 | 50,0 | | * | | | | * | | | 0,00 | | 0,00 | NE | 1,0000 | | >999.99 | | 0,00 | NE |
| Race/ethnicity (eCRF) | Asian | 62 | 52,5 | 3 | 4,8 | 59 | 61,5 | 12 | 20,3 | 0,20 | | 0,05 | 0,75 | -0,155 | | -0,271 | -0,039 | 0,24 | | 0,07 | 0,80 | 0,0204 | 0,8582 | 4,20 | | 1,25 | 14,15 |
| | Non-Asian | 45 | 38,1 | 4 | 8,9 | 31 | 32,3 | 10 | 32,3 | 0,20 | | 0,06 | 0,73 | -0,234 | | -0,418 | -0,049 | 0,28 | | 0,09 | 0,80 | 0,0177 | | 3,63 | | 1,25 | 10,53 |
| | Unknown | 2 | 1,7 | 1 | 50,0 | 1 | 1,0 | 0 | 0,0 | | * | | | | * | | | | * | | | | | | * | | |
| Baseline ECOG | 0 | 59 | 50,0 | 4 | 6,8 | 44 | 45,8 | 7 | 15,9 | 0,38 | | 0,11 | 1,41 | -0,091 | | -0,217 | 0,034 | 0,43 | | 0,13 | 1,37 | 0,1512 | 0,5032 | 2,35 | | 0,73 | 7,52 |
| | 1 | 50 | 42,4 | 4 | 8,0 | 47 | 49,0 | 15 | 31,9 | 0,19 | | 0,06 | 0,61 | -0,239 | | -0,392 | -0,086 | 0,25 | | 0,09 | 0,70 | 0,0084 | | 3,99 | | 1,43 | 11,16 |
| Extent of disease (eCRF) | Stage IB | 13 | 11,0 | 3 | 23,1 | 7 | 7,3 | 2 | 28,6 | 0,75 | | 0,09 | 6,04 | -0,055 | | -0,460 | 0,351 | 0,81 | | 0,17 | 3,75 | 0,7851 | 0,3467 | 1,24 | | 0,27 | 5,75 |
| | Stage II | 35 | 29,7 | 2 | 5,7 | 34 | 35,4 | 8 | 23,5 | 0,20 | | 0,04 | 1,01 | -0,178 | | -0,340 | -0,016 | 0,24 | | 0,06 | 1,06 | 0,0602 | | 4,12 | | 0,94 | 18,01 |
| | Stage IIIA | 61 | 51,7 | 3 | 4,9 | 50 | 52,1 | 12 | 24,0 | 0,16 | | 0,04 | 0,62 | -0,191 | | -0,321 | -0,061 | 0,20 | | 0,06 | 0,69 | 0,0102 | | 4,88 | | 1,46 | 16,34 |
| Smoking history | Never | 73 | 61,9 | 7 | 9,6 | 55 | 57,3 | 13 | 23,6 | 0,34 | | 0,13 | 0,93 | -0,140 | | -0,272 | -0,009 | 0,41 | | 0,17 | 0,95 | 0,0374 | 0,1894 | 2,46 | | 1,05 | 5,76 |
| | Previous/Current | 36 | 30,5 | 1 | 2,8 | 36 | 37,5 | 9 | 25,0 | 0,09 | | 0,01 | 0,72 | -0,222 | | -0,374 | -0,071 | 0,11 | | 0,01 | 0,83 | 0,0325 | | 9,00 | | 1,20 | 67,42 |

Test for interaction based on RR (Log-binomial regression)
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_sg_MCSD96_SF36EV12_IT_26JUN2023_40336.xls
19MAR2024 7:57

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.2 Verschlechterung des mentalen Gesundheitszustands (MCS)**

**3.1.2.2.2 Ergänzende Analysen MCS - Individuelle Domänen zu Verschlechterung des mentalen Gesundheitszustands (MCS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 9 Points Mental Health [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 116 | 98,3 | 11 | 9,5 | 96 | 100,0 | 16 | 16,7 | 0,53 | | 0,23 | 1,19 | -0,071 | | -0,162 | 0,021 | 0,57 | | 0,28 | 1,16 | 0,1189 | 1,77 | | 0,86 | 3,62 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_MHD9_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:19

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 6 Points Role Emotional [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 117 | 99,2 | 22 | 18,8 | 96 | 100,0 | 38 | 39,6 | 0,34 | | 0,18 | 0,63 | -0,209 | | -0,328 | -0,089 | 0,46 | | 0,29 | 0,72 | 0,0006 | 2,18 | | 1,40 | 3,40 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_RED6_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:03

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 6 Points Social Role [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 117 | 99,2 | 15 | 12,8 | 96 | 100,0 | 22 | 22,9 | 0,49 | | 0,24 | 1,01 | -0,100 | | -0,204 | 0,004 | 0,55 | | 0,30 | 1,00 | 0,0494 | | 1,82 | | 1,00 | 3,32 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_SFD6_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:08

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 7 Vitality [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 116 | 98,3 | 17 | 14,7 | 96 | 100,0 | 25 | 26,0 | 0,50 | | 0,25 | 1,00 | -0,119 | | -0,227 | -0,012 | 0,58 | | 0,33 | 1,01 | 0,0539 | 1,73 | | 0,99 | 3,02 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_VTD7_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 17:10

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.2 Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.2.2 Verschlechterung des mentalen Gesundheitszustands (MCS)**

**3.1.2.2.3 Sensitivitätsanalyse MCS - Verschlechterung des mentalen Gesundheitszustands (MCS), MID = 10**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable at Week 12 for SF36v2**
**ENDPOINT: Deterioration of 10 Points Mental Component Summary [SF-36V2] at Week 12**
**MODEL: Stratified Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Dichotomous Analysis (Efficacy)**

| | | Alectinib (N=118) | | | | Platinum-Based Chemotherapy (N=96) | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | | | | | | | | | | Platinum-Based Chemotherapy vs. Alectimib | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Patients | | Patients with Event | | Odds Ratio | | | | Absolute Risk Difference | | | | Relative Risk | | | | | | Relative Risk | | | |
| Name | Level | n | % | n | % | n | % | n | % | Odds Ratio | | 95% Lower CL | 95% Upper CL | Absolute Risk | | 95% Lower CL | 95% Upper CL | Relative Risk | | 95% Lower CL | 95% Upper CL | p-value (Wald) | Relative Risk | | 95% Lower CL | 95% Upper CL |
| All | n/a | 109 | 92,4 | 8 | 7,3 | 91 | 94,8 | 21 | 23,1 | 0,27 | | 0,11 | 0,64 | -0,160 | | -0,257 | -0,063 | 0,32 | | 0,15 | 0,68 | 0,0032 | 3,16 | | 1,47 | 6,78 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_resp_str_MCSD10_SF36EV12_IT_26JUN2023_40336.xls
26JAN2024 16:53

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.3 MMRM-Analysen Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.3 MMRM-Analysen Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.3.1 Verschlechterung des körperlichen Gesundheitszustands (PCS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Physical Component Summary**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Physical Component Summary (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Physical Component Summary (PCS) | All | n/a | 125 | 121 | 121 | -0,46 | 0,53 | 119 | 112 | 111 | -0,73 | 0,55 | 0,27 | 0,66 | -1,03 | 1,57 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |
| | | | | | | | | | | | | | | | | | | |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_PCS_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 16:55

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.3 MMRM-Analysen Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.3.1 Verschlechterung des körperlichen Gesundheitszustands (PCS)**

**3.1.3.1.1 Individuelle Domänen zu Verschlechterung des körperlichen Gesundheitszustands (PCS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Bodily Pain**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Bodily Pain (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Bodily Pain (BP) | All | n/a | 125 | 124 | 124 | 2,82 | 0,75 | 119 | 119 | 119 | 0,32 | 0,77 | 2,50 | 0,94 | 0,65 | 4,35 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_BP_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 16:49

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: General Health**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: General Health (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: General Health (GH) | All | n/a | 125 | 122 | 122 | -0,77 | 0,61 | 119 | 112 | 112 | -2,40 | 0,63 | 1,63 | 0,76 | 0,13 | 3,13 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_GH_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 17:17

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Physical Functioning**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Physical Functioning (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Physical Functioning (PF) | All | n/a | 125 | 124 | 124 | -1,98 | 0,59 | 119 | 119 | 118 | -1,18 | 0,61 | -0,80 | 0,74 | -2,26 | 0,67 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_PF_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 16:57

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Role-Physical**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Role-Physical (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Role-Physical (RP) | All | n/a | 125 | 124 | 124 | 1,82 | 0,78 | 119 | 119 | 119 | -1,59 | 0,80 | 3,42 | 0,97 | 1,52 | 5,32 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_RP_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 17:00

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.3 MMRM-Analysen Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.3.2 Verschlechterung des mentalen Gesundheitszustands (MCS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Mental Component Summary**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Mental Component Summary (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Mental Component Summary (MCS) | All | n/a | 125 | 121 | 121 | 2,62 | 0,82 | 119 | 112 | 111 | -2,88 | 0,85 | 5,50 | 1,02 | 3,49 | 7,51 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |
| | | | | | | | | | | | | | | | | | | |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_MCS_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 16:52

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**3 Gesundheitsbezogene Lebensqualität (QoL)**

**3.1 Gesundheitsbezogene Lebensqualität anhand des SF-36v2**

**3.1.3 MMRM-Analysen Verschlechterung der gesundheitsbezogenen Lebensqualität anhand des SF-36v2**

**3.1.3.2 Verschlechterung des mentalen Gesundheitszustands (MCS)**

**3.1.3.2.1 Individuelle Domänen zu Verschlechterung des mentalen Gesundheitszustands (MCS)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Mental Health**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Mental Health (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Mental Health (MH) | All | n/a | 125 | 124 | 124 | 3,23 | 0,73 | 119 | 119 | 119 | -0,96 | 0,75 | 4,19 | 0,91 | 2,39 | 5,98 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_MH_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 17:17

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Role Emotional**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Role Emotional (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Role Emotional (RE) | All | n/a | 125 | 124 | 124 | 1,73 | 0,97 | 119 | 119 | 119 | -3,26 | 0,99 | 4,98 | 1,20 | 2,61 | 7,35 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_RE_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 16:59

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Social Functioning**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Social Functioning (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Social Functionning (SF) | All | n/a | 125 | 125 | 125 | 2,83 | 0,76 | 119 | 119 | 119 | -2,47 | 0,78 | 5,30 | 0,95 | 3,43 | 7,17 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_SF_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 17:02

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: SF-36V2: Vitality**
**MODEL: Adjusted Analysis by Ethnicity (IxRS), Extent of disease (IxRS)**
**STUDY: BO40336**
**Change from Baseline in SF-36V2: Vitality (Analysis of MMRM)**

| | | | Alectinib (N=125) | | | | | Platinum-Based Chemotherapy (N=119) | | | | | Difference between Treatments (Alectimib - Platinum-Based Chemotherapy) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | N | | | Statistics | | N | | | Statistics | | Statistics | | | | | |
| Endpoint | Name | Level | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | Total | with baseline value | included in analysis[1] | LSMeans[2] | SE (LSMeans) | LSMeans[3] | SE (LSMeans) | 95% CI (LL) | 95% CI (UL) | Population | Method |
| SF-36V2: Vitality (VT) | All | n/a | 125 | 124 | 124 | 1,54 | 0,75 | 119 | 119 | 119 | -1,87 | 0,77 | 3,42 | 0,94 | 1,57 | 5,26 | Intent-To-Treat Population, PRO-Evaluable for SF36v2 | adjusted |

[1] Patients with a value at baseline and at least one post-baseline value until Week 12 or recurrence of disease
[2] LSMeans of change from baseline from MMRM (including all available records from all visits until Week 12 or recurrence of disease)
[3] Contrasts from MMRM, Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value. In addition, for the total population, adjusted for randomization stratification factors.
Data as observed (no imputation of missing values). Only data until progressive disease as per RECIST 1.1 are included.
Covariance matrix: unstructured
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_eff_mmrm.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_eff_mmrm_adj_VT_SF36EVAL_IT_26JUN2023_40336.xls
26JAN2024 17:04

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.1 Unerwünschte Ereignisse (UE)**

**4.1.1.1 Patienten mit Unerwünschten Ereignissen (UE), Overall und Subgruppenanalysen**

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 126 | 98,4 | 2 | 1,6 | 120 | 100,0 | 112 | 93,3 | 8 | 6,7 | 0,2912 | 0,86 | 0,65 | 1,14 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 52 | 96,3 | 2 | 3,7 | 64 | 53,3 | 58 | 90,6 | 6 | 9,4 | 0,3232 | 0,82 | 0,55 | 1,22 | | 0,9260 |
| | Female | 74 | 57,8 | 74 | 100,0 | 0 | 0,0 | 56 | 46,7 | 54 | 96,4 | 2 | 3,6 | 0,4578 | 0,86 | 0,58 | 1,28 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 99 | 98,0 | 2 | 2,0 | 87 | 72,5 | 81 | 93,1 | 6 | 6,9 | 0,2428 | 0,82 | 0,59 | 1,14 | | 0,5796 |
| | >= 65 | 27 | 21,1 | 27 | 100,0 | 0 | 0,0 | 33 | 27,5 | 31 | 93,9 | 2 | 6,1 | 0,9831 | 0,99 | 0,57 | 1,74 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 72 | 98,6 | 1 | 1,4 | 69 | 57,5 | 64 | 92,8 | 5 | 7,2 | 0,4598 | 0,87 | 0,59 | 1,27 | | 0,9140 |
| | Europe | 53 | 41,4 | 52 | 98,1 | 1 | 1,9 | 47 | 39,2 | 44 | 93,6 | 3 | 6,4 | 0,4529 | 0,85 | 0,55 | 1,31 | | |
| | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 4 | 100,0 | 0 | 0,0 | 1,0000 | 1,00 | 0,15 | 6,61 | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 71 | 98,6 | 1 | 1,4 | 60 | 50,0 | 56 | 93,3 | 4 | 6,7 | 0,2479 | 0,80 | 0,54 | 1,17 | | 0,5453 |
| | 1 | 56 | 43,8 | 55 | 98,2 | 1 | 1,8 | 60 | 50,0 | 56 | 93,3 | 4 | 6,7 | 0,6829 | 0,92 | 0,61 | 1,39 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTAE_SE_26JUN2023_40336.xls
26JAN2024 16:28

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**




| | | | | | | |
|---|---|---|---|---|---|---|
| Patients at risk | | | | | | |
| Alectinib | 128 | 3 | 2 | 2 | 1 | 1 |
| Platinum-Based Chemotherapy | 120 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | |
| Alectinib | 0 | 1 | 1 | 1 | 1 | 1 |
| Platinum-Based Chemotherapy | 0 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:15

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.1 Unerwünschte Ereignisse (UE)**

**4.1.1.2 Patienten mit schweren unerwünschten Ereignissen (UE ≥ Grad 3), Overall und Subgruppenanalysen**

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 38 | 29,7 | 90 | 70,3 | 120 | 100,0 | 37 | 30,8 | 83 | 69,2 | 0,0088 | 0,50 | 0,29 | 0,85 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 15 | 27,8 | 39 | 72,2 | 64 | 53,3 | 24 | 37,5 | 40 | 62,5 | 0,0179 | 0,41 | 0,19 | 0,88 | | 0,2053 |
| | Female | 74 | 57,8 | 23 | 31,1 | 51 | 68,9 | 56 | 46,7 | 13 | 23,2 | 43 | 76,8 | 0,2960 | 0,66 | 0,30 | 1,45 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 28 | 27,7 | 73 | 72,3 | 87 | 72,5 | 25 | 28,7 | 62 | 71,3 | 0,0092 | 0,43 | 0,22 | 0,82 | | 0,7185 |
| | >= 65 | 27 | 21,1 | 10 | 37,0 | 17 | 63,0 | 33 | 27,5 | 12 | 36,4 | 21 | 63,6 | 0,5266 | 0,75 | 0,30 | 1,85 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 20 | 27,4 | 53 | 72,6 | 69 | 57,5 | 19 | 27,5 | 50 | 72,5 | 0,0856 | 0,53 | 0,25 | 1,11 | | 0,9598 |
| | Europe | 53 | 41,4 | 17 | 32,1 | 36 | 67,9 | 47 | 39,2 | 16 | 34,0 | 31 | 66,0 | 0,0506 | 0,46 | 0,20 | 1,02 | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,7822 | 0,71 | 0,06 | 8,02 | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 23 | 31,9 | 49 | 68,1 | 60 | 50,0 | 18 | 30,0 | 42 | 70,0 | 0,1526 | 0,61 | 0,30 | 1,21 | | 0,6485 |
| | 1 | 56 | 43,8 | 15 | 26,8 | 41 | 73,2 | 60 | 50,0 | 19 | 31,7 | 41 | 68,3 | 0,0168 | 0,36 | 0,15 | 0,86 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTGR35AE_SE_26JUN2023_40336.xls
26JAN2024 16:37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 102 | 94 | 92 | 85 | 82 | 61 |
| Platinum-Based Chemotherapy | 120 | 9 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 4 | 6 | 6 | 8 | 9 | 29 |
| Platinum-Based Chemotherapy | 0 | 74 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 13:21

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 37 | 28,9 | 91 | 71,1 | 120 | 100,0 | 35 | 29,2 | 85 | 70,8 | 0,0115 | 0,50 | 0,29 | 0,86 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 15 | 27,8 | 39 | 72,2 | 64 | 53,3 | 23 | 35,9 | 41 | 64,1 | 0,0268 | 0,43 | 0,20 | 0,93 | | 0,2384 |
| | Female | 74 | 57,8 | 22 | 29,7 | 52 | 70,3 | 56 | 46,7 | 12 | 21,4 | 44 | 78,6 | 0,3007 | 0,65 | 0,29 | 1,48 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 27 | 26,7 | 74 | 73,3 | 87 | 72,5 | 25 | 28,7 | 62 | 71,3 | 0,0049 | 0,39 | 0,20 | 0,77 | | 0,4172 |
| | >= 65 | 27 | 21,1 | 10 | 37,0 | 17 | 63,0 | 33 | 27,5 | 10 | 30,3 | 23 | 69,7 | 0,8338 | 0,90 | 0,35 | 2,32 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 19 | 26,0 | 54 | 74,0 | 69 | 57,5 | 18 | 26,1 | 51 | 73,9 | 0,0752 | 0,50 | 0,23 | 1,09 | | 0,9923 |
| | Europe | 53 | 41,4 | 17 | 32,1 | 36 | 67,9 | 47 | 39,2 | 15 | 31,9 | 32 | 68,1 | 0,0816 | 0,49 | 0,22 | 1,11 | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,7822 | 0,71 | 0,06 | 8,02 | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 22 | 30,6 | 50 | 69,4 | 60 | 50,0 | 17 | 28,3 | 43 | 71,7 | 0,1515 | 0,59 | 0,29 | 1,22 | | 0,7392 |
| | 1 | 56 | 43,8 | 15 | 26,8 | 41 | 73,2 | 60 | 50,0 | 18 | 30,0 | 42 | 70,0 | 0,0264 | 0,38 | 0,16 | 0,92 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTGR3AE_SE_26JUN2023_40336.xls
26JAN2024 16:30

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 103 | 95 | 93 | 86 | 83 | 62 |
| Platinum-Based Chemotherapy | 120 | 9 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 4 | 6 | 6 | 8 | 9 | 29 |
| Platinum-Based Chemotherapy | 0 | 76 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:16

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,0857 | 0,19 | 0,02 | 1,60 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1102 | 0,00 | 0,00 | NE | | 0,9784 |
| | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,4063 | 0,38 | 0,03 | 4,15 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,2475 | 0,29 | 0,03 | 2,75 | | 0,9137 |
| | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1980 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,2900 | 0,31 | 0,03 | 3,03 | | 0,9561 |
| | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1346 | 0,00 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,4583 | 0,41 | 0,04 | 4,58 | | 0,0440 |
| | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0935 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTGR4AE_SE_26JUN2023_40336.xls
26JAN2024 16:33

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 110 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 13:18

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Baseline ECOG, 0




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib, 0 | 72 | 68 | 65 | 65 | 63 | 62 | 48 |
| Platinum-Based Chemotherapy, 0 | 60 | 8 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib, 0 | 0 | 3 | 5 | 5 | 5 | 6 | 20 |
| Platinum-Based Chemotherapy, 0 | 0 | 50 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_sg2_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 13:10

Page 1 of 2

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Baseline ECOG, 1




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib, 1 | 56 | 52 | 50 | 50 | 47 | 46 | 32 |
| Platinum-Based Chemotherapy, 1 | 60 | 10 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib, 1 | 0 | 4 | 6 | 6 | 9 | 10 | 24 |
| Platinum-Based Chemotherapy, 1 | 0 | 47 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_sg2_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 13:10

Page 2 of 2

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTGR5AE_SE_26JUN2023_40336.xls
26JAN2024 16:35

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 5 Adverse Event**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTGR5AE_SE_26JUN2023_40336.pdf
26JAN2024 13:19

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.1 Unerwünschte Ereignisse (UE)**

**4.1.1.3 Patienten mit schwerwiegenden unerwünschten Ereignissen (SUE), Overall und Subgruppenanalysen**

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 17 | 13,3 | 111 | 86,7 | 120 | 100,0 | 10 | 8,3 | 110 | 91,7 | 0,0477 | 0,32 | 0,10 | 1,04 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 7 | 13,0 | 47 | 87,0 | 64 | 53,3 | 6 | 9,4 | 58 | 90,6 | 0,1258 | 0,29 | 0,06 | 1,51 | | 0,7520 |
| | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,2335 | 0,37 | 0,07 | 2,03 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 12 | 11,9 | 89 | 88,1 | 87 | 72,5 | 6 | 6,9 | 81 | 93,1 | 0,0531 | 0,23 | 0,05 | 1,13 | | 0,9183 |
| | >= 65 | 27 | 21,1 | 5 | 18,5 | 22 | 81,5 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,5726 | 0,62 | 0,11 | 3,38 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 11 | 15,1 | 62 | 84,9 | 69 | 57,5 | 6 | 8,7 | 63 | 91,3 | 0,1206 | 0,30 | 0,06 | 1,50 | | 0,9779 |
| | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 4 | 8,5 | 43 | 91,5 | 0,1913 | 0,32 | 0,05 | 1,91 | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 8 | 11,1 | 64 | 88,9 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0220 | 0,10 | 0,01 | 1,00 | | 0,5621 |
| | 1 | 56 | 43,8 | 9 | 16,1 | 47 | 83,9 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,5487 | 0,65 | 0,16 | 2,69 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTSAE_SE_26JUN2023_40336.xls
26JAN2024 16:39

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 111 | 108 | 103 | 99 | 74 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 10 | 10 | 11 | 13 | 37 |
| Platinum-Based Chemotherapy | 0 | 93 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 13:22

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.1 Unerwünschte Ereignisse (UE)**

**4.1.1.4 Patienten mit Therapieabbruch aufgrund Unerwünschten Ereignissen (UE), Overall und Subgruppenanalysen**

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event leading to Treatment Discontinuation**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 15 | 12,5 | 105 | 87,5 | 0,0053 | 0,24 | 0,08 | 0,71 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,0129 | 0,00 | 0,00 | NE | | 0,7395 |
| | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 8 | 14,3 | 48 | 85,7 | 0,0776 | 0,35 | 0,11 | 1,18 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 10 | 11,5 | 77 | 88,5 | 0,0005 | 0,00 | 0,00 | NE | | 0,0278 |
| | >= 65 | 27 | 21,1 | 5 | 18,5 | 22 | 81,5 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,9421 | 0,95 | 0,26 | 3,55 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 6 | 8,7 | 63 | 91,3 | 0,1242 | 0,31 | 0,06 | 1,52 | | 0,9115 |
| | Europe | 53 | 41,4 | 5 | 9,4 | 48 | 90,6 | 47 | 39,2 | 9 | 19,1 | 38 | 80,9 | 0,0136 | 0,18 | 0,04 | 0,83 | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,0030 | 0,09 | 0,01 | 0,67 | | 0,6378 |
| | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,3548 | 0,53 | 0,13 | 2,10 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_TTWDAE_SE_26JUN2023_40336.xls
26JAN2024 16:40

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event leading to Treatment Discontinuation**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 3 | 5 | 5 | 8 | 10 | 38 |
| Platinum-Based Chemotherapy | 0 | 88 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_TTWDAE_SE_26JUN2023_40336.pdf
26JAN2024 13:27

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event leading to Treatment Discontinuation**
**STUDY: BO40336**
Age, <65




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib, <65 | 101 | 99 | 97 | 97 | 94 | 92 | 67 |
| Platinum-Based Chemotherapy, <65 | 87 | 14 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib, <65 | 0 | 2 | 2 | 2 | 5 | 7 | 32 |
| Platinum-Based Chemotherapy, <65 | 0 | 63 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..6/data_analysis/ACE_INTERIM_2023/prod/output/g_km_sg2_TTWDAE_SE_26JUN2023_40336.pdf
26JAN2024 13:26

Page 1 of 2

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event leading to Treatment Discontinuation**
**STUDY: BO40336**
Age, >=65




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib, >=65 | 27 | 22 | 19 | 19 | 19 | 19 | 16 |
| Platinum-Based Chemotherapy, >=65 | 33 | 3 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib, >=65 | 0 | 1 | 3 | 3 | 3 | 3 | 6 |
| Platinum-Based Chemotherapy, >=65 | 0 | 25 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..6/data_analysis/ACE_INTERIM_2023/prod/output/g_km_sg2_TTWDAE_SE_26JUN2023_40336.pdf
26JAN2024 13:26

Page 2 of 2

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.2 Unerwünschte Ereignisse UE nach Systemorganklassen (SOC) und Preferred Terms (PT)**

**4.1.2.1 Patienten mit Unerwünschten Ereignissen (UE)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: All

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | n/a | 128 | 100,0 | 36 | 28,1 | 92 | 71,9 | 120 | 100,0 | 46 | 38,3 | 74 | 61,7 | <.0001 | 0,36 | 0,22 | 0,61 | NE |
| Blood and lymphatic system disorders | Anaemia | n/a | 128 | 100,0 | 30 | 23,4 | 98 | 76,6 | 120 | 100,0 | 31 | 25,8 | 89 | 74,2 | 0,0202 | 0,51 | 0,29 | 0,91 | NE |
| Blood and lymphatic system disorders | Febrile neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Haemolysis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Iron deficiency anaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Leukopenia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | 0,0016 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Myelosuppression | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Neutropenia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 19 | 15,8 | 101 | 84,2 | <.0001 | 0,09 | 0,02 | 0,39 | NE |
| Blood and lymphatic system disorders | Neutrophilia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7528 | >999.99 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Thrombocytopenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1455 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Thrombocytosis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3310 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | n/a | 128 | 100,0 | 20 | 15,6 | 108 | 84,4 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0136 | 4,28 | 1,22 | 15,05 | NE |
| Cardiac disorders | Acute myocardial infarction | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Angina pectoris | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Atrial fibrillation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Cardiac disorders | Atrioventricular block first degree | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Cardiac disorders | Bradycardia | n/a | 128 | 100,0 | 10 | 7,8 | 118 | 92,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0164 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Cardiac failure | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Cor pulmonale chronic | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Coronary artery disease | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Palpitations | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1703 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Pericardial effusion | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Sinus bradycardia | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | NE |
| Cardiac disorders | Tachycardia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9451 | 0,91 | 0,06 | 14,51 | NE |
| Cardiac disorders | Ventricular extrasystoles | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Congenital, familial and genetic disorders | | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7971 | >999.99 | 0,00 | NE | NE |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Congenital, familial and genetic disorders | Gilbert's syndrome | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7971 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Ear and labyrinth disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,3642 | 0,46 | 0,08 | 2,54 | NE |
| Ear and labyrinth disorders | Deafness | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5247 | 0,47 | 0,04 | 5,15 | NE |
| Ear and labyrinth disorders | Ear pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9658 | 0,94 | 0,06 | 15,05 | NE |
| Ear and labyrinth disorders | Eustachian tube dysfunction | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Ear and labyrinth disorders | Tinnitus | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5216 | 0,46 | 0,04 | 5,13 | NE |
| | | | | | | | | | | | | | | | | | | | |
| Endocrine disorders | | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3616 | 2,75 | 0,29 | 26,43 | NE |
| Endocrine disorders | Hyperthyroidism | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,6262 | 1,80 | 0,16 | 19,89 | NE |
| Endocrine disorders | Hypothyroidism | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Eye disorders | | n/a | 128 | 100,0 | 12 | 9,4 | 116 | 90,6 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,7130 | 1,32 | 0,30 | 5,76 | NE |
| Eye disorders | Dry eye | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1685 | >999.99 | 0,00 | NE | NE |
| Eye disorders | Episcleritis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Eye irritation | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | NE |
| Eye disorders | Lacrimation increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Eye disorders | Photophobia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Eye disorders | Photopsia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Punctate keratitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Vision blurred | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3416 | 2,86 | 0,30 | 27,45 | NE |
| Eye disorders | Visual acuity reduced | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | n/a | 128 | 100,0 | 87 | 68,0 | 41 | 32,0 | 120 | 100,0 | 95 | 79,2 | 25 | 20,8 | <.0001 | 0,42 | 0,31 | 0,58 | NE |
| Gastrointestinal disorders | Abdominal discomfort | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1676 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Abdominal distension | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Abdominal pain | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,6467 | 0,71 | 0,16 | 3,13 | NE |
| Gastrointestinal disorders | Abdominal pain lower | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Abdominal pain upper | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,2171 | 0,37 | 0,07 | 1,91 | NE |
| Gastrointestinal disorders | Anal haemorrhage | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Anal inflammation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Chronic gastritis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Gastrointestinal disorders | Colitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3172 | 0,09 | 0,00 | 12,40 | NE |
| Gastrointestinal disorders | Constipation | n/a | 128 | 100,0 | 54 | 42,2 | 74 | 57,8 | 120 | 100,0 | 30 | 25,0 | 90 | 75,0 | 0,0212 | 1,70 | 1,08 | 2,67 | NE |
| Gastrointestinal disorders | Dental caries | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Diarrhoea | n/a | 128 | 100,0 | 16 | 12,5 | 112 | 87,5 | 120 | 100,0 | 10 | 8,3 | 110 | 91,7 | 0,3376 | 0,63 | 0,24 | 1,63 | NE |
| Gastrointestinal disorders | Dry mouth | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Dyspepsia | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,9168 | 1,08 | 0,24 | 4,91 | NE |
| Gastrointestinal disorders | Epigastric discomfort | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0731 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Faeces discoloured | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Faeces hard | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Gastritis | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0924 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastrointestinal pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0762 | 0,05 | 0,00 | 2,16 | NE |
| Gastrointestinal disorders | Gingival pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Gingival swelling | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Haematochezia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Haemorrhoids | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5321 | 0,47 | 0,04 | 5,22 | NE |
| Gastrointestinal disorders | Ileus paralytic | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Mouth ulceration | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Nausea | n/a | 128 | 100,0 | 10 | 7,8 | 118 | 92,2 | 120 | 100,0 | 87 | 72,5 | 33 | 27,5 | <.0001 | 0,04 | 0,02 | 0,09 | NE |
| Gastrointestinal disorders | Pancreatitis acute | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Regurgitation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Stomatitis | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,9426 | 0,94 | 0,19 | 4,67 | NE |
| Gastrointestinal disorders | Toothache | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Umbilical hernia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Vomiting | n/a | 128 | 100,0 | 9 | 7,0 | 119 | 93,0 | 120 | 100,0 | 30 | 25,0 | 90 | 75,0 | <.0001 | 0,16 | 0,07 | 0,40 | NE |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | n/a | 128 | 100,0 | 56 | 43,8 | 72 | 56,3 | 120 | 100,0 | 54 | 45,0 | 66 | 55,0 | 0,0077 | 0,57 | 0,38 | 0,87 | NE |
| General disorders and administration site conditions | Asthenia | n/a | 128 | 100,0 | 14 | 10,9 | 114 | 89,1 | 120 | 100,0 | 19 | 15,8 | 101 | 84,2 | 0,0464 | 0,47 | 0,22 | 1,01 | NE |
| General disorders and administration site conditions | Chest discomfort | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0380 | 0,00 | 0,00 | NE | NE |
| General disorders and administration site conditions | Chest pain | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,6890 | 1,43 | 0,24 | 8,49 | NE |
| General disorders and administration site conditions | Face oedema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5241 | 0,47 | 0,04 | 5,16 | NE |
| General disorders and administration site conditions | Fatigue | n/a | 128 | 100,0 | 18 | 14,1 | 110 | 85,9 | 120 | 100,0 | 16 | 13,3 | 104 | 86,7 | 0,3967 | 0,73 | 0,35 | 1,52 | NE |
| General disorders and administration site conditions | Gait disturbance | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Hyperthermia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| General disorders and administration site conditions | Ill-defined disorder | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| General disorders and administration site conditions | Influenza like illness | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,6036 | 1,87 | 0,17 | 20,61 | NE |
| General disorders and administration site conditions | Infusion site extravasation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1433 | 0,00 | 0,00 | NE | NE |
| General disorders and administration site conditions | Infusion site injury | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3074 | 0,00 | 0,00 | NE | NE |
| General disorders and administration site conditions | Localised oedema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| General disorders and administration site conditions | Malaise | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 16 | 13,3 | 104 | 86,7 | 0,0066 | 0,27 | 0,10 | 0,74 | NE |
| General disorders and administration site conditions | Mucosal inflammation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| General disorders and administration site conditions | Non-cardiac chest pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Oedema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Oedema peripheral | n/a | 128 | 100,0 | 13 | 10,2 | 115 | 89,8 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,0138 | 8,62 | 1,09 | 68,07 | NE |
| General disorders and administration site conditions | Pain | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,9577 | 0,95 | 0,13 | 6,73 | NE |
| General disorders and administration site conditions | Peripheral swelling | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0842 | >999.99 | 0,00 | NE | NE |
| General disorders and administration site conditions | Pyrexia | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,3669 | 0,47 | 0,09 | 2,55 | NE |
| General disorders and administration site conditions | Suprapubic pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Swelling face | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | n/a | 128 | 100,0 | 8 | 6,3 | 120 | 93,8 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0164 | >999.99 | 0,00 | NE | NE |
| Hepatobiliary disorders | Cholelithiasis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Hepatobiliary disorders | Hepatotoxicity | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Hepatobiliary disorders | Hyperbilirubinaemia | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0507 | >999.99 | 0,00 | NE | NE |
| Hepatobiliary disorders | Ocular icterus | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Immune system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Immune system disorders | Hypersensitivity | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | n/a | 128 | 100,0 | 74 | 57,8 | 54 | 42,2 | 120 | 100,0 | 13 | 10,8 | 107 | 89,2 | 0,2056 | 1,55 | 0,78 | 3,08 | NE |
| Infections and infestations | Acute sinusitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Appendicitis | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,9276 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Bronchiolitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Bronchitis | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | COVID-19 | n/a | 128 | 100,0 | 37 | 28,9 | 91 | 71,1 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,8993 | 1,18 | 0,09 | 14,91 | NE |
| Infections and infestations | Chronic sinusitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Conjunctivitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Infections and infestations | Cystitis | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Folliculitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9658 | 0,94 | 0,06 | 15,05 | NE |
| Infections and infestations | Gastroenteritis | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,9276 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Herpes zoster | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Infections and infestations | Infection | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| Infections and infestations | Influenza | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0919 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Laryngopharyngitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Lower respiratory tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,6628 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Nail infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Nasopharyngitis | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,8443 | 1,28 | 0,11 | 15,58 | NE |
| Infections and infestations | Otitis media | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Periodontitis | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9121 | 0,85 | 0,05 | 13,71 | NE |
| Infections and infestations | Pharyngitis | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,8507 | 1,27 | 0,10 | 15,48 | NE |
| Infections and infestations | Pneumonia | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,8426 | 1,29 | 0,11 | 15,46 | NE |
| Infections and infestations | Pneumonia viral | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Pulpitis dental | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9447 | 0,91 | 0,06 | 14,50 | NE |
| Infections and infestations | Respiratory tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Respiratory tract infection viral | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Rhinitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Infections and infestations | Sinusitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3167 | 0,09 | 0,00 | 12,29 | NE |
| Infections and infestations | Tonsillitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Upper respiratory tract infection | n/a | 128 | 100,0 | 9 | 7,0 | 119 | 93,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3537 | 2,79 | 0,29 | 26,81 | NE |
| Infections and infestations | Urethritis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urinary tract infection | n/a | 128 | 100,0 | 11 | 8,6 | 117 | 91,4 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,4202 | 1,97 | 0,37 | 10,62 | NE |
| Infections and infestations | Urosepsis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Viral upper respiratory tract infection | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Injury, poisoning and procedural complications | | n/a | 128 | 100,0 | 49 | 38,3 | 79 | 61,7 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0002 | 7,38 | 2,21 | 24,67 | NE |
| Injury, poisoning and procedural complications | Accidental overdose | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3421 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Accidental underdose | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7851 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Arthropod sting | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Contusion | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Extra dose administered | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Fall | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1685 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Immunisation reaction | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Incorrect dose administered | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0291 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Intentional product misuse | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Limb injury | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Medication error | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Overdose | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Product dose omission in error | n/a | 128 | 100,0 | 16 | 12,5 | 112 | 87,5 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0492 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Product dose omission issue | n/a | 128 | 100,0 | 21 | 16,4 | 107 | 83,6 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0044 | >999.99 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Radius fracture | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Injury, poisoning and procedural complications | Thermal burn | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Injury, poisoning and procedural complications | Vaccination complication | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Injury, poisoning and procedural complications | Wound complication | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Investigations | | n/a | 128 | 100,0 | 97 | 75,8 | 31 | 24,2 | 120 | 100,0 | 45 | 37,5 | 75 | 62,5 | <.0001 | 2,66 | 1,83 | 3,85 | NE |
| Investigations | Activated partial thromboplastin time prolonged | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Alanine aminotransferase increased | n/a | 128 | 100,0 | 43 | 33,6 | 85 | 66,4 | 120 | 100,0 | 11 | 9,2 | 109 | 90,8 | 0,0014 | 2,93 | 1,47 | 5,82 | NE |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0731 | 0,00 | 0,00 | NE | NE |
| Investigations | Aspartate aminotransferase increased | n/a | 128 | 100,0 | 53 | 41,4 | 75 | 58,6 | 120 | 100,0 | 6 | 5,0 | 114 | 95,0 | <.0001 | 7,77 | 3,29 | 18,35 | NE |
| Investigations | Bacterial test positive | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Investigations | Bile acids increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Investigations | Bilirubin conjugated increased | n/a | 128 | 100,0 | 11 | 8,6 | 117 | 91,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0018 | >999.99 | 0,00 | NE | NE |
| Investigations | Blood alkaline phosphatase increased | n/a | 128 | 100,0 | 32 | 25,0 | 96 | 75,0 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | <.0001 | 6,95 | 2,42 | 19,91 | NE |
| Investigations | Blood bilirubin increased | n/a | 128 | 100,0 | 43 | 33,6 | 85 | 66,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | <.0001 | 37,19 | 5,09 | 271,77 | NE |
| Investigations | Blood bilirubin unconjugated increased | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3291 | >999.99 | 0,00 | NE | NE |
| Investigations | Blood cholesterol increased | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood creatine phosphokinase MB increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Investigations | Blood creatine phosphokinase increased | n/a | 128 | 100,0 | 55 | 43,0 | 73 | 57,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | <.0001 | 69,51 | 9,55 | 505,70 | NE |
| Investigations | Blood creatinine increased | n/a | 128 | 100,0 | 19 | 14,8 | 109 | 85,2 | 120 | 100,0 | 6 | 5,0 | 114 | 95,0 | 0,1779 | 1,93 | 0,73 | 5,13 | NE |
| Investigations | Blood fibrinogen increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood lactate dehydrogenase increased | n/a | 128 | 100,0 | 9 | 7,0 | 119 | 93,0 | 120 | 100,0 | 6 | 5,0 | 114 | 95,0 | 0,9105 | 0,94 | 0,30 | 2,91 | NE |
| Investigations | Blood thyroid stimulating hormone decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood thyroid stimulating hormone increased | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Investigations | Blood triglycerides increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood urea increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,1041 | 0,14 | 0,01 | 1,82 | NE |
| Investigations | Blood uric acid increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Creatinine renal clearance decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,4618 | 0,31 | 0,01 | 7,69 | NE |
| Investigations | Electrocardiogram Q wave abnormal | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Investigations | Electrocardiogram QRS complex abnormal | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Investigations | Electrocardiogram QT prolonged | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Investigations | Gamma-glutamyltransferase increased | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 7 | 5,8 | 113 | 94,2 | 0,1630 | 0,39 | 0,10 | 1,53 | NE |
| Investigations | Glomerular filtration rate decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Heart rate increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3310 | >999.99 | 0,00 | NE | NE |
| Investigations | International normalised ratio increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| Investigations | Liver function test increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Investigations | Lymphocyte count decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,2852 | 0,31 | 0,03 | 3,00 | NE |
| Investigations | Neutrophil count decreased | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 21 | 17,5 | 99 | 82,5 | <.0001 | 0,08 | 0,02 | 0,35 | NE |
| Investigations | Neutrophil count increased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Investigations | Platelet count decreased | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 6 | 5,0 | 114 | 95,0 | 0,0443 | 0,15 | 0,02 | 1,27 | NE |
| Investigations | Protein total decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Red blood cells urine positive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Investigations | SARS-CoV-2 test positive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7971 | >999.99 | 0,00 | NE | NE |
| Investigations | Transaminases increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,5924 | 1,90 | 0,17 | 21,01 | NE |
| Investigations | Urinary occult blood positive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Investigations | Urine ketone body present | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Investigations | Urobilinogen urine increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Investigations | Vitamin B12 decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Weight decreased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0728 | 0,00 | 0,00 | NE | NE |
| Investigations | Weight increased | n/a | 128 | 100,0 | 17 | 13,3 | 111 | 86,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,0208 | 7,93 | 1,00 | 63,09 | NE |
| Investigations | White blood cell count decreased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 23 | 19,2 | 97 | 80,8 | <.0001 | 0,07 | 0,02 | 0,31 | NE |
| Investigations | White blood cell count increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5231 | 0,47 | 0,04 | 5,14 | NE |
| Investigations | White blood cells urine positive | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1712 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | n/a | 128 | 100,0 | 39 | 30,5 | 89 | 69,5 | 120 | 100,0 | 48 | 40,0 | 72 | 60,0 | 0,0004 | 0,43 | 0,27 | 0,69 | NE |
| Metabolism and nutrition disorders | Cell death | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Decreased appetite | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 35 | 29,2 | 85 | 70,8 | <.0001 | 0,16 | 0,07 | 0,36 | NE |
| Metabolism and nutrition disorders | Electrolyte imbalance | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypercalcaemia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1392 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hyperchloraemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypercreatininaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hyperglycaemia | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,9871 | 0,99 | 0,25 | 3,85 | NE |
| Metabolism and nutrition disorders | Hyperkalaemia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5278 | 0,47 | 0,04 | 5,18 | NE |
| Metabolism and nutrition disorders | Hyperlipidaemia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,2814 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypermagnesaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypernatraemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3310 | >999.99 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hyperphosphataemia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,6013 | 1,88 | 0,17 | 20,69 | NE |
| Metabolism and nutrition disorders | Hyperuricaemia | n/a | 128 | 100,0 | 12 | 9,4 | 116 | 90,6 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1626 | 2,95 | 0,60 | 14,47 | NE |
| Metabolism and nutrition disorders | Hypoalbuminaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5321 | 0,47 | 0,04 | 5,22 | NE |
| Metabolism and nutrition disorders | Hypocalcaemia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7161 | >999.99 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypoglycaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hypokalaemia | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,5972 | 1,89 | 0,17 | 20,84 | NE |
| Metabolism and nutrition disorders | Hypomagnesaemia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,1178 | 0,16 | 0,01 | 1,92 | NE |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Metabolism and nutrition disorders | Hyponatraemia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,3648 | 0,46 | 0,09 | 2,54 | | NE |
| Metabolism and nutrition disorders | Hypophosphataemia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | | NE |
| Metabolism and nutrition disorders | Hypoproteinaemia | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1601 | >999.99 | 0,00 | NE | | NE |
| Metabolism and nutrition disorders | Polydipsia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9740 | 0,96 | 0,06 | 14,92 | | NE |
| Metabolism and nutrition disorders | Vitamin D deficiency | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | n/a | 128 | 100,0 | 65 | 50,8 | 63 | 49,2 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | <.0001 | 6,16 | 3,02 | 12,58 | | NE |
| Musculoskeletal and connective tissue disorders | Arthralgia | n/a | 128 | 100,0 | 10 | 7,8 | 118 | 92,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,9741 | 0,97 | 0,14 | 6,67 | | NE |
| Musculoskeletal and connective tissue disorders | Back pain | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,5903 | 1,91 | 0,17 | 20,82 | | NE |
| Musculoskeletal and connective tissue disorders | Bone pain | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,2863 | 0,31 | 0,03 | 3,00 | | NE |
| Musculoskeletal and connective tissue disorders | Flank pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Muscle spasms | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Muscular weakness | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0895 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3310 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Myalgia | n/a | 128 | 100,0 | 36 | 28,1 | 92 | 71,9 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | <.0001 | 17,56 | 4,21 | 73,27 | | NE |
| Musculoskeletal and connective tissue disorders | Myositis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Neck pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Osteoporosis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Pain in extremity | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,3900 | 2,05 | 0,39 | 10,82 | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1702 | >999.99 | 0,00 | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3314 | >999.99 | 0,00 | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Nervous system disorders | | n/a | 128 | 100,0 | 40 | 31,3 | 88 | 68,8 | 120 | 100,0 | 24 | 20,0 | 96 | 80,0 | 0,6498 | 1,14 | 0,66 | 1,96 | | NE |
| Nervous system disorders | Amnesia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Anosmia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7971 | >999.99 | 0,00 | NE | | NE |
| Nervous system disorders | Cerebral ischaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Cognitive disorder | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7971 | >999.99 | 0,00 | NE | | NE |
| Nervous system disorders | Dizziness | n/a | 128 | 100,0 | 9 | 7,0 | 119 | 93,0 | 120 | 100,0 | 11 | 9,2 | 109 | 90,8 | 0,1097 | 0,44 | 0,16 | 1,23 | | NE |
| Nervous system disorders | Dysgeusia | n/a | 128 | 100,0 | 13 | 10,2 | 115 | 89,8 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0349 | 3,61 | 1,01 | 12,92 | | NE |
| Nervous system disorders | Headache | n/a | 128 | 100,0 | 14 | 10,9 | 114 | 89,1 | 120 | 100,0 | 8 | 6,7 | 112 | 93,3 | 0,8843 | 1,07 | 0,41 | 2,79 | | NE |
| Nervous system disorders | Hypoaesthesia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3055 | 0,00 | 0,00 | NE | | NE |
| Nervous system disorders | Hypokinesia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Lethargy | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Nervous system disorders | Memory impairment | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7971 | >999.99 | 0,00 | NE | | NE |
| Nervous system disorders | Neuropathy peripheral | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,2772 | 0,31 | 0,03 | 2,94 | | NE |
| Nervous system disorders | Paraesthesia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0835 | 0,17 | 0,02 | 1,60 | | NE |
| Nervous system disorders | Parosmia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Nervous system disorders | Somnolence | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3454 | 2,83 | 0,29 | 27,25 | | NE |
| Nervous system disorders | Taste disorder | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,1981 | 3,81 | 0,43 | 34,14 | | NE |
| Nervous system disorders | Vascular encephalopathy | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Psychiatric disorders | | n/a | 128 | 100,0 | 8 | 6,3 | 120 | 93,8 | 120 | 100,0 | 8 | 6,7 | 112 | 93,3 | 0,3568 | 0,60 | 0,20 | 1,79 | | NE |
| Psychiatric disorders | Agitation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Psychiatric disorders | Anxiety | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1725 | >999.99 | 0,00 | NE | | NE |
| Psychiatric disorders | Depressed mood | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3033 | 0,00 | 0,00 | NE | | NE |
| Psychiatric disorders | Depression | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | | NE |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Psychiatric disorders | Insomnia | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,4255 | 0,56 | 0,13 | 2,36 | NE |
| Psychiatric disorders | Panic attack | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Psychiatric disorders | Restlessness | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Renal and urinary disorders | | n/a | 128 | 100,0 | 12 | 9,4 | 116 | 90,6 | 120 | 100,0 | 8 | 6,7 | 112 | 93,3 | 0,8155 | 1,12 | 0,44 | 2,83 | NE |
| Renal and urinary disorders | Azotaemia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| Renal and urinary disorders | Dysuria | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9679 | 0,94 | 0,06 | 15,10 | NE |
| Renal and urinary disorders | Glycosuria | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Renal and urinary disorders | Haematuria | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,7708 | 1,25 | 0,28 | 5,58 | NE |
| Renal and urinary disorders | Leukocyturia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3310 | >999.99 | 0,00 | NE | NE |
| Renal and urinary disorders | Nephrolithiasis | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3421 | >999.99 | 0,00 | NE | NE |
| Renal and urinary disorders | Nocturia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,6015 | >999.99 | 0,00 | NE | NE |
| Renal and urinary disorders | Proteinuria | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,2706 | 2,43 | 0,48 | 12,39 | NE |
| Renal and urinary disorders | Renal failure | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Renal and urinary disorders | Renal impairment | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | n/a | 128 | 100,0 | 9 | 7,0 | 119 | 93,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,4590 | 1,88 | 0,34 | 10,26 | NE |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Reproductive system and breast disorders | Balanoposthitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Cervical cyst | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Cervical polyp | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Reproductive system and breast disorders | Erectile dysfunction | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Galactorrhoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Hypomenorrhoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Reproductive system and breast disorders | Menstruation irregular | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,2925 | 0,00 | 0,00 | NE | NE |
| Reproductive system and breast disorders | Prostatitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Uterine prolapse | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Vaginal discharge | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Vaginal haemorrhage | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | n/a | 128 | 100,0 | 39 | 30,5 | 89 | 69,5 | 120 | 100,0 | 19 | 15,8 | 101 | 84,2 | 0,9770 | 1,01 | 0,55 | 1,87 | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Cough | n/a | 128 | 100,0 | 19 | 14,8 | 109 | 85,2 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,2747 | 1,93 | 0,58 | 6,37 | NE |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | n/a | 128 | 100,0 | 13 | 10,2 | 115 | 89,8 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0986 | 2,86 | 0,78 | 10,49 | NE |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,6360 | 0,60 | 0,07 | 4,97 | NE |
| Respiratory, thoracic and mediastinal disorders | Hiccups | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | 0,0017 | 0,00 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,7528 | >999.99 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,5542 | 0,51 | 0,05 | 4,94 | NE |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9612 | 0,93 | 0,06 | 14,92 | NE |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1712 | >999.99 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9687 | 1,05 | 0,08 | 14,66 | NE |
| Respiratory, thoracic and mediastinal disorders | Productive cough | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,0533 | >999.99 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1462 | 0,00 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | n/a | 128 | 100,0 | 50 | 39,1 | 78 | 60,9 | 120 | 100,0 | 22 | 18,3 | 98 | 81,7 | 0,2166 | 1,40 | 0,82 | 2,41 | NE |
| Skin and subcutaneous tissue disorders | Acne | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Skin and subcutaneous tissue disorders | Alopecia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 7 | 5,8 | 113 | 94,2 | 0,0296 | 0,17 | 0,03 | 0,99 | NE |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9634 | 0,94 | 0,06 | 14,98 | NE |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Skin and subcutaneous tissue disorders | Drug eruption | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Dry skin | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,1160 | 4,75 | 0,56 | 40,69 | NE |
| Skin and subcutaneous tissue disorders | Eczema | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3472 | 2,82 | 0,29 | 27,15 | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Erythema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,1414 | 0,19 | 0,02 | 2,08 | | NE |
| Skin and subcutaneous tissue disorders | Hirsutism | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,8557 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Nail disorder | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1685 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Pruritus | n/a | 128 | 100,0 | 8 | 6,3 | 120 | 93,8 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,9244 | 0,93 | 0,19 | 4,58 | | NE |
| Skin and subcutaneous tissue disorders | Psoriasis | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash | n/a | 128 | 100,0 | 18 | 14,1 | 110 | 85,9 | 120 | 100,0 | 7 | 5,8 | 113 | 94,2 | 0,2914 | 1,64 | 0,65 | 4,16 | | NE |
| Skin and subcutaneous tissue disorders | Rash erythematous | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9612 | 0,93 | 0,06 | 14,92 | | NE |
| Skin and subcutaneous tissue disorders | Rash papular | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Scar pain | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Skin atrophy | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Skin fissures | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3421 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Urticaria | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1703 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Xeroderma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Surgical and medical procedures | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | Cataract operation | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | n/a | 128 | 100,0 | 11 | 8,6 | 117 | 91,4 | 120 | 100,0 | 17 | 14,2 | 103 | 85,8 | 0,0201 | 0,37 | 0,15 | 0,89 | | NE |
| Vascular disorders | Embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0728 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Essential hypertension | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Flushing | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0724 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Haematoma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Hypertension | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 6 | 5,0 | 114 | 95,0 | 0,1260 | 0,31 | 0,06 | 1,52 | | NE |
| Vascular disorders | Hypotension | n/a | 128 | 100,0 | 5 | 3,9 | 123 | 96,1 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,1141 | 4,79 | 0,56 | 40,97 | | NE |
| Vascular disorders | Lymphoedema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Phlebitis | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1433 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Vasculitis | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0723 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Venous thrombosis | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTAE_SE_26JUN2023_40336.xls
26JAN2024 16:40

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 100 | 89 | 85 | 83 | 79 | 64 |
| Platinum-Based Chemotherapy | 120 | 6 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 13 | 14 | 28 |
| Platinum-Based Chemotherapy | 0 | 68 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 1 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Anaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 103 | 92 | 90 | 88 | 83 | 67 |
| Platinum-Based Chemotherapy | 120 | 11 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 31 |
| Platinum-Based Chemotherapy | 0 | 78 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 2 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Febrile neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 3 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Haemolysis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 4 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Iron deficiency anaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 5 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Leukopenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 14 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 6 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Myelosuppression




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 7 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 83 |
| Platinum-Based Chemotherapy | 120 | 11 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 90 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 8 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Neutrophilia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 9 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Normochromic normocytic anaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 10 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Thrombocytopenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 11 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Thrombocytosis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 12 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 108 | 100 | 97 | 94 | 92 | 70 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 38 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 13 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Acute myocardial infarction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 14 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Angina pectoris




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 15 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Atrial fibrillation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 16 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Atrioventricular block first degree




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 17 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Bradycardia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 109 | 107 | 104 | 101 | 77 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 41 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 18 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Cardiac failure




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 19 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Cor pulmonale chronic




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 20 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Coronary artery disease




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 21 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Palpitations




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 22 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Pericardial effusion




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 23 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Sinus bradycardia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 111 | 111 | 107 | 105 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 24 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Tachycardia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 25 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Ventricular extrasystoles




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 26 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Congenital, familial and genetic disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 27 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Congenital, familial and genetic disorders, Cerebral arteriovenous malformation haemorrhagic




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 28 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Congenital, familial and genetic disorders, Gilbert's syndrome




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 29 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Ear and labyrinth disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 30 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Ear and labyrinth disorders, Deafness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 31 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Ear and labyrinth disorders, Ear pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 32 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Ear and labyrinth disorders, Eustachian tube dysfunction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 33 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Ear and labyrinth disorders, Tinnitus




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 34 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Endocrine disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 112 | 109 | 107 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 35 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Endocrine disorders, Hyperthyroidism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 36 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Endocrine disorders, Hypothyroidism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 37 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, All




| Patients at risk | | | | | | | |
|---|---|---|---|---|---|---|---|
| Alectinib | 128 | 117 | 110 | 108 | 102 | 99 | 74 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| **Patients censored** | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 38 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Dry eye




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 112 | 108 | 106 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 39 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Episcleritis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 40 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Eye irritation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 41 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Lacrimation increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 42 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Photophobia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 43 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Photopsia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 44 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Punctate keratitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 45 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Retinal detachment




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 46 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Retinal haemorrhage




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 47 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Vision blurred




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 112 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 48 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Eye disorders, Visual acuity reduced




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 49 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 53 | 45 | 41 | 38 | 36 | 23 |
| Platinum-Based Chemotherapy | 120 | 4 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 3 | 4 | 4 | 5 | 7 | 18 |
| Platinum-Based Chemotherapy | 0 | 21 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 50 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal discomfort




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 51 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal distension




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 52 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 112 | 112 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 53 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal pain lower




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 54 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal pain upper




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 111 | 108 | 106 | 78 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 55 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Anal haemorrhage




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 56 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Anal inflammation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 57 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Chronic gastritis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 58 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Colitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 59 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Constipation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 72 | 68 | 68 | 63 | 61 | 46 |
| Platinum-Based Chemotherapy | 120 | 14 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 8 | 8 | 11 | 13 | 28 |
| Platinum-Based Chemotherapy | 0 | 76 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 60 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Dental caries




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 61 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Diarrhoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 114 | 106 | 104 | 100 | 98 | 71 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 15 | 41 |
| Platinum-Based Chemotherapy | 0 | 92 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 62 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Dry mouth




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 63 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Dyspepsia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 111 | 110 | 107 | 105 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 64 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Epigastric discomfort




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 65 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Faeces discoloured




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 66 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Faeces hard




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 67 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gastritis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 113 | 110 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 68 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gastritis erosive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 69 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gastrointestinal pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 70 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gastrooesophageal reflux disease




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 114 | 113 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 71 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gingival pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 72 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gingival swelling




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 73 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Haematochezia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 74 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Haemorrhoids




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 75 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Ileus paralytic




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 76 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Mouth ulceration




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 109 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 77 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Nausea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 114 | 108 | 107 | 103 | 101 | 76 |
| Platinum-Based Chemotherapy | 120 | 4 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 29 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 78 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Pancreatitis acute




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 79 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Regurgitation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 80 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Stomatitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 113 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 81 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Toothache




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 82 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Umbilical hernia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 83 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Vomiting




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 110 | 108 | 105 | 103 | 78 |
| Platinum-Based Chemotherapy | 120 | 15 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 75 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 84 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 84 | 74 | 70 | 64 | 59 | 42 |
| Platinum-Based Chemotherapy | 120 | 10 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 9 | 9 | 12 | 13 | 30 |
| Platinum-Based Chemotherapy | 0 | 56 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 85 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Asthenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 111 | 105 | 104 | 101 | 98 | 72 |
| Platinum-Based Chemotherapy | 120 | 14 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 87 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 86 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Chest discomfort




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 87 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Chest pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 112 | 109 | 107 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 88 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Face oedema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 89 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Fatigue




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 109 | 102 | 101 | 98 | 96 | 72 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 15 | 38 |
| Platinum-Based Chemotherapy | 0 | 86 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 90 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Gait disturbance




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 91 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
General disorders and administration site conditions, Hyperthermia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 92 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
General disorders and administration site conditions, Ill-defined disorder




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 93 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Influenza like illness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 113 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 94 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Infusion site extravasation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 95 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Infusion site injury




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 96 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Localised oedema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 97 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Malaise




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 111 | 111 | 108 | 105 | 78 |
| Platinum-Based Chemotherapy | 120 | 15 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 89 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 98 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Mucosal inflammation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 99 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Non-cardiac chest pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 100 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Oedema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 101 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Oedema peripheral




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 112 | 106 | 104 | 100 | 98 | 73 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 102 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
General disorders and administration site conditions, Pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 113 | 110 | 106 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 103 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Peripheral swelling




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 111 | 111 | 108 | 106 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 104 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
General disorders and administration site conditions, Pyrexia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 113 | 107 | 104 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 105 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Suprapubic pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 106 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Swelling face




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 107 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 112 | 111 | 108 | 105 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 10 | 10 | 13 | 15 | 40 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 108 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, Cholelithiasis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 109 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, Hepatotoxicity




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 110 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, Hyperbilirubinaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 113 | 111 | 108 | 106 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 111 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, Ocular icterus




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 112 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Immune system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 113 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Immune system disorders, Hypersensitivity




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 114 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 100 | 87 | 71 | 58 | 49 | 34 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 9 | 9 | 10 | 12 | 22 |
| Platinum-Based Chemotherapy | 0 | 91 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 115 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Acute sinusitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 116 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Appendicitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 117 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Bronchiolitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 118 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Bronchitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 111 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 119 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, COVID-19




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 110 | 104 | 94 | 83 | 66 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 28 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 120 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Chronic sinusitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 121 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Conjunctivitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 122 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Cystitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 123 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Folliculitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 124 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Gastroenteritis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 125 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Herpes zoster




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 126 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 127 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Influenza




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 110 | 108 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 128 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Laryngopharyngitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 129 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Lower respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 130 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Nail infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 131 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Nasopharyngitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 110 | 108 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 132 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Otitis media




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 133 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Periodontitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 134 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pharyngitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 135 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pneumonia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 111 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 12 | 14 | 41 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 136 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pneumonia viral




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 137 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pulpitis dental




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 138 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 139 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Infections and infestations, Respiratory tract infection viral




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 140 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Rhinitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 141 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Sinusitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 142 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Tonsillitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 143 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Upper respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 111 | 108 | 105 | 102 | 74 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 144 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urethritis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 145 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urinary tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 112 | 107 | 103 | 101 | 76 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 146 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urosepsis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 147 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Infections and infestations, Viral upper respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 110 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 148 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 100 | 84 | 79 | 73 | 68 | 50 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 13 | 15 | 30 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 149 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Accidental overdose




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 110 | 108 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 150 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Accidental underdose




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 151 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Airway complication of anaesthesia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 152 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Arthropod sting




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 153 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Contusion




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 154 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Extra dose administered




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 155 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Fall




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 156 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Immunisation reaction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 157 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Incorrect dose administered




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 111 | 111 | 108 | 106 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 158 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Intentional product misuse




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 159 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Limb injury




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 160 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Medication error




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 161 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Overdose




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 162 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Product dose omission in error




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 108 | 106 | 102 | 96 | 77 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 35 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 163 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Product dose omission issue




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 112 | 103 | 99 | 93 | 91 | 65 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 164 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Radius fracture




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 165 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Thermal burn




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 166 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Injury, poisoning and procedural complications, Vaccination complication




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 167 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Injury, poisoning and procedural complications, Wound complication




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 168 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 33 | 29 | 27 | 25 | 24 | 17 |
| Platinum-Based Chemotherapy | 120 | 7 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 6 | 6 | 6 | 7 | 14 |
| Platinum-Based Chemotherapy | 0 | 68 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 169 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Activated partial thromboplastin time prolonged




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 113 | 110 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 170 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Alanine aminotransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 89 | 80 | 77 | 75 | 72 | 52 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 9 | 9 | 11 | 13 | 33 |
| Platinum-Based Chemotherapy | 0 | 93 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 171 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Alpha hydroxybutyrate dehydrogenase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 172 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Aspartate aminotransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 79 | 73 | 70 | 67 | 63 | 46 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 9 | 9 | 10 | 12 | 29 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 173 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Bacterial test positive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 174 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Bile acids increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 175 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Bilirubin conjugated increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 111 | 107 | 106 | 103 | 101 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 38 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 176 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood alkaline phosphatase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 96 | 89 | 87 | 85 | 83 | 65 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 9 | 9 | 11 | 13 | 31 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 177 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood bilirubin increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 87 | 80 | 76 | 73 | 72 | 54 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 10 | 10 | 12 | 13 | 31 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 178 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood bilirubin unconjugated increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 113 | 113 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 179 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood cholesterol increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 180 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatine phosphokinase MB increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 181 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatine phosphokinase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 68 | 64 | 63 | 62 | 61 | 49 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 10 | 10 | 11 | 12 | 24 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 182 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatinine increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 110 | 105 | 101 | 98 | 95 | 75 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 12 | 14 | 34 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 183 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood fibrinogen increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 184 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood lactate dehydrogenase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 108 | 107 | 104 | 102 | 76 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 185 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood thyroid stimulating hormone decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 186 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood thyroid stimulating hormone increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 187 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood triglycerides increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 188 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood urea increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 189 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Blood uric acid increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 190 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Creatinine renal clearance decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 191 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Electrocardiogram Q wave abnormal




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 192 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Electrocardiogram QRS complex abnormal




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 193 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Electrocardiogram QT prolonged




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 194 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Gamma-glutamyltransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 112 | 110 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 195 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Glomerular filtration rate decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 196 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Heart rate increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 197 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, International normalised ratio increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 198 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Liver function test increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 199 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Lymphocyte count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 200 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Neutrophil count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 113 | 110 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 13 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 86 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 201 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Neutrophil count increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 202 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Platelet count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 203 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Protein total decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 204 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Red blood cells urine positive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 205 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, SARS-CoV-2 test positive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 206 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Transaminases increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 207 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Urinary occult blood positive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 208 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Urine ketone body present




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 209 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Urobilinogen urine increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 210 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Vitamin B12 decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 211 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Weight decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 212 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, Weight increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 113 | 102 | 100 | 98 | 95 | 75 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 36 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 213 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, White blood cell count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 10 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 87 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 214 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, White blood cell count increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 215 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Investigations, White blood cells urine positive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 216 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 97 | 87 | 83 | 80 | 77 | 62 |
| Platinum-Based Chemotherapy | 120 | 11 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 9 | 9 | 10 | 12 | 27 |
| Platinum-Based Chemotherapy | 0 | 61 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 217 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Cell death




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 218 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Metabolism and nutrition disorders, Decreased appetite




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 110 | 110 | 107 | 105 | 79 |
| Platinum-Based Chemotherapy | 120 | 11 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 74 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 219 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Metabolism and nutrition disorders, Electrolyte imbalance




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 220 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypercalcaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 221 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyperchloraemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 222 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypercreatininaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 223 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyperglycaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 111 | 111 | 108 | 106 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 224 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyperkalaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 225 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyperlipidaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 226 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypermagnesaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 227 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypernatraemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 228 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyperphosphataemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 111 | 109 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 229 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypertriglyceridaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 13 | 15 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 230 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyperuricaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 108 | 105 | 101 | 99 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 38 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 231 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypoalbuminaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 232 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypocalcaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 114 | 114 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 233 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypoglycaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 234 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypokalaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 112 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 235 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypomagnesaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 110 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 236 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hyponatraemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 113 | 110 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 237 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypophosphataemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 238 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypoproteinaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 113 | 111 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 239 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Polydipsia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 240 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Type 2 diabetes mellitus




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 241 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Vitamin D deficiency




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 242 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 73 | 62 | 60 | 57 | 53 | 36 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 9 | 9 | 10 | 11 | 27 |
| Platinum-Based Chemotherapy | 0 | 94 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 243 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Musculoskeletal and connective tissue disorders, Arthralgia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 112 | 111 | 106 | 101 | 75 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 244 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Back pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 111 | 110 | 106 | 104 | 77 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 245 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Bone pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 246 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Musculoskeletal and connective tissue disorders, Flank pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 247 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Muscle fatigue




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 248 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Muscle spasms




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 113 | 113 | 110 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 249 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Musculoskeletal and connective tissue disorders, Muscular weakness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 112 | 112 | 109 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 250 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Musculoskeletal and connective tissue disorders, Musculoskeletal chest pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 251 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Musculoskeletal and connective tissue disorders, Musculoskeletal stiffness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 252 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Myalgia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 89 | 85 | 83 | 82 | 79 | 54 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 11 | 13 | 38 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 253 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Myositis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 254 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Neck pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 255 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Osteoporosis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 256 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Musculoskeletal and connective tissue disorders, Pain in extremity




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 112 | 112 | 108 | 105 | 79 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 257 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 113 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 13 | 15 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 258 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Adrenal neoplasm




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 259 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Benign breast neoplasm




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 260 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Neoplasms benign, malignant and unspecified (incl cysts and polyps), Bladder cancer




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 261 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Lipoma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 262 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Non-small cell lung cancer metastatic




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 263 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Skin papilloma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 264 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 95 | 87 | 83 | 78 | 74 | 55 |
| Platinum-Based Chemotherapy | 120 | 15 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 12 | 14 | 33 |
| Platinum-Based Chemotherapy | 0 | 81 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 265 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Amnesia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 266 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Anosmia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 267 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Cerebral ischaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 268 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Cognitive disorder




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 269 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Dizziness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 109 | 107 | 105 | 103 | 78 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 92 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 270 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Dysgeusia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 110 | 104 | 104 | 100 | 98 | 72 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 271 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Headache




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 112 | 106 | 104 | 100 | 98 | 74 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 40 |
| Platinum-Based Chemotherapy | 0 | 94 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 272 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Nervous system disorders, Hypoaesthesia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 273 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Hypokinesia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 274 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Lethargy




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 275 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Memory impairment




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 276 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Neuropathy peripheral




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 277 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Paraesthesia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 278 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Parosmia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 279 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Somnolence




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 113 | 110 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 280 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Taste disorder




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 113 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 281 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Nervous system disorders, Vascular encephalopathy




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 282 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 112 | 112 | 109 | 106 | 77 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 10 | 10 | 13 | 15 | 43 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 283 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Agitation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 284 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Anxiety




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 115 | 115 | 112 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 285 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Depressed mood




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 286 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Depression




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 287 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Insomnia




| Patients at risk | | | | | | | |
|---|---|---|---|---|---|---|---|
| Alectinib | 128 | 118 | 114 | 114 | 111 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| **Patients censored** | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 288 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Panic attack




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 289 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Psychiatric disorders, Restlessness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 290 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 112 | 107 | 107 | 104 | 102 | 80 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 14 | 36 |
| Platinum-Based Chemotherapy | 0 | 94 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 291 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Azotaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 292 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Dysuria




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 293 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Glycosuria




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 294 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Haematuria




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 112 | 112 | 109 | 108 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 295 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Leukocyturia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 296 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Nephrolithiasis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 297 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Nocturia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 298 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Proteinuria




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 111 | 111 | 108 | 106 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 39 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 299 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Renal failure




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 300 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Renal and urinary disorders, Renal impairment




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 301 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 110 | 109 | 104 | 103 | 76 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 302 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Atrophic vulvovaginitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 303 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Balanoposthitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 304 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Benign prostatic hyperplasia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 305 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Cervical cyst




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 306 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Cervical polyp




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 307 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Erectile dysfunction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 308 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Galactorrhoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 309 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Haemorrhagic ovarian cyst




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 310 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Hypomenorrhoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 311 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Menstruation irregular




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 312 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Prostatitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 313 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Uterine prolapse




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 314 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Vaginal discharge




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 315 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Vaginal haemorrhage




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 316 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 103 | 89 | 85 | 82 | 80 | 60 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 7 | 7 | 9 | 10 | 30 |
| Platinum-Based Chemotherapy | 0 | 83 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 317 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Asthma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 318 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Cough




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 114 | 104 | 101 | 97 | 95 | 71 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 13 | 14 | 38 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 319 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Dyspnoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 113 | 106 | 105 | 102 | 100 | 74 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 15 | 41 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 320 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Dyspnoea exertional




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 115 | 112 | 109 | 107 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 321 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Epistaxis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 113 | 113 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 322 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Hiccups




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 93 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 323 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Hydrothorax




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 324 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Nasal congestion




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 325 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Nasal dryness




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 326 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Oropharyngeal pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 327 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pleural effusion




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 115 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 13 | 15 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 328 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pneumonitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 9 | 9 | 12 | 14 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 329 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pneumothorax




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 330 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Productive cough




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 111 | 111 | 108 | 105 | 79 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 331 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pulmonary embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 332 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Rhinorrhoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 333 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Throat irritation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 334 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 89 | 75 | 70 | 66 | 63 | 45 |
| Platinum-Based Chemotherapy | 120 | 13 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 34 |
| Platinum-Based Chemotherapy | 0 | 85 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 335 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Acne




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 336 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Alopecia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 337 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Dermatitis acneiform




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 338 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Dermatitis bullous




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 339 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Drug eruption




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 340 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Dry skin




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 110 | 110 | 107 | 105 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 341 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Eczema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 113 | 112 | 109 | 107 | 81 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 342 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Erythema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 343 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Hirsutism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 344 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Nail disorder




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 345 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**

Skin and subcutaneous tissue disorders, Photosensitivity reaction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 112 | 109 | 107 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 346 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Pigmentation disorder




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 347 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Pruritus




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 118 | 112 | 111 | 106 | 103 | 75 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 348 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Psoriasis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 114 | 110 | 108 | 80 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 349 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 110 | 102 | 99 | 96 | 94 | 70 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 40 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 350 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash erythematous




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 351 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash maculo-papular




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 352 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash papular




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 353 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Scar pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 354 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Seborrhoeic dermatitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 355 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Skin atrophy




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 356 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Skin fissures




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 357 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Skin hypopigmentation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 358 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Urticaria




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 359 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Xeroderma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 360 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Surgical and medical procedures, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 361 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Surgical and medical procedures, Cataract operation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 362 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 114 | 108 | 107 | 104 | 101 | 77 |
| Platinum-Based Chemotherapy | 120 | 14 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 40 |
| Platinum-Based Chemotherapy | 0 | 89 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 363 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 364 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Essential hypertension




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 365 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Flushing




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 366 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Haematoma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 367 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Hypertension




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 113 | 113 | 110 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 368 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Hypotension




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 116 | 111 | 111 | 108 | 106 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 369 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Lymphoedema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 370 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Phlebitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 371 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Vasculitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 372 of 373

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**STUDY: BO40336**
Vascular disorders, Venous thrombosis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTAE_SE_26JUN2023_40336.pdf
26JAN2024 13:01

Page 373 of 373

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Sex

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Male | 54 | 42,2 | 8 | 14,8 | 46 | 85,2 | 64 | 53,3 | 27 | 42,2 | 37 | 57,8 | <.0001 | 0,17 | 0,07 | 0,45 | 0,0032 |
| Blood and lymphatic system disorders | | Female | 74 | 57,8 | 28 | 37,8 | 46 | 62,2 | 56 | 46,7 | 19 | 33,9 | 37 | 66,1 | 0,1168 | 0,59 | 0,30 | 1,15 | |
| Blood and lymphatic system disorders | Anaemia | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 17 | 26,6 | 47 | 73,4 | 0,0062 | 0,24 | 0,08 | 0,73 | 0,0083 |
| Blood and lymphatic system disorders | Anaemia | Female | 74 | 57,8 | 25 | 33,8 | 49 | 66,2 | 56 | 46,7 | 14 | 25,0 | 42 | 75,0 | 0,4292 | 0,74 | 0,35 | 1,56 | |
| Blood and lymphatic system disorders | Febrile neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Blood and lymphatic system disorders | Febrile neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Haemolysis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Haemolysis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Iron deficiency anaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Blood and lymphatic system disorders | Iron deficiency anaemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Blood and lymphatic system disorders | Leukopenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 6 | 9,4 | 58 | 90,6 | 0,0217 | 0,00 | 0,00 | NE | 0,2192 |
| Blood and lymphatic system disorders | Leukopenia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0453 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Myelosuppression | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Blood and lymphatic system disorders | Myelosuppression | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutropenia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 11 | 17,2 | 53 | 82,8 | 0,0060 | 0,10 | 0,01 | 0,76 | 0,9471 |
| Blood and lymphatic system disorders | Neutropenia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 8 | 14,3 | 48 | 85,7 | 0,0040 | 0,09 | 0,01 | 0,71 | |
| Blood and lymphatic system disorders | Neutrophilia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Neutrophilia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7137 | >999.99 | 0,00 | NE | 0,9972 |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Thrombocytopenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,9979 |
| Blood and lymphatic system disorders | Thrombocytopenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Thrombocytosis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | 0,9966 |
| Blood and lymphatic system disorders | Thrombocytosis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Male | 54 | 42,2 | 10 | 18,5 | 44 | 81,5 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,0800 | 3,81 | 0,76 | 19,03 | 0,8549 |
| Cardiac disorders | | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,0717 | 5,53 | 0,68 | 45,02 | |
| Cardiac disorders | Acute myocardial infarction | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Angina pectoris | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Cardiac disorders | Angina pectoris | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrial fibrillation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Cardiac disorders | Atrial fibrillation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrioventricular block first degree | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,9963 |
| Cardiac disorders | Atrioventricular block first degree | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Bradycardia | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0570 | >999.99 | 0,00 | NE | 0,9978 |
| Cardiac disorders | Bradycardia | Female | 74 | 57,8 | 6 | 8,1 | 68 | 91,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,1277 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cardiac failure | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Cardiac disorders | Cardiac failure | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cor pulmonale chronic | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Cardiac disorders | Cor pulmonale chronic | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Coronary artery disease | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Coronary artery disease | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Palpitations | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9968 |
| Cardiac disorders | Palpitations | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2185 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Pericardial effusion | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Cardiac disorders | Pericardial effusion | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Sinus bradycardia | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9965 |
| Cardiac disorders | Sinus bradycardia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Tachycardia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Cardiac disorders | Tachycardia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8341 | 0,74 | 0,05 | 11,90 | |
| Cardiac disorders | Ventricular extrasystoles | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Cardiac disorders | Ventricular extrasystoles | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Congenital, familial and genetic disorders | | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7565 | >999.99 | 0,00 | NE | 0,9974 |
| Congenital, familial and genetic disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | 1,00 | 0,00 | NE | NE |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Gilbert's syndrome | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7565 | >999.99 | 0,00 | NE | 0,9964 |
| Congenital, familial and genetic disorders | Gilbert's syndrome | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Ear and labyrinth disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,4250 |
| Ear and labyrinth disorders | | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,4329 | 0,50 | 0,08 | 2,97 | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Ear and labyrinth disorders | Deafness | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,3794 |
| Ear and labyrinth disorders | Deafness | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8382 | 0,75 | 0,05 | 11,99 | |
| Ear and labyrinth disorders | Ear pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Ear and labyrinth disorders | Ear pain | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8471 | 0,76 | 0,05 | 12,18 | |
| Ear and labyrinth disorders | Eustachian tube dysfunction | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Ear and labyrinth disorders | Eustachian tube dysfunction | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Ear and labyrinth disorders | Tinnitus | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9974 |
| Ear and labyrinth disorders | Tinnitus | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,3999 | 0,37 | 0,03 | 4,10 | |
| | | | | | | | | | | | | | | | | | | | |
| Endocrine disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9521 | 1,09 | 0,07 | 17,45 | 0,1871 |
| Endocrine disorders | | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2143 | >999.99 | 0,00 | NE | |
| Endocrine disorders | Hyperthyroidism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3126 | 0,00 | 0,00 | NE | 0,0694 |
| Endocrine disorders | Hyperthyroidism | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2143 | >999.99 | 0,00 | NE | |
| Endocrine disorders | Hypothyroidism | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9975 |
| Endocrine disorders | Hypothyroidism | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Eye disorders | | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,2888 | 0,23 | 0,01 | 3,76 | 0,1669 |
| Eye disorders | | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2795 | 3,14 | 0,35 | 28,14 | |
| Eye disorders | Dry eye | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9959 |
| Eye disorders | Dry eye | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2143 | >999.99 | 0,00 | NE | |
| Eye disorders | Episcleritis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Episcleritis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Eye irritation | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7341 | >999.99 | 0,00 | NE | 0,9972 |
| Eye disorders | Eye irritation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Lacrimation increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9958 |
| Eye disorders | Lacrimation increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Eye disorders | Photophobia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Eye disorders | Photophobia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photopsia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Photopsia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Punctate keratitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Punctate keratitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Eye disorders | Retinal detachment | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Retinal haemorrhage | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Eye disorders | Vision blurred | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,0372 |
| Eye disorders | Vision blurred | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,1277 | >999.99 | 0,00 | NE | |
| Eye disorders | Visual acuity reduced | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Visual acuity reduced | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Male | 54 | 42,2 | 33 | 61,1 | 21 | 38,9 | 64 | 53,3 | 51 | 79,7 | 13 | 20,3 | <.0001 | 0,36 | 0,23 | 0,58 | 0,3811 |
| Gastrointestinal disorders | | Female | 74 | 57,8 | 54 | 73,0 | 20 | 27,0 | 56 | 46,7 | 44 | 78,6 | 12 | 21,4 | 0,0005 | 0,47 | 0,30 | 0,72 | |
| Gastrointestinal disorders | Abdominal discomfort | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Gastrointestinal disorders | Abdominal discomfort | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2143 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal distension | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Gastrointestinal disorders | Abdominal distension | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal pain | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1218 | >999.99 | 0,00 | NE | 0,0056 |
| Gastrointestinal disorders | Abdominal pain | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,0881 | 0,18 | 0,02 | 1,64 | |
| Gastrointestinal disorders | Abdominal pain lower | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Abdominal pain lower | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain upper | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,2390 | 0,29 | 0,03 | 2,60 | 0,0652 |
| Gastrointestinal disorders | Abdominal pain upper | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8471 | 0,76 | 0,05 | 12,18 | |
| Gastrointestinal disorders | Anal haemorrhage | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Anal haemorrhage | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Anal inflammation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Anal inflammation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Chronic gastritis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Chronic gastritis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3956 | 0,15 | 0,00 | 12,03 | 0,9965 |
| Gastrointestinal disorders | Colitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | Male | 54 | 42,2 | 22 | 40,7 | 32 | 59,3 | 64 | 53,3 | 17 | 26,6 | 47 | 73,4 | 0,2620 | 1,44 | 0,76 | 2,75 | 0,4708 |
| Gastrointestinal disorders | Constipation | Female | 74 | 57,8 | 32 | 43,2 | 42 | 56,8 | 56 | 46,7 | 13 | 23,2 | 43 | 76,8 | 0,0404 | 1,97 | 1,02 | 3,80 | |
| Gastrointestinal disorders | Dental caries | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Gastrointestinal disorders | Dental caries | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Diarrhoea | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,1416 | 0,33 | 0,07 | 1,54 | 0,0663 |
| Gastrointestinal disorders | Diarrhoea | Female | 74 | 57,8 | 12 | 16,2 | 62 | 83,8 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,8045 | 1,20 | 0,29 | 4,95 | |
| Gastrointestinal disorders | Dry mouth | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | 0,2363 |
| Gastrointestinal disorders | Dry mouth | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Dyspepsia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8167 | 1,36 | 0,10 | 18,67 | 0,7671 |
| Gastrointestinal disorders | Dyspepsia | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,8971 | 0,89 | 0,14 | 5,58 | |
| Gastrointestinal disorders | Epigastric discomfort | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,4875 |
| Gastrointestinal disorders | Epigastric discomfort | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Faeces discoloured | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Gastrointestinal disorders | Faeces discoloured | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Gastrointestinal disorders | Faeces hard | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Gastrointestinal disorders | Faeces hard | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastritis | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1213 | >999.99 | 0,00 | NE | 0,9974 |
| Gastrointestinal disorders | Gastritis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastritis erosive | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastrointestinal pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2749 | >999.99 | 0,00 | NE | 0,9966 |
| Gastrointestinal disorders | Gastrointestinal pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,1144 |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0453 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Gingival pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Gastrointestinal disorders | Gingival pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival swelling | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Gastrointestinal disorders | Gingival swelling | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haematochezia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9975 |
| Gastrointestinal disorders | Haematochezia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Gastrointestinal disorders | Haemorrhoids | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,3758 |
| Gastrointestinal disorders | Haemorrhoids | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8538 | 0,77 | 0,05 | 12,33 | |
| Gastrointestinal disorders | Ileus paralytic | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Ileus paralytic | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Mouth ulceration | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9975 |
| Gastrointestinal disorders | Mouth ulceration | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Nausea | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 46 | 71,9 | 18 | 28,1 | <.0001 | 0,03 | 0,01 | 0,12 | 0,5907 |
| Gastrointestinal disorders | Nausea | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 41 | 73,2 | 15 | 26,8 | <.0001 | 0,05 | 0,02 | 0,12 | |
| Gastrointestinal disorders | Pancreatitis acute | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Pancreatitis acute | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Gastrointestinal disorders | Regurgitation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Stomatitis | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,6608 | 0,59 | 0,05 | 6,48 | 0,8719 |
| Gastrointestinal disorders | Stomatitis | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,7247 | 1,53 | 0,14 | 16,92 | |
| Gastrointestinal disorders | Toothache | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Gastrointestinal disorders | Toothache | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2471 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Umbilical hernia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Umbilical hernia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Vomiting | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 14 | 21,9 | 50 | 78,1 | 0,0012 | 0,08 | 0,01 | 0,58 | 0,4691 |
| Gastrointestinal disorders | Vomiting | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 16 | 28,6 | 40 | 71,4 | 0,0006 | 0,20 | 0,07 | 0,56 | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Male | 54 | 42,2 | 20 | 37,0 | 34 | 63,0 | 64 | 53,3 | 25 | 39,1 | 39 | 60,9 | 0,0487 | 0,51 | 0,26 | 1,01 | 0,8313 |
| General disorders and administration site conditions | | Female | 74 | 57,8 | 36 | 48,6 | 38 | 51,4 | 56 | 46,7 | 29 | 51,8 | 27 | 48,2 | 0,0264 | 0,55 | 0,32 | 0,94 | |
| General disorders and administration site conditions | Asthenia | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 9 | 14,1 | 55 | 85,9 | 0,2515 | 0,51 | 0,16 | 1,65 | 0,6706 |
| General disorders and administration site conditions | Asthenia | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 10 | 17,9 | 46 | 82,1 | 0,0816 | 0,42 | 0,15 | 1,15 | |
| General disorders and administration site conditions | Chest discomfort | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9956 |
| General disorders and administration site conditions | Chest discomfort | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,0200 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Chest pain | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1231 | >999.99 | 0,00 | NE | 0,1322 |
| General disorders and administration site conditions | Chest pain | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,4203 | 0,40 | 0,04 | 4,04 | |
| General disorders and administration site conditions | Face oedema | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9974 |
| General disorders and administration site conditions | Face oedema | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,4018 | 0,37 | 0,03 | 4,12 | |
| General disorders and administration site conditions | Fatigue | Male | 54 | 42,2 | 9 | 16,7 | 45 | 83,3 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,7042 | 0,80 | 0,26 | 2,50 | 0,2705 |
| General disorders and administration site conditions | Fatigue | Female | 74 | 57,8 | 9 | 12,2 | 65 | 87,8 | 56 | 46,7 | 9 | 16,1 | 47 | 83,9 | 0,3604 | 0,64 | 0,25 | 1,67 | |
| General disorders and administration site conditions | Gait disturbance | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Gait disturbance | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Hyperthermia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| General disorders and administration site conditions | Hyperthermia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| General disorders and administration site conditions | Ill-defined disorder | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| General disorders and administration site conditions | Ill-defined disorder | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Influenza like illness | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,4697 | 2,36 | 0,21 | 26,03 | 0,3570 |
| General disorders and administration site conditions | Influenza like illness | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| General disorders and administration site conditions | Infusion site extravasation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | | 0,9968 |
| General disorders and administration site conditions | Infusion site extravasation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Infusion site injury | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| General disorders and administration site conditions | Infusion site injury | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2568 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Localised oedema | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| General disorders and administration site conditions | Localised oedema | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Malaise | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,1359 | 0,32 | 0,07 | 1,55 | | 0,4433 |
| General disorders and administration site conditions | Malaise | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 9 | 16,1 | 47 | 83,9 | 0,0164 | 0,23 | 0,06 | 0,85 | | |
| General disorders and administration site conditions | Mucosal inflammation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| General disorders and administration site conditions | Mucosal inflammation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Non-cardiac chest pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Non-cardiac chest pain | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Oedema | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema peripheral | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,5038 |
| General disorders and administration site conditions | Oedema peripheral | Female | 74 | 57,8 | 11 | 14,9 | 63 | 85,1 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,0301 | 7,09 | 0,90 | 56,02 | | |
| General disorders and administration site conditions | Pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,5947 |
| General disorders and administration site conditions | Pain | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,7247 | 1,53 | 0,14 | 16,92 | | |
| General disorders and administration site conditions | Peripheral swelling | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9954 |
| General disorders and administration site conditions | Peripheral swelling | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,1167 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Pyrexia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,6559 | 0,58 | 0,05 | 6,43 | | 0,7128 |
| General disorders and administration site conditions | Pyrexia | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,4125 | 0,38 | 0,03 | 4,20 | | |
| General disorders and administration site conditions | Suprapubic pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Suprapubic pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Swelling face | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| General disorders and administration site conditions | Swelling face | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1213 | >999.99 | 0,00 | NE | | 0,9978 |
| Hepatobiliary disorders | | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0792 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Cholelithiasis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Hepatobiliary disorders | Cholelithiasis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hepatotoxicity | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Hepatobiliary disorders | Hepatotoxicity | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1213 | >999.99 | 0,00 | NE | | 0,9970 |
| Hepatobiliary disorders | Hyperbilirubinaemia | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Ocular icterus | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Hepatobiliary disorders | Ocular icterus | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Immune system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Immune system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Immune system disorders | Hypersensitivity | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Immune system disorders | Hypersensitivity | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Male | 54 | 42,2 | 28 | 51,9 | 26 | 48,1 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,3043 | 1,65 | 0,63 | 4,36 | | 0,7034 |
| Infections and infestations | | Female | 74 | 57,8 | 46 | 62,2 | 28 | 37,8 | 56 | 46,7 | 6 | 10,7 | 50 | 89,3 | 0,4256 | 1,49 | 0,56 | 3,96 | | |
| Infections and infestations | Acute sinusitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Acute sinusitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,8897 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Bronchiolitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Bronchiolitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Bronchitis | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Bronchitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | COVID-19 | Male | 54 | 42,2 | 13 | 24,1 | 41 | 75,9 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9017 | 1,19 | 0,07 | 19,05 | 0,2150 |
| Infections and infestations | COVID-19 | Female | 74 | 57,8 | 24 | 32,4 | 50 | 67,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,7180 | >999.99 | 0,00 | NE | |
| Infections and infestations | Chronic sinusitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Chronic sinusitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Conjunctivitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9973 |
| Infections and infestations | Conjunctivitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Cystitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Infections and infestations | Cystitis | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Infections and infestations | Folliculitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,0711 |
| Infections and infestations | Folliculitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Infections and infestations | Gastroenteritis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,8897 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Gastroenteritis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Herpes zoster | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Infections and infestations | Herpes zoster | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Infections and infestations | Infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,3923 |
| Infections and infestations | Infection | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Influenza | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0575 | >999.99 | 0,00 | NE | 0,9974 |
| Infections and infestations | Influenza | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Laryngopharyngitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Laryngopharyngitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Lower respiratory tract infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,6456 | >999.99 | 0,00 | NE | 0,9970 |
| Infections and infestations | Lower respiratory tract infection | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nail infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Nail infection | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nasopharyngitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Infections and infestations | Nasopharyngitis | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,9563 | 1,07 | 0,09 | 12,83 | |
| Infections and infestations | Otitis media | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Infections and infestations | Otitis media | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Infections and infestations | Periodontitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Infections and infestations | Periodontitis | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8002 | 0,70 | 0,04 | 11,22 | |
| Infections and infestations | Pharyngitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9039 | 1,19 | 0,07 | 19,21 | 0,3716 |
| Infections and infestations | Pharyngitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,6524 | >999.99 | 0,00 | NE | |
| Infections and infestations | Pneumonia | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2433 | >999.99 | 0,00 | NE | 0,2349 |
| Infections and infestations | Pneumonia | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Infections and infestations | Pneumonia viral | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Pneumonia viral | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Pulpitis dental | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Infections and infestations | Pulpitis dental | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8368 | 0,75 | 0,05 | 11,96 | |
| Infections and infestations | Respiratory tract infection | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Respiratory tract infection | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection viral | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9975 |
| Infections and infestations | Respiratory tract infection viral | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Rhinitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9973 |
| Infections and infestations | Rhinitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Sinusitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9961 |
| Infections and infestations | Sinusitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2471 | 0,00 | 0,00 | NE | |
| Infections and infestations | Tonsillitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Infections and infestations | Tonsillitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Infections and infestations | Upper respiratory tract infection | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | 0,2190 |
| Infections and infestations | Upper respiratory tract infection | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,7352 | 1,51 | 0,14 | 16,64 | |
| Infections and infestations | Urethritis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urethritis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urinary tract infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,2906 | 0,23 | 0,01 | 3,78 | 0,0133 |
| Infections and infestations | Urinary tract infection | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0785 | >999.99 | 0,00 | NE | |
| Infections and infestations | Urosepsis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Viral upper respiratory tract infection | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2749 | >999.99 | 0,00 | NE | 0,9975 |
| Infections and infestations | Viral upper respiratory tract infection | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Injury, poisoning and procedural complications | | Male | 54 | 42,2 | 17 | 31,5 | 37 | 68,5 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,0256 | 3,97 | 1,08 | 14,61 | 0,0305 |
| Injury, poisoning and procedural complications | | Female | 74 | 57,8 | 32 | 43,2 | 42 | 56,8 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0015 | >999.99 | 0,00 | NE | |
| Injury, poisoning and procedural complications | Accidental overdose | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Injury, poisoning and procedural complications | Accidental overdose | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Injury, poisoning and procedural complications | Accidental underdose | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Injury, poisoning and procedural complications | Accidental underdose | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9972 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,8097 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Arthropod sting | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Arthropod sting | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Contusion | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Contusion | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Extra dose administered | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Extra dose administered | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Fall | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9979 |
| Injury, poisoning and procedural complications | Fall | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Immunisation reaction | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Immunisation reaction | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Incorrect dose administered | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1221 | >999.99 | 0,00 | NE | | 0,9966 |
| Injury, poisoning and procedural complications | Incorrect dose administered | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,1291 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Intentional product misuse | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Intentional product misuse | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Limb injury | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Limb injury | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Medication error | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | 1,00 | 0,00 | NE | | NE |
| Injury, poisoning and procedural complications | Medication error | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Overdose | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9972 |
| Injury, poisoning and procedural complications | Overdose | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,7878 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Product dose omission in error | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0571 | >999.99 | 0,00 | NE | | 0,9968 |
| Injury, poisoning and procedural complications | Product dose omission in error | Female | 74 | 57,8 | 11 | 14,9 | 63 | 85,1 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3615 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Product dose omission issue | Male | 54 | 42,2 | 7 | 13,0 | 47 | 87,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0532 | >999.99 | 0,00 | NE | | 0,9973 |
| Injury, poisoning and procedural complications | Product dose omission issue | Female | 74 | 57,8 | 14 | 18,9 | 60 | 81,1 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0412 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Radius fracture | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Radius fracture | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Thermal burn | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Injury, poisoning and procedural complications | Thermal burn | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Vaccination complication | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,1303 |
| Injury, poisoning and procedural complications | Vaccination complication | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Wound complication | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9973 |
| Injury, poisoning and procedural complications | Wound complication | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Male | 54 | 42,2 | 40 | 74,1 | 14 | 25,9 | 64 | 53,3 | 24 | 37,5 | 40 | 62,5 | 0,0013 | 2,32 | 1,37 | 3,92 | | 0,5908 |
| Investigations | | Female | 74 | 57,8 | 57 | 77,0 | 17 | 23,0 | 56 | 46,7 | 21 | 37,5 | 35 | 62,5 | <.0001 | 3,07 | 1,81 | 5,20 | | |
| Investigations | Activated partial thromboplastin time prolonged | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Activated partial thromboplastin time prolonged | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Alanine aminotransferase increased | Male | 54 | 42,2 | 17 | 31,5 | 37 | 68,5 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,0073 | 4,13 | 1,35 | 12,65 | | 0,4286 |
| Investigations | Alanine aminotransferase increased | Female | 74 | 57,8 | 26 | 35,1 | 48 | 64,9 | 56 | 46,7 | 7 | 12,5 | 49 | 87,5 | 0,0683 | 2,21 | 0,92 | 5,28 | | |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1928 | 0,00 | 0,00 | NE | | 0,9974 |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Investigations | Aspartate aminotransferase increased | Male | 54 | 42,2 | 17 | 31,5 | 37 | 68,5 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,0002 | 17,69 | 2,31 | 135,35 | | 0,2430 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Aspartate aminotransferase increased | Female | 74 | 57,8 | 36 | 48,6 | 38 | 51,4 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,0001 | 5,31 | 2,04 | 13,80 | |
| Investigations | Bacterial test positive | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Investigations | Bacterial test positive | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Bile acids increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Bile acids increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Investigations | Bilirubin conjugated increased | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0567 | >999.99 | 0,00 | NE | 0,9971 |
| Investigations | Bilirubin conjugated increased | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0185 | >999.99 | 0,00 | NE | |
| Investigations | Blood alkaline phosphatase increased | Male | 54 | 42,2 | 12 | 22,2 | 42 | 77,8 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,0059 | 10,51 | 1,32 | 83,81 | 0,3775 |
| Investigations | Blood alkaline phosphatase increased | Female | 74 | 57,8 | 20 | 27,0 | 54 | 73,0 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0033 | 5,22 | 1,53 | 17,75 | |
| Investigations | Blood bilirubin increased | Male | 54 | 42,2 | 19 | 35,2 | 35 | 64,8 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | <.0001 | >999.99 | 0,00 | NE | 0,2047 |
| Investigations | Blood bilirubin increased | Female | 74 | 57,8 | 24 | 32,4 | 50 | 67,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,0001 | 17,53 | 2,35 | 130,84 | |
| Investigations | Blood bilirubin unconjugated increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | 0,9975 |
| Investigations | Blood bilirubin unconjugated increased | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3811 | >999.99 | 0,00 | NE | |
| Investigations | Blood cholesterol increased | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood cholesterol increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase MB increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Blood creatine phosphokinase MB increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatine phosphokinase increased | Male | 54 | 42,2 | 23 | 42,6 | 31 | 57,4 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | <.0001 | 37,03 | 4,96 | 276,20 | 0,2661 |
| Investigations | Blood creatine phosphokinase increased | Female | 74 | 57,8 | 32 | 43,2 | 42 | 56,8 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | <.0001 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | Male | 54 | 42,2 | 10 | 18,5 | 44 | 81,5 | 64 | 53,3 | 5 | 7,8 | 59 | 92,2 | 0,7377 | 1,23 | 0,36 | 4,16 | 0,3333 |
| Investigations | Blood creatinine increased | Female | 74 | 57,8 | 9 | 12,2 | 65 | 87,8 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,0720 | 5,53 | 0,68 | 44,96 | |
| Investigations | Blood fibrinogen increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood fibrinogen increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood lactate dehydrogenase increased | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,8129 | 1,18 | 0,30 | 4,73 | 0,9940 |
| Investigations | Blood lactate dehydrogenase increased | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,7800 | 0,76 | 0,11 | 5,37 | |
| Investigations | Blood thyroid stimulating hormone decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood thyroid stimulating hormone decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2749 | >999.99 | 0,00 | NE | 0,9975 |
| Investigations | Blood thyroid stimulating hormone increased | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood triglycerides increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood triglycerides increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood urea increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7137 | >999.99 | 0,00 | NE | 0,0928 |
| Investigations | Blood urea increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0440 | 0,00 | 0,00 | NE | |
| Investigations | Blood uric acid increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | 1,00 | 0,00 | NE | NE |
| Investigations | Blood uric acid increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Creatinine renal clearance decreased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7137 | >999.99 | 0,00 | NE | 0,0701 |
| Investigations | Creatinine renal clearance decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Investigations | Electrocardiogram Q wave abnormal | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,9963 |
| Investigations | Electrocardiogram Q wave abnormal | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram QRS complex abnormal | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,9963 |
| Investigations | Electrocardiogram QRS complex abnormal | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram QT prolonged | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Investigations | Electrocardiogram QT prolonged | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Investigations | Gamma-glutamyltransferase increased | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,5202 | 0,58 | 0,11 | 3,15 | 0,3563 |
| Investigations | Gamma-glutamyltransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,1990 | 0,25 | 0,03 | 2,44 | |
| Investigations | Glomerular filtration rate decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Glomerular filtration rate decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Heart rate increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Heart rate increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Investigations | International normalised ratio increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,1294 |
| Investigations | International normalised ratio increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Liver function test increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Liver function test increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Investigations | Lymphocyte count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1104 | 0,00 | 0,00 | NE | 0,0486 |
| Investigations | Lymphocyte count decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Investigations | Neutrophil count decreased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 10 | 15,6 | 54 | 84,4 | 0,0026 | 0,00 | 0,00 | NE | 0,9285 |
| Investigations | Neutrophil count decreased | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 11 | 19,6 | 45 | 80,4 | 0,0014 | 0,13 | 0,03 | 0,57 | |
| Investigations | Neutrophil count increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Investigations | Neutrophil count increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Platelet count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,0608 | 0,00 | 0,00 | NE | 0,0552 |
| Investigations | Platelet count decreased | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,4071 | 0,38 | 0,03 | 4,15 | |
| Investigations | Protein total decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Protein total decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Red blood cells urine positive | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Red blood cells urine positive | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Investigations | SARS-CoV-2 test positive | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Investigations | SARS-CoV-2 test positive | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,8348 | >999.99 | 0,00 | NE | |
| Investigations | Transaminases increased | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,4536 | 2,43 | 0,22 | 26,81 | 0,9974 |
| Investigations | Transaminases increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urinary occult blood positive | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Urinary occult blood positive | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Investigations | Urine ketone body present | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Urine ketone body present | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Investigations | Urobilinogen urine increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Urobilinogen urine increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Vitamin B12 decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Vitamin B12 decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Weight decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,3636 |
| Investigations | Weight decreased | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | |
| Investigations | Weight increased | Male | 54 | 42,2 | 7 | 13,0 | 47 | 87,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0267 | >999.99 | 0,00 | NE | 0,2284 |
| Investigations | Weight increased | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2645 | 3,23 | 0,37 | 28,26 | |
| Investigations | White blood cell count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 9 | 14,1 | 55 | 85,9 | 0,0045 | 0,00 | 0,00 | NE | 0,2611 |
| Investigations | White blood cell count decreased | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 14 | 25,0 | 42 | 75,0 | 0,0001 | 0,09 | 0,02 | 0,42 | |
| Investigations | White blood cell count increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,6598 | 0,59 | 0,05 | 6,47 | 0,9974 |
| Investigations | White blood cell count increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cells urine positive | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9968 |
| Investigations | White blood cells urine positive | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2202 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Male | 54 | 42,2 | 14 | 25,9 | 40 | 74,1 | 64 | 53,3 | 27 | 42,2 | 37 | 57,8 | 0,0022 | 0,33 | 0,16 | 0,69 | 0,2989 |
| Metabolism and nutrition disorders | | Female | 74 | 57,8 | 25 | 33,8 | 49 | 66,2 | 56 | 46,7 | 21 | 37,5 | 35 | 62,5 | 0,0490 | 0,53 | 0,28 | 1,01 | |
| Metabolism and nutrition disorders | Cell death | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Metabolism and nutrition disorders | Cell death | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Decreased appetite | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 20 | 31,3 | 44 | 68,8 | <.0001 | 0,05 | 0,01 | 0,37 | 0,0878 |
| Metabolism and nutrition disorders | Decreased appetite | Female | 74 | 57,8 | 6 | 8,1 | 68 | 91,9 | 56 | 46,7 | 15 | 26,8 | 41 | 73,2 | 0,0033 | 0,26 | 0,10 | 0,68 | |
| Metabolism and nutrition disorders | Electrolyte imbalance | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Metabolism and nutrition disorders | Electrolyte imbalance | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypercalcaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9952 |
| Metabolism and nutrition disorders | Hypercalcaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1020 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperchloraemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Metabolism and nutrition disorders | Hyperchloraemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypercreatininaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,1268 |
| Metabolism and nutrition disorders | Hypercreatininaemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperglycaemia | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,6271 | 0,68 | 0,14 | 3,30 | 0,1469 |
| Metabolism and nutrition disorders | Hyperglycaemia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2185 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperkalaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | 0,0303 |
| Metabolism and nutrition disorders | Hyperkalaemia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperlipidaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Metabolism and nutrition disorders | Hyperlipidaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2380 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypermagnesaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Metabolism and nutrition disorders | Hypermagnesaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypernatraemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | 0,9966 |
| Metabolism and nutrition disorders | Hypernatraemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperphosphataemia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hyperphosphataemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,2475 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2158 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperuricaemia | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,1203 | 4,82 | 0,54 | 43,24 | 0,7476 |
| Metabolism and nutrition disorders | Hyperuricaemia | Female | 74 | 57,8 | 6 | 8,1 | 68 | 91,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,6586 | 1,69 | 0,16 | 17,51 | |
| Metabolism and nutrition disorders | Hypoalbuminaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1949 | 0,00 | 0,00 | NE | 0,0706 |
| Metabolism and nutrition disorders | Hypoalbuminaemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypocalcaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | 0,9975 |
| Metabolism and nutrition disorders | Hypocalcaemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,7501 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypoglycaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hypoglycaemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypokalaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,1873 |
| Metabolism and nutrition disorders | Hypokalaemia | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypomagnesaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1935 | 0,00 | 0,00 | NE | 0,5843 |
| Metabolism and nutrition disorders | Hypomagnesaemia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,4054 | 0,28 | 0,01 | 6,33 | |
| Metabolism and nutrition disorders | Hyponatraemia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,6714 | 0,60 | 0,05 | 6,60 | 0,4565 |
| Metabolism and nutrition disorders | Hyponatraemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,3947 | 0,37 | 0,03 | 4,06 | |
| Metabolism and nutrition disorders | Hypophosphataemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Metabolism and nutrition disorders | Hypophosphataemia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypoproteinaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9961 |
| Metabolism and nutrition disorders | Hypoproteinaemia | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2039 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Polydipsia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Polydipsia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8758 | 1,24 | 0,08 | 19,06 | 0,9974 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Vitamin D deficiency | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Vitamin D deficiency | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | Male | 54 | 42,2 | 24 | 44,4 | 30 | 55,6 | 64 | 53,3 | 5 | 7,8 | 59 | 92,2 | 0,0009 | 4,70 | 1,73 | 12,76 | 0,5521 |
| Musculoskeletal and connective tissue disorders | | Female | 74 | 57,8 | 41 | 55,4 | 33 | 44,6 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | <.0001 | 7,62 | 2,68 | 21,62 | |
| Musculoskeletal and connective tissue disorders | Arthralgia | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9087 | 1,18 | 0,07 | 18,80 | 0,7659 |
| Musculoskeletal and connective tissue disorders | Arthralgia | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8616 | 0,79 | 0,05 | 11,96 | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Musculoskeletal and connective tissue disorders | Back pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,1025 |
| Musculoskeletal and connective tissue disorders | Back pain | Female | 74 | 57,8 | 6 | 8,1 | 68 | 91,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2116 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Bone pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,3512 |
| Musculoskeletal and connective tissue disorders | Bone pain | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,4084 | 0,38 | 0,03 | 4,17 | | |
| Musculoskeletal and connective tissue disorders | Flank pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,0700 |
| Musculoskeletal and connective tissue disorders | Flank pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9979 |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle spasms | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | | 0,9975 |
| Musculoskeletal and connective tissue disorders | Muscle spasms | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscular weakness | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2653 | >999.99 | 0,00 | NE | | 0,9972 |
| Musculoskeletal and connective tissue disorders | Muscular weakness | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | 1,00 | 0,00 | NE | | 0,9975 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | | 0,9975 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | Male | 54 | 42,2 | 13 | 24,1 | 41 | 75,9 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,0016 | 7,71 | 1,72 | 34,58 | | 0,0824 |
| Musculoskeletal and connective tissue disorders | Myalgia | Female | 74 | 57,8 | 23 | 31,1 | 51 | 68,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | <.0001 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Myositis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9966 |
| Musculoskeletal and connective tissue disorders | Myositis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Neck pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,1277 |
| Musculoskeletal and connective tissue disorders | Neck pain | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Osteoporosis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Musculoskeletal and connective tissue disorders | Osteoporosis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,8457 | 1,21 | 0,17 | 8,62 | | 0,1485 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,1945 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2794 | >999.99 | 0,00 | NE | | 0,9979 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2794 | >999.99 | 0,00 | NE | | 0,9966 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Nervous system disorders | | Male | 54 | 42,2 | 12 | 22,2 | 42 | 77,8 | 64 | 53,3 | 15 | 23,4 | 49 | 76,6 | 0,2764 | 0,62 | 0,26 | 1,47 | 0,0462 |
| Nervous system disorders | | Female | 74 | 57,8 | 28 | 37,8 | 46 | 62,2 | 56 | 46,7 | 9 | 16,1 | 47 | 83,9 | 0,1333 | 1,82 | 0,82 | 4,02 | |
| Nervous system disorders | Amnesia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Amnesia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Nervous system disorders | Anosmia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Nervous system disorders | Anosmia | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,8348 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Cerebral ischaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Cerebral ischaemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Cognitive disorder | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Nervous system disorders | Cognitive disorder | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,8348 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Dizziness | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 6 | 9,4 | 58 | 90,6 | 0,2157 | 0,38 | 0,08 | 1,87 | 0,6209 |
| Nervous system disorders | Dizziness | Female | 74 | 57,8 | 6 | 8,1 | 68 | 91,9 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,3046 | 0,50 | 0,13 | 1,94 | |
| Nervous system disorders | Dysgeusia | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,5103 | 1,81 | 0,30 | 10,82 | 0,4060 |
| Nervous system disorders | Dysgeusia | Female | 74 | 57,8 | 9 | 12,2 | 65 | 87,8 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,0432 | 6,45 | 0,81 | 51,55 | |
| Nervous system disorders | Headache | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 5 | 7,8 | 59 | 92,2 | 0,3611 | 0,47 | 0,09 | 2,44 | 0,0544 |
| Nervous system disorders | Headache | Female | 74 | 57,8 | 12 | 16,2 | 62 | 83,8 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,3784 | 1,82 | 0,47 | 7,06 | |
| Nervous system disorders | Hypoaesthesia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9958 |
| Nervous system disorders | Hypoaesthesia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2536 | 0,00 | 0,00 | NE | |
| Nervous system disorders | Hypokinesia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Hypokinesia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Lethargy | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Nervous system disorders | Lethargy | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Memory impairment | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Nervous system disorders | Memory impairment | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,8348 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Neuropathy peripheral | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,6469 | 0,57 | 0,05 | 6,34 | 0,2065 |
| Nervous system disorders | Neuropathy peripheral | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Nervous system disorders | Paraesthesia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,0249 | 0,00 | 0,00 | NE | 0,0358 |
| Nervous system disorders | Paraesthesia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Parosmia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Nervous system disorders | Parosmia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Somnolence | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8990 | 1,20 | 0,07 | 19,13 | 0,2520 |
| Nervous system disorders | Somnolence | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Taste disorder | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,0369 |
| Nervous system disorders | Taste disorder | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0787 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Vascular encephalopathy | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Vascular encephalopathy | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Psychiatric disorders | | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1663 | 3,01 | 0,58 | 15,51 | 0,0102 |
| Psychiatric disorders | | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 6 | 10,7 | 50 | 89,3 | 0,0058 | 0,07 | 0,01 | 0,69 | |
| Psychiatric disorders | Agitation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Psychiatric disorders | Agitation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Psychiatric disorders | Anxiety | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1270 | >999.99 | 0,00 | NE | 0,9967 |
| Psychiatric disorders | Anxiety | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Depressed mood | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Psychiatric disorders | Depressed mood | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Psychiatric disorders | Depression | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Psychiatric disorders | Depression | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Insomnia | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,5095 | 1,81 | 0,30 | 10,83 | 0,0130 |
| Psychiatric disorders | Insomnia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0455 | 0,00 | 0,00 | NE | |
| Psychiatric disorders | Panic attack | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Psychiatric disorders | Panic attack | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Psychiatric disorders | Restlessness | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Psychiatric disorders | Restlessness | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,7878 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Renal and urinary disorders | | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,7662 | 1,23 | 0,32 | 4,78 | 0,8958 |
| Renal and urinary disorders | | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,9812 | 1,02 | 0,28 | 3,66 | |
| Renal and urinary disorders | Azotaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Renal and urinary disorders | Azotaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Dysuria | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | 0,0706 |
| Renal and urinary disorders | Dysuria | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Renal and urinary disorders | Glycosuria | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Renal and urinary disorders | Glycosuria | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Renal and urinary disorders | Haematuria | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,6669 | 0,59 | 0,05 | 6,55 | 0,4051 |
| Renal and urinary disorders | Haematuria | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,4617 | 2,28 | 0,24 | 21,97 | |
| Renal and urinary disorders | Leukocyturia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | 0,9966 |
| Renal and urinary disorders | Leukocyturia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Nephrolithiasis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2909 | >999.99 | 0,00 | NE | 0,9975 |
| Renal and urinary disorders | Nephrolithiasis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Renal and urinary disorders | Nocturia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9967 |
| Renal and urinary disorders | Nocturia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,6301 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Renal and urinary disorders | Proteinuria | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,7952 | 1,41 | 0,10 | 18,98 | | 0,8816 |
| Renal and urinary disorders | Proteinuria | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2964 | 3,03 | 0,34 | 27,14 | | |
| Renal and urinary disorders | Renal failure | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Renal and urinary disorders | Renal failure | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Renal and urinary disorders | Renal impairment | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Renal and urinary disorders | Renal impairment | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2749 | >999.99 | 0,00 | NE | | 0,0943 |
| Reproductive system and breast disorders | | Female | 74 | 57,8 | 5 | 6,8 | 69 | 93,2 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,8923 | 1,13 | 0,19 | 6,77 | | |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Reproductive system and breast disorders | Balanoposthitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2749 | >999.99 | 0,00 | NE | | 0,9966 |
| Reproductive system and breast disorders | Balanoposthitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Cervical cyst | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Cervical cyst | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Cervical polyp | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Reproductive system and breast disorders | Cervical polyp | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Reproductive system and breast disorders | Erectile dysfunction | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Erectile dysfunction | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Galactorrhoea | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Reproductive system and breast disorders | Galactorrhoea | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Hypomenorrhoea | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Reproductive system and breast disorders | Hypomenorrhoea | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Reproductive system and breast disorders | Menstruation irregular | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Reproductive system and breast disorders | Menstruation irregular | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2471 | 0,00 | 0,00 | NE | | |
| Reproductive system and breast disorders | Prostatitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Prostatitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Vaginal discharge | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Vaginal discharge | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Vaginal haemorrhage | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Reproductive system and breast disorders | Vaginal haemorrhage | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Male | 54 | 42,2 | 15 | 27,8 | 39 | 72,2 | 64 | 53,3 | 13 | 20,3 | 51 | 79,7 | 0,7972 | 0,90 | 0,40 | 2,03 | | 0,1651 |
| Respiratory, thoracic and mediastinal disorders | | Female | 74 | 57,8 | 24 | 32,4 | 50 | 67,6 | 56 | 46,7 | 6 | 10,7 | 50 | 89,3 | 0,5648 | 1,34 | 0,50 | 3,60 | | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Cough | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,1145 | 4,91 | 0,55 | 43,93 | | 0,4941 |
| Respiratory, thoracic and mediastinal disorders | Cough | Female | 74 | 57,8 | 13 | 17,6 | 61 | 82,4 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,9771 | 1,02 | 0,23 | 4,50 | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1973 | 2,83 | 0,55 | 14,61 | | 0,7804 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2551 | 3,29 | 0,38 | 28,82 | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,1877 |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,9479 | 0,92 | 0,07 | 11,89 | | |
| Respiratory, thoracic and mediastinal disorders | Hiccups | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 8 | 12,5 | 56 | 87,5 | 0,0076 | 0,00 | 0,00 | NE | | 0,9973 |
| Respiratory, thoracic and mediastinal disorders | Hiccups | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,7137 | >999.99 | 0,00 | NE | | 0,9972 |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9087 | 1,18 | 0,07 | 18,80 | 0,9133 |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2758 | 0,10 | 0,00 | 7,28 | |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,2373 |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | 0,9979 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2202 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8167 | 1,36 | 0,10 | 18,67 | 0,9974 |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Productive cough | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0639 | >999.99 | 0,00 | NE | 0,9969 |
| Respiratory, thoracic and mediastinal disorders | Productive cough | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1935 | 0,00 | 0,00 | NE | 0,9969 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | Male | 54 | 42,2 | 20 | 37,0 | 34 | 63,0 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,1540 | 1,96 | 0,76 | 5,05 | 0,1015 |
| Skin and subcutaneous tissue disorders | | Female | 74 | 57,8 | 30 | 40,5 | 44 | 59,5 | 56 | 46,7 | 15 | 26,8 | 41 | 73,2 | 0,8905 | 1,05 | 0,54 | 2,03 | |
| Skin and subcutaneous tissue disorders | Acne | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Skin and subcutaneous tissue disorders | Acne | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Alopecia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1928 | 0,00 | 0,00 | NE | 0,2896 |
| Skin and subcutaneous tissue disorders | Alopecia | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,0464 | 0,18 | 0,03 | 1,15 | |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9034 | 1,19 | 0,07 | 18,98 | 0,9964 |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2559 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Drug eruption | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Drug eruption | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dry skin | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,2320 | 3,63 | 0,38 | 34,89 | 0,4748 |
| Skin and subcutaneous tissue disorders | Dry skin | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Eczema | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9142 | 1,16 | 0,07 | 18,62 | 0,3501 |
| Skin and subcutaneous tissue disorders | Eczema | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Erythema | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Skin and subcutaneous tissue disorders | Erythema | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0906 | 0,16 | 0,01 | 1,70 | |
| Skin and subcutaneous tissue disorders | Hirsutism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Skin and subcutaneous tissue disorders | Hirsutism | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,9042 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Nail disorder | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Nail disorder | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9979 |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2143 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Pruritus | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,0570 | >999.99 | 0,00 | NE | 0,0043 |
| Skin and subcutaneous tissue disorders | Pruritus | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0445 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Psoriasis | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Psoriasis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash | Male | 54 | 42,2 | 7 | 13,0 | 47 | 87,0 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,7786 | 1,25 | 0,26 | 5,97 | 0,7565 |
| Skin and subcutaneous tissue disorders | Rash | Female | 74 | 57,8 | 11 | 14,9 | 63 | 85,1 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,3626 | 1,72 | 0,53 | 5,58 | |
| Skin and subcutaneous tissue disorders | Rash erythematous | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Rash erythematous | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,1248 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Rash papular | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Skin and subcutaneous tissue disorders | Rash papular | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Scar pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Scar pain | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin atrophy | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Skin atrophy | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin fissures | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Skin fissures | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Urticaria | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9968 |
| Skin and subcutaneous tissue disorders | Urticaria | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2185 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Xeroderma | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Xeroderma | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Surgical and medical procedures | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Surgical and medical procedures | Cataract operation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | Cataract operation | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | Male | 54 | 42,2 | 5 | 9,3 | 49 | 90,7 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,1453 | 0,33 | 0,07 | 1,59 | | 0,3906 |
| Vascular disorders | | Female | 74 | 57,8 | 6 | 8,1 | 68 | 91,9 | 56 | 46,7 | 10 | 17,9 | 46 | 82,1 | 0,0471 | 0,35 | 0,12 | 1,03 | | |
| Vascular disorders | Embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1098 | 0,00 | 0,00 | NE | | 0,9961 |
| Vascular disorders | Embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Flushing | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9974 |
| Vascular disorders | Flushing | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Haematoma | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Haematoma | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Hypertension | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2718 | >999.99 | 0,00 | NE | | 0,0018 |
| Vascular disorders | Hypertension | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 6 | 10,7 | 50 | 89,3 | 0,0188 | 0,12 | 0,01 | 1,00 | | |
| Vascular disorders | Hypotension | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8937 | 1,21 | 0,08 | 19,31 | | 0,1471 |
| Vascular disorders | Hypotension | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0778 | >999.99 | 0,00 | NE | | |
| Vascular disorders | Lymphoedema | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Phlebitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9952 |
| Vascular disorders | Phlebitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Vasculitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | | 0,9974 |
| Vascular disorders | Vasculitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2471 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Venous thrombosis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Vascular disorders | Venous thrombosis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTAE_SE_26JUN2023_40336.xls
26JAN2024 16:40

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Age

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | < 65 | 101 | 78,9 | 29 | 28,7 | 72 | 71,3 | 87 | 72,5 | 31 | 35,6 | 56 | 64,4 | 0,0042 | 0,44 | 0,24 | 0,78 | 0,4781 |
| Blood and lymphatic system disorders | | >= 65 | 27 | 21,1 | 7 | 25,9 | 20 | 74,1 | 33 | 27,5 | 15 | 45,5 | 18 | 54,5 | 0,0044 | 0,21 | 0,07 | 0,68 | |
| Blood and lymphatic system disorders | Anaemia | < 65 | 101 | 78,9 | 24 | 23,8 | 77 | 76,2 | 87 | 72,5 | 22 | 25,3 | 65 | 74,7 | 0,0746 | 0,56 | 0,29 | 1,07 | 0,9319 |
| Blood and lymphatic system disorders | Anaemia | >= 65 | 27 | 21,1 | 6 | 22,2 | 21 | 77,8 | 33 | 27,5 | 9 | 27,3 | 24 | 72,7 | 0,1206 | 0,37 | 0,10 | 1,37 | |
| Blood and lymphatic system disorders | Febrile neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Blood and lymphatic system disorders | Febrile neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Haemolysis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Haemolysis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Iron deficiency anaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | 0,9967 |
| Blood and lymphatic system disorders | Iron deficiency anaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Leukopenia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0038 | 0,00 | 0,00 | NE | 0,6045 |
| Blood and lymphatic system disorders | Leukopenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1956 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Myelosuppression | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | 0,9968 |
| Blood and lymphatic system disorders | Myelosuppression | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Neutropenia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 14 | 16,1 | 73 | 83,9 | 0,0005 | 0,11 | 0,03 | 0,50 | 0,3432 |
| Blood and lymphatic system disorders | Neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,0362 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutrophilia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Neutrophilia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | |
| Blood and lymphatic system disorders | Thrombocytopenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1293 | 0,00 | 0,00 | NE | 0,9955 |
| Blood and lymphatic system disorders | Thrombocytopenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Thrombocytosis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3510 | >999.99 | 0,00 | NE | 0,9967 |
| Blood and lymphatic system disorders | Thrombocytosis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | < 65 | 101 | 78,9 | 17 | 16,8 | 84 | 83,2 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,0074 | 6,01 | 1,35 | 26,70 | 0,6188 |
| Cardiac disorders | | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Cardiac disorders | Acute myocardial infarction | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Angina pectoris | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Cardiac disorders | Angina pectoris | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrial fibrillation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | 0,9968 |
| Cardiac disorders | Atrial fibrillation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrioventricular block first degree | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Cardiac disorders | Atrioventricular block first degree | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Cardiac disorders | Bradycardia | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0211 | >999.99 | 0,00 | NE | 0,9978 |
| Cardiac disorders | Bradycardia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Cardiac failure | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Cardiac disorders | Cardiac failure | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Cor pulmonale chronic | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Cardiac disorders | Cor pulmonale chronic | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Coronary artery disease | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Coronary artery disease | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Palpitations | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1873 | >999.99 | 0,00 | NE | 0,9972 |
| Cardiac disorders | Palpitations | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Pericardial effusion | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9967 |
| Cardiac disorders | Pericardial effusion | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Sinus bradycardia | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | 0,9964 |
| Cardiac disorders | Sinus bradycardia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Tachycardia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9049 | 0,84 | 0,05 | 13,51 | 0,9971 |
| Cardiac disorders | Tachycardia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Ventricular extrasystoles | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Cardiac disorders | Ventricular extrasystoles | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Congenital, familial and genetic disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Congenital, familial and genetic disorders | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Gilbert's syndrome | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9955 |
| Congenital, familial and genetic disorders | Gilbert's syndrome | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Ear and labyrinth disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,8718 | 0,85 | 0,12 | 6,04 | 0,1979 |
| Ear and labyrinth disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1974 | 0,00 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Ear and labyrinth disorders | Deafness | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9126 | 0,86 | 0,05 | 13,69 | 0,3627 |
| Ear and labyrinth disorders | Deafness | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Ear and labyrinth disorders | Ear pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,1181 |
| Ear and labyrinth disorders | Ear pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Ear and labyrinth disorders | Eustachian tube dysfunction | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Ear and labyrinth disorders | Eustachian tube dysfunction | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Ear and labyrinth disorders | Tinnitus | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4724 | 0,43 | 0,04 | 4,70 | 0,9978 |
| Ear and labyrinth disorders | Tinnitus | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Endocrine disorders | | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,3961 | 2,57 | 0,27 | 24,73 | 0,4167 |
| Endocrine disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Endocrine disorders | Hyperthyroidism | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,6634 | 1,69 | 0,15 | 18,69 | 0,9965 |
| Endocrine disorders | Hyperthyroidism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Endocrine disorders | Hypothyroidism | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9975 |
| Endocrine disorders | Hypothyroidism | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Eye disorders | | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,7904 | 1,22 | 0,28 | 5,33 | 0,1414 |
| Eye disorders | | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Dry eye | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1860 | >999.99 | 0,00 | NE | 0,9979 |
| Eye disorders | Dry eye | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Episcleritis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Episcleritis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Eye irritation | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | 0,9963 |
| Eye disorders | Eye irritation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Lacrimation increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | 0,0675 |
| Eye disorders | Lacrimation increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photophobia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Eye disorders | Photophobia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photopsia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Photopsia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Punctate keratitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Punctate keratitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Retinal detachment | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Retinal haemorrhage | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Vision blurred | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,3815 | 2,64 | 0,27 | 25,41 | 0,9973 |
| Eye disorders | Vision blurred | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Visual acuity reduced | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Visual acuity reduced | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | < 65 | 101 | 78,9 | 67 | 66,3 | 34 | 33,7 | 87 | 72,5 | 73 | 83,9 | 14 | 16,1 | <.0001 | 0,34 | 0,23 | 0,49 | 0,0224 |
| Gastrointestinal disorders | | >= 65 | 27 | 21,1 | 20 | 74,1 | 7 | 25,9 | 33 | 27,5 | 22 | 66,7 | 11 | 33,3 | 0,5426 | 0,82 | 0,44 | 1,54 | |
| Gastrointestinal disorders | Abdominal discomfort | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1849 | >999.99 | 0,00 | NE | 0,9970 |
| Gastrointestinal disorders | Abdominal discomfort | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal distension | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Gastrointestinal disorders | Abdominal distension | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,5472 | 0,59 | 0,10 | 3,41 | 0,8139 |
| Gastrointestinal disorders | Abdominal pain | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8807 | 1,24 | 0,08 | 19,76 | |
| Gastrointestinal disorders | Abdominal pain lower | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Abdominal pain lower | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain upper | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 4 | 4,6 | 83 | 95,4 | 0,3115 | 0,43 | 0,08 | 2,33 | 0,8536 |
| Gastrointestinal disorders | Abdominal pain upper | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Anal haemorrhage | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Gastrointestinal disorders | Anal haemorrhage | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Anal inflammation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Gastrointestinal disorders | Anal inflammation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Chronic gastritis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Chronic gastritis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2998 | 0,09 | 0,00 | 9,93 | 0,9973 |
| Gastrointestinal disorders | Colitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | < 65 | 101 | 78,9 | 39 | 38,6 | 62 | 61,4 | 87 | 72,5 | 23 | 26,4 | 64 | 73,6 | 0,1461 | 1,47 | 0,87 | 2,49 | 0,2104 |
| Gastrointestinal disorders | Constipation | >= 65 | 27 | 21,1 | 15 | 55,6 | 12 | 44,4 | 33 | 27,5 | 7 | 21,2 | 26 | 78,8 | 0,0338 | 2,60 | 1,04 | 6,51 | |
| Gastrointestinal disorders | Dental caries | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Gastrointestinal disorders | Dental caries | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Diarrhoea | < 65 | 101 | 78,9 | 13 | 12,9 | 88 | 87,1 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,5173 | 0,66 | 0,18 | 2,36 | 0,2643 |
| Gastrointestinal disorders | Diarrhoea | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,6615 | 0,73 | 0,17 | 3,05 | |
| Gastrointestinal disorders | Dry mouth | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2837 | 0,00 | 0,00 | NE | 0,9959 |
| Gastrointestinal disorders | Dry mouth | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Dyspepsia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,2905 | 0,35 | 0,05 | 2,60 | 0,0397 |
| Gastrointestinal disorders | Dyspepsia | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1066 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Epigastric discomfort | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0614 | 0,00 | 0,00 | NE | 0,9965 |
| Gastrointestinal disorders | Epigastric discomfort | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Faeces discoloured | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | 0,9967 |
| Gastrointestinal disorders | Faeces discoloured | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Gastrointestinal disorders | Faeces hard | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Gastrointestinal disorders | Faeces hard | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | 0,9974 |
| Gastrointestinal disorders | Gastritis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2717 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastritis erosive | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastrointestinal pain | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Gastrointestinal disorders | Gastrointestinal pain | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2717 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0647 | 0,05 | 0,00 | 1,85 | 0,1379 |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Gastrointestinal disorders | Gingival pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival swelling | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Gastrointestinal disorders | Gingival swelling | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haematochezia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9962 |
| Gastrointestinal disorders | Haematochezia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haemorrhoids | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4859 | 0,44 | 0,04 | 4,81 | 0,9979 |
| Gastrointestinal disorders | Haemorrhoids | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Ileus paralytic | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Ileus paralytic | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Mouth ulceration | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Mouth ulceration | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Nausea | < 65 | 101 | 78,9 | 7 | 6,9 | 94 | 93,1 | 87 | 72,5 | 67 | 77,0 | 20 | 23,0 | <.0001 | 0,02 | 0,01 | 0,07 | 0,1730 |
| Gastrointestinal disorders | Nausea | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 20 | 60,6 | 13 | 39,4 | <.0001 | 0,12 | 0,04 | 0,41 | |
| Gastrointestinal disorders | Pancreatitis acute | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Gastrointestinal disorders | Pancreatitis acute | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Gastrointestinal disorders | Regurgitation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Stomatitis | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,7726 | 1,30 | 0,22 | 7,79 | 0,2226 |
| Gastrointestinal disorders | Stomatitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3747 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Toothache | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | 0,9968 |
| Gastrointestinal disorders | Toothache | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Umbilical hernia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | 0,9968 |
| Gastrointestinal disorders | Umbilical hernia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Vomiting | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 24 | 27,6 | 63 | 72,4 | <.0001 | 0,09 | 0,03 | 0,31 | 0,1519 |
| Gastrointestinal disorders | Vomiting | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 6 | 18,2 | 27 | 81,8 | 0,4033 | 0,55 | 0,14 | 2,25 | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | < 65 | 101 | 78,9 | 42 | 41,6 | 59 | 58,4 | 87 | 72,5 | 40 | 46,0 | 47 | 54,0 | 0,0036 | 0,49 | 0,30 | 0,80 | 0,1491 |
| General disorders and administration site conditions | | >= 65 | 27 | 21,1 | 14 | 51,9 | 13 | 48,1 | 33 | 27,5 | 14 | 42,4 | 19 | 57,6 | 0,8256 | 0,92 | 0,42 | 2,02 | |
| General disorders and administration site conditions | Asthenia | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 16 | 18,4 | 71 | 81,6 | 0,0033 | 0,25 | 0,09 | 0,68 | 0,0142 |
| General disorders and administration site conditions | Asthenia | >= 65 | 27 | 21,1 | 6 | 22,2 | 21 | 77,8 | 33 | 27,5 | 3 | 9,1 | 30 | 90,9 | 0,3006 | 2,10 | 0,50 | 8,80 | |
| General disorders and administration site conditions | Chest discomfort | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0609 | 0,00 | 0,00 | NE | 0,5881 |
| General disorders and administration site conditions | Chest discomfort | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Chest pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4782 | 0,43 | 0,04 | 4,75 | 0,0166 |
| General disorders and administration site conditions | Chest pain | >= 65 | 27 | 21,1 | 4 | 14,8 | 23 | 85,2 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1185 | >999.99 | 0,00 | NE | |
| General disorders and administration site conditions | Face oedema | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1266 | 0,00 | 0,00 | NE | 0,0377 |
| General disorders and administration site conditions | Face oedema | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| General disorders and administration site conditions | Fatigue | < 65 | 101 | 78,9 | 16 | 15,8 | 85 | 84,2 | 87 | 72,5 | 10 | 11,5 | 77 | 88,5 | 0,9864 | 1,01 | 0,44 | 2,33 | 0,1478 |
| General disorders and administration site conditions | Fatigue | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 6 | 18,2 | 27 | 81,8 | 0,0792 | 0,18 | 0,02 | 1,54 | |
| General disorders and administration site conditions | Gait disturbance | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Gait disturbance | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Hyperthermia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| General disorders and administration site conditions | Hyperthermia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Ill-defined disorder | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| General disorders and administration site conditions | Ill-defined disorder | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Influenza like illness | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,6557 | 1,72 | 0,16 | 18,91 | 0,9973 |
| General disorders and administration site conditions | Influenza like illness | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| General disorders and administration site conditions | Infusion site extravasation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9965 |
| General disorders and administration site conditions | Infusion site extravasation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Infusion site injury | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| General disorders and administration site conditions | Infusion site injury | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3841 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Localised oedema | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| General disorders and administration site conditions | Localised oedema | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Malaise | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 12 | 13,8 | 75 | 86,2 | 0,0137 | 0,26 | 0,08 | 0,82 | | 0,9566 |
| General disorders and administration site conditions | Malaise | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,2468 | 0,29 | 0,03 | 2,65 | | |
| General disorders and administration site conditions | Mucosal inflammation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| General disorders and administration site conditions | Mucosal inflammation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Non-cardiac chest pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| General disorders and administration site conditions | Non-cardiac chest pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Oedema | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema peripheral | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,1435 | 4,34 | 0,51 | 37,12 | | 0,2469 |
| General disorders and administration site conditions | Oedema peripheral | >= 65 | 27 | 21,1 | 5 | 18,5 | 22 | 81,5 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0234 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Pain | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,8929 | 0,87 | 0,12 | 6,20 | | 0,3036 |
| General disorders and administration site conditions | Pain | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Peripheral swelling | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0963 | >999.99 | 0,00 | NE | | 0,9960 |
| General disorders and administration site conditions | Peripheral swelling | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Pyrexia | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,5386 | 0,57 | 0,10 | 3,44 | | 0,9118 |
| General disorders and administration site conditions | Pyrexia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Suprapubic pain | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Suprapubic pain | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Swelling face | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,9967 |
| General disorders and administration site conditions | Swelling face | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0602 | >999.99 | 0,00 | NE | | 0,9978 |
| Hepatobiliary disorders | | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1145 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Cholelithiasis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,9967 |
| Hepatobiliary disorders | Cholelithiasis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hepatotoxicity | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Hepatobiliary disorders | Hepatotoxicity | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1044 | >999.99 | 0,00 | NE | | 0,9969 |
| Hepatobiliary disorders | Hyperbilirubinaemia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Ocular icterus | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Hepatobiliary disorders | Ocular icterus | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Immune system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Immune system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Immune system disorders | Hypersensitivity | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Immune system disorders | Hypersensitivity | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | < 65 | 101 | 78,9 | 58 | 57,4 | 43 | 42,6 | 87 | 72,5 | 9 | 10,3 | 78 | 89,7 | 0,4845 | 1,34 | 0,59 | 3,09 | | 0,8251 |
| Infections and infestations | | >= 65 | 27 | 21,1 | 16 | 59,3 | 11 | 40,7 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,1497 | 2,39 | 0,71 | 8,09 | | |
| Infections and infestations | Acute sinusitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Acute sinusitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Appendicitis | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Bronchiolitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Bronchiolitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Bronchitis | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Bronchitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | COVID-19 | < 65 | 101 | 78,9 | 30 | 29,7 | 71 | 70,3 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,4883 | 0,35 | 0,02 | 7,42 | 0,4212 |
| Infections and infestations | COVID-19 | >= 65 | 27 | 21,1 | 7 | 25,9 | 20 | 74,1 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Infections and infestations | Chronic sinusitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Chronic sinusitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Conjunctivitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9968 |
| Infections and infestations | Conjunctivitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Infections and infestations | Cystitis | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9962 |
| Infections and infestations | Cystitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Folliculitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9187 | 0,87 | 0,05 | 13,84 | 0,9971 |
| Infections and infestations | Folliculitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Gastroenteritis | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Gastroenteritis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Herpes zoster | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2837 | 0,00 | 0,00 | NE | 0,2299 |
| Infections and infestations | Herpes zoster | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Infection | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | 0,9960 |
| Infections and infestations | Infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Influenza | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1860 | >999.99 | 0,00 | NE | 0,9974 |
| Infections and infestations | Influenza | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Infections and infestations | Laryngopharyngitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Laryngopharyngitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Lower respiratory tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,6613 | >999.99 | 0,00 | NE | 0,9958 |
| Infections and infestations | Lower respiratory tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nail infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Nail infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nasopharyngitis | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,5805 | 0,44 | 0,02 | 8,36 | 0,3974 |
| Infections and infestations | Nasopharyngitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Infections and infestations | Otitis media | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Infections and infestations | Otitis media | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Periodontitis | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,8799 | 0,81 | 0,05 | 12,93 | 0,9977 |
| Infections and infestations | Periodontitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pharyngitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,6374 | >999.99 | 0,00 | NE | 0,3654 |
| Infections and infestations | Pharyngitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8860 | 1,23 | 0,07 | 20,09 | |
| Infections and infestations | Pneumonia | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3505 | >999.99 | 0,00 | NE | 0,1933 |
| Infections and infestations | Pneumonia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,6748 | 0,53 | 0,03 | 10,81 | |
| Infections and infestations | Pneumonia viral | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Pneumonia viral | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pulpitis dental | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9077 | 0,85 | 0,05 | 13,57 | 0,9972 |
| Infections and infestations | Pulpitis dental | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Respiratory tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection viral | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | 0,9975 |
| Infections and infestations | Respiratory tract infection viral | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Infections and infestations | Rhinitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,0618 |
| Infections and infestations | Rhinitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Sinusitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,3018 | 0,09 | 0,00 | 10,05 | 0,9974 |
| Infections and infestations | Sinusitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Tonsillitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9967 |
| Infections and infestations | Tonsillitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Upper respiratory tract infection | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,6516 | 1,73 | 0,16 | 19,04 | 0,2880 |
| Infections and infestations | Upper respiratory tract infection | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,3074 | >999.99 | 0,00 | NE | |
| Infections and infestations | Urethritis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urethritis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urinary tract infection | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,5977 | 1,87 | 0,18 | 19,65 | 0,5470 |
| Infections and infestations | Urinary tract infection | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,4302 | 2,54 | 0,23 | 28,02 | |
| Infections and infestations | Urosepsis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Viral upper respiratory tract infection | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9959 |
| Infections and infestations | Viral upper respiratory tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Injury, poisoning and procedural complications | | < 65 | 101 | 78,9 | 42 | 41,6 | 59 | 58,4 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,0005 | 8,75 | 2,04 | 37,58 | 0,5996 |
| Injury, poisoning and procedural complications | | >= 65 | 27 | 21,1 | 7 | 25,9 | 20 | 74,1 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,1951 | 4,04 | 0,42 | 39,09 | |
| Injury, poisoning and procedural complications | Accidental overdose | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3570 | >999.99 | 0,00 | NE | 0,9959 |
| Injury, poisoning and procedural complications | Accidental overdose | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Injury, poisoning and procedural complications | Accidental underdose | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Injury, poisoning and procedural complications | Accidental underdose | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,7903 | >999.99 | 0,00 | NE | 0,9963 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Arthropod sting | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Arthropod sting | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Contusion | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Contusion | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Extra dose administered | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Extra dose administered | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Fall | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1860 | >999.99 | 0,00 | NE | | 0,9972 |
| Injury, poisoning and procedural complications | Fall | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Immunisation reaction | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Immunisation reaction | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Incorrect dose administered | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0614 | >999.99 | 0,00 | NE | | 0,9966 |
| Injury, poisoning and procedural complications | Incorrect dose administered | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Intentional product misuse | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Intentional product misuse | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Limb injury | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Limb injury | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Medication error | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Medication error | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Overdose | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | | 0,9963 |
| Injury, poisoning and procedural complications | Overdose | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Product dose omission in error | < 65 | 101 | 78,9 | 15 | 14,9 | 86 | 85,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0584 | >999.99 | 0,00 | NE | | 0,9968 |
| Injury, poisoning and procedural complications | Product dose omission in error | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Product dose omission issue | < 65 | 101 | 78,9 | 16 | 15,8 | 85 | 84,2 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0117 | >999.99 | 0,00 | NE | | 0,9973 |
| Injury, poisoning and procedural complications | Product dose omission issue | >= 65 | 27 | 21,1 | 5 | 18,5 | 22 | 81,5 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2262 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Radius fracture | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Radius fracture | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Thermal burn | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Injury, poisoning and procedural complications | Thermal burn | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Vaccination complication | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,1315 |
| Injury, poisoning and procedural complications | Vaccination complication | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Wound complication | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9964 |
| Injury, poisoning and procedural complications | Wound complication | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | < 65 | 101 | 78,9 | 76 | 75,2 | 25 | 24,8 | 87 | 72,5 | 30 | 34,5 | 57 | 65,5 | <.0001 | 3,03 | 1,95 | 4,72 | | 0,3351 |
| Investigations | | >= 65 | 27 | 21,1 | 21 | 77,8 | 6 | 22,2 | 33 | 27,5 | 15 | 45,5 | 18 | 54,5 | 0,0653 | 1,91 | 0,95 | 3,85 | | |
| Investigations | Activated partial thromboplastin time prolonged | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Activated partial thromboplastin time prolonged | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Alanine aminotransferase increased | < 65 | 101 | 78,9 | 36 | 35,6 | 65 | 64,4 | 87 | 72,5 | 9 | 10,3 | 78 | 89,7 | 0,0039 | 2,89 | 1,36 | 6,15 | | 0,8178 |
| Investigations | Alanine aminotransferase increased | >= 65 | 27 | 21,1 | 7 | 25,9 | 20 | 74,1 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,2568 | 2,58 | 0,47 | 14,09 | | |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0614 | 0,00 | 0,00 | NE | | 0,9967 |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | < 65 | 101 | 78,9 | 42 | 41,6 | 59 | 58,4 | 87 | 72,5 | 6 | 6,9 | 81 | 93,1 | <.0001 | 5,53 | 2,31 | 13,25 | | 0,0514 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Aspartate aminotransferase increased | >= 65 | 27 | 21,1 | 11 | 40,7 | 16 | 59,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0003 | >999.99 | 0,00 | NE | |
| Investigations | Bacterial test positive | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Investigations | Bacterial test positive | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Investigations | Bile acids increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Bile acids increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Investigations | Bilirubin conjugated increased | < 65 | 101 | 78,9 | 10 | 9,9 | 91 | 90,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0043 | >999.99 | 0,00 | NE | 0,9971 |
| Investigations | Bilirubin conjugated increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Investigations | Blood alkaline phosphatase increased | < 65 | 101 | 78,9 | 22 | 21,8 | 79 | 78,2 | 87 | 72,5 | 4 | 4,6 | 83 | 95,4 | 0,0025 | 4,57 | 1,55 | 13,44 | 0,0435 |
| Investigations | Blood alkaline phosphatase increased | >= 65 | 27 | 21,1 | 10 | 37,0 | 17 | 63,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0019 | >999.99 | 0,00 | NE | |
| Investigations | Blood bilirubin increased | < 65 | 101 | 78,9 | 34 | 33,7 | 67 | 66,3 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | <.0001 | 28,27 | 3,84 | 207,87 | 0,4155 |
| Investigations | Blood bilirubin increased | >= 65 | 27 | 21,1 | 9 | 33,3 | 18 | 66,7 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0044 | >999.99 | 0,00 | NE | |
| Investigations | Blood bilirubin unconjugated increased | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | 0,9975 |
| Investigations | Blood bilirubin unconjugated increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2599 | >999.99 | 0,00 | NE | |
| Investigations | Blood cholesterol increased | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood cholesterol increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase MB increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Investigations | Blood creatine phosphokinase MB increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase increased | < 65 | 101 | 78,9 | 46 | 45,5 | 55 | 54,5 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | <.0001 | 53,65 | 7,34 | 391,97 | 0,5168 |
| Investigations | Blood creatine phosphokinase increased | >= 65 | 27 | 21,1 | 9 | 33,3 | 18 | 66,7 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0003 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | < 65 | 101 | 78,9 | 11 | 10,9 | 90 | 89,1 | 87 | 72,5 | 4 | 4,6 | 83 | 95,4 | 0,6884 | 1,29 | 0,37 | 4,59 | 0,3346 |
| Investigations | Blood creatinine increased | >= 65 | 27 | 21,1 | 8 | 29,6 | 19 | 70,4 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,0607 | 4,12 | 0,83 | 20,35 | |
| Investigations | Blood fibrinogen increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood fibrinogen increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood lactate dehydrogenase increased | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,9532 | 1,04 | 0,32 | 3,40 | 0,9648 |
| Investigations | Blood lactate dehydrogenase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Investigations | Blood thyroid stimulating hormone decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood thyroid stimulating hormone decreased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone increased | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | 0,9975 |
| Investigations | Blood thyroid stimulating hormone increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | |
| Investigations | Blood triglycerides increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood triglycerides increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood urea increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0593 | 0,00 | 0,00 | NE | 0,0053 |
| Investigations | Blood urea increased | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | |
| Investigations | Blood uric acid increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood uric acid increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Creatinine renal clearance decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2837 | 0,00 | 0,00 | NE | 0,0768 |
| Investigations | Creatinine renal clearance decreased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | |
| Investigations | Electrocardiogram Q wave abnormal | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Investigations | Electrocardiogram Q wave abnormal | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Investigations | Electrocardiogram QRS complex abnormal | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Investigations | Electrocardiogram QRS complex abnormal | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Investigations | Electrocardiogram QT prolonged | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Investigations | Electrocardiogram QT prolonged | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Gamma-glutamyltransferase increased | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 6 | 6,9 | 81 | 93,1 | 0,0957 | 0,28 | 0,06 | 1,39 | 0,4744 |
| Investigations | Gamma-glutamyltransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8764 | 1,25 | 0,08 | 19,91 | |
| Investigations | Glomerular filtration rate decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Glomerular filtration rate decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Heart rate increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Investigations | Heart rate increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Investigations | International normalised ratio increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | 0,9964 |
| Investigations | International normalised ratio increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Liver function test increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Liver function test increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2717 | >999.99 | 0,00 | NE | |
| Investigations | Lymphocyte count decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4826 | 0,43 | 0,04 | 4,79 | 0,4656 |
| Investigations | Lymphocyte count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Investigations | Neutrophil count decreased | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 15 | 17,2 | 72 | 82,8 | 0,0003 | 0,11 | 0,02 | 0,47 | 0,2500 |
| Investigations | Neutrophil count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 6 | 18,2 | 27 | 81,8 | 0,0207 | 0,00 | 0,00 | NE | |
| Investigations | Neutrophil count increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Investigations | Neutrophil count increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Platelet count decreased | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0609 | 0,00 | 0,00 | NE | 0,8991 |
| Investigations | Platelet count decreased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 3 | 9,1 | 30 | 90,9 | 0,3926 | 0,39 | 0,04 | 3,72 | |
| Investigations | Protein total decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Protein total decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Red blood cells urine positive | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Red blood cells urine positive | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Investigations | SARS-CoV-2 test positive | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,8055 | >999.99 | 0,00 | NE | 0,9964 |
| Investigations | SARS-CoV-2 test positive | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Transaminases increased | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | 0,0670 |
| Investigations | Transaminases increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3841 | 0,00 | 0,00 | NE | |
| Investigations | Urinary occult blood positive | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Urinary occult blood positive | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Investigations | Urine ketone body present | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9967 |
| Investigations | Urine ketone body present | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urobilinogen urine increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Urobilinogen urine increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Vitamin B12 decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Vitamin B12 decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Weight decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1274 | 0,00 | 0,00 | NE | 0,5099 |
| Investigations | Weight decreased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Investigations | Weight increased | < 65 | 101 | 78,9 | 17 | 16,8 | 84 | 83,2 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,0277 | 7,35 | 0,92 | 58,46 | 0,9970 |
| Investigations | Weight increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cell count decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 15 | 17,2 | 72 | 82,8 | <.0001 | 0,05 | 0,01 | 0,40 | 0,5441 |
| Investigations | White blood cell count decreased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 8 | 24,2 | 25 | 75,8 | 0,0257 | 0,13 | 0,02 | 1,07 | |
| Investigations | White blood cell count increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4742 | 0,43 | 0,04 | 4,71 | 0,9978 |
| Investigations | White blood cell count increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cells urine positive | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9978 |
| Investigations | White blood cells urine positive | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | < 65 | 101 | 78,9 | 27 | 26,7 | 74 | 73,3 | 87 | 72,5 | 36 | 41,4 | 51 | 58,6 | 0,0002 | 0,36 | 0,20 | 0,63 | 0,0846 |
| Metabolism and nutrition disorders | | >= 65 | 27 | 21,1 | 12 | 44,4 | 15 | 55,6 | 33 | 27,5 | 12 | 36,4 | 21 | 63,6 | 0,5042 | 0,74 | 0,30 | 1,81 | |
| Metabolism and nutrition disorders | Cell death | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | 0,9968 |
| Metabolism and nutrition disorders | Cell death | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Decreased appetite | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 25 | 28,7 | 62 | 71,3 | <.0001 | 0,12 | 0,04 | 0,34 | 0,2426 |
| Metabolism and nutrition disorders | Decreased appetite | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 10 | 30,3 | 23 | 69,7 | 0,0685 | 0,32 | 0,09 | 1,16 | |
| Metabolism and nutrition disorders | Electrolyte imbalance | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Metabolism and nutrition disorders | Electrolyte imbalance | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypercalcaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1259 | 0,00 | 0,00 | NE | 0,9955 |
| Metabolism and nutrition disorders | Hypercalcaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperchloraemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Metabolism and nutrition disorders | Hyperchloraemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypercreatininaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,1339 |
| Metabolism and nutrition disorders | Hypercreatininaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperglycaemia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,7660 | 1,31 | 0,22 | 7,85 | 0,9687 |
| Metabolism and nutrition disorders | Hyperglycaemia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,7809 | 0,73 | 0,08 | 6,54 | |
| Metabolism and nutrition disorders | Hyperkalaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | 0,0100 |
| Metabolism and nutrition disorders | Hyperkalaemia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperlipidaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2748 | 0,00 | 0,00 | NE | 0,9969 |
| Metabolism and nutrition disorders | Hyperlipidaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypermagnesaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Metabolism and nutrition disorders | Hypermagnesaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypernatraemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3510 | >999.99 | 0,00 | NE | 0,9967 |
| Metabolism and nutrition disorders | Hypernatraemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperphosphataemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hyperphosphataemia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,6499 | 1,73 | 0,16 | 19,09 | 0,9976 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperuricaemia | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,3067 | 2,28 | 0,45 | 11,58 | 0,2192 |
| Metabolism and nutrition disorders | Hyperuricaemia | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypoalbuminaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9244 | 0,87 | 0,05 | 13,98 | 0,3586 |
| Metabolism and nutrition disorders | Hypoalbuminaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypocalcaemia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,7171 | >999.99 | 0,00 | NE | 0,9970 |
| Metabolism and nutrition disorders | Hypocalcaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoglycaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hypoglycaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypokalaemia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,1922 |
| Metabolism and nutrition disorders | Hypokalaemia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1145 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypomagnesaemia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,2118 | 0,20 | 0,01 | 2,90 | 0,7934 |
| Metabolism and nutrition disorders | Hypomagnesaemia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyponatraemia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,5362 | 0,57 | 0,10 | 3,43 | 0,3334 |
| Metabolism and nutrition disorders | Hyponatraemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | 0,9963 |
| Metabolism and nutrition disorders | Hypophosphataemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoproteinaemia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1754 | >999.99 | 0,00 | NE | 0,9976 |
| Metabolism and nutrition disorders | Hypoproteinaemia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Polydipsia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Polydipsia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,3018 | 0,09 | 0,00 | 10,05 | 0,2450 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2717 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Vitamin D deficiency | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Vitamin D deficiency | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | < 65 | 101 | 78,9 | 52 | 51,5 | 49 | 48,5 | 87 | 72,5 | 9 | 10,3 | 78 | 89,7 | <.0001 | 4,44 | 2,14 | 9,19 | 0,0181 |
| Musculoskeletal and connective tissue disorders | | >= 65 | 27 | 21,1 | 13 | 48,1 | 14 | 51,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0001 | >999.99 | 0,00 | NE | |
| Musculoskeletal and connective tissue disorders | Arthralgia | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,8821 | 0,86 | 0,12 | 6,12 | 0,2620 |
| Musculoskeletal and connective tissue disorders | Arthralgia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,8312 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Musculoskeletal and connective tissue disorders | Back pain | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,3176 | 0,13 | 0,00 | 7,83 | | 0,2182 |
| Musculoskeletal and connective tissue disorders | Back pain | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1136 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Bone pain | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,2496 | 0,29 | 0,03 | 2,76 | | 0,9973 |
| Musculoskeletal and connective tissue disorders | Bone pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Flank pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9964 |
| Musculoskeletal and connective tissue disorders | Flank pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9978 |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle spasms | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,9975 |
| Musculoskeletal and connective tissue disorders | Muscle spasms | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 1,0000 | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscular weakness | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1806 | >999.99 | 0,00 | NE | | 0,9972 |
| Musculoskeletal and connective tissue disorders | Muscular weakness | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9958 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3510 | >999.99 | 0,00 | NE | | 0,9962 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | < 65 | 101 | 78,9 | 29 | 28,7 | 72 | 71,3 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | <.0001 | 12,59 | 2,98 | 53,14 | | 0,2779 |
| Musculoskeletal and connective tissue disorders | Myalgia | >= 65 | 27 | 21,1 | 7 | 25,9 | 20 | 74,1 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0019 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Myositis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Musculoskeletal and connective tissue disorders | Myositis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Neck pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9964 |
| Musculoskeletal and connective tissue disorders | Neck pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Osteoporosis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,9967 |
| Musculoskeletal and connective tissue disorders | Osteoporosis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,6699 | 1,45 | 0,26 | 8,23 | | 0,3799 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | | 0,9979 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | | 0,9967 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | | < 65 | 101 | 78,9 | 35 | 34,7 | 66 | 65,3 | 87 | 72,5 | 19 | 21,8 | 68 | 78,2 | 0,6905 | 1,13 | 0,62 | 2,07 | | 0,7170 |
| Nervous system disorders | | >= 65 | 27 | 21,1 | 5 | 18,5 | 22 | 81,5 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,9900 | 0,99 | 0,27 | 3,71 | | |
| Nervous system disorders | Amnesia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Nervous system disorders | Amnesia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Anosmia | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,8055 | >999.99 | 0,00 | NE | | 0,9972 |
| Nervous system disorders | Anosmia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Cerebral ischaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Cerebral ischaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Cognitive disorder | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,8055 | >999.99 | 0,00 | NE | | 0,9964 |
| Nervous system disorders | Cognitive disorder | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Dizziness | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 9 | 10,3 | 78 | 89,7 | 0,1055 | 0,41 | 0,13 | 1,25 | | 0,9167 |
| Nervous system disorders | Dizziness | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,6797 | 0,61 | 0,05 | 6,69 | | |
| Nervous system disorders | Dysgeusia | < 65 | 101 | 78,9 | 11 | 10,9 | 90 | 89,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,0319 | 4,55 | 1,00 | 20,72 | | 0,6493 |
| Nervous system disorders | Dysgeusia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8764 | 1,25 | 0,08 | 19,91 | | |
| Nervous system disorders | Headache | < 65 | 101 | 78,9 | 14 | 13,9 | 87 | 86,1 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,8052 | 1,13 | 0,42 | 3,05 | | 0,1999 |
| Nervous system disorders | Headache | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Nervous system disorders | Hypoaesthesia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | 0,1387 |
| Nervous system disorders | Hypoaesthesia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3747 | 0,00 | 0,00 | NE | | |
| Nervous system disorders | Hypokinesia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Hypokinesia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Lethargy | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Nervous system disorders | Lethargy | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Memory impairment | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,8055 | >999.99 | 0,00 | NE | | 0,9972 |
| Nervous system disorders | Memory impairment | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Neuropathy peripheral | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,5265 |
| Nervous system disorders | Neuropathy peripheral | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,9200 | 1,15 | 0,07 | 18,45 | | |
| Nervous system disorders | Paraesthesia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,1527 | 0,21 | 0,02 | 2,15 | | 0,5257 |
| Nervous system disorders | Paraesthesia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,2850 | 0,00 | 0,00 | NE | | |
| Nervous system disorders | Parosmia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Nervous system disorders | Parosmia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Somnolence | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,6513 | 1,73 | 0,16 | 19,05 | | 0,3460 |
| Nervous system disorders | Somnolence | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Nervous system disorders | Taste disorder | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,3854 | 2,62 | 0,27 | 25,22 | | 0,4174 |
| Nervous system disorders | Taste disorder | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Nervous system disorders | Vascular encephalopathy | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Nervous system disorders | Vascular encephalopathy | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0614 | 0,27 | 0,06 | 1,16 | | 0,1059 |
| Psychiatric disorders | | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,2056 | 3,88 | 0,40 | 37,31 | | |
| Psychiatric disorders | Agitation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Psychiatric disorders | Agitation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | Anxiety | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1877 | >999.99 | 0,00 | NE | | 0,9970 |
| Psychiatric disorders | Anxiety | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | Depressed mood | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Psychiatric disorders | Depressed mood | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3613 | 0,00 | 0,00 | NE | | |
| Psychiatric disorders | Depression | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Psychiatric disorders | Depression | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | Insomnia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0152 | 0,00 | 0,00 | NE | | 0,0030 |
| Psychiatric disorders | Insomnia | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0509 | >999.99 | 0,00 | NE | | |
| Psychiatric disorders | Panic attack | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Psychiatric disorders | Panic attack | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | Restlessness | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | | 0,9963 |
| Psychiatric disorders | Restlessness | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Renal and urinary disorders | | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 6 | 6,9 | 81 | 93,1 | 0,8503 | 1,11 | 0,38 | 3,19 | | 0,7628 |
| Renal and urinary disorders | | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,8907 | 1,15 | 0,16 | 8,16 | | |
| Renal and urinary disorders | Azotaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | | 0,9968 |
| Renal and urinary disorders | Azotaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Renal and urinary disorders | Dysuria | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9182 | 0,86 | 0,05 | 13,83 | | 0,9971 |
| Renal and urinary disorders | Dysuria | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Renal and urinary disorders | Glycosuria | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9968 |
| Renal and urinary disorders | Glycosuria | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Renal and urinary disorders | Haematuria | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,5197 | 1,73 | 0,32 | 9,47 | | 0,2098 |
| Renal and urinary disorders | Haematuria | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Renal and urinary disorders | Leukocyturia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3510 | >999.99 | 0,00 | NE | | 0,9967 |
| Renal and urinary disorders | Leukocyturia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Renal and urinary disorders | Nephrolithiasis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Renal and urinary disorders | Nephrolithiasis | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2888 | >999.99 | 0,00 | NE | | |
| Renal and urinary disorders | Nocturia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,6015 | >999.99 | 0,00 | NE | | 0,9955 |
| Renal and urinary disorders | Nocturia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Renal and urinary disorders | Proteinuria | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2170 | 3,62 | 0,41 | 32,01 | 0,4721 |
| Renal and urinary disorders | Proteinuria | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8764 | 1,25 | 0,08 | 19,91 | |
| Renal and urinary disorders | Renal failure | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2837 | 0,00 | 0,00 | NE | 0,9968 |
| Renal and urinary disorders | Renal failure | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Renal impairment | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Renal and urinary disorders | Renal impairment | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,5174 | 1,74 | 0,32 | 9,50 | 0,4332 |
| Reproductive system and breast disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9967 |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Balanoposthitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | 0,9967 |
| Reproductive system and breast disorders | Balanoposthitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical cyst | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Cervical cyst | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical polyp | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9967 |
| Reproductive system and breast disorders | Cervical polyp | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Erectile dysfunction | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Erectile dysfunction | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Galactorrhoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Reproductive system and breast disorders | Galactorrhoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Hypomenorrhoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Reproductive system and breast disorders | Hypomenorrhoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Menstruation irregular | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2776 | 0,00 | 0,00 | NE | 0,9969 |
| Reproductive system and breast disorders | Menstruation irregular | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Prostatitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Prostatitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Uterine prolapse | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Uterine prolapse | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal discharge | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Vaginal discharge | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal haemorrhage | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Reproductive system and breast disorders | Vaginal haemorrhage | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | < 65 | 101 | 78,9 | 29 | 28,7 | 72 | 71,3 | 87 | 72,5 | 15 | 17,2 | 72 | 82,8 | 0,5412 | 0,80 | 0,39 | 1,64 | 0,2338 |
| Respiratory, thoracic and mediastinal disorders | | >= 65 | 27 | 21,1 | 10 | 37,0 | 17 | 63,0 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,2644 | 2,00 | 0,58 | 6,89 | |
| Respiratory, thoracic and mediastinal disorders | Asthma | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | < 65 | 101 | 78,9 | 14 | 13,9 | 87 | 86,1 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,5956 | 1,47 | 0,35 | 6,07 | 0,6027 |
| Respiratory, thoracic and mediastinal disorders | Cough | >= 65 | 27 | 21,1 | 5 | 18,5 | 22 | 81,5 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,2048 | 3,89 | 0,40 | 37,39 | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,2395 | 2,53 | 0,51 | 12,45 | 0,8123 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | >= 65 | 27 | 21,1 | 4 | 14,8 | 23 | 85,2 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,1896 | 4,03 | 0,43 | 37,79 | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9979 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,2145 | 0,21 | 0,01 | 2,90 | 0,2032 |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Hiccups | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0151 | 0,00 | 0,00 | NE | 0,9973 |
| Respiratory, thoracic and mediastinal disorders | Hiccups | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,0638 | 0,00 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | NE |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4724 | 0,43 | 0,04 | 4,70 | | 0,2066 |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,8312 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,2327 |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | 0,9978 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1190 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9178 | 0,86 | 0,05 | 13,82 | | 0,2479 |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,7630 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Productive cough | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1037 | >999.99 | 0,00 | NE | | 0,9968 |
| Respiratory, thoracic and mediastinal disorders | Productive cough | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2980 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,9962 |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | < 65 | 101 | 78,9 | 39 | 38,6 | 62 | 61,4 | 87 | 72,5 | 17 | 19,5 | 70 | 80,5 | 0,3065 | 1,37 | 0,75 | 2,52 | | 0,4993 |
| Skin and subcutaneous tissue disorders | | >= 65 | 27 | 21,1 | 11 | 40,7 | 16 | 59,3 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,5353 | 1,45 | 0,44 | 4,79 | | |
| Skin and subcutaneous tissue disorders | Acne | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | | 0,9967 |
| Skin and subcutaneous tissue disorders | Acne | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Alopecia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0205 | 0,16 | 0,03 | 0,90 | | 0,9978 |
| Skin and subcutaneous tissue disorders | Alopecia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9154 | 0,86 | 0,05 | 13,76 | | 0,9971 |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Drug eruption | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Drug eruption | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Dry skin | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1062 | >999.99 | 0,00 | NE | | 0,3320 |
| Skin and subcutaneous tissue disorders | Dry skin | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,4549 | 2,43 | 0,22 | 26,75 | | |
| Skin and subcutaneous tissue disorders | Eczema | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,6481 | 1,74 | 0,16 | 19,15 | | 0,4030 |
| Skin and subcutaneous tissue disorders | Eczema | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Erythema | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,2504 | 0,24 | 0,02 | 3,12 | | 0,4740 |
| Skin and subcutaneous tissue disorders | Erythema | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Hirsutism | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,8618 | >999.99 | 0,00 | NE | | 0,9966 |
| Skin and subcutaneous tissue disorders | Hirsutism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Nail disorder | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Nail disorder | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1860 | >999.99 | 0,00 | NE | | 0,9966 |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Pruritus | < 65 | 101 | 78,9 | 7 | 6,9 | 94 | 93,1 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,8372 | 0,85 | 0,17 | 4,19 | | 0,3126 |
| Skin and subcutaneous tissue disorders | Pruritus | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Psoriasis | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Psoriasis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash | < 65 | 101 | 78,9 | 15 | 14,9 | 86 | 85,1 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,2862 | 1,78 | 0,61 | 5,18 | | 0,7703 |
| Skin and subcutaneous tissue disorders | Rash | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,8639 | 1,19 | 0,17 | 8,43 | | |
| Skin and subcutaneous tissue disorders | Rash erythematous | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash erythematous | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 1,0000 | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,1174 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Rash papular | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Skin and subcutaneous tissue disorders | Rash papular | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Scar pain | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Scar pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin atrophy | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Skin atrophy | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin fissures | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Skin and subcutaneous tissue disorders | Skin fissures | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3570 | >999.99 | 0,00 | NE | | 0,9967 |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Urticaria | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1873 | >999.99 | 0,00 | NE | | 0,9972 |
| Skin and subcutaneous tissue disorders | Urticaria | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Xeroderma | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Skin and subcutaneous tissue disorders | Xeroderma | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Surgical and medical procedures | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Surgical and medical procedures | Cataract operation | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | Cataract operation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 12 | 13,8 | 75 | 86,2 | 0,0616 | 0,40 | 0,15 | 1,08 | | 0,6491 |
| Vascular disorders | | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,1527 | 0,24 | 0,03 | 2,03 | | |
| Vascular disorders | Embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1292 | 0,00 | 0,00 | NE | | 0,9974 |
| Vascular disorders | Embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Essential hypertension | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Flushing | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0605 | 0,00 | 0,00 | NE | | 0,9967 |
| Vascular disorders | Flushing | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Haematoma | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Haematoma | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Hypertension | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,1730 | 0,34 | 0,07 | 1,74 | | 0,3833 |
| Vascular disorders | Hypertension | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Hypotension | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,0614 | >999.99 | 0,00 | NE | | 0,1355 |
| Vascular disorders | Hypotension | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8902 | 1,22 | 0,08 | 19,43 | | |
| Vascular disorders | Lymphoedema | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Phlebitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9955 |
| Vascular disorders | Phlebitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Vasculitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9974 |
| Vascular disorders | Vasculitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Venous thrombosis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Vascular disorders | Venous thrombosis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTAE_SE_26JUN2023_40336.xls
26JAN2024 16:40

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Geographic region

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Asia Pacific | 73 | 57,0 | 26 | 35,6 | 47 | 64,4 | 69 | 57,5 | 20 | 29,0 | 49 | 71,0 | 0,2863 | 0,70 | 0,36 | 1,35 | 0,0041 |
| Blood and lymphatic system disorders | | Europe | 53 | 41,4 | 10 | 18,9 | 43 | 81,1 | 47 | 39,2 | 24 | 51,1 | 23 | 48,9 | <.0001 | 0,14 | 0,05 | 0,37 | |
| Blood and lymphatic system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Anaemia | Asia Pacific | 73 | 57,0 | 21 | 28,8 | 52 | 71,2 | 69 | 57,5 | 13 | 18,8 | 56 | 81,2 | 0,8145 | 0,91 | 0,42 | 1,96 | 0,0430 |
| Blood and lymphatic system disorders | Anaemia | Europe | 53 | 41,4 | 9 | 17,0 | 44 | 83,0 | 47 | 39,2 | 17 | 36,2 | 30 | 63,8 | 0,0018 | 0,23 | 0,08 | 0,63 | |
| Blood and lymphatic system disorders | Anaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Febrile neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Febrile neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Febrile neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Haemolysis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Haemolysis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Haemolysis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Iron deficiency anaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Iron deficiency anaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Iron deficiency anaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Leukopenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 6 | 8,7 | 63 | 91,3 | 0,0102 | 0,00 | 0,00 | NE | 0,3570 |
| Blood and lymphatic system disorders | Leukopenia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0642 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Leukopenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Myelosuppression | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Myelosuppression | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Myelosuppression | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Neutropenia | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 7 | 10,1 | 62 | 89,9 | 0,0680 | 0,26 | 0,05 | 1,24 | 0,1467 |
| Blood and lymphatic system disorders | Neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 10 | 21,3 | 37 | 78,7 | 0,0004 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutrophilia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Neutrophilia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Blood and lymphatic system disorders | Neutrophilia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,7353 | >999.99 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Thrombocytopenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Blood and lymphatic system disorders | Thrombocytopenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1346 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Thrombocytopenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Thrombocytosis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3276 | >999.99 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Thrombocytosis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Thrombocytosis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Asia Pacific | 73 | 57,0 | 13 | 17,8 | 60 | 82,2 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,0590 | 4,00 | 0,85 | 18,93 | 0,6574 |
| Cardiac disorders | | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2149 | 3,65 | 0,41 | 32,66 | |
| Cardiac disorders | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Acute myocardial infarction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Acute myocardial infarction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Angina pectoris | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Cardiac disorders | Angina pectoris | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Angina pectoris | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrial fibrillation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Cardiac disorders | Atrial fibrillation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | |
| Cardiac disorders | Atrial fibrillation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrioventricular block first degree | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3070 | 0,00 | 0,00 | NE | 1,0000 |
| Cardiac disorders | Atrioventricular block first degree | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrioventricular block first degree | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Bradycardia | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0494 | >999.99 | 0,00 | NE | 1,0000 |
| Cardiac disorders | Bradycardia | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Bradycardia | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cardiac failure | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Cardiac disorders | Cardiac failure | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cardiac failure | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Cor pulmonale chronic | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Cardiac disorders | Cor pulmonale chronic | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cor pulmonale chronic | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Coronary artery disease | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Coronary artery disease | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Coronary artery disease | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Palpitations | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 1,0000 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Cardiac disorders | Palpitations | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Palpitations | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Pericardial effusion | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Cardiac disorders | Pericardial effusion | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Pericardial effusion | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Sinus bradycardia | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | 1,0000 |
| Cardiac disorders | Sinus bradycardia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Sinus bradycardia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Tachycardia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 0,2589 |
| Cardiac disorders | Tachycardia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3652 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Tachycardia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Ventricular extrasystoles | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Cardiac disorders | Ventricular extrasystoles | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Ventricular extrasystoles | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Congenital, familial and genetic disorders | | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | 1,0000 |
| Congenital, familial and genetic disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8864 | >999.99 | 0,00 | NE | |
| Congenital, familial and genetic disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Gilbert's syndrome | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | 1,0000 |
| Congenital, familial and genetic disorders | Gilbert's syndrome | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8864 | >999.99 | 0,00 | NE | |
| Congenital, familial and genetic disorders | Gilbert's syndrome | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Ear and labyrinth disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9721 | 0,95 | 0,06 | 15,22 | 0,8022 |
| Ear and labyrinth disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,2489 | 0,29 | 0,03 | 2,76 | |
| Ear and labyrinth disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Ear and labyrinth disorders | Deafness | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 0,1401 |
| Ear and labyrinth disorders | Deafness | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| Ear and labyrinth disorders | Deafness | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Ear and labyrinth disorders | Ear pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 0,2568 |
| Ear and labyrinth disorders | Ear pain | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Ear and labyrinth disorders | Ear pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Ear and labyrinth disorders | Eustachian tube dysfunction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Ear and labyrinth disorders | Eustachian tube dysfunction | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Ear and labyrinth disorders | Eustachian tube dysfunction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Ear and labyrinth disorders | Tinnitus | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 0,1399 |
| Ear and labyrinth disorders | Tinnitus | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| Ear and labyrinth disorders | Tinnitus | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Endocrine disorders | | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,6177 | 1,83 | 0,17 | 20,16 | 0,7843 |
| Endocrine disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Endocrine disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Endocrine disorders | Hyperthyroidism | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9307 | 0,88 | 0,06 | 14,15 | 0,6045 |
| Endocrine disorders | Hyperthyroidism | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Endocrine disorders | Hyperthyroidism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Endocrine disorders | Hypothyroidism | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Endocrine disorders | Hypothyroidism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Endocrine disorders | Hypothyroidism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Eye disorders | | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3112 | 3,02 | 0,32 | 28,35 | 0,3978 |
| Eye disorders | | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,4974 | 0,45 | 0,04 | 4,91 | |
| Eye disorders | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Dry eye | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1678 | >999.99 | 0,00 | NE | 1,0000 |
| Eye disorders | Dry eye | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Eye disorders | Dry eye | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Episcleritis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Episcleritis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Episcleritis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Eye irritation | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,7518 | >999.99 | 0,00 | NE | 1,0000 |
| Eye disorders | Eye irritation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Eye irritation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Lacrimation increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Eye disorders | Lacrimation increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | |
| Eye disorders | Lacrimation increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photophobia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Eye disorders | Photophobia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Eye disorders | Photophobia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photopsia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Photopsia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photopsia | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Eye disorders | Punctate keratitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Punctate keratitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Punctate keratitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Vision blurred | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,5921 | 1,91 | 0,17 | 21,02 | 0,7811 |
| Eye disorders | Vision blurred | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | NE |
| Eye disorders | Vision blurred | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Visual acuity reduced | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Visual acuity reduced | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Visual acuity reduced | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Asia Pacific | 73 | 57,0 | 50 | 68,5 | 23 | 31,5 | 69 | 57,5 | 56 | 81,2 | 13 | 18,8 | <.0001 | 0,36 | 0,24 | 0,56 | 0,3514 |
| Gastrointestinal disorders | | Europe | 53 | 41,4 | 35 | 66,0 | 18 | 34,0 | 47 | 39,2 | 35 | 74,5 | 12 | 25,5 | 0,0062 | 0,50 | 0,30 | 0,83 | |
| Gastrointestinal disorders | | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 4 | 100,0 | 0 | 0,0 | 0,5521 | 1,88 | 0,23 | 15,47 | |
| Gastrointestinal disorders | Abdominal discomfort | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3276 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Abdominal discomfort | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal discomfort | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal distension | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Abdominal distension | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal distension | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1555 | 0,08 | 0,00 | 3,34 | 0,7785 |
| Gastrointestinal disorders | Abdominal pain | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,7493 | 1,34 | 0,22 | 8,00 | |
| Gastrointestinal disorders | Abdominal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain lower | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Gastrointestinal disorders | Abdominal pain lower | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain lower | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain upper | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,1543 | 0,23 | 0,03 | 2,08 | 0,2651 |
| Gastrointestinal disorders | Abdominal pain upper | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9376 | 0,90 | 0,06 | 14,31 | |
| Gastrointestinal disorders | Abdominal pain upper | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Anal haemorrhage | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Anal haemorrhage | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Anal haemorrhage | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Anal inflammation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Anal inflammation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Anal inflammation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Chronic gastritis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Gastrointestinal disorders | Chronic gastritis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Chronic gastritis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Colitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | Asia Pacific | 73 | 57,0 | 32 | 43,8 | 41 | 56,2 | 69 | 57,5 | 23 | 33,3 | 46 | 66,7 | 0,2740 | 1,35 | 0,79 | 2,34 | 0,1153 |
| Gastrointestinal disorders | Constipation | Europe | 53 | 41,4 | 20 | 37,7 | 33 | 62,3 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,0236 | 2,79 | 1,10 | 7,06 | |
| Gastrointestinal disorders | Constipation | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,0177 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Dental caries | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Dental caries | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Dental caries | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Diarrhoea | Asia Pacific | 73 | 57,0 | 9 | 12,3 | 64 | 87,7 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,6894 | 0,71 | 0,13 | 3,78 | 0,2974 |
| Gastrointestinal disorders | Diarrhoea | Europe | 53 | 41,4 | 7 | 13,2 | 46 | 86,8 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,4699 | 0,64 | 0,19 | 2,15 | |
| Gastrointestinal disorders | Diarrhoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Dry mouth | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | 0,1506 |
| Gastrointestinal disorders | Dry mouth | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Dry mouth | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Dyspepsia | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9492 | 1,09 | 0,08 | 14,73 | 0,8875 |
| Gastrointestinal disorders | Dyspepsia | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,9532 | 1,06 | 0,17 | 6,66 | |
| Gastrointestinal disorders | Dyspepsia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Epigastric discomfort | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0726 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Epigastric discomfort | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Epigastric discomfort | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Faeces discoloured | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Faeces discoloured | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Faeces discoloured | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Faeces hard | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Faeces hard | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Faeces hard | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1694 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Gastritis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastritis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis erosive | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Gastrointestinal disorders | Gastritis erosive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastrointestinal pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Gastrointestinal pain | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastrointestinal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | 0,7137 |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival pain | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Gingival pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival swelling | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Gingival swelling | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gingival swelling | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haematochezia | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Haematochezia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haematochezia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haemorrhoids | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,5359 | 0,48 | 0,04 | 5,26 | 1,0000 |
| Gastrointestinal disorders | Haemorrhoids | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Haemorrhoids | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Ileus paralytic | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Gastrointestinal disorders | Ileus paralytic | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Ileus paralytic | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Mouth ulceration | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Mouth ulceration | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Mouth ulceration | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Nausea | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 49 | 71,0 | 20 | 29,0 | <.0001 | 0,02 | 0,01 | 0,09 | 0,2897 |
| Gastrointestinal disorders | Nausea | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 34 | 72,3 | 13 | 27,7 | <.0001 | 0,07 | 0,03 | 0,19 | |
| Gastrointestinal disorders | Nausea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 4 | 100,0 | 0 | 0,0 | 0,0494 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Pancreatitis acute | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Pancreatitis acute | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Pancreatitis acute | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Regurgitation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Stomatitis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,6063 | 0,63 | 0,10 | 3,75 | 0,5424 |
| Gastrointestinal disorders | Stomatitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Stomatitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Toothache | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Toothache | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Toothache | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Umbilical hernia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Umbilical hernia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2918 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Umbilical hernia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Vomiting | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 18 | 26,1 | 51 | 73,9 | 0,0002 | 0,14 | 0,04 | 0,47 | 0,8162 |
| Gastrointestinal disorders | Vomiting | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 11 | 23,4 | 36 | 76,6 | 0,0090 | 0,21 | 0,06 | 0,76 | |
| Gastrointestinal disorders | Vomiting | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Asia Pacific | 73 | 57,0 | 32 | 43,8 | 41 | 56,2 | 69 | 57,5 | 32 | 46,4 | 37 | 53,6 | 0,0669 | 0,61 | 0,36 | 1,04 | 0,9189 |
| General disorders and administration site conditions | | Europe | 53 | 41,4 | 23 | 43,4 | 30 | 56,6 | 47 | 39,2 | 20 | 42,6 | 27 | 57,4 | 0,0539 | 0,51 | 0,25 | 1,02 | |
| General disorders and administration site conditions | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,8304 | 0,76 | 0,06 | 9,89 | |
| General disorders and administration site conditions | Asthenia | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 6 | 8,7 | 63 | 91,3 | 0,4415 | 0,61 | 0,17 | 2,17 | 0,6799 |
| General disorders and administration site conditions | Asthenia | Europe | 53 | 41,4 | 9 | 17,0 | 44 | 83,0 | 47 | 39,2 | 12 | 25,5 | 35 | 74,5 | 0,0659 | 0,41 | 0,15 | 1,09 | |
| General disorders and administration site conditions | Asthenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Chest discomfort | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0740 | 0,00 | 0,00 | NE | 0,7793 |
| General disorders and administration site conditions | Chest discomfort | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Chest discomfort | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Chest pain | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,9449 | 0,93 | 0,13 | 6,65 | 0,2438 |
| General disorders and administration site conditions | Chest pain | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3445 | >999.99 | 0,00 | NE | |
| General disorders and administration site conditions | Chest pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Face oedema | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3276 | >999.99 | 0,00 | NE | 0,1394 |
| General disorders and administration site conditions | Face oedema | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1312 | 0,00 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| General disorders and administration site conditions | Face oedema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | Asia Pacific | 73 | 57,0 | 11 | 15,1 | 62 | 84,9 | 69 | 57,5 | 7 | 10,1 | 62 | 89,9 | 0,9319 | 0,96 | 0,34 | 2,69 | | 0,6646 |
| General disorders and administration site conditions | Fatigue | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 7 | 14,9 | 40 | 85,1 | 0,4129 | 0,62 | 0,20 | 1,96 | | |
| General disorders and administration site conditions | Fatigue | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,9358 | 0,91 | 0,08 | 10,04 | | |
| General disorders and administration site conditions | Gait disturbance | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| General disorders and administration site conditions | Gait disturbance | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Gait disturbance | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Hyperthermia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| General disorders and administration site conditions | Hyperthermia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Hyperthermia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Ill-defined disorder | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Ill-defined disorder | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Ill-defined disorder | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Influenza like illness | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,6000 | 1,88 | 0,17 | 20,74 | | 1,0000 |
| General disorders and administration site conditions | Influenza like illness | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Influenza like illness | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Infusion site extravasation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Infusion site extravasation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Infusion site extravasation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Infusion site injury | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3104 | 0,00 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Infusion site injury | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Infusion site injury | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Localised oedema | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| General disorders and administration site conditions | Localised oedema | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Localised oedema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Malaise | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 16 | 23,2 | 53 | 76,8 | 0,0046 | 0,26 | 0,09 | 0,71 | | 1,0000 |
| General disorders and administration site conditions | Malaise | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Malaise | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Mucosal inflammation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| General disorders and administration site conditions | Mucosal inflammation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Mucosal inflammation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Non-cardiac chest pain | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Non-cardiac chest pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Non-cardiac chest pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Oedema | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema peripheral | Asia Pacific | 73 | 57,0 | 8 | 11,0 | 65 | 89,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0156 | >999.99 | 0,00 | NE | | 0,2808 |
| General disorders and administration site conditions | Oedema peripheral | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6325 | 1,78 | 0,16 | 19,65 | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| General disorders and administration site conditions | Oedema peripheral | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Pain | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,9657 | 0,96 | 0,13 | 6,80 | | 0,4452 |
| General disorders and administration site conditions | Pain | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| General disorders and administration site conditions | Pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Peripheral swelling | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3011 | >999.99 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Peripheral swelling | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,1809 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Peripheral swelling | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Pyrexia | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,5944 | 1,90 | 0,17 | 20,94 | | 0,3666 |
| General disorders and administration site conditions | Pyrexia | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1308 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Pyrexia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Suprapubic pain | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| General disorders and administration site conditions | Suprapubic pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Suprapubic pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Swelling face | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Swelling face | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Swelling face | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | | 1,0000 |
| Hepatobiliary disorders | | Europe | 53 | 41,4 | 5 | 9,4 | 48 | 90,6 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0554 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Cholelithiasis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Hepatobiliary disorders | Cholelithiasis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Cholelithiasis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hepatotoxicity | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Hepatobiliary disorders | Hepatotoxicity | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hepatotoxicity | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | | 1,0000 |
| Hepatobiliary disorders | Hyperbilirubinaemia | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,1809 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Ocular icterus | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Hepatobiliary disorders | Ocular icterus | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Ocular icterus | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Immune system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Immune system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Immune system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Immune system disorders | Hypersensitivity | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Immune system disorders | Hypersensitivity | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Immune system disorders | Hypersensitivity | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Asia Pacific | 73 | 57,0 | 48 | 65,8 | 25 | 34,2 | 69 | 57,5 | 7 | 10,1 | 62 | 89,9 | 0,1303 | 1,98 | 0,80 | 4,88 | | 0,5976 |
| Infections and infestations | | Europe | 53 | 41,4 | 25 | 47,2 | 28 | 52,8 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,6934 | 1,25 | 0,41 | 3,86 | | |
| Infections and infestations | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Acute sinusitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Acute sinusitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Acute sinusitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Appendicitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Bronchiolitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Bronchiolitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Bronchiolitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Bronchitis | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Bronchitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Bronchitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | COVID-19 | Asia Pacific | 73 | 57,0 | 23 | 31,5 | 50 | 68,5 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | 0,0135 |
| Infections and infestations | COVID-19 | Europe | 53 | 41,4 | 14 | 26,4 | 39 | 73,6 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3196 | >999.99 | 0,00 | NE | | |
| Infections and infestations | COVID-19 | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Chronic sinusitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Chronic sinusitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Chronic sinusitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Conjunctivitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Infections and infestations | Conjunctivitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Infections and infestations | Conjunctivitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Cystitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | 1,0000 |
| Infections and infestations | Cystitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Infections and infestations | Cystitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Folliculitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9721 | 0,95 | 0,06 | 15,22 | 1,0000 |
| Infections and infestations | Folliculitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Folliculitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Gastroenteritis | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Gastroenteritis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Gastroenteritis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Herpes zoster | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3070 | 0,00 | 0,00 | NE | 1,0000 |
| Infections and infestations | Herpes zoster | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Herpes zoster | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Infection | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 0,5852 |
| Infections and infestations | Infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Influenza | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1678 | >999.99 | 0,00 | NE | 1,0000 |
| Infections and infestations | Influenza | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Infections and infestations | Influenza | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Laryngopharyngitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Laryngopharyngitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Laryngopharyngitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Lower respiratory tract infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Infections and infestations | Lower respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,6514 | >999.99 | 0,00 | NE | |
| Infections and infestations | Lower respiratory tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nail infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Nail infection | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nail infection | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nasopharyngitis | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,8556 | 1,26 | 0,10 | 15,49 | 1,0000 |
| Infections and infestations | Nasopharyngitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nasopharyngitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Otitis media | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Infections and infestations | Otitis media | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Infections and infestations | Otitis media | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Periodontitis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9173 | 0,86 | 0,05 | 13,84 | 1,0000 |
| Infections and infestations | Periodontitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Periodontitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pharyngitis | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,8602 | 1,25 | 0,10 | 15,52 | 1,0000 |
| Infections and infestations | Pharyngitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pharyngitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pneumonia | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 0,3321 |
| Infections and infestations | Pneumonia | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6014 | 0,47 | 0,03 | 8,61 | |
| Infections and infestations | Pneumonia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pneumonia viral | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Pneumonia viral | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pneumonia viral | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pulpitis dental | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9499 | 0,91 | 0,06 | 14,63 | 1,0000 |
| Infections and infestations | Pulpitis dental | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pulpitis dental | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection viral | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Infections and infestations | Respiratory tract infection viral | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Infections and infestations | Respiratory tract infection viral | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Rhinitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Infections and infestations | Rhinitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Infections and infestations | Rhinitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Sinusitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 0,2507 |
| Infections and infestations | Sinusitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Sinusitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Tonsillitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 1,0000 |
| Infections and infestations | Tonsillitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Tonsillitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Upper respiratory tract infection | Asia Pacific | 73 | 57,0 | 8 | 11,0 | 65 | 89,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,5917 | 1,91 | 0,17 | 21,03 | 0,8985 |
| Infections and infestations | Upper respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3711 | >999.99 | 0,00 | NE | |
| Infections and infestations | Upper respiratory tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urethritis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urethritis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urethritis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urinary tract infection | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0874 | >999.99 | 0,00 | NE | 0,1684 |
| Infections and infestations | Urinary tract infection | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,4980 | 0,45 | 0,04 | 4,92 | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Infections and infestations | Urinary tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Viral upper respiratory tract infection | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | | 1,0000 |
| Infections and infestations | Viral upper respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Viral upper respiratory tract infection | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Injury, poisoning and procedural complications | | Asia Pacific | 73 | 57,0 | 37 | 50,7 | 36 | 49,3 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0084 | 4,64 | 1,33 | 16,17 | | 0,4827 |
| Injury, poisoning and procedural complications | | Europe | 53 | 41,4 | 12 | 22,6 | 41 | 77,4 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0053 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Accidental overdose | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3387 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Accidental overdose | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Accidental overdose | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Accidental underdose | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Accidental underdose | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Accidental underdose | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,7697 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Arthropod sting | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Arthropod sting | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Arthropod sting | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Contusion | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Contusion | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Contusion | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Extra dose administered | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Extra dose administered | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Extra dose administered | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Fall | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Fall | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,1767 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Fall | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Immunisation reaction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Immunisation reaction | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Immunisation reaction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Incorrect dose administered | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1676 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Incorrect dose administered | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0995 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Incorrect dose administered | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Intentional product misuse | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Intentional product misuse | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Intentional product misuse | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Limb injury | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Limb injury | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Injury, poisoning and procedural complications | Limb injury | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Medication error | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Medication error | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Medication error | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Overdose | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,7518 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Overdose | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Overdose | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Product dose omission in error | Asia Pacific | 73 | 57,0 | 15 | 20,5 | 58 | 79,5 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0474 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Product dose omission in error | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Product dose omission in error | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Product dose omission issue | Asia Pacific | 73 | 57,0 | 15 | 20,5 | 58 | 79,5 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0226 | >999.99 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Product dose omission issue | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0929 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Product dose omission issue | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Radius fracture | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Radius fracture | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | 1,00 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Radius fracture | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Thermal burn | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Thermal burn | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Thermal burn | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Vaccination complication | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Vaccination complication | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Vaccination complication | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Wound complication | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Injury, poisoning and procedural complications | Wound complication | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Wound complication | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Asia Pacific | 73 | 57,0 | 64 | 87,7 | 9 | 12,3 | 69 | 57,5 | 27 | 39,1 | 42 | 60,9 | <.0001 | 3,05 | 1,89 | 4,92 | | 0,0426 |
| Investigations | | Europe | 53 | 41,4 | 31 | 58,5 | 22 | 41,5 | 47 | 39,2 | 18 | 38,3 | 29 | 61,7 | 0,0334 | 1,90 | 1,04 | 3,46 | | |
| Investigations | | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,0177 | >999.99 | 0,00 | NE | | |
| Investigations | Activated partial thromboplastin time prolonged | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Activated partial thromboplastin time prolonged | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | Activated partial thromboplastin time prolonged | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Alanine aminotransferase increased | Asia Pacific | 73 | 57,0 | 30 | 41,1 | 43 | 58,9 | 69 | 57,5 | 10 | 14,5 | 59 | 85,5 | 0,0402 | 2,16 | 1,02 | 4,59 | | 0,0758 |
| Investigations | Alanine aminotransferase increased | Europe | 53 | 41,4 | 11 | 20,8 | 42 | 79,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,0220 | 7,80 | 0,98 | 62,19 | | |
| Investigations | Alanine aminotransferase increased | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,0177 | >999.99 | 0,00 | NE | | |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0726 | 0,00 | 0,00 | NE | | 1,0000 |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | Asia Pacific | 73 | 57,0 | 38 | 52,1 | 35 | 47,9 | 69 | 57,5 | 6 | 8,7 | 63 | 91,3 | <.0001 | 5,79 | 2,40 | 13,98 | | 0,1731 |
| Investigations | Aspartate aminotransferase increased | Europe | 53 | 41,4 | 14 | 26,4 | 39 | 73,6 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0010 | >999.99 | 0,00 | NE | | |
| Investigations | Aspartate aminotransferase increased | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Investigations | Bacterial test positive | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Investigations | Bacterial test positive | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Investigations | Bacterial test positive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Bile acids increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Investigations | Bile acids increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Bile acids increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Bilirubin conjugated increased | Asia Pacific | 73 | 57,0 | 9 | 12,3 | 64 | 87,7 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0027 | >999.99 | 0,00 | NE | | 1,0000 |
| Investigations | Bilirubin conjugated increased | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Bilirubin conjugated increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood alkaline phosphatase increased | Asia Pacific | 73 | 57,0 | 19 | 26,0 | 54 | 74,0 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0031 | 5,37 | 1,55 | 18,55 | 0,8439 |
| Investigations | Blood alkaline phosphatase increased | Europe | 53 | 41,4 | 13 | 24,5 | 40 | 75,5 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,0037 | 11,19 | 1,44 | 86,72 | |
| Investigations | Blood alkaline phosphatase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood bilirubin increased | Asia Pacific | 73 | 57,0 | 31 | 42,5 | 42 | 57,5 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | <.0001 | 27,14 | 3,67 | 200,89 | 0,7514 |
| Investigations | Blood bilirubin increased | Europe | 53 | 41,4 | 12 | 22,6 | 41 | 77,4 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0017 | >999.99 | 0,00 | NE | |
| Investigations | Blood bilirubin increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood bilirubin unconjugated increased | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3242 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Blood bilirubin unconjugated increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood bilirubin unconjugated increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood cholesterol increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood cholesterol increased | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood cholesterol increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase MB increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Blood creatine phosphokinase MB increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase MB increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase increased | Asia Pacific | 73 | 57,0 | 36 | 49,3 | 37 | 50,7 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | <.0001 | >999.99 | 0,00 | NE | 0,2850 |
| Investigations | Blood creatine phosphokinase increased | Europe | 53 | 41,4 | 18 | 34,0 | 35 | 66,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | <.0001 | 19,08 | 2,51 | 144,70 | |
| Investigations | Blood creatine phosphokinase increased | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | Asia Pacific | 73 | 57,0 | 12 | 16,4 | 61 | 83,6 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,2236 | 2,26 | 0,59 | 8,75 | 0,3578 |
| Investigations | Blood creatinine increased | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,8059 | 1,20 | 0,27 | 5,28 | |
| Investigations | Blood creatinine increased | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Investigations | Blood fibrinogen increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood fibrinogen increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood fibrinogen increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood lactate dehydrogenase increased | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 5 | 7,2 | 64 | 92,8 | 0,4073 | 0,55 | 0,13 | 2,31 | 0,2841 |
| Investigations | Blood lactate dehydrogenase increased | Europe | 53 | 41,4 | 5 | 9,4 | 48 | 90,6 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,3632 | 2,74 | 0,28 | 26,31 | |
| Investigations | Blood lactate dehydrogenase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone decreased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood thyroid stimulating hormone decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone increased | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Blood thyroid stimulating hormone increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood triglycerides increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood triglycerides increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood triglycerides increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood urea increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | 0,2532 |
| Investigations | Blood urea increased | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,3644 | 0,22 | 0,01 | 6,40 | |
| Investigations | Blood urea increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood uric acid increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood uric acid increased | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood uric acid increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Creatinine renal clearance decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3070 | 0,00 | 0,00 | NE | 0,2718 |
| Investigations | Creatinine renal clearance decreased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8046 | >999.99 | 0,00 | NE | |
| Investigations | Creatinine renal clearance decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram Q wave abnormal | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3070 | 0,00 | 0,00 | NE | 1,0000 |
| Investigations | Electrocardiogram Q wave abnormal | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram Q wave abnormal | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram QRS complex abnormal | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3070 | 0,00 | 0,00 | NE | 1,0000 |
| Investigations | Electrocardiogram QRS complex abnormal | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram QRS complex abnormal | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram QT prolonged | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Investigations | Electrocardiogram QT prolonged | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Electrocardiogram QT prolonged | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Gamma-glutamyltransferase increased | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,3661 | 0,47 | 0,09 | 2,54 | 0,8281 |
| Investigations | Gamma-glutamyltransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,2547 | 0,29 | 0,03 | 2,80 | |
| Investigations | Gamma-glutamyltransferase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Glomerular filtration rate decreased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Glomerular filtration rate decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Glomerular filtration rate decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Heart rate increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3276 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Heart rate increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Heart rate increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | International normalised ratio increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | International normalised ratio increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2918 | 0,00 | 0,00 | NE | |
| Investigations | International normalised ratio increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Liver function test increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | Liver function test increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | |
| Investigations | Liver function test increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Lymphocyte count decreased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,5204 | 0,46 | 0,04 | 5,13 | 0,7032 |
| Investigations | Lymphocyte count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Investigations | Lymphocyte count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Neutrophil count decreased | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 16 | 23,2 | 53 | 76,8 | 0,0003 | 0,11 | 0,02 | 0,46 | 0,4866 |
| Investigations | Neutrophil count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,0162 | 0,00 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Neutrophil count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Neutrophil count increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Investigations | Neutrophil count increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Neutrophil count increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Platelet count decreased | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,1526 | 0,23 | 0,03 | 2,07 | 0,3826 |
| Investigations | Platelet count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| Investigations | Platelet count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Protein total decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Protein total decreased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | 1,00 | 0,00 | NE | |
| Investigations | Protein total decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Red blood cells urine positive | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Red blood cells urine positive | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Red blood cells urine positive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | SARS-CoV-2 test positive | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | SARS-CoV-2 test positive | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8864 | >999.99 | 0,00 | NE | |
| Investigations | SARS-CoV-2 test positive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Transaminases increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | Transaminases increased | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6197 | 1,82 | 0,17 | 20,07 | |
| Investigations | Transaminases increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urinary occult blood positive | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Urinary occult blood positive | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urinary occult blood positive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urine ketone body present | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Urine ketone body present | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urine ketone body present | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urobilinogen urine increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Urobilinogen urine increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Urobilinogen urine increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Vitamin B12 decreased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Vitamin B12 decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Vitamin B12 decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Weight decreased | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 0,2402 |
| Investigations | Weight decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| Investigations | Weight decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Weight increased | Asia Pacific | 73 | 57,0 | 15 | 20,5 | 58 | 79,5 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,0326 | 7,10 | 0,88 | 57,26 | 0,8966 |
| Investigations | Weight increased | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Investigations | Weight increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cell count decreased | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 16 | 23,2 | 53 | 76,8 | 0,0002 | 0,10 | 0,02 | 0,45 | 0,5081 |
| Investigations | White blood cell count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 7 | 14,9 | 40 | 85,1 | 0,0040 | 0,00 | 0,00 | NE | |
| Investigations | White blood cell count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cell count increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | 0,1535 |
| Investigations | White blood cell count increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Investigations | White blood cell count increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cells urine positive | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1709 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | White blood cells urine positive | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cells urine positive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Asia Pacific | 73 | 57,0 | 24 | 32,9 | 49 | 67,1 | 69 | 57,5 | 37 | 53,6 | 32 | 46,4 | 0,0008 | 0,41 | 0,24 | 0,70 | 0,0869 |
| Metabolism and nutrition disorders | | Europe | 53 | 41,4 | 15 | 28,3 | 38 | 71,7 | 47 | 39,2 | 10 | 21,3 | 37 | 78,7 | 0,1129 | 0,45 | 0,16 | 1,24 | |
| Metabolism and nutrition disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Cell death | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Metabolism and nutrition disorders | Cell death | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Cell death | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Decreased appetite | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 28 | 40,6 | 41 | 59,4 | <.0001 | 0,11 | 0,04 | 0,31 | 0,2914 |
| Metabolism and nutrition disorders | Decreased appetite | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,2082 | 0,42 | 0,11 | 1,69 | |
| Metabolism and nutrition disorders | Decreased appetite | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Electrolyte imbalance | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Electrolyte imbalance | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Electrolyte imbalance | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypercalcaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1408 | 0,00 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypercalcaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypercalcaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperchloraemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hyperchloraemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperchloraemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypercreatininaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypercreatininaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypercreatininaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperglycaemia | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,7530 | 1,27 | 0,28 | 5,69 | 0,9738 |
| Metabolism and nutrition disorders | Hyperglycaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,3912 | 0,23 | 0,01 | 7,08 | |
| Metabolism and nutrition disorders | Hyperglycaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperkalaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,5335 | 0,47 | 0,04 | 5,23 | 0,4248 |
| Metabolism and nutrition disorders | Hyperkalaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperkalaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperlipidaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2846 | 0,00 | 0,00 | NE | 1,0000 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Metabolism and nutrition disorders | Hyperlipidaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperlipidaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypermagnesaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypermagnesaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypermagnesaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypernatraemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3276 | >999.99 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypernatraemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypernatraemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperphosphataemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hyperphosphataemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperphosphataemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,6038 | 1,87 | 0,17 | 20,61 | 0,7174 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyperuricaemia | Asia Pacific | 73 | 57,0 | 10 | 13,7 | 63 | 86,3 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1731 | 2,89 | 0,58 | 14,35 | 0,7277 |
| Metabolism and nutrition disorders | Hyperuricaemia | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,7264 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperuricaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoalbuminaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9717 | 0,95 | 0,06 | 15,21 | 0,5782 |
| Metabolism and nutrition disorders | Hypoalbuminaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypoalbuminaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypocalcaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypocalcaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,7264 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypocalcaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoglycaemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hypoglycaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoglycaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypokalaemia | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,5887 | 1,92 | 0,17 | 21,14 | 0,7833 |
| Metabolism and nutrition disorders | Hypokalaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypokalaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypomagnesaemia | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,7199 | >999.99 | 0,00 | NE | 0,1417 |
| Metabolism and nutrition disorders | Hypomagnesaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0651 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypomagnesaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyponatraemia | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,3620 | 0,46 | 0,08 | 2,53 | 1,0000 |
| Metabolism and nutrition disorders | Hyponatraemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hyponatraemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypophosphataemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoproteinaemia | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypoproteinaemia | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3245 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypoproteinaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Polydipsia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Polydipsia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Polydipsia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 0,5933 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Vitamin D deficiency | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Vitamin D deficiency | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Vitamin D deficiency | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | Asia Pacific | 73 | 57,0 | 37 | 50,7 | 36 | 49,3 | 69 | 57,5 | 5 | 7,2 | 64 | 92,8 | <.0001 | 6,32 | 2,43 | 16,44 | 0,9921 |
| Musculoskeletal and connective tissue disorders | | Europe | 53 | 41,4 | 26 | 49,1 | 27 | 50,9 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0003 | 6,87 | 2,03 | 23,26 | |
| Musculoskeletal and connective tissue disorders | | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,2072 | 4,22 | 0,37 | 47,51 | |
| Musculoskeletal and connective tissue disorders | Arthralgia | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 0,9989 |
| Musculoskeletal and connective tissue disorders | Arthralgia | Europe | 53 | 41,4 | 5 | 9,4 | 48 | 90,6 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6082 | 1,85 | 0,17 | 20,13 | |
| Musculoskeletal and connective tissue disorders | Arthralgia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Back pain | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | 0,0839 |
| Musculoskeletal and connective tissue disorders | Back pain | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Back pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Musculoskeletal and connective tissue disorders | Bone pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1426 | 0,00 | 0,00 | NE | 0,0437 |
| Musculoskeletal and connective tissue disorders | Bone pain | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Musculoskeletal and connective tissue disorders | Bone pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Musculoskeletal and connective tissue disorders | Flank pain | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | 0,2555 |
| Musculoskeletal and connective tissue disorders | Flank pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Flank pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle spasms | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Muscle spasms | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle spasms | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscular weakness | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Muscular weakness | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3379 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscular weakness | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3276 | >999.99 | 0,00 | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | Asia Pacific | 73 | 57,0 | 20 | 27,4 | 53 | 72,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | <.0001 | 19,31 | 2,57 | 144,96 | | 0,3079 |
| Musculoskeletal and connective tissue disorders | Myalgia | Europe | 53 | 41,4 | 14 | 26,4 | 39 | 73,6 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0003 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,2072 | 4,22 | 0,37 | 47,51 | | |
| Musculoskeletal and connective tissue disorders | Myositis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Myositis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Myositis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Neck pain | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Musculoskeletal and connective tissue disorders | Neck pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Neck pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Osteoporosis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Osteoporosis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Osteoporosis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2917 | 3,13 | 0,34 | 29,05 | | 0,5820 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9376 | 0,90 | 0,06 | 14,31 | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1693 | >999.99 | 0,00 | NE | | 1,0000 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | | 1,0000 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Nervous system disorders | | Asia Pacific | 73 | 57,0 | 22 | 30,1 | 51 | 69,9 | 69 | 57,5 | 13 | 18,8 | 56 | 81,2 | 0,8129 | 1,09 | 0,52 | 2,32 | 0,9793 |
| Nervous system disorders | | Europe | 53 | 41,4 | 16 | 30,2 | 37 | 69,8 | 47 | 39,2 | 9 | 19,1 | 38 | 80,9 | 0,5404 | 1,31 | 0,55 | 3,12 | |
| Nervous system disorders | | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,7857 | 1,32 | 0,18 | 9,53 | |
| Nervous system disorders | Amnesia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Amnesia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Amnesia | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Anosmia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Nervous system disorders | Anosmia | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8864 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Anosmia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Cerebral ischaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Cerebral ischaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Nervous system disorders | Cerebral ischaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Cognitive disorder | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Cognitive disorder | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Cognitive disorder | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,4795 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Dizziness | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 6 | 8,7 | 63 | 91,3 | 0,3217 | 0,52 | 0,14 | 1,94 | 0,1320 |
| Nervous system disorders | Dizziness | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 4 | 8,5 | 43 | 91,5 | 0,1362 | 0,22 | 0,02 | 1,96 | |
| Nervous system disorders | Dizziness | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,6949 | 1,73 | 0,11 | 27,89 | |
| Nervous system disorders | Dysgeusia | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,0621 | 5,90 | 0,71 | 49,01 | 0,7854 |
| Nervous system disorders | Dysgeusia | Europe | 53 | 41,4 | 5 | 9,4 | 48 | 90,6 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,1222 | 4,66 | 0,54 | 39,99 | |
| Nervous system disorders | Dysgeusia | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 1,0000 | 1,00 | 0,05 | 18,91 | |
| Nervous system disorders | Headache | Asia Pacific | 73 | 57,0 | 8 | 11,0 | 65 | 89,0 | 69 | 57,5 | 5 | 7,2 | 64 | 92,8 | 0,9525 | 0,96 | 0,28 | 3,33 | 0,3681 |
| Nervous system disorders | Headache | Europe | 53 | 41,4 | 6 | 11,3 | 47 | 88,7 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,4753 | 1,84 | 0,34 | 10,07 | |
| Nervous system disorders | Headache | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Nervous system disorders | Hypoaesthesia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3104 | 0,00 | 0,00 | NE | 1,0000 |
| Nervous system disorders | Hypoaesthesia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Hypoaesthesia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Hypokinesia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Nervous system disorders | Hypokinesia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Hypokinesia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Lethargy | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Nervous system disorders | Lethargy | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Lethargy | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Memory impairment | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Nervous system disorders | Memory impairment | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Nervous system disorders | Memory impairment | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,4795 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Neuropathy peripheral | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9680 | 0,94 | 0,06 | 15,10 | 0,9262 |
| Nervous system disorders | Neuropathy peripheral | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1232 | 0,00 | 0,00 | NE | |
| Nervous system disorders | Neuropathy peripheral | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Paraesthesia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 0,8907 |
| Nervous system disorders | Paraesthesia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,2440 | 0,28 | 0,03 | 2,73 | |
| Nervous system disorders | Paraesthesia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,3173 | 0,00 | 0,00 | NE | |
| Nervous system disorders | Parosmia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Nervous system disorders | Parosmia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Parosmia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Somnolence | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 0,1084 |
| Nervous system disorders | Somnolence | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0996 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Somnolence | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Taste disorder | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9721 | 0,95 | 0,06 | 15,22 | 0,3381 |
| Nervous system disorders | Taste disorder | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,0995 | >999.99 | 0,00 | NE | |
| Nervous system disorders | Taste disorder | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Vascular encephalopathy | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Nervous system disorders | Vascular encephalopathy | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Nervous system disorders | Vascular encephalopathy | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Psychiatric disorders | | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 7 | 10,1 | 62 | 89,9 | 0,2996 | 0,53 | 0,15 | 1,80 | 0,8202 |
| Psychiatric disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9973 | 1,00 | 0,07 | 14,00 | |
| Psychiatric disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Agitation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Psychiatric disorders | Agitation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Agitation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Anxiety | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3387 | >999.99 | 0,00 | NE | 1,0000 |
| Psychiatric disorders | Anxiety | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | |
| Psychiatric disorders | Anxiety | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Depressed mood | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | 1,0000 |
| Psychiatric disorders | Depressed mood | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Depressed mood | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Depression | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Psychiatric disorders | Depression | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Depression | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Insomnia | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 5 | 7,2 | 64 | 92,8 | 0,4275 | 0,56 | 0,13 | 2,36 | 1,0000 |
| Psychiatric disorders | Insomnia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Insomnia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Panic attack | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Psychiatric disorders | Panic attack | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Psychiatric disorders | Panic attack | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Psychiatric disorders | Restlessness | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Psychiatric disorders | Restlessness | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8046 | >999.99 | 0,00 | NE | |
| Psychiatric disorders | Restlessness | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Renal and urinary disorders | | Asia Pacific | 73 | 57,0 | 9 | 12,3 | 64 | 87,7 | 69 | 57,5 | 7 | 10,1 | 62 | 89,9 | 0,9790 | 1,01 | 0,37 | 2,79 | 0,8017 |
| Renal and urinary disorders | | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6431 | 1,75 | 0,16 | 19,31 | |
| Renal and urinary disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Azotaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 1,0000 |
| Renal and urinary disorders | Azotaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Azotaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Dysuria | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3242 | >999.99 | 0,00 | NE | 0,2382 |
| Renal and urinary disorders | Dysuria | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Renal and urinary disorders | Dysuria | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Glycosuria | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | 1,0000 |
| Renal and urinary disorders | Glycosuria | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Glycosuria | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Haematuria | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,9341 | 0,93 | 0,19 | 4,63 | 0,5460 |
| Renal and urinary disorders | Haematuria | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Renal and urinary disorders | Haematuria | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Leukocyturia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Renal and urinary disorders | Leukocyturia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Renal and urinary disorders | Leukocyturia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Nephrolithiasis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Renal and urinary disorders | Nephrolithiasis | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3594 | >999.99 | 0,00 | NE | |
| Renal and urinary disorders | Nephrolithiasis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Nocturia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,6024 | >999.99 | 0,00 | NE | 1,0000 |
| Renal and urinary disorders | Nocturia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Nocturia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Proteinuria | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,2640 | 2,46 | 0,48 | 12,53 | 1,0000 |
| Renal and urinary disorders | Proteinuria | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Proteinuria | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Renal failure | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3070 | 0,00 | 0,00 | NE | 1,0000 |
| Renal and urinary disorders | Renal failure | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Renal failure | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Renal impairment | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Renal and urinary disorders | Renal impairment | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Renal impairment | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,7048 | 1,41 | 0,24 | 8,44 | 0,3559 |
| Reproductive system and breast disorders | | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Reproductive system and breast disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 1,0000 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Balanoposthitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Reproductive system and breast disorders | Balanoposthitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Balanoposthitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical cyst | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Cervical cyst | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical cyst | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical polyp | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 1,0000 |
| Reproductive system and breast disorders | Cervical polyp | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical polyp | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Erectile dysfunction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Erectile dysfunction | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Erectile dysfunction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Galactorrhoea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Reproductive system and breast disorders | Galactorrhoea | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Reproductive system and breast disorders | Galactorrhoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Hypomenorrhoea | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Reproductive system and breast disorders | Hypomenorrhoea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Hypomenorrhoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Menstruation irregular | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2960 | 0,00 | 0,00 | NE | 1,0000 |
| Reproductive system and breast disorders | Menstruation irregular | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Menstruation irregular | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Prostatitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Prostatitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Prostatitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Uterine prolapse | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Uterine prolapse | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Reproductive system and breast disorders | Uterine prolapse | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal discharge | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Vaginal discharge | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal discharge | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal haemorrhage | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Reproductive system and breast disorders | Vaginal haemorrhage | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal haemorrhage | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Asia Pacific | 73 | 57,0 | 19 | 26,0 | 54 | 74,0 | 69 | 57,5 | 12 | 17,4 | 57 | 82,6 | 0,9523 | 1,02 | 0,47 | 2,24 | 0,4884 |
| Respiratory, thoracic and mediastinal disorders | | Europe | 53 | 41,4 | 19 | 35,8 | 34 | 64,2 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,9598 | 0,97 | 0,33 | 2,86 | |
| Respiratory, thoracic and mediastinal disorders | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,6171 | 2,00 | 0,13 | 31,97 | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,7691 | 1,25 | 0,28 | 5,59 | 0,2481 |
| Respiratory, thoracic and mediastinal disorders | Cough | Europe | 53 | 41,4 | 11 | 20,8 | 42 | 79,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,3569 | 2,77 | 0,29 | 26,45 | |
| Respiratory, thoracic and mediastinal disorders | Cough | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,1902 | 3,89 | 0,43 | 34,79 | 0,2743 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Europe | 53 | 41,4 | 8 | 15,1 | 45 | 84,9 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,1071 | 4,91 | 0,58 | 41,33 | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,3173 | 0,00 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3107 | >999.99 | 0,00 | NE | 0,0316 |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Hiccups | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 8 | 11,6 | 61 | 88,4 | 0,0029 | 0,00 | 0,00 | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Hiccups | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Hiccups | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8046 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9641 | 0,94 | 0,06 | 15,00 | | 0,9238 |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,3252 | 0,13 | 0,00 | 8,10 | | |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9641 | 0,94 | 0,06 | 15,00 | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9631 | 0,94 | 0,06 | 14,98 | | 0,6122 |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8864 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Productive cough | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0502 | >999.99 | 0,00 | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Productive cough | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Productive cough | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1382 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | Asia Pacific | 73 | 57,0 | 33 | 45,2 | 40 | 54,8 | 69 | 57,5 | 13 | 18,8 | 56 | 81,2 | 0,0582 | 1,90 | 0,97 | 3,74 | | 0,0791 |
| Skin and subcutaneous tissue disorders | | Europe | 53 | 41,4 | 15 | 28,3 | 38 | 71,7 | 47 | 39,2 | 9 | 19,1 | 38 | 80,9 | 0,4347 | 0,68 | 0,26 | 1,78 | | |
| Skin and subcutaneous tissue disorders | | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Acne | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Acne | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Acne | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Alopecia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0718 | 0,00 | 0,00 | NE | 0,2772 |
| Skin and subcutaneous tissue disorders | Alopecia | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 4 | 8,5 | 43 | 91,5 | 0,1358 | 0,24 | 0,03 | 1,82 | |
| Skin and subcutaneous tissue disorders | Alopecia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9680 | 0,94 | 0,06 | 15,10 | 1,0000 |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Drug eruption | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Drug eruption | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Drug eruption | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dry skin | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,1934 | 3,85 | 0,43 | 34,49 | 0,8543 |
| Skin and subcutaneous tissue disorders | Dry skin | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Dry skin | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Eczema | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,5981 | 1,89 | 0,17 | 20,80 | 0,5646 |
| Skin and subcutaneous tissue disorders | Eczema | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Eczema | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Erythema | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Erythema | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,1328 | 0,19 | 0,02 | 2,01 | |
| Skin and subcutaneous tissue disorders | Erythema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Hirsutism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Hirsutism | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,8864 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Hirsutism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Nail disorder | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Nail disorder | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Nail disorder | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,1767 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Pruritus | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,9432 | 0,93 | 0,13 | 6,61 | 0,7401 |
| Skin and subcutaneous tissue disorders | Pruritus | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9262 | 0,88 | 0,05 | 14,02 | |
| Skin and subcutaneous tissue disorders | Pruritus | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Psoriasis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Psoriasis | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Psoriasis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash | Asia Pacific | 73 | 57,0 | 15 | 20,5 | 58 | 79,5 | 69 | 57,5 | 5 | 7,2 | 64 | 92,8 | 0,2025 | 1,98 | 0,68 | 5,79 | 0,7507 |
| Skin and subcutaneous tissue disorders | Rash | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,8939 | 0,87 | 0,12 | 6,21 | |
| Skin and subcutaneous tissue disorders | Rash | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash erythematous | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Rash erythematous | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash erythematous | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9641 | 0,94 | 0,06 | 15,00 | 1,0000 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash papular | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Rash papular | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Rash papular | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Scar pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Scar pain | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Scar pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Skin atrophy | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Skin atrophy | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Skin atrophy | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Skin fissures | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Skin fissures | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Skin fissures | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3387 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Urticaria | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1694 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Urticaria | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Urticaria | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Xeroderma | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Xeroderma | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Xeroderma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Surgical and medical procedures | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Surgical and medical procedures | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Surgical and medical procedures | Cataract operation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Surgical and medical procedures | Cataract operation | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Surgical and medical procedures | Cataract operation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 10 | 14,5 | 59 | 85,5 | 0,0684 | 0,36 | 0,11 | 1,14 | | 0,5832 |
| Vascular disorders | | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,1011 | 0,29 | 0,06 | 1,41 | | |
| Vascular disorders | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4504 | 2,83 | 0,17 | 47,15 | | |
| Vascular disorders | Embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1409 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Flushing | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Flushing | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Flushing | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Haematoma | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Haematoma | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Haematoma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Hypertension | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,5992 | 0,62 | 0,10 | 3,72 | | 0,7042 |
| Vascular disorders | Hypertension | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0635 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Hypertension | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Hypotension | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | | 0,3285 |
| Vascular disorders | Hypotension | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6244 | 1,81 | 0,16 | 19,91 | | |
| Vascular disorders | Hypotension | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Vascular disorders | Lymphoedema | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Lymphoedema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Phlebitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Phlebitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Phlebitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Vasculitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0718 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Vasculitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Vasculitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Venous thrombosis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Venous thrombosis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Venous thrombosis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTAE_SE_26JUN2023_40336.xls
26JAN2024 16:40

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Baseline ECOG

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | 0 | 72 | 56,3 | 14 | 19,4 | 58 | 80,6 | 60 | 50,0 | 20 | 33,3 | 40 | 66,7 | 0,0002 | 0,21 | 0,08 | 0,52 | 0,1701 |
| Blood and lymphatic system disorders | | 1 | 56 | 43,8 | 22 | 39,3 | 34 | 60,7 | 60 | 50,0 | 26 | 43,3 | 34 | 56,7 | 0,0600 | 0,55 | 0,29 | 1,03 | |
| Blood and lymphatic system disorders | Anaemia | 0 | 72 | 56,3 | 13 | 18,1 | 59 | 81,9 | 60 | 50,0 | 13 | 21,7 | 47 | 78,3 | 0,0262 | 0,35 | 0,13 | 0,92 | 0,5450 |
| Blood and lymphatic system disorders | Anaemia | 1 | 56 | 43,8 | 17 | 30,4 | 39 | 69,6 | 60 | 50,0 | 18 | 30,0 | 42 | 70,0 | 0,3222 | 0,69 | 0,33 | 1,44 | |
| Blood and lymphatic system disorders | Febrile neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Blood and lymphatic system disorders | Febrile neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Haemolysis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Haemolysis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Iron deficiency anaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Blood and lymphatic system disorders | Iron deficiency anaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |
| Blood and lymphatic system disorders | Leukopenia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0260 | 0,00 | 0,00 | NE | 0,2687 |
| Blood and lymphatic system disorders | Leukopenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0291 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Myelosuppression | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Blood and lymphatic system disorders | Myelosuppression | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutropenia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 10 | 16,7 | 50 | 83,3 | 0,0014 | 0,08 | 0,01 | 0,59 | 0,7856 |
| Blood and lymphatic system disorders | Neutropenia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,0121 | 0,11 | 0,01 | 0,89 | |
| Blood and lymphatic system disorders | Neutrophilia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Blood and lymphatic system disorders | Neutrophilia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Blood and lymphatic system disorders | Normochromic normocytic anaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7565 | >999.99 | 0,00 | NE | |
| Blood and lymphatic system disorders | Thrombocytopenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Blood and lymphatic system disorders | Thrombocytopenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1779 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Thrombocytosis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Blood and lymphatic system disorders | Thrombocytosis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2963 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | 0 | 72 | 56,3 | 9 | 12,5 | 63 | 87,5 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0911 | 5,14 | 0,62 | 42,73 | 0,8851 |
| Cardiac disorders | | 1 | 56 | 43,8 | 11 | 19,6 | 45 | 80,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,0613 | 4,02 | 0,83 | 19,44 | |
| Cardiac disorders | Acute myocardial infarction | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Angina pectoris | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Cardiac disorders | Angina pectoris | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Atrial fibrillation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Cardiac disorders | Atrial fibrillation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrioventricular block first degree | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Cardiac disorders | Atrioventricular block first degree | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Cardiac disorders | Bradycardia | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | 0,9978 |
| Cardiac disorders | Bradycardia | 1 | 56 | 43,8 | 7 | 12,5 | 49 | 87,5 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0345 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cardiac failure | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Cardiac disorders | Cardiac failure | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Cor pulmonale chronic | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Cardiac disorders | Cor pulmonale chronic | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Coronary artery disease | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Coronary artery disease | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Palpitations | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9979 |
| Cardiac disorders | Palpitations | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Cardiac disorders | Pericardial effusion | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9964 |
| Cardiac disorders | Pericardial effusion | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Sinus bradycardia | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | 0,9979 |
| Cardiac disorders | Sinus bradycardia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Tachycardia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3798 | >999.99 | 0,00 | NE | 0,1127 |
| Cardiac disorders | Tachycardia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Cardiac disorders | Ventricular extrasystoles | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Cardiac disorders | Ventricular extrasystoles | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Congenital, familial and genetic disorders | | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,9970 |
| Congenital, familial and genetic disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7815 | >999.99 | 0,00 | NE | |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Congenital, familial and genetic disorders | Cerebral arteriovenous malformation haemorrhagic | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Congenital, familial and genetic disorders | Gilbert's syndrome | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,9969 |
| Congenital, familial and genetic disorders | Gilbert's syndrome | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7815 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Ear and labyrinth disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,4533 | 0,41 | 0,04 | 4,55 | 0,8816 |
| Ear and labyrinth disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6014 | 0,53 | 0,05 | 5,88 | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Ear and labyrinth disorders | Deafness | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,2694 |
| Ear and labyrinth disorders | Deafness | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9658 | 1,06 | 0,07 | 16,99 | |
| Ear and labyrinth disorders | Ear pain | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,1113 |
| Ear and labyrinth disorders | Ear pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Ear and labyrinth disorders | Eustachian tube dysfunction | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Ear and labyrinth disorders | Eustachian tube dysfunction | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Ear and labyrinth disorders | Tinnitus | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,2695 |
| Ear and labyrinth disorders | Tinnitus | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9658 | 1,06 | 0,07 | 16,99 | |
| | | | | | | | | | | | | | | | | | | | |
| Endocrine disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,5284 |
| Endocrine disorders | | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5302 | 2,12 | 0,19 | 23,41 | |
| Endocrine disorders | Hyperthyroidism | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,3512 |
| Endocrine disorders | Hyperthyroidism | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9818 | 1,03 | 0,06 | 16,56 | |
| Endocrine disorders | Hypothyroidism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9957 |
| Endocrine disorders | Hypothyroidism | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Eye disorders | | 0 | 72 | 56,3 | 7 | 9,7 | 65 | 90,3 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,9126 | 0,90 | 0,14 | 5,93 | 0,6128 |
| Eye disorders | | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5091 | 2,20 | 0,20 | 24,25 | |
| Eye disorders | Dry eye | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9979 |
| Eye disorders | Dry eye | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Eye disorders | Episcleritis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Episcleritis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Eye irritation | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7681 | >999.99 | 0,00 | NE | 0,9972 |
| Eye disorders | Eye irritation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Lacrimation increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9957 |
| Eye disorders | Lacrimation increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photophobia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Eye disorders | Photophobia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Photopsia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Photopsia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Punctate keratitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Punctate keratitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Retinal detachment | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal detachment | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Eye disorders | Retinal haemorrhage | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Eye disorders | Retinal haemorrhage | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Eye disorders | Vision blurred | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1977 | >999.99 | 0,00 | NE | 0,3241 |
| Eye disorders | Vision blurred | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9498 | 1,09 | 0,07 | 17,48 | |
| Eye disorders | Visual acuity reduced | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Eye disorders | Visual acuity reduced | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | 0 | 72 | 56,3 | 53 | 73,6 | 19 | 26,4 | 60 | 50,0 | 51 | 85,0 | 9 | 15,0 | <.0001 | 0,40 | 0,27 | 0,61 | 0,8381 |
| Gastrointestinal disorders | | 1 | 56 | 43,8 | 34 | 60,7 | 22 | 39,3 | 60 | 50,0 | 44 | 73,3 | 16 | 26,7 | 0,0002 | 0,39 | 0,24 | 0,65 | |
| Gastrointestinal disorders | Abdominal discomfort | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9967 |
| Gastrointestinal disorders | Abdominal discomfort | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1341 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal distension | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Gastrointestinal disorders | Abdominal distension | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal pain | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,8119 | 1,24 | 0,21 | 7,38 | 0,0864 |
| Gastrointestinal disorders | Abdominal pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal pain lower | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Gastrointestinal disorders | Abdominal pain lower | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain upper | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,2313 | 0,28 | 0,03 | 2,64 | 0,9908 |
| Gastrointestinal disorders | Abdominal pain upper | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,5944 | 0,53 | 0,05 | 5,81 | |
| Gastrointestinal disorders | Anal haemorrhage | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Gastrointestinal disorders | Anal haemorrhage | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Anal inflammation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Gastrointestinal disorders | Anal inflammation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Chronic gastritis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Chronic gastritis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9961 |
| Gastrointestinal disorders | Colitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | 0 | 72 | 56,3 | 36 | 50,0 | 36 | 50,0 | 60 | 50,0 | 22 | 36,7 | 38 | 63,3 | 0,4042 | 1,26 | 0,73 | 2,18 | 0,1967 |
| Gastrointestinal disorders | Constipation | 1 | 56 | 43,8 | 18 | 32,1 | 38 | 67,9 | 60 | 50,0 | 8 | 13,3 | 52 | 86,7 | 0,0167 | 2,68 | 1,16 | 6,19 | |
| Gastrointestinal disorders | Dental caries | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Dental caries | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Diarrhoea | 0 | 72 | 56,3 | 10 | 13,9 | 62 | 86,1 | 60 | 50,0 | 7 | 11,7 | 53 | 88,3 | 0,4407 | 0,66 | 0,22 | 1,93 | 0,4636 |
| Gastrointestinal disorders | Diarrhoea | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,3526 | 0,36 | 0,04 | 3,44 | |
| Gastrointestinal disorders | Dry mouth | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Gastrointestinal disorders | Dry mouth | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Dyspepsia | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,9629 | 0,96 | 0,15 | 6,10 | 0,5066 |
| Gastrointestinal disorders | Dyspepsia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8912 | 1,20 | 0,09 | 16,65 | |
| Gastrointestinal disorders | Epigastric discomfort | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,3583 |
| Gastrointestinal disorders | Epigastric discomfort | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Faeces discoloured | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Gastrointestinal disorders | Faeces discoloured | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Gastrointestinal disorders | Faeces hard | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Gastrointestinal disorders | Faeces hard | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1127 | >999.99 | 0,00 | NE | 0,9962 |
| Gastrointestinal disorders | Gastritis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis erosive | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastrointestinal pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Gastrointestinal disorders | Gastrointestinal pain | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,8278 |
| Gastrointestinal disorders | Gastrooesophageal reflux disease | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1868 | 0,10 | 0,00 | 3,63 | |
| Gastrointestinal disorders | Gingival pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Gastrointestinal disorders | Gingival pain | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Gingival swelling | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Gastrointestinal disorders | Gingival swelling | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Haematochezia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9957 |
| Gastrointestinal disorders | Haematochezia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Haemorrhoids | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,2631 |
| Gastrointestinal disorders | Haemorrhoids | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9508 | 1,09 | 0,07 | 17,45 | |
| Gastrointestinal disorders | Ileus paralytic | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Ileus paralytic | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Gastrointestinal disorders | Mouth ulceration | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9957 |
| Gastrointestinal disorders | Mouth ulceration | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Nausea | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 47 | 78,3 | 13 | 21,7 | <.0001 | 0,04 | 0,02 | 0,10 | 0,7090 |
| Gastrointestinal disorders | Nausea | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 40 | 66,7 | 20 | 33,3 | <.0001 | 0,03 | 0,01 | 0,14 | |
| Gastrointestinal disorders | Pancreatitis acute | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Pancreatitis acute | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Regurgitation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Regurgitation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Stomatitis | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,8157 | 0,83 | 0,17 | 4,10 | 0,9976 |
| Gastrointestinal disorders | Stomatitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Toothache | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Gastrointestinal disorders | Toothache | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Umbilical hernia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Umbilical hernia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Vomiting | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 12 | 20,0 | 48 | 80,0 | 0,0104 | 0,25 | 0,08 | 0,79 | 0,2441 |
| Gastrointestinal disorders | Vomiting | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 18 | 30,0 | 42 | 70,0 | 0,0002 | 0,10 | 0,02 | 0,44 | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | 0 | 72 | 56,3 | 36 | 50,0 | 36 | 50,0 | 60 | 50,0 | 28 | 46,7 | 32 | 53,3 | 0,0631 | 0,59 | 0,34 | 1,03 | 0,3891 |
| General disorders and administration site conditions | | 1 | 56 | 43,8 | 20 | 35,7 | 36 | 64,3 | 60 | 50,0 | 26 | 43,3 | 34 | 56,7 | 0,0532 | 0,54 | 0,29 | 1,02 | |
| General disorders and administration site conditions | Asthenia | 0 | 72 | 56,3 | 8 | 11,1 | 64 | 88,9 | 60 | 50,0 | 8 | 13,3 | 52 | 86,7 | 0,2334 | 0,51 | 0,17 | 1,57 | 0,5824 |
| General disorders and administration site conditions | Asthenia | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 11 | 18,3 | 49 | 81,7 | 0,1311 | 0,45 | 0,16 | 1,30 | |
| General disorders and administration site conditions | Chest discomfort | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,1684 |
| General disorders and administration site conditions | Chest discomfort | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0935 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Chest pain | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,8348 | >999.99 | 0,00 | NE | 0,2470 |
| General disorders and administration site conditions | Chest pain | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,5833 | 1,64 | 0,27 | 9,87 | |
| General disorders and administration site conditions | Face oedema | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,0611 |
| General disorders and administration site conditions | Face oedema | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1700 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Fatigue | 0 | 72 | 56,3 | 15 | 20,8 | 57 | 79,2 | 60 | 50,0 | 7 | 11,7 | 53 | 88,3 | 0,4327 | 1,45 | 0,57 | 3,66 | 0,0280 |
| General disorders and administration site conditions | Fatigue | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,0076 | 0,10 | 0,01 | 0,79 | |
| General disorders and administration site conditions | Gait disturbance | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| General disorders and administration site conditions | Gait disturbance | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| General disorders and administration site conditions | Hyperthermia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| General disorders and administration site conditions | Hyperthermia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Ill-defined disorder | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| General disorders and administration site conditions | Ill-defined disorder | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Influenza like illness | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8926 | 0,83 | 0,05 | 13,21 | 0,2316 |
| General disorders and administration site conditions | Influenza like illness | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| General disorders and administration site conditions | Infusion site extravasation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,9951 |
| General disorders and administration site conditions | Infusion site extravasation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Infusion site injury | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| General disorders and administration site conditions | Infusion site injury | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Localised oedema | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| General disorders and administration site conditions | Localised oedema | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Malaise | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 10 | 16,7 | 50 | 83,3 | 0,0145 | 0,23 | 0,06 | 0,83 | | 0,4033 |
| General disorders and administration site conditions | Malaise | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,1637 | 0,34 | 0,07 | 1,68 | | |
| General disorders and administration site conditions | Mucosal inflammation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| General disorders and administration site conditions | Mucosal inflammation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Non-cardiac chest pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| General disorders and administration site conditions | Non-cardiac chest pain | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| General disorders and administration site conditions | Oedema | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Oedema peripheral | 0 | 72 | 56,3 | 7 | 9,7 | 65 | 90,3 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0388 | >999.99 | 0,00 | NE | | 0,2714 |
| General disorders and administration site conditions | Oedema peripheral | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,1531 | 4,33 | 0,48 | 38,83 | | |
| General disorders and administration site conditions | Pain | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8948 | 0,83 | 0,05 | 13,26 | | 0,9584 |
| General disorders and administration site conditions | Pain | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9560 | 1,08 | 0,07 | 17,29 | | |
| General disorders and administration site conditions | Peripheral swelling | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | | 0,9971 |
| General disorders and administration site conditions | Peripheral swelling | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2655 | >999.99 | 0,00 | NE | | |
| General disorders and administration site conditions | Pyrexia | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,4476 | 0,41 | 0,04 | 4,49 | | 0,9974 |
| General disorders and administration site conditions | Pyrexia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6083 | 0,54 | 0,05 | 5,95 | | |
| General disorders and administration site conditions | Suprapubic pain | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| General disorders and administration site conditions | Suprapubic pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Swelling face | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| General disorders and administration site conditions | Swelling face | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0665 | >999.99 | 0,00 | NE | | 0,9978 |
| Hepatobiliary disorders | | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1396 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Cholelithiasis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9964 |
| Hepatobiliary disorders | Cholelithiasis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hepatotoxicity | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9964 |
| Hepatobiliary disorders | Hepatotoxicity | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1977 | >999.99 | 0,00 | NE | | 0,9970 |
| Hepatobiliary disorders | Hyperbilirubinaemia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1396 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Ocular icterus | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Hepatobiliary disorders | Ocular icterus | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Immune system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Immune system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Immune system disorders | Hypersensitivity | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Immune system disorders | Hypersensitivity | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | 0 | 72 | 56,3 | 40 | 55,6 | 32 | 44,4 | 60 | 50,0 | 7 | 11,7 | 53 | 88,3 | 0,7947 | 1,14 | 0,43 | 2,99 | | 0,5802 |
| Infections and infestations | | 1 | 56 | 43,8 | 34 | 60,7 | 22 | 39,3 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,1142 | 2,17 | 0,81 | 5,79 | | |
| Infections and infestations | Acute sinusitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Acute sinusitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Appendicitis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Appendicitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Bronchiolitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Bronchiolitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Bronchitis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Bronchitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | COVID-19 | 0 | 72 | 56,3 | 19 | 26,4 | 53 | 73,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,9042 | >999.99 | 0,00 | NE | 0,2930 |
| Infections and infestations | COVID-19 | 1 | 56 | 43,8 | 18 | 32,1 | 38 | 67,9 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8101 | 1,36 | 0,11 | 17,32 | |
| Infections and infestations | Chronic sinusitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Chronic sinusitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Conjunctivitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9957 |
| Infections and infestations | Conjunctivitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Cystitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9975 |
| Infections and infestations | Cystitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Folliculitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9012 | 0,84 | 0,05 | 13,42 | 0,9964 |
| Infections and infestations | Folliculitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Gastroenteritis | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Gastroenteritis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Herpes zoster | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,0666 |
| Infections and infestations | Herpes zoster | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Infections and infestations | Infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,2560 |
| Infections and infestations | Infection | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Influenza | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1993 | >999.99 | 0,00 | NE | 0,9974 |
| Infections and infestations | Influenza | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Infections and infestations | Laryngopharyngitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Laryngopharyngitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Lower respiratory tract infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | 0,9969 |
| Infections and infestations | Lower respiratory tract infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nail infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Nail infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Nasopharyngitis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5418 | 0,41 | 0,02 | 7,72 | 0,4210 |
| Infections and infestations | Nasopharyngitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Infections and infestations | Otitis media | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Infections and infestations | Otitis media | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Periodontitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,4614 |
| Infections and infestations | Periodontitis | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9856 | 0,97 | 0,06 | 15,63 | |
| Infections and infestations | Pharyngitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8969 | 0,83 | 0,05 | 13,45 | 0,2687 |
| Infections and infestations | Pharyngitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6171 | >999.99 | 0,00 | NE | |
| Infections and infestations | Pneumonia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,6442 |
| Infections and infestations | Pneumonia | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,7461 | 1,50 | 0,13 | 17,95 | |
| Infections and infestations | Pneumonia viral | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Pneumonia viral | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pulpitis dental | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Infections and infestations | Pulpitis dental | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9598 | 1,07 | 0,07 | 17,19 | |
| Infections and infestations | Respiratory tract infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Respiratory tract infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Respiratory tract infection viral | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9957 |
| Infections and infestations | Respiratory tract infection viral | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Infections and infestations | Rhinitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,1135 |
| Infections and infestations | Rhinitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Infections and infestations | Sinusitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9961 |
| Infections and infestations | Sinusitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Tonsillitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Infections and infestations | Tonsillitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Infections and infestations | Upper respiratory tract infection | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,6973 | 1,60 | 0,15 | 17,69 | 0,3290 |
| Infections and infestations | Upper respiratory tract infection | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |
| Infections and infestations | Urethritis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Urethritis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Urinary tract infection | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,4125 |
| Infections and infestations | Urinary tract infection | 1 | 56 | 43,8 | 8 | 14,3 | 48 | 85,7 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,1350 | 4,60 | 0,52 | 41,00 | |
| Infections and infestations | Urosepsis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Viral upper respiratory tract infection | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9975 |
| Infections and infestations | Viral upper respiratory tract infection | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Injury, poisoning and procedural complications | | 0 | 72 | 56,3 | 28 | 38,9 | 44 | 61,1 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,0043 | 6,55 | 1,49 | 28,78 | 0,6035 |
| Injury, poisoning and procedural complications | | 1 | 56 | 43,8 | 21 | 37,5 | 35 | 62,5 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0175 | 8,40 | 1,04 | 67,58 | |
| Injury, poisoning and procedural complications | Accidental overdose | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3711 | >999.99 | 0,00 | NE | 0,9975 |
| Injury, poisoning and procedural complications | Accidental overdose | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Injury, poisoning and procedural complications | Accidental underdose | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Injury, poisoning and procedural complications | Accidental underdose | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9973 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Injury, poisoning and procedural complications | Airway complication of anaesthesia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7815 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Arthropod sting | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Arthropod sting | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Contusion | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Contusion | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Extra dose administered | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Extra dose administered | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Fall | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9979 |
| Injury, poisoning and procedural complications | Fall | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Immunisation reaction | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Immunisation reaction | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Incorrect dose administered | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0649 | >999.99 | 0,00 | NE | | 0,9966 |
| Injury, poisoning and procedural complications | Incorrect dose administered | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Intentional product misuse | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Intentional product misuse | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Limb injury | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Limb injury | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Medication error | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Medication error | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Overdose | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9972 |
| Injury, poisoning and procedural complications | Overdose | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7565 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Product dose omission in error | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9968 |
| Injury, poisoning and procedural complications | Product dose omission in error | 1 | 56 | 43,8 | 12 | 21,4 | 44 | 78,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0673 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Product dose omission issue | 0 | 72 | 56,3 | 18 | 25,0 | 54 | 75,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0188 | >999.99 | 0,00 | NE | | 0,9973 |
| Injury, poisoning and procedural complications | Product dose omission issue | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1377 | >999.99 | 0,00 | NE | | |
| Injury, poisoning and procedural complications | Radius fracture | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Injury, poisoning and procedural complications | Radius fracture | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Thermal burn | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Injury, poisoning and procedural complications | Thermal burn | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Vaccination complication | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9957 |
| Injury, poisoning and procedural complications | Vaccination complication | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Injury, poisoning and procedural complications | Wound complication | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9973 |
| Injury, poisoning and procedural complications | Wound complication | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | 0 | 72 | 56,3 | 48 | 66,7 | 24 | 33,3 | 60 | 50,0 | 22 | 36,7 | 38 | 63,3 | 0,0055 | 2,07 | 1,23 | 3,49 | | 0,1454 |
| Investigations | | 1 | 56 | 43,8 | 49 | 87,5 | 7 | 12,5 | 60 | 50,0 | 23 | 38,3 | 37 | 61,7 | <.0001 | 3,76 | 2,22 | 6,39 | | |
| Investigations | Activated partial thromboplastin time prolonged | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Investigations | Activated partial thromboplastin time prolonged | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | Alanine aminotransferase increased | 0 | 72 | 56,3 | 23 | 31,9 | 49 | 68,1 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0223 | 3,03 | 1,12 | 8,24 | | 0,9976 |
| Investigations | Alanine aminotransferase increased | 1 | 56 | 43,8 | 20 | 35,7 | 36 | 64,3 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,0217 | 2,91 | 1,12 | 7,53 | | |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0547 | 0,00 | 0,00 | NE | | 0,9964 |
| Investigations | Alpha hydroxybutyrate dehydrogenase increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | 0 | 72 | 56,3 | 25 | 34,7 | 47 | 65,3 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | <.0001 | 20,84 | 2,80 | 155,37 | | 0,2448 |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Aspartate aminotransferase increased | 1 | 56 | 43,8 | 28 | 50,0 | 28 | 50,0 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0002 | 5,30 | 1,99 | 14,14 | |
| Investigations | Bacterial test positive | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Investigations | Bacterial test positive | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Bile acids increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Bile acids increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Investigations | Bilirubin conjugated increased | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | 0,9972 |
| Investigations | Bilirubin conjugated increased | 1 | 56 | 43,8 | 8 | 14,3 | 48 | 85,7 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0022 | >999.99 | 0,00 | NE | |
| Investigations | Blood alkaline phosphatase increased | 0 | 72 | 56,3 | 9 | 12,5 | 63 | 87,5 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0321 | 7,07 | 0,88 | 56,77 | 0,8331 |
| Investigations | Blood alkaline phosphatase increased | 1 | 56 | 43,8 | 23 | 41,1 | 33 | 58,9 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | <.0001 | 8,01 | 2,36 | 27,20 | |
| Investigations | Blood bilirubin increased | 0 | 72 | 56,3 | 18 | 25,0 | 54 | 75,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0003 | >999.99 | 0,00 | NE | 0,3835 |
| Investigations | Blood bilirubin increased | 1 | 56 | 43,8 | 25 | 44,6 | 31 | 55,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | <.0001 | 26,57 | 3,56 | 198,45 | |
| Investigations | Blood bilirubin unconjugated increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9975 |
| Investigations | Blood bilirubin unconjugated increased | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood cholesterol increased | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood cholesterol increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase MB increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Blood creatine phosphokinase MB increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatine phosphokinase increased | 0 | 72 | 56,3 | 31 | 43,1 | 41 | 56,9 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | <.0001 | 33,97 | 4,60 | 250,78 | 0,2477 |
| Investigations | Blood creatine phosphokinase increased | 1 | 56 | 43,8 | 24 | 42,9 | 32 | 57,1 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | <.0001 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | 0 | 72 | 56,3 | 10 | 13,9 | 62 | 86,1 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1528 | 2,98 | 0,62 | 14,36 | 0,5662 |
| Investigations | Blood creatinine increased | 1 | 56 | 43,8 | 9 | 16,1 | 47 | 83,9 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,6175 | 1,39 | 0,38 | 5,09 | |
| Investigations | Blood fibrinogen increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood fibrinogen increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood lactate dehydrogenase increased | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,5197 | 0,61 | 0,14 | 2,75 | 0,4764 |
| Investigations | Blood lactate dehydrogenase increased | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,5810 | 1,65 | 0,28 | 9,85 | |
| Investigations | Blood thyroid stimulating hormone decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood thyroid stimulating hormone decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood thyroid stimulating hormone increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Investigations | Blood thyroid stimulating hormone increased | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |
| Investigations | Blood triglycerides increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood triglycerides increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood urea increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1107 | 0,00 | 0,00 | NE | 0,6066 |
| Investigations | Blood urea increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4915 | 0,32 | 0,01 | 8,62 | |
| Investigations | Blood uric acid increased | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Blood uric acid increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Creatinine renal clearance decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Creatinine renal clearance decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4963 | 0,32 | 0,01 | 8,77 | |
| Investigations | Electrocardiogram Q wave abnormal | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Investigations | Electrocardiogram Q wave abnormal | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Investigations | Electrocardiogram QRS complex abnormal | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Investigations | Electrocardiogram QRS complex abnormal | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Investigations | Electrocardiogram QT prolonged | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Investigations | Electrocardiogram QT prolonged | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Investigations | Gamma-glutamyltransferase increased | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,2810 | 0,41 | 0,07 | 2,21 | 0,6494 |
| Investigations | Gamma-glutamyltransferase increased | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,3526 | 0,36 | 0,04 | 3,44 | |
| Investigations | Glomerular filtration rate decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Glomerular filtration rate decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Heart rate increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Heart rate increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2963 | >999.99 | 0,00 | NE | |
| Investigations | International normalised ratio increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Investigations | International normalised ratio increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | |
| Investigations | Liver function test increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9964 |
| Investigations | Liver function test increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Lymphocyte count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1156 | 0,00 | 0,00 | NE | 0,1524 |
| Investigations | Lymphocyte count decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9549 | 1,08 | 0,07 | 17,32 | |
| Investigations | Neutrophil count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 10 | 16,7 | 50 | 83,3 | 0,0003 | 0,00 | 0,00 | NE | 0,0363 |
| Investigations | Neutrophil count decreased | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 11 | 18,3 | 49 | 81,7 | 0,0130 | 0,18 | 0,04 | 0,83 | |
| Investigations | Neutrophil count increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Investigations | Neutrophil count increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Platelet count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,2946 |
| Investigations | Platelet count decreased | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,1143 | 0,21 | 0,02 | 1,79 | |
| Investigations | Protein total decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Protein total decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | 1,00 | 0,00 | NE | |
| Investigations | Red blood cells urine positive | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Red blood cells urine positive | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Investigations | SARS-CoV-2 test positive | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,8097 | >999.99 | 0,00 | NE | 0,9973 |
| Investigations | SARS-CoV-2 test positive | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Transaminases increased | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | 0,0618 |
| Investigations | Transaminases increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | |
| Investigations | Urinary occult blood positive | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Urinary occult blood positive | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Investigations | Urine ketone body present | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Urine ketone body present | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Investigations | Urobilinogen urine increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Urobilinogen urine increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Investigations | Vitamin B12 decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Vitamin B12 decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Weight decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | 0,0613 |
| Investigations | Weight decreased | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Investigations | Weight increased | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | 0,6069 |
| Investigations | Weight increased | 1 | 56 | 43,8 | 14 | 25,0 | 42 | 75,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0362 | 7,02 | 0,85 | 57,85 | |
| Investigations | White blood cell count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 10 | 16,7 | 50 | 83,3 | 0,0003 | 0,00 | 0,00 | NE | 0,1065 |
| Investigations | White blood cell count decreased | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 13 | 21,7 | 47 | 78,3 | 0,0038 | 0,15 | 0,03 | 0,66 | |
| Investigations | White blood cell count increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | 0,0405 |
| Investigations | White blood cell count increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2963 | >999.99 | 0,00 | NE | |
| Investigations | White blood cells urine positive | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9951 |
| Investigations | White blood cells urine positive | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1411 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | 0 | 72 | 56,3 | 15 | 20,8 | 57 | 79,2 | 60 | 50,0 | 21 | 35,0 | 39 | 65,0 | 0,0002 | 0,22 | 0,09 | 0,53 | 0,1152 |
| Metabolism and nutrition disorders | | 1 | 56 | 43,8 | 24 | 42,9 | 32 | 57,1 | 60 | 50,0 | 27 | 45,0 | 33 | 55,0 | 0,2235 | 0,70 | 0,39 | 1,25 | |
| Metabolism and nutrition disorders | Cell death | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Metabolism and nutrition disorders | Cell death | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Decreased appetite | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 16 | 26,7 | 44 | 73,3 | <.0001 | 0,09 | 0,02 | 0,39 | 0,2325 |
| Metabolism and nutrition disorders | Decreased appetite | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 19 | 31,7 | 41 | 68,3 | 0,0025 | 0,24 | 0,09 | 0,66 | |
| Metabolism and nutrition disorders | Electrolyte imbalance | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Metabolism and nutrition disorders | Electrolyte imbalance | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypercalcaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9969 |
| Metabolism and nutrition disorders | Hypercalcaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1722 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperchloraemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Metabolism and nutrition disorders | Hyperchloraemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypercreatininaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Metabolism and nutrition disorders | Hypercreatininaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperglycaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1175 | 0,00 | 0,00 | NE | 0,0297 |
| Metabolism and nutrition disorders | Hyperglycaemia | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,3207 | 2,29 | 0,43 | 12,34 | |
| Metabolism and nutrition disorders | Hyperkalaemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | 0,1522 |
| Metabolism and nutrition disorders | Hyperkalaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperlipidaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Metabolism and nutrition disorders | Hyperlipidaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3173 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypermagnesaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Metabolism and nutrition disorders | Hypermagnesaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypernatraemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Metabolism and nutrition disorders | Hypernatraemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2963 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hyperphosphataemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hyperphosphataemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,4633 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5122 | 2,19 | 0,20 | 24,12 | |
| Metabolism and nutrition disorders | Hyperuricaemia | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2003 | >999.99 | 0,00 | NE | 0,3738 |
| Metabolism and nutrition disorders | Hyperuricaemia | 1 | 56 | 43,8 | 9 | 16,1 | 47 | 83,9 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,3096 | 2,33 | 0,44 | 12,43 | |
| Metabolism and nutrition disorders | Hypoalbuminaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,2631 |
| Metabolism and nutrition disorders | Hypoalbuminaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9508 | 1,09 | 0,07 | 17,45 | |
| Metabolism and nutrition disorders | Hypocalcaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9962 |
| Metabolism and nutrition disorders | Hypocalcaemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6949 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypoglycaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Hypoglycaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypokalaemia | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9012 | 0,84 | 0,05 | 13,42 | 0,2338 |
| Metabolism and nutrition disorders | Hypokalaemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypomagnesaemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,8654 |
| Metabolism and nutrition disorders | Hypomagnesaemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,2789 | 0,24 | 0,02 | 3,55 | |
| Metabolism and nutrition disorders | Hyponatraemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,2169 |
| Metabolism and nutrition disorders | Hyponatraemia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,7190 | 0,72 | 0,12 | 4,33 | |
| Metabolism and nutrition disorders | Hypophosphataemia | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9973 |
| Metabolism and nutrition disorders | Hypophosphataemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypoproteinaemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,9977 |
| Metabolism and nutrition disorders | Hypoproteinaemia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1296 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Polydipsia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Polydipsia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,0646 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Vitamin D deficiency | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Metabolism and nutrition disorders | Vitamin D deficiency | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | 0 | 72 | 56,3 | 40 | 55,6 | 32 | 44,4 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | <.0001 | 7,58 | 2,66 | 21,60 | 0,4556 |
| Musculoskeletal and connective tissue disorders | | 1 | 56 | 43,8 | 25 | 44,6 | 31 | 55,4 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0005 | 4,89 | 1,83 | 13,10 | |
| Musculoskeletal and connective tissue disorders | Arthralgia | 0 | 72 | 56,3 | 8 | 11,1 | 64 | 88,9 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,8851 | 0,87 | 0,13 | 5,90 | 0,3190 |
| Musculoskeletal and connective tissue disorders | Arthralgia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Musculoskeletal and connective tissue disorders | Back pain | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,3762 |
| Musculoskeletal and connective tissue disorders | Back pain | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4968 | 2,24 | 0,21 | 24,47 | | |
| Musculoskeletal and connective tissue disorders | Bone pain | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9012 | 0,84 | 0,05 | 13,42 | | 0,1145 |
| Musculoskeletal and connective tissue disorders | Bone pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1723 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Flank pain | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,1135 |
| Musculoskeletal and connective tissue disorders | Flank pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | | 0,9969 |
| Musculoskeletal and connective tissue disorders | Muscle fatigue | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscle spasms | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9975 |
| Musculoskeletal and connective tissue disorders | Muscle spasms | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Muscular weakness | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7501 | >999.99 | 0,00 | NE | | 0,9972 |
| Musculoskeletal and connective tissue disorders | Muscular weakness | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0704 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,9975 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal chest pain | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9973 |
| Musculoskeletal and connective tissue disorders | Musculoskeletal stiffness | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | 0 | 72 | 56,3 | 24 | 33,3 | 48 | 66,7 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | <.0001 | 21,58 | 2,90 | 160,45 | | 0,7160 |
| Musculoskeletal and connective tissue disorders | Myalgia | 1 | 56 | 43,8 | 12 | 21,4 | 44 | 78,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0017 | 12,72 | 1,64 | 98,62 | | |
| Musculoskeletal and connective tissue disorders | Myositis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9964 |
| Musculoskeletal and connective tissue disorders | Myositis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Neck pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9973 |
| Musculoskeletal and connective tissue disorders | Neck pain | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Osteoporosis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Musculoskeletal and connective tissue disorders | Osteoporosis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | | 0,2132 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,7991 | 1,27 | 0,20 | 8,10 | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,9979 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1377 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Adrenal neoplasm | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Benign breast neoplasm | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Lipoma | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin papilloma | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Nervous system disorders | | 0 | 72 | 56,3 | 25 | 34,7 | 47 | 65,3 | 60 | 50,0 | 12 | 20,0 | 48 | 80,0 | 0,2440 | 1,53 | 0,74 | 3,13 | | 0,4949 |
| Nervous system disorders | | 1 | 56 | 43,8 | 15 | 26,8 | 41 | 73,2 | 60 | 50,0 | 12 | 20,0 | 48 | 80,0 | 0,3794 | 0,67 | 0,27 | 1,66 | | |
| Nervous system disorders | Amnesia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Nervous system disorders | Amnesia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Anosmia | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,8097 | >999.99 | 0,00 | NE | | 0,9963 |
| Nervous system disorders | Anosmia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Cerebral ischaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Cerebral ischaemia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Nervous system disorders | Cognitive disorder | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,8097 | >999.99 | 0,00 | NE | | 0,9973 |
| Nervous system disorders | Cognitive disorder | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Dizziness | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,7616 | 0,81 | 0,20 | 3,23 | | 0,5553 |
| Nervous system disorders | Dizziness | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 7 | 11,7 | 53 | 88,3 | 0,0580 | 0,23 | 0,04 | 1,18 | | |
| Nervous system disorders | Dysgeusia | 0 | 72 | 56,3 | 12 | 16,7 | 60 | 83,3 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0109 | 9,06 | 1,16 | 70,77 | | 0,0420 |
| Nervous system disorders | Dysgeusia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6016 | 0,53 | 0,05 | 5,88 | | |
| Nervous system disorders | Headache | 0 | 72 | 56,3 | 8 | 11,1 | 64 | 88,9 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,7623 | 1,19 | 0,38 | 3,79 | | 0,6077 |
| Nervous system disorders | Headache | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,7253 | 0,73 | 0,12 | 4,35 | | |
| Nervous system disorders | Hypoaesthesia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9956 |
| Nervous system disorders | Hypoaesthesia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3428 | 0,00 | 0,00 | NE | | |
| Nervous system disorders | Hypokinesia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Hypokinesia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Nervous system disorders | Lethargy | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Nervous system disorders | Lethargy | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Nervous system disorders | Memory impairment | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,8097 | >999.99 | 0,00 | NE | | 0,9963 |
| Nervous system disorders | Memory impairment | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Neuropathy peripheral | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,4394 | 0,40 | 0,04 | 4,42 | | 0,3283 |
| Nervous system disorders | Neuropathy peripheral | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Nervous system disorders | Paraesthesia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,4245 |
| Nervous system disorders | Paraesthesia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,2099 | 0,25 | 0,02 | 2,54 | | |
| Nervous system disorders | Parosmia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Nervous system disorders | Parosmia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Nervous system disorders | Somnolence | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4040 | 2,53 | 0,26 | 24,36 | | 0,9970 |
| Nervous system disorders | Somnolence | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Nervous system disorders | Taste disorder | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | | 0,3195 |
| Nervous system disorders | Taste disorder | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5135 | 2,18 | 0,20 | 24,06 | | |
| Nervous system disorders | Vascular encephalopathy | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Nervous system disorders | Vascular encephalopathy | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Psychiatric disorders | | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,5361 | 1,69 | 0,31 | 9,10 | | 0,0733 |
| Psychiatric disorders | | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,0720 | 0,18 | 0,02 | 1,48 | | |
| Psychiatric disorders | Agitation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Psychiatric disorders | Agitation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Psychiatric disorders | Anxiety | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2023 | >999.99 | 0,00 | NE | | 0,9979 |
| Psychiatric disorders | Anxiety | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | Depressed mood | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Psychiatric disorders | Depressed mood | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | | |
| Psychiatric disorders | Depression | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Psychiatric disorders | Depression | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Psychiatric disorders | Insomnia | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,8443 | 0,82 | 0,12 | 5,85 | | 0,9422 |
| Psychiatric disorders | Insomnia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,3689 | 0,37 | 0,04 | 3,55 | | |
| Psychiatric disorders | Panic attack | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Psychiatric disorders | Panic attack | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Psychiatric disorders | Restlessness | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7681 | >999.99 | 0,00 | NE | | 0,9972 |
| Psychiatric disorders | Restlessness | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Renal and urinary disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0260 | 0,00 | 0,00 | NE | | 0,0134 |
| Renal and urinary disorders | | 1 | 56 | 43,8 | 11 | 19,6 | 45 | 80,4 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0892 | 2,64 | 0,83 | 8,45 | | |
| Renal and urinary disorders | Azotaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Renal and urinary disorders | Azotaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | | |
| Renal and urinary disorders | Dysuria | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,0798 |
| Renal and urinary disorders | Dysuria | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2918 | >999.99 | 0,00 | NE | | |
| Renal and urinary disorders | Glycosuria | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Renal and urinary disorders | Glycosuria | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Renal and urinary disorders | Haematuria | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9976 |
| Renal and urinary disorders | Haematuria | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,6334 | 1,44 | 0,32 | 6,42 | | |
| Renal and urinary disorders | Leukocyturia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Renal and urinary disorders | Leukocyturia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2963 | >999.99 | 0,00 | NE | | |
| Renal and urinary disorders | Nephrolithiasis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,9975 |
| Renal and urinary disorders | Nephrolithiasis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3083 | >999.99 | 0,00 | NE | | |
| Renal and urinary disorders | Nocturia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9969 |
| Renal and urinary disorders | Nocturia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,5675 | >999.99 | 0,00 | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Renal and urinary disorders | Proteinuria | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9974 |
| Renal and urinary disorders | Proteinuria | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1891 | 2,85 | 0,56 | 14,55 | |
| Renal and urinary disorders | Renal failure | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Renal and urinary disorders | Renal failure | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Renal and urinary disorders | Renal impairment | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Renal and urinary disorders | Renal impairment | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,6775 | 1,66 | 0,15 | 18,25 | 0,7888 |
| Reproductive system and breast disorders | | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5227 | 2,15 | 0,19 | 23,68 | |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Reproductive system and breast disorders | Atrophic vulvovaginitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Reproductive system and breast disorders | Balanoposthitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9963 |
| Reproductive system and breast disorders | Balanoposthitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical cyst | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Cervical cyst | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Reproductive system and breast disorders | Cervical polyp | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Reproductive system and breast disorders | Cervical polyp | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Reproductive system and breast disorders | Erectile dysfunction | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Erectile dysfunction | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Galactorrhoea | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Reproductive system and breast disorders | Galactorrhoea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Haemorrhagic ovarian cyst | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Reproductive system and breast disorders | Hypomenorrhoea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Reproductive system and breast disorders | Hypomenorrhoea | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Reproductive system and breast disorders | Menstruation irregular | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2636 | 0,00 | 0,00 | NE | 0,9965 |
| Reproductive system and breast disorders | Menstruation irregular | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Prostatitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Prostatitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Reproductive system and breast disorders | Uterine prolapse | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Uterine prolapse | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal discharge | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Vaginal discharge | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Vaginal haemorrhage | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Reproductive system and breast disorders | Vaginal haemorrhage | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | 0 | 72 | 56,3 | 23 | 31,9 | 49 | 68,1 | 60 | 50,0 | 11 | 18,3 | 49 | 81,7 | 0,6214 | 0,81 | 0,36 | 1,85 | 0,6731 |
| Respiratory, thoracic and mediastinal disorders | | 1 | 56 | 43,8 | 16 | 28,6 | 40 | 71,4 | 60 | 50,0 | 8 | 13,3 | 52 | 86,7 | 0,5480 | 1,33 | 0,53 | 3,35 | |
| Respiratory, thoracic and mediastinal disorders | Asthma | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | 0 | 72 | 56,3 | 15 | 20,8 | 57 | 79,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,3329 | 2,20 | 0,43 | 11,24 | 0,3293 |
| Respiratory, thoracic and mediastinal disorders | Cough | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6040 | 1,60 | 0,27 | 9,57 | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 0 | 72 | 56,3 | 7 | 9,7 | 65 | 90,3 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,1283 | 4,54 | 0,54 | 38,19 | 0,6575 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,4161 | 2,00 | 0,36 | 10,99 | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,9979 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea exertional | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1414 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9894 | 1,02 | 0,08 | 13,12 | 0,8225 |
| Respiratory, thoracic and mediastinal disorders | Epistaxis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Hiccups | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 7 | 11,7 | 53 | 88,3 | 0,0029 | 0,00 | 0,00 | NE | 0,9973 |
| Respiratory, thoracic and mediastinal disorders | Hiccups | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1760 | 0,00 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9972 |
| Respiratory, thoracic and mediastinal disorders | Hydrothorax | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7565 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Respiratory, thoracic and mediastinal disorders | Nasal dryness | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3477 | 0,19 | 0,01 | 6,71 | 0,6004 |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9658 | 1,06 | 0,07 | 16,99 | |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9974 |
| Respiratory, thoracic and mediastinal disorders | Pleural effusion | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9658 | 1,06 | 0,07 | 16,99 | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | 0,9964 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1411 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8858 | 0,82 | 0,05 | 13,06 | 0,2634 |
| Respiratory, thoracic and mediastinal disorders | Pneumothorax | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7815 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Productive cough | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9968 |
| Respiratory, thoracic and mediastinal disorders | Productive cough | 1 | 56 | 43,8 | 4 | 7,1 | 52 | 92,9 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0719 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1154 | 0,00 | 0,00 | NE | 0,9951 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9973 |
| Respiratory, thoracic and mediastinal disorders | Rhinorrhoea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Throat irritation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | 0 | 72 | 56,3 | 34 | 47,2 | 38 | 52,8 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,0436 | 2,18 | 1,00 | 4,72 | 0,0525 |
| Skin and subcutaneous tissue disorders | | 1 | 56 | 43,8 | 16 | 28,6 | 40 | 71,4 | 60 | 50,0 | 13 | 21,7 | 47 | 78,3 | 0,6083 | 0,81 | 0,35 | 1,83 | |
| Skin and subcutaneous tissue disorders | Acne | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Skin and subcutaneous tissue disorders | Acne | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2873 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Alopecia | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,2223 | 0,27 | 0,03 | 2,59 | 0,6203 |
| Skin and subcutaneous tissue disorders | Alopecia | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0692 | 0,12 | 0,01 | 1,47 | |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8926 | 0,83 | 0,05 | 13,21 | 0,9964 |
| Skin and subcutaneous tissue disorders | Dermatitis acneiform | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Skin and subcutaneous tissue disorders | Dermatitis bullous | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Drug eruption | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Drug eruption | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Dry skin | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2461 | 3,39 | 0,38 | 30,30 | 0,5203 |
| Skin and subcutaneous tissue disorders | Dry skin | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Eczema | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1951 | >999.99 | 0,00 | NE | 0,1644 |
| Skin and subcutaneous tissue disorders | Eczema | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9539 | 1,09 | 0,07 | 17,35 | |
| Skin and subcutaneous tissue disorders | Erythema | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,2298 | 0,23 | 0,02 | 2,96 | 0,4594 |
| Skin and subcutaneous tissue disorders | Erythema | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3428 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Hirsutism | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,8348 | >999.99 | 0,00 | NE | 0,9974 |
| Skin and subcutaneous tissue disorders | Hirsutism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Nail disorder | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Nail disorder | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1977 | >999.99 | 0,00 | NE | 0,9960 |
| Skin and subcutaneous tissue disorders | Photosensitivity reaction | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Skin and subcutaneous tissue disorders | Pigmentation disorder | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Pruritus | 0 | 72 | 56,3 | 7 | 9,7 | 65 | 90,3 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4124 | 2,49 | 0,26 | 23,99 | 0,1108 |
| Skin and subcutaneous tissue disorders | Pruritus | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Psoriasis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Psoriasis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash | 0 | 72 | 56,3 | 9 | 12,5 | 63 | 87,5 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,1478 | 4,28 | 0,50 | 36,62 | 0,1459 |
| Skin and subcutaneous tissue disorders | Rash | 1 | 56 | 43,8 | 9 | 16,1 | 47 | 83,9 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,6668 | 1,27 | 0,43 | 3,75 | |
| Skin and subcutaneous tissue disorders | Rash erythematous | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Rash erythematous | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8926 | 0,83 | 0,05 | 13,21 | 0,9964 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash papular | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Skin and subcutaneous tissue disorders | Rash papular | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Scar pain | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Skin and subcutaneous tissue disorders | Scar pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Seborrhoeic dermatitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin atrophy | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Skin and subcutaneous tissue disorders | Skin atrophy | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin fissures | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Skin fissures | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3711 | >999.99 | 0,00 | NE | | 0,9964 |
| Skin and subcutaneous tissue disorders | Skin hypopigmentation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Urticaria | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1977 | >999.99 | 0,00 | NE | | 0,9969 |
| Skin and subcutaneous tissue disorders | Urticaria | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Xeroderma | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Xeroderma | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Surgical and medical procedures | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Surgical and medical procedures | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Surgical and medical procedures | Cataract operation | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Surgical and medical procedures | Cataract operation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 11 | 18,3 | 49 | 81,7 | 0,0080 | 0,21 | 0,06 | 0,75 | | 0,1413 |
| Vascular disorders | | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,5855 | 0,70 | 0,20 | 2,50 | | |
| Vascular disorders | Embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0528 | 0,00 | 0,00 | NE | | 0,9964 |
| Vascular disorders | Embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Flushing | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,9974 |
| Vascular disorders | Flushing | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Haematoma | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Vascular disorders | Haematoma | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Hypertension | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0255 | 0,00 | 0,00 | NE | | 0,1140 |
| Vascular disorders | Hypertension | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,9398 | 1,08 | 0,15 | 7,66 | | |
| Vascular disorders | Hypotension | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4072 | 2,52 | 0,26 | 24,22 | | 0,2948 |
| Vascular disorders | Hypotension | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1414 | >999.99 | 0,00 | NE | | |
| Vascular disorders | Lymphoedema | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Phlebitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9979 |
| Vascular disorders | Phlebitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Vasculitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,9974 |
| Vascular disorders | Vasculitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Venous thrombosis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Vascular disorders | Venous thrombosis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3473 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTAE_SE_26JUN2023_40336.xls
26JAN2024 16:40

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.2 Unerwünschte Ereignisse UE nach Systemorganklassen (SOC) und Preferred Terms (PT)**

**4.1.2.2 Patienten mit schweren unerwünschten Ereignissen (UE ≥ Grad 3)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: All

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 12 | 10,0 | 108 | 90,0 | 0,0002 | 0,00 | 0,00 | NE | | NE |
| Blood and lymphatic system disorders | Anaemia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Blood and lymphatic system disorders | Febrile neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Blood and lymphatic system disorders | Leukopenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Blood and lymphatic system disorders | Neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 10 | 8,3 | 110 | 91,7 | 0,0009 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Atrial fibrillation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | 0,0591 | 0,30 | 0,08 | 1,13 | | NE |
| Gastrointestinal disorders | Abdominal pain | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Colitis | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Constipation | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9612 | 0,93 | 0,06 | 14,92 | | NE |
| Gastrointestinal disorders | Diarrhoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9648 | 0,94 | 0,06 | 15,02 | | NE |
| Gastrointestinal disorders | Epigastric discomfort | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Nausea | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,0199 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Pancreatitis acute | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Regurgitation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Stomatitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Vomiting | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1433 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,0289 | 0,10 | 0,01 | 1,05 | | NE |
| General disorders and administration site conditions | Asthenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0732 | 0,00 | 0,00 | NE | | NE |
| General disorders and administration site conditions | Fatigue | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,2101 | 0,18 | 0,01 | 2,98 | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Hepatobiliary disorders | Hyperbilirubinaemia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | n/a | 128 | 100,0 | 11 | 8,6 | 117 | 91,4 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,6967 | 0,67 | 0,09 | 5,15 | | NE |
| Infections and infestations | Appendicitis | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,9276 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Influenza | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Lower respiratory tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,6628 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Pneumonia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3192 | 0,09 | 0,00 | 12,49 | | NE |
| Infections and infestations | Urinary tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | | NE |
| Infections and infestations | Urosepsis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | n/a | 128 | 100,0 | 15 | 11,7 | 113 | 88,3 | 120 | 100,0 | 15 | 12,5 | 105 | 87,5 | 0,4506 | 0,75 | 0,35 | 1,60 | | NE |
| Investigations | Alanine aminotransferase increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Investigations | Aspartate aminotransferase increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Blood bilirubin increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | | NE |
| Investigations | Blood creatine phosphokinase increased | n/a | 128 | 100,0 | 8 | 6,3 | 120 | 93,8 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,0384 | 6,77 | 0,83 | 55,13 | | NE |
| Investigations | Blood creatinine increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | | NE |
| Investigations | Liver function test increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | | NE |
| Investigations | Lymphocyte count decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | | NE |
| Investigations | Neutrophil count decreased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 12 | 10,0 | 108 | 90,0 | 0,0003 | 0,00 | 0,00 | NE | | NE |
| Investigations | Weight increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | White blood cell count decreased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0376 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,2851 | 0,31 | 0,03 | 2,99 | | NE |
| Metabolism and nutrition disorders | Decreased appetite | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Metabolism and nutrition disorders | Hypophosphataemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | | NE |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9658 | 0,94 | 0,06 | 15,05 | | NE |
| Musculoskeletal and connective tissue disorders | Myalgia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Musculoskeletal and connective tissue disorders | Pain in extremity | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Respiratory, thoracic and mediastinal disorders | | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,5958 | 1,89 | 0,17 | 20,89 | | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Cough | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Vascular disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Essential hypertension | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR35AE_SE_26JUN2023_40336.xls
26JAN2024 16:54

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 13 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 1 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Anaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 2 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Febrile neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 3 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Leukopenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 4 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 15 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 5 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 6 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Acute myocardial infarction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 7 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Atrial fibrillation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 8 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 115 | 115 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 15 | 43 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 9 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 10 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Colitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 11 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Constipation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 12 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Diarrhoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 13 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Epigastric discomfort




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 14 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gastritis erosive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 15 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Nausea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 16 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Pancreatitis acute




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 17 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Regurgitation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 18 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Stomatitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 19 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Vomiting




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 20 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 21 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Asthenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 22 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Fatigue




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 23 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 24 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, Hyperbilirubinaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 25 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Infections and infestations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 111 | 110 | 105 | 102 | 76 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 26 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Appendicitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 27 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Influenza




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 28 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Infections and infestations, Lower respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 29 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pneumonia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 114 | 113 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 30 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urinary tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 31 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urosepsis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 32 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 110 | 105 | 104 | 101 | 99 | 74 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 14 | 39 |
| Platinum-Based Chemotherapy | 0 | 88 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 33 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Alanine aminotransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 34 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Aspartate aminotransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 35 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Blood bilirubin increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 36 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatine phosphokinase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 114 | 109 | 108 | 105 | 104 | 77 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 37 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatinine increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 38 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Liver function test increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 39 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Lymphocyte count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 40 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Neutrophil count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 91 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 41 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, Weight increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 42 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Investigations, White blood cell count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 43 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 44 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Decreased appetite




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 45 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypertriglyceridaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 46 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypophosphataemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 47 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Type 2 diabetes mellitus




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 48 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 49 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Myalgia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 50 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Pain in extremity




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 51 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 52 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, Benign prostatic hyperplasia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 53 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Uterine prolapse




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 54 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 55 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Asthma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 56 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Cough




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 57 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Dyspnoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 58 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pneumonitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 59 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pulmonary embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 60 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 61 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 62 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash maculo-papular




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 63 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Vascular disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 64 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Vascular disorders, Embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 65 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Vascular disorders, Essential hypertension




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 66 of 67

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**STUDY: BO40336**
Vascular disorders, Lymphoedema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR35AE_SE_26JUN2023_40336.pdf
26JAN2024 14:05

Page 67 of 67

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Sex

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 9 | 14,1 | 55 | 85,9 | 0,0044 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0440 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Anaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Blood and lymphatic system disorders | Anaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Blood and lymphatic system disorders | Febrile neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Leukopenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Blood and lymphatic system disorders | Leukopenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,0129 | 0,00 | 0,00 | NE | | 0,9971 |
| Blood and lymphatic system disorders | Neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0440 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9969 |
| Cardiac disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Atrial fibrillation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Cardiac disorders | Atrial fibrillation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,5309 | 0,59 | 0,11 | 3,19 | | 0,1487 |
| Gastrointestinal disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,0434 | 0,15 | 0,02 | 1,27 | | |
| Gastrointestinal disorders | Abdominal pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Gastrointestinal disorders | Abdominal pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Colitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Gastrointestinal disorders | Colitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Constipation | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,0711 |
| Gastrointestinal disorders | Constipation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Diarrhoea | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9019 | 1,19 | 0,07 | 19,03 | | 0,9964 |
| Gastrointestinal disorders | Diarrhoea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Gastrointestinal disorders | Epigastric discomfort | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9966 |
| Gastrointestinal disorders | Nausea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,0198 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Gastrointestinal disorders | Pancreatitis acute | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Gastrointestinal disorders | Regurgitation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Stomatitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Gastrointestinal disorders | Stomatitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Gastrointestinal disorders | Vomiting | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9952 |
| Gastrointestinal disorders | Vomiting | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1631 | 0,18 | 0,01 | 2,32 | | 0,2666 |
| General disorders and administration site conditions | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1027 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Asthenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1943 | 0,00 | 0,00 | NE | | 0,9974 |
| General disorders and administration site conditions | Asthenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Fatigue | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,5441 | 0,37 | 0,01 | 9,59 | | 0,2416 |
| General disorders and administration site conditions | Fatigue | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9958 |
| Hepatobiliary disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9958 |
| Hepatobiliary disorders | Hyperbilirubinaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,7309 | 1,55 | 0,12 | 19,32 | | 0,9633 |
| Infections and infestations | | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Appendicitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,8897 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Influenza | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9966 |
| Infections and infestations | Influenza | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,6456 | >999.99 | 0,00 | NE | | 0,9970 |
| Infections and infestations | Lower respiratory tract infection | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Infections and infestations | Pneumonia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9968 |
| Infections and infestations | Pneumonia | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urinary tract infection | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | | 0,1277 |
| Infections and infestations | Urinary tract infection | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 10 | 15,6 | 54 | 84,4 | 0,3415 | 0,60 | 0,20 | 1,75 | | 0,3938 |
| Investigations | | Female | 74 | 57,8 | 9 | 12,2 | 65 | 87,8 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,9243 | 1,06 | 0,34 | 3,33 | | |
| Investigations | Alanine aminotransferase increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9975 |
| Investigations | Alanine aminotransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Aspartate aminotransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | Blood bilirubin increased | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1219 | >999.99 | 0,00 | NE | | 0,9952 |
| Investigations | Blood bilirubin increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood creatine phosphokinase increased | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,2267 | 3,68 | 0,38 | 35,35 | | 0,3417 |
| Investigations | Blood creatine phosphokinase increased | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0787 | >999.99 | 0,00 | NE | | |
| Investigations | Blood creatinine increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Investigations | Blood creatinine increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| Investigations | Liver function test increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Investigations | Liver function test increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Investigations | Lymphocyte count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Investigations | Lymphocyte count decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 8 | 12,5 | 56 | 87,5 | 0,0077 | 0,00 | 0,00 | NE | | 0,9969 |
| Investigations | Neutrophil count decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,0201 | 0,00 | 0,00 | NE | | |
| Investigations | Weight increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Weight increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | White blood cell count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | | 0,9970 |
| Investigations | White blood cell count decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1102 | 0,00 | 0,00 | NE | | 0,1840 |
| Metabolism and nutrition disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Decreased appetite | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | | 0,9963 |
| Metabolism and nutrition disorders | Decreased appetite | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9973 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypophosphataemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Metabolism and nutrition disorders | Hypophosphataemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8990 | 1,20 | 0,07 | 19,13 | | 0,9964 |
| Musculoskeletal and connective tissue disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9966 |
| Musculoskeletal and connective tissue disorders | Myalgia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8971 | 1,20 | 0,08 | 19,19 | | 0,2536 |
| Respiratory, thoracic and mediastinal disorders | | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Cough | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Cough | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9966 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9968 |
| Skin and subcutaneous tissue disorders | | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Rash | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Rash | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,3893 |
| Vascular disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Vascular disorders | Embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Lymphoedema | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR35AE_SE_26JUN2023_40336.xls
26JAN2024 16:54

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Age

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0037 | 0,00 | 0,00 | NE | | 0,9969 |
| Blood and lymphatic system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,0362 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Anaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | Anaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | Febrile neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Leukopenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Blood and lymphatic system disorders | Leukopenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 6 | 6,9 | 81 | 93,1 | 0,0075 | 0,00 | 0,00 | NE | | 0,9971 |
| Blood and lymphatic system disorders | Neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,0631 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,0309 |
| Cardiac disorders | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Atrial fibrillation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9968 |
| Cardiac disorders | Atrial fibrillation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0522 | 0,24 | 0,05 | 1,15 | | 0,6704 |
| Gastrointestinal disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,6877 | 0,61 | 0,06 | 6,78 | | |
| Gastrointestinal disorders | Abdominal pain | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Abdominal pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Colitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Constipation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9977 |
| Gastrointestinal disorders | Constipation | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8956 | 1,20 | 0,08 | 19,24 | | |
| Gastrointestinal disorders | Diarrhoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,1176 |
| Gastrointestinal disorders | Diarrhoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3747 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Epigastric discomfort | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0148 | 0,00 | 0,00 | NE | | 0,9957 |
| Gastrointestinal disorders | Nausea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Pancreatitis acute | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Regurgitation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Stomatitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Gastrointestinal disorders | Stomatitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9955 |
| Gastrointestinal disorders | Vomiting | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0220 | 0,09 | 0,01 | 0,97 | | 0,9971 |
| General disorders and administration site conditions | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Asthenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0609 | 0,00 | 0,00 | NE | | 0,9967 |
| General disorders and administration site conditions | Asthenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1893 | 0,18 | 0,01 | 2,76 | | 0,9966 |
| General disorders and administration site conditions | Fatigue | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Hepatobiliary disorders | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Hepatobiliary disorders | Hyperbilirubinaemia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | < 65 | 101 | 78,9 | 10 | 9,9 | 91 | 90,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3103 | >999.99 | 0,00 | NE | | 0,0140 |
| Infections and infestations | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1970 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Appendicitis | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Infections and infestations | Influenza | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,6613 | >999.99 | 0,00 | NE | | 0,9958 |
| Infections and infestations | Lower respiratory tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Infections and infestations | Pneumonia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | 0,0461 |
| Infections and infestations | Pneumonia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urinary tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,1411 |
| Infections and infestations | Urinary tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urosepsis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 10 | 11,5 | 77 | 88,5 | 0,2983 | 0,60 | 0,23 | 1,58 | | 0,3428 |
| Investigations | | >= 65 | 27 | 21,1 | 6 | 22,2 | 21 | 77,8 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,7378 | 1,24 | 0,36 | 4,30 | | |
| Investigations | Alanine aminotransferase increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9975 |
| Investigations | Alanine aminotransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Aspartate aminotransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 1,0000 | NE | NE | NE | | |
| Investigations | Blood bilirubin increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9978 |
| Investigations | Blood bilirubin increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Investigations | Blood creatine phosphokinase increased | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,1374 | 4,43 | 0,52 | 37,93 | | 0,3917 |
| Investigations | Blood creatine phosphokinase increased | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1148 | >999.99 | 0,00 | NE | | |
| Investigations | Blood creatinine increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Investigations | Blood creatinine increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | | |
| Investigations | Liver function test increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Investigations | Liver function test increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2717 | >999.99 | 0,00 | NE | | |
| Investigations | Lymphocyte count decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,9967 |
| Investigations | Lymphocyte count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Neutrophil count decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 9 | 10,3 | 78 | 89,7 | 0,0010 | 0,00 | 0,00 | NE | | 0,9969 |
| Investigations | Neutrophil count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 3 | 9,1 | 30 | 90,9 | 0,1137 | 0,00 | 0,00 | NE | | |
| Investigations | Weight increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Weight increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Investigations | White blood cell count decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9970 |
| Investigations | White blood cell count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1974 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,2482 | 0,29 | 0,03 | 2,75 | | 0,9973 |
| Metabolism and nutrition disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Decreased appetite | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2837 | 0,00 | 0,00 | NE | | 0,9968 |
| Metabolism and nutrition disorders | Decreased appetite | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9963 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypophosphataemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | | 0,9967 |
| Metabolism and nutrition disorders | Hypophosphataemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | | 0,9968 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9187 | 0,87 | 0,05 | 13,84 | | 0,9971 |
| Musculoskeletal and connective tissue disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Musculoskeletal and connective tissue disorders | Myalgia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,2508 |
| Respiratory, thoracic and mediastinal disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8807 | 1,24 | 0,08 | 19,76 | | |
| Respiratory, thoracic and mediastinal disorders | Asthma | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Cough | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Respiratory, thoracic and mediastinal disorders | Cough | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | | 0,9971 |
| Skin and subcutaneous tissue disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Skin and subcutaneous tissue disorders | Rash | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,3984 |
| Vascular disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Vascular disorders | Embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Essential hypertension | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Lymphoedema | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR35AE_SE_26JUN2023_40336.xls
26JAN2024 16:54

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Geographic region

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,0371 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,0075 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Anaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Blood and lymphatic system disorders | Anaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Anaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | Febrile neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Leukopenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Blood and lymphatic system disorders | Leukopenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Leukopenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0719 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | Neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,0152 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | 0,6049 |
| Cardiac disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Cardiac disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Atrial fibrillation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Cardiac disorders | Atrial fibrillation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Cardiac disorders | Atrial fibrillation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,1520 | 0,23 | 0,03 | 2,06 | | 0,8103 |
| Gastrointestinal disorders | | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,1804 | 0,34 | 0,07 | 1,77 | | |
| Gastrointestinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Abdominal pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Abdominal pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Abdominal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Colitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Constipation | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9641 | 0,94 | 0,06 | 15,00 | | 1,0000 |
| Gastrointestinal disorders | Constipation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Constipation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Diarrhoea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Gastrointestinal disorders | Diarrhoea | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9301 | 0,88 | 0,06 | 14,12 | | |
| Gastrointestinal disorders | Diarrhoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Epigastric discomfort | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Nausea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0630 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Nausea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Gastrointestinal disorders | Pancreatitis acute | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Regurgitation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Stomatitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Gastrointestinal disorders | Stomatitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Gastrointestinal disorders | Stomatitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Vomiting | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Vomiting | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| General disorders and administration site conditions | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,2210 | 0,19 | 0,01 | 3,06 | | 0,4265 |
| General disorders and administration site conditions | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0630 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Asthenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3104 | 0,00 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Asthenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Asthenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,4630 | 0,31 | 0,01 | 7,70 | | 0,5720 |
| General disorders and administration site conditions | Fatigue | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Fatigue | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Hepatobiliary disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Hepatobiliary disorders | Hyperbilirubinaemia | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Asia Pacific | 73 | 57,0 | 9 | 12,3 | 64 | 87,7 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 0,0578 |
| Infections and infestations | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,2521 | 0,24 | 0,02 | 3,15 | | |
| Infections and infestations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Appendicitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Infections and infestations | Influenza | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Infections and infestations | Lower respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,6514 | >999.99 | 0,00 | NE | | |
| Infections and infestations | Lower respiratory tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 0,1047 |
| Infections and infestations | Pneumonia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Pneumonia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urinary tract infection | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | 0,2555 |
| Infections and infestations | Urinary tract infection | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urinary tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Asia Pacific | 73 | 57,0 | 6 | 8,2 | 67 | 91,8 | 69 | 57,5 | 10 | 14,5 | 59 | 85,5 | 0,2592 | 0,56 | 0,20 | 1,55 | | 0,1171 |
| Investigations | | Europe | 53 | 41,4 | 8 | 15,1 | 45 | 84,9 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,8413 | 0,88 | 0,25 | 3,05 | | |
| Investigations | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Investigations | Alanine aminotransferase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Investigations | Alanine aminotransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Alanine aminotransferase increased | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| Investigations | Aspartate aminotransferase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Aspartate aminotransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood bilirubin increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Investigations | Blood bilirubin increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Investigations | Blood bilirubin increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood creatine phosphokinase increased | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0275 | >999.99 | 0,00 | NE | | 0,3950 |
| Investigations | Blood creatine phosphokinase increased | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6237 | 1,81 | 0,16 | 19,94 | | |
| Investigations | Blood creatine phosphokinase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood creatinine increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Investigations | Blood creatinine increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | | |
| Investigations | Blood creatinine increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Liver function test increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Investigations | Liver function test increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | | |
| Investigations | Liver function test increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Lymphocyte count decreased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | | 1,0000 |
| Investigations | Lymphocyte count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Lymphocyte count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Neutrophil count decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 10 | 14,5 | 59 | 85,5 | 0,0008 | 0,00 | 0,00 | NE | | 1,0000 |
| Investigations | Neutrophil count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1346 | 0,00 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Weight increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Weight increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Weight increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | White blood cell count decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | | 1,0000 |
| Investigations | White blood cell count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | | |
| Investigations | White blood cell count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Metabolism and nutrition disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,5245 | 0,47 | 0,04 | 5,15 | | 0,2909 |
| Metabolism and nutrition disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Decreased appetite | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Decreased appetite | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Decreased appetite | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 0,2508 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypophosphataemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | | 1,0000 |
| Metabolism and nutrition disorders | Hypophosphataemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypophosphataemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 1,0000 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9376 | 0,90 | 0,06 | 14,31 | | |
| Musculoskeletal and connective tissue disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Myalgia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Reproductive system and breast disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 0,7080 |
| Respiratory, thoracic and mediastinal disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9426 | 0,90 | 0,06 | 14,44 | | |
| Respiratory, thoracic and mediastinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Cough | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Cough | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Cough | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | | 1,0000 |
| Skin and subcutaneous tissue disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Skin and subcutaneous tissue disorders | Rash | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 0,1427 |
| Vascular disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Vascular disorders | Essential hypertension | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Lymphoedema | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Lymphoedema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR35AE_SE_26JUN2023_40336.xls
26JAN2024 16:54

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3-5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Baseline ECOG

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0127 | 0,00 | 0,00 | NE | | 0,9969 |
| Blood and lymphatic system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 7 | 11,7 | 53 | 88,3 | 0,0089 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Anaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Blood and lymphatic system disorders | Anaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Blood and lymphatic system disorders | Febrile neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Leukopenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Blood and lymphatic system disorders | Leukopenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0265 | 0,00 | 0,00 | NE | | 0,9971 |
| Blood and lymphatic system disorders | Neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,0159 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,2561 |
| Cardiac disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Cardiac disorders | Atrial fibrillation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Cardiac disorders | Atrial fibrillation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,3107 | 0,48 | 0,12 | 2,03 | | 0,0816 |
| Gastrointestinal disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0514 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Abdominal pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Gastrointestinal disorders | Abdominal pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Colitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Gastrointestinal disorders | Colitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Constipation | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8926 | 0,83 | 0,05 | 13,21 | | 0,9964 |
| Gastrointestinal disorders | Constipation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Diarrhoea | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,1139 |
| Gastrointestinal disorders | Diarrhoea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3428 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Gastrointestinal disorders | Epigastric discomfort | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0557 | 0,00 | 0,00 | NE | | 0,9966 |
| Gastrointestinal disorders | Nausea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Gastrointestinal disorders | Pancreatitis acute | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Regurgitation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Gastrointestinal disorders | Regurgitation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Stomatitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9964 |
| Gastrointestinal disorders | Stomatitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,9951 |
| Gastrointestinal disorders | Vomiting | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4117 | 0,27 | 0,01 | 6,78 | | 0,1268 |
| General disorders and administration site conditions | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0514 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Asthenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9974 |
| General disorders and administration site conditions | Asthenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1740 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Fatigue | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7681 | >999.99 | 0,00 | NE | | 0,0608 |
| General disorders and administration site conditions | Fatigue | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9957 |
| Hepatobiliary disorders | | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9957 |
| Hepatobiliary disorders | Hyperbilirubinaemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | | 0,1942 |
| Infections and infestations | | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6384 | 0,58 | 0,06 | 5,92 | | |
| Infections and infestations | Appendicitis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Appendicitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Infections and infestations | Influenza | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Infections and infestations | Lower respiratory tract infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | | 0,9969 |
| Infections and infestations | Lower respiratory tract infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Infections and infestations | Pneumonia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Infections and infestations | Pneumonia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3756 | 0,15 | 0,00 | 10,70 | | |
| Infections and infestations | Urinary tract infection | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9973 |
| Infections and infestations | Urinary tract infection | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urosepsis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | 0 | 72 | 56,3 | 10 | 13,9 | 62 | 86,1 | 60 | 50,0 | 10 | 16,7 | 50 | 83,3 | 0,5282 | 0,75 | 0,30 | 1,85 | | 0,7475 |
| Investigations | | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,5317 | 0,64 | 0,15 | 2,66 | | |
| Investigations | Alanine aminotransferase increased | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9973 |
| Investigations | Alanine aminotransferase increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Aspartate aminotransferase increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Investigations | Aspartate aminotransferase increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood bilirubin increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9979 |
| Investigations | Blood bilirubin increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Investigations | Blood creatine phosphokinase increased | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0875 | 5,23 | 0,63 | 43,50 | | 0,4240 |
| Investigations | Blood creatine phosphokinase increased | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Investigations | Blood creatinine increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9963 |
| Investigations | Blood creatinine increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Liver function test increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9964 |
| Investigations | Liver function test increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Lymphocyte count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Investigations | Lymphocyte count decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 8 | 13,3 | 52 | 86,7 | 0,0013 | 0,00 | 0,00 | NE | | 0,9969 |
| Investigations | Neutrophil count decreased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0519 | 0,00 | 0,00 | NE | | |
| Investigations | Weight increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | Weight increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | White blood cell count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,9970 |
| Investigations | White blood cell count decreased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,0135 |
| Metabolism and nutrition disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0936 | 0,00 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Decreased appetite | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Metabolism and nutrition disorders | Decreased appetite | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,1152 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Metabolism and nutrition disorders | Hypophosphataemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9963 |
| Metabolism and nutrition disorders | Hypophosphataemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,1113 |
| Musculoskeletal and connective tissue disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Musculoskeletal and connective tissue disorders | Myalgia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9964 |
| Musculoskeletal and connective tissue disorders | Myalgia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,0260 |
| Respiratory, thoracic and mediastinal disorders | | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1414 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Asthma | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Cough | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Cough | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9979 |
| Skin and subcutaneous tissue disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Skin and subcutaneous tissue disorders | Rash | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Skin and subcutaneous tissue disorders | Rash | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9964 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,2609 |
| Vascular disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Vascular disorders | Embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Essential hypertension | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Essential hypertension | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Vascular disorders | Lymphoedema | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR35AE_SE_26JUN2023_40336.xls
26JAN2024 16:54

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: All

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 11 | 9,2 | 109 | 90,8 | 0,0005 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Anaemia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Febrile neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Leukopenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Blood and lymphatic system disorders | Neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 8 | 6,7 | 112 | 93,3 | 0,0030 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Cardiac disorders | Acute myocardial infarction | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Atrial fibrillation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | 0,0591 | 0,30 | 0,08 | 1,13 | NE |
| Gastrointestinal disorders | Abdominal pain | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Colitis | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Constipation | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9612 | 0,93 | 0,06 | 14,92 | NE |
| Gastrointestinal disorders | Diarrhoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9648 | 0,94 | 0,06 | 15,02 | NE |
| Gastrointestinal disorders | Epigastric discomfort | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Nausea | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,0199 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Pancreatitis acute | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Regurgitation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Gastrointestinal disorders | Stomatitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Gastrointestinal disorders | Vomiting | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1433 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 5 | 4,2 | 115 | 95,8 | 0,0289 | 0,10 | 0,01 | 1,05 | NE |
| General disorders and administration site conditions | Asthenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0732 | 0,00 | 0,00 | NE | NE |
| General disorders and administration site conditions | Fatigue | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,2101 | 0,18 | 0,01 | 2,98 | NE |
| | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Hepatobiliary disorders | Hyperbilirubinaemia | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | n/a | 128 | 100,0 | 11 | 8,6 | 117 | 91,4 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,6967 | 0,67 | 0,09 | 5,15 | NE |
| Infections and infestations | Appendicitis | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,9276 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Influenza | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Lower respiratory tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,6628 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Pneumonia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3192 | 0,09 | 0,00 | 12,49 | NE |
| Infections and infestations | Urinary tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Infections and infestations | Urosepsis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Investigations | | n/a | 128 | 100,0 | 14 | 10,9 | 114 | 89,1 | 120 | 100,0 | 14 | 11,7 | 106 | 88,3 | 0,4351 | 0,73 | 0,33 | 1,61 | NE |
| Investigations | Alanine aminotransferase increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Investigations | Aspartate aminotransferase increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Blood bilirubin increased | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | NE |
| Investigations | Blood creatine phosphokinase increased | n/a | 128 | 100,0 | 7 | 5,5 | 121 | 94,5 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,0662 | 5,77 | 0,69 | 48,02 | NE |
| Investigations | Blood creatinine increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Investigations | Liver function test increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Investigations | Lymphocyte count decreased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3336 | >999.99 | 0,00 | NE | NE |
| Investigations | Neutrophil count decreased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | 0,0017 | 0,00 | 0,00 | NE | NE |
| Investigations | Weight increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | White blood cell count decreased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0376 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,2851 | 0,31 | 0,03 | 2,99 | NE |
| Metabolism and nutrition disorders | Decreased appetite | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Hypophosphataemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | NE |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,9658 | 0,94 | 0,06 | 15,05 | NE |
| Musculoskeletal and connective tissue disorders | Myalgia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | NE |
| Musculoskeletal and connective tissue disorders | Pain in extremity | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | NE |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Respiratory, thoracic and mediastinal disorders | Cough | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Essential hypertension | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR3AE_SE_26JUN2023_40336.xls
26JAN2024 16:44

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 13 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 1 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Anaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 2 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Febrile neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 3 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Leukopenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 4 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 15 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 5 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 6 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Acute myocardial infarction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 7 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Atrial fibrillation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 8 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 115 | 115 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 15 | 43 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 9 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 10 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Colitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 11 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Constipation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 12 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Diarrhoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 13 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Epigastric discomfort




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 14 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Gastritis erosive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 15 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Nausea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 16 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Pancreatitis acute




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 17 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Regurgitation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 18 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Stomatitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 19 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Vomiting




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 20 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 96 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 21 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Asthenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 22 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Fatigue




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 23 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 24 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Hepatobiliary disorders, Hyperbilirubinaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 25 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Infections and infestations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 111 | 110 | 105 | 102 | 76 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 26 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Appendicitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 27 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Influenza




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 28 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Infections and infestations, Lower respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 29 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pneumonia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 114 | 113 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 30 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urinary tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 31 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urosepsis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 32 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 111 | 106 | 105 | 102 | 100 | 75 |
| Platinum-Based Chemotherapy | 120 | 17 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 14 | 39 |
| Platinum-Based Chemotherapy | 0 | 89 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 33 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Alanine aminotransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 34 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Aspartate aminotransferase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 35 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Blood bilirubin increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 36 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatine phosphokinase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 115 | 110 | 109 | 106 | 105 | 78 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 37 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatinine increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 38 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Investigations, Liver function test increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 39 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Lymphocyte count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 40 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Neutrophil count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 93 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 41 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, Weight increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 42 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Investigations, White blood cell count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 43 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 44 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Metabolism and nutrition disorders, Decreased appetite




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 45 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypertriglyceridaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 46 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypophosphataemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 47 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Type 2 diabetes mellitus




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 48 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 49 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Myalgia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 50 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Musculoskeletal and connective tissue disorders, Pain in extremity




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 51 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 52 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Benign prostatic hyperplasia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 53 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 114 | 114 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 54 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Asthma




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 55 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Cough




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 56 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Dyspnoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 57 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pneumonitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 58 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 59 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Skin and subcutaneous tissue disorders, Rash




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 60 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**

Skin and subcutaneous tissue disorders, Rash maculo-papular




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 61 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Vascular disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 62 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Vascular disorders, Embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 63 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Vascular disorders, Essential hypertension




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 64 of 65

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**STUDY: BO40336**
Vascular disorders, Lymphoedema




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR3AE_SE_26JUN2023_40336.pdf
26JAN2024 13:56

Page 65 of 65

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Sex

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 9 | 14,1 | 55 | 85,9 | 0,0044 | 0,00 | 0,00 | NE | 0,9970 |
| Blood and lymphatic system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Anaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Blood and lymphatic system disorders | Anaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Febrile neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Blood and lymphatic system disorders | Febrile neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Leukopenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Blood and lymphatic system disorders | Leukopenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 6 | 9,4 | 58 | 90,6 | 0,0219 | 0,00 | 0,00 | NE | 0,9974 |
| Blood and lymphatic system disorders | Neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9973 |
| Cardiac disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Acute myocardial infarction | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrial fibrillation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Cardiac disorders | Atrial fibrillation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,5309 | 0,59 | 0,11 | 3,19 | 0,1487 |
| Gastrointestinal disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,0434 | 0,15 | 0,02 | 1,27 | |
| Gastrointestinal disorders | Abdominal pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Gastrointestinal disorders | Abdominal pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Colitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Colitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,0711 |
| Gastrointestinal disorders | Constipation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Diarrhoea | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,9019 | 1,19 | 0,07 | 19,03 | 0,9964 |
| Gastrointestinal disorders | Diarrhoea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Epigastric discomfort | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Epigastric discomfort | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis erosive | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Nausea | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9966 |
| Gastrointestinal disorders | Nausea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | 0,0198 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Pancreatitis acute | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Gastrointestinal disorders | Pancreatitis acute | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9966 |
| Gastrointestinal disorders | Regurgitation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Stomatitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Gastrointestinal disorders | Stomatitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Vomiting | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9952 |
| Gastrointestinal disorders | Vomiting | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1631 | 0,18 | 0,01 | 2,32 | 0,2666 |
| General disorders and administration site conditions | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1027 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Asthenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1943 | 0,00 | 0,00 | NE | 0,9974 |
| General disorders and administration site conditions | Asthenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Fatigue | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,5441 | 0,37 | 0,01 | 9,59 | 0,2416 |
| General disorders and administration site conditions | Fatigue | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9958 |
| Hepatobiliary disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9958 |
| Hepatobiliary disorders | Hyperbilirubinaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,7309 | 1,55 | 0,12 | 19,32 | 0,9633 |
| Infections and infestations | | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |
| Infections and infestations | Appendicitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,8897 | >999.99 | 0,00 | NE | NE |
| Infections and infestations | Appendicitis | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Influenza | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Infections and infestations | Influenza | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Lower respiratory tract infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,6456 | >999.99 | 0,00 | NE | 0,9970 |
| Infections and infestations | Lower respiratory tract infection | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pneumonia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9968 |
| Infections and infestations | Pneumonia | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Urinary tract infection | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,1277 |
| Infections and infestations | Urinary tract infection | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urosepsis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Investigations | | Male | 54 | 42,2 | 6 | 11,1 | 48 | 88,9 | 64 | 53,3 | 9 | 14,1 | 55 | 85,9 | 0,4642 | 0,67 | 0,22 | 1,99 | 0,6052 |
| Investigations | | Female | 74 | 57,8 | 8 | 10,8 | 66 | 89,2 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,8592 | 0,90 | 0,27 | 2,95 | |
| Investigations | Alanine aminotransferase increased | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9975 |
| Investigations | Alanine aminotransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Aspartate aminotransferase increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Aspartate aminotransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood bilirubin increased | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,1219 | >999.99 | 0,00 | NE | 0,9952 |
| Investigations | Blood bilirubin increased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase increased | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,2267 | 3,68 | 0,38 | 35,35 | 0,4000 |
| Investigations | Blood creatine phosphokinase increased | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,1291 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Blood creatinine increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Investigations | Liver function test increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Liver function test increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Investigations | Lymphocyte count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Investigations | Lymphocyte count decreased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | |
| Investigations | Neutrophil count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 6 | 9,4 | 58 | 90,6 | 0,0220 | 0,00 | 0,00 | NE | 0,9973 |
| Investigations | Neutrophil count decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 3 | 5,4 | 53 | 94,6 | 0,0453 | 0,00 | 0,00 | NE | |
| Investigations | Weight increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Weight increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | White blood cell count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | 0,9970 |
| Investigations | White blood cell count decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,1102 | 0,00 | 0,00 | NE | 0,0488 |
| Metabolism and nutrition disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Decreased appetite | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | 0,9963 |
| Metabolism and nutrition disorders | Decreased appetite | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Metabolism and nutrition disorders | Hypophosphataemia | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8990 | 1,20 | 0,07 | 19,13 | 0,9964 |
| Musculoskeletal and connective tissue disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Myalgia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Musculoskeletal and connective tissue disorders | Myalgia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | 0,9963 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9979 |
| Respiratory, thoracic and mediastinal disorders | | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Cough | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | 0,9966 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9968 |
| Skin and subcutaneous tissue disorders | | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Rash | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Skin and subcutaneous tissue disorders | Rash | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | 0,9963 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,3893 |
| Vascular disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | 0,9963 |
| Vascular disorders | Embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Essential hypertension | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | NE |
| Vascular disorders | Essential hypertension | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Vascular disorders | Lymphoedema | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR3AE_SE_26JUN2023_40336.xls
26JAN2024 16:44

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Age

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0037 | 0,00 | 0,00 | NE | | 0,9970 |
| Blood and lymphatic system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,0639 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Anaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | Anaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | Febrile neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Leukopenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Blood and lymphatic system disorders | Leukopenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0149 | 0,00 | 0,00 | NE | | 0,9974 |
| Blood and lymphatic system disorders | Neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 3 | 9,1 | 30 | 90,9 | 0,1115 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,0661 |
| Cardiac disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Atrial fibrillation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9968 |
| Cardiac disorders | Atrial fibrillation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0522 | 0,24 | 0,05 | 1,15 | | 0,6704 |
| Gastrointestinal disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,6877 | 0,61 | 0,06 | 6,78 | | |
| Gastrointestinal disorders | Abdominal pain | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Abdominal pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Colitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Constipation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9977 |
| Gastrointestinal disorders | Constipation | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8956 | 1,20 | 0,08 | 19,24 | | |
| Gastrointestinal disorders | Diarrhoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | | 0,1176 |
| Gastrointestinal disorders | Diarrhoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3747 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Epigastric discomfort | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0148 | 0,00 | 0,00 | NE | | 0,9957 |
| Gastrointestinal disorders | Nausea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Pancreatitis acute | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Regurgitation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Stomatitis | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Gastrointestinal disorders | Stomatitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9955 |
| Gastrointestinal disorders | Vomiting | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 5 | 5,7 | 82 | 94,3 | 0,0220 | 0,09 | 0,01 | 0,97 | | 0,9971 |
| General disorders and administration site conditions | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Asthenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0609 | 0,00 | 0,00 | NE | | 0,9967 |
| General disorders and administration site conditions | Asthenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1893 | 0,18 | 0,01 | 2,76 | | 0,9966 |
| General disorders and administration site conditions | Fatigue | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Hepatobiliary disorders | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Hepatobiliary disorders | Hyperbilirubinaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Hepatobiliary disorders | Hyperbilirubinaemia | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | < 65 | 101 | 78,9 | 10 | 9,9 | 91 | 90,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3103 | >999.99 | 0,00 | NE | | 0,0140 |
| Infections and infestations | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1970 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Appendicitis | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Infections and infestations | Influenza | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,6613 | >999.99 | 0,00 | NE | | 0,9958 |
| Infections and infestations | Lower respiratory tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | 0,0461 |
| Infections and infestations | Pneumonia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Urinary tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,1411 |
| Infections and infestations | Urinary tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | |
| Infections and infestations | Urosepsis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Investigations | | < 65 | 101 | 78,9 | 8 | 7,9 | 93 | 92,1 | 87 | 72,5 | 10 | 11,5 | 77 | 88,5 | 0,1865 | 0,51 | 0,19 | 1,41 | 0,1717 |
| Investigations | | >= 65 | 27 | 21,1 | 6 | 22,2 | 21 | 77,8 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,5086 | 1,56 | 0,41 | 5,85 | |
| Investigations | Alanine aminotransferase increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9975 |
| Investigations | Alanine aminotransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Aspartate aminotransferase increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Aspartate aminotransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 1,0000 | NE | NE | NE | |
| Investigations | Blood bilirubin increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9978 |
| Investigations | Blood bilirubin increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatine phosphokinase increased | < 65 | 101 | 78,9 | 5 | 5,0 | 96 | 95,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2293 | 3,52 | 0,39 | 31,52 | 0,3563 |
| Investigations | Blood creatine phosphokinase increased | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1148 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Blood creatinine increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | |
| Investigations | Liver function test increased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Investigations | Liver function test increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2717 | >999.99 | 0,00 | NE | |
| Investigations | Lymphocyte count decreased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3513 | >999.99 | 0,00 | NE | 0,9967 |
| Investigations | Lymphocyte count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | Neutrophil count decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0038 | 0,00 | 0,00 | NE | 0,9973 |
| Investigations | Neutrophil count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1995 | 0,00 | 0,00 | NE | |
| Investigations | Weight increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Weight increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cell count decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | 0,9970 |
| Investigations | White blood cell count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1974 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,2482 | 0,29 | 0,03 | 2,75 | 0,9976 |
| Metabolism and nutrition disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Decreased appetite | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2837 | 0,00 | 0,00 | NE | 0,9968 |
| Metabolism and nutrition disorders | Decreased appetite | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3485 | >999.99 | 0,00 | NE | 0,9967 |
| Metabolism and nutrition disorders | Hypophosphataemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2833 | 0,00 | 0,00 | NE | 0,9968 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,9187 | 0,87 | 0,05 | 13,84 | 0,9971 |
| Musculoskeletal and connective tissue disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Myalgia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Musculoskeletal and connective tissue disorders | Myalgia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | 0,9968 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9978 |
| Respiratory, thoracic and mediastinal disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Asthma | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Respiratory, thoracic and mediastinal disorders | Cough | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | 0,9971 |
| Skin and subcutaneous tissue disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Skin and subcutaneous tissue disorders | Rash | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | 0,9967 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,3984 |
| Vascular disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | |
| Vascular disorders | Embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | 0,9971 |
| Vascular disorders | Embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | |
| Vascular disorders | Essential hypertension | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | NE |
| Vascular disorders | Essential hypertension | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Vascular disorders | Lymphoedema | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR3AE_SE_26JUN2023_40336.xls
26JAN2024 16:44

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Geographic region

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0728 | 0,00 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 6 | 12,8 | 41 | 87,2 | 0,0075 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Anaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Blood and lymphatic system disorders | Anaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Anaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Febrile neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Febrile neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Febrile neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Leukopenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Blood and lymphatic system disorders | Leukopenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Leukopenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | 1,0000 |
| Blood and lymphatic system disorders | Neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 4 | 8,5 | 43 | 91,5 | 0,0308 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Cardiac disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | |
| Cardiac disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Acute myocardial infarction | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Acute myocardial infarction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Cardiac disorders | Atrial fibrillation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Cardiac disorders | Atrial fibrillation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | |
| Cardiac disorders | Atrial fibrillation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,1520 | 0,23 | 0,03 | 2,06 | 0,8103 |
| Gastrointestinal disorders | | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,1804 | 0,34 | 0,07 | 1,77 | |
| Gastrointestinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Abdominal pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Abdominal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Colitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Colitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,9641 | 0,94 | 0,06 | 15,00 | 1,0000 |
| Gastrointestinal disorders | Constipation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Diarrhoea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Diarrhoea | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9301 | 0,88 | 0,06 | 14,12 | |
| Gastrointestinal disorders | Diarrhoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Epigastric discomfort | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Epigastric discomfort | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Epigastric discomfort | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis erosive | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis erosive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Nausea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Nausea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0630 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Nausea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Pancreatitis acute | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Pancreatitis acute | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Pancreatitis acute | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Regurgitation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Regurgitation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Stomatitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Gastrointestinal disorders | Stomatitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Gastrointestinal disorders | Stomatitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Vomiting | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Gastrointestinal disorders | Vomiting | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Vomiting | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,2210 | 0,19 | 0,01 | 3,06 | 0,4265 |
| General disorders and administration site conditions | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 3 | 6,4 | 44 | 93,6 | 0,0630 | 0,00 | 0,00 | NE | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| General disorders and administration site conditions | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Asthenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3104 | 0,00 | 0,00 | NE | 1,0000 |
| General disorders and administration site conditions | Asthenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Asthenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| General disorders and administration site conditions | Fatigue | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,4630 | 0,31 | 0,01 | 7,70 | 0,5720 |
| General disorders and administration site conditions | Fatigue | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Fatigue | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Hepatobiliary disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Hepatobiliary disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Hepatobiliary disorders | Hyperbilirubinaemia | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Hepatobiliary disorders | Hyperbilirubinaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Asia Pacific | 73 | 57,0 | 9 | 12,3 | 64 | 87,7 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 0,0578 |
| Infections and infestations | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,2521 | 0,24 | 0,02 | 3,15 | |
| Infections and infestations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Appendicitis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Appendicitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Infections and infestations | Appendicitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Influenza | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Infections and infestations | Influenza | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Influenza | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Lower respiratory tract infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Infections and infestations | Lower respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,6514 | >999.99 | 0,00 | NE | |
| Infections and infestations | Lower respiratory tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pneumonia | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 0,1047 |
| Infections and infestations | Pneumonia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Infections and infestations | Pneumonia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urinary tract infection | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | 0,2555 |
| Infections and infestations | Urinary tract infection | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Infections and infestations | Urinary tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urosepsis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Urosepsis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Investigations | | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 10 | 14,5 | 59 | 85,5 | 0,1493 | 0,46 | 0,16 | 1,35 | 0,0583 |
| Investigations | | Europe | 53 | 41,4 | 8 | 15,1 | 45 | 84,9 | 47 | 39,2 | 4 | 8,5 | 43 | 91,5 | 0,8838 | 1,10 | 0,30 | 4,11 | |
| Investigations | | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Investigations | Alanine aminotransferase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | Alanine aminotransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Alanine aminotransferase increased | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | |
| Investigations | Aspartate aminotransferase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Aspartate aminotransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Aspartate aminotransferase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood bilirubin increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Blood bilirubin increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Investigations | Blood bilirubin increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatine phosphokinase increased | Asia Pacific | 73 | 57,0 | 4 | 5,5 | 69 | 94,5 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0494 | >999.99 | 0,00 | NE | 0,4526 |
| Investigations | Blood creatine phosphokinase increased | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,6237 | 1,81 | 0,16 | 19,94 | |
| Investigations | Blood creatine phosphokinase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood creatinine increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | Blood creatinine increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Liver function test increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Investigations | Liver function test increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3428 | >999.99 | 0,00 | NE | |
| Investigations | Liver function test increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Lymphocyte count decreased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | 1,0000 |
| Investigations | Lymphocyte count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Lymphocyte count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Neutrophil count decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 8 | 11,6 | 61 | 88,4 | 0,0028 | 0,00 | 0,00 | NE | 1,0000 |
| Investigations | Neutrophil count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Investigations | Neutrophil count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | Weight increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Weight increased | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Investigations | Weight increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cell count decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | 1,0000 |
| Investigations | White blood cell count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,1311 | 0,00 | 0,00 | NE | |
| Investigations | White blood cell count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,5245 | 0,47 | 0,04 | 5,15 | 0,8101 |
| Metabolism and nutrition disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Decreased appetite | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Metabolism and nutrition disorders | Decreased appetite | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Decreased appetite | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,4795 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3313 | >999.99 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Hypophosphataemia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 1,0000 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Musculoskeletal and connective tissue disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9376 | 0,90 | 0,06 | 14,31 | |
| Musculoskeletal and connective tissue disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Myalgia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Musculoskeletal and connective tissue disorders | Myalgia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Musculoskeletal and connective tissue disorders | Myalgia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Asthma | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Cough | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Rash | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | 1,0000 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 0,1427 |
| Vascular disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Vascular disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | 1,0000 |
| Vascular disorders | Embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Essential hypertension | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Vascular disorders | Essential hypertension | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Vascular disorders | Essential hypertension | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Lymphoedema | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | NE |
| Vascular disorders | Lymphoedema | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | |
| Vascular disorders | Lymphoedema | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR3AE_SE_26JUN2023_40336.xls

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |

26JAN2024 16:44

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 3 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Baseline ECOG

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,0127 | 0,00 | 0,00 | NE | 0,9970 |
| Blood and lymphatic system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,0158 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Anaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Blood and lymphatic system disorders | Anaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Febrile neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Blood and lymphatic system disorders | Febrile neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Blood and lymphatic system disorders | Leukopenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Blood and lymphatic system disorders | Leukopenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Blood and lymphatic system disorders | Neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0265 | 0,00 | 0,00 | NE | 0,9974 |
| Blood and lymphatic system disorders | Neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0509 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,0776 |
| Cardiac disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Acute myocardial infarction | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Cardiac disorders | Acute myocardial infarction | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Cardiac disorders | Atrial fibrillation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Cardiac disorders | Atrial fibrillation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,3107 | 0,48 | 0,12 | 2,03 | 0,0816 |
| Gastrointestinal disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0514 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Abdominal pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Abdominal pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Colitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9965 |
| Gastrointestinal disorders | Colitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Constipation | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,8926 | 0,83 | 0,05 | 13,21 | 0,9964 |
| Gastrointestinal disorders | Constipation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Diarrhoea | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,1139 |
| Gastrointestinal disorders | Diarrhoea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3428 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Epigastric discomfort | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Gastrointestinal disorders | Epigastric discomfort | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Gastritis erosive | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Gastrointestinal disorders | Gastritis erosive | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Nausea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0557 | 0,00 | 0,00 | NE | 0,9966 |
| Gastrointestinal disorders | Nausea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Pancreatitis acute | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Pancreatitis acute | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Regurgitation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Gastrointestinal disorders | Regurgitation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Gastrointestinal disorders | Stomatitis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Gastrointestinal disorders | Stomatitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Gastrointestinal disorders | Vomiting | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | 0,9951 |
| Gastrointestinal disorders | Vomiting | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,4117 | 0,27 | 0,01 | 6,78 | 0,1268 |
| General disorders and administration site conditions | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0514 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Asthenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | 0,9974 |
| General disorders and administration site conditions | Asthenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1740 | 0,00 | 0,00 | NE | |
| General disorders and administration site conditions | Fatigue | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,7681 | >999.99 | 0,00 | NE | 0,0608 |
| General disorders and administration site conditions | Fatigue | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Hepatobiliary disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9957 |
| Hepatobiliary disorders | | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Hepatobiliary disorders | Hyperbilirubinaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9957 |
| Hepatobiliary disorders | Hyperbilirubinaemia | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | 0,1942 |
| Infections and infestations | | 1 | 56 | 43,8 | 6 | 10,7 | 50 | 89,3 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6384 | 0,58 | 0,06 | 5,92 | |
| Infections and infestations | Appendicitis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Appendicitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Influenza | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Infections and infestations | Influenza | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Infections and infestations | Lower respiratory tract infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | 0,9969 |
| Infections and infestations | Lower respiratory tract infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Infections and infestations | Pneumonia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9970 |
| Infections and infestations | Pneumonia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3756 | 0,15 | 0,00 | 10,70 | |

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | p-value (likelihood ratio) |
| Infections and infestations | Urinary tract infection | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9973 |
| Infections and infestations | Urinary tract infection | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Infections and infestations | Urosepsis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Infections and infestations | Urosepsis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Investigations | | 0 | 72 | 56,3 | 9 | 12,5 | 63 | 87,5 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,5256 | 0,74 | 0,28 | 1,91 | 0,7436 |
| Investigations | | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,5317 | 0,64 | 0,15 | 2,66 | |
| Investigations | Alanine aminotransferase increased | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9973 |
| Investigations | Alanine aminotransferase increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Aspartate aminotransferase increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Investigations | Aspartate aminotransferase increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Blood bilirubin increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9979 |
| Investigations | Blood bilirubin increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatine phosphokinase increased | 0 | 72 | 56,3 | 5 | 6,9 | 67 | 93,1 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,1452 | 4,32 | 0,50 | 37,04 | 0,3891 |
| Investigations | Blood creatine phosphokinase increased | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Investigations | Blood creatinine increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9963 |
| Investigations | Blood creatinine increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Liver function test increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9964 |
| Investigations | Liver function test increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | Lymphocyte count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Investigations | Lymphocyte count decreased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,2955 | >999.99 | 0,00 | NE | |
| Investigations | Neutrophil count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | 0,0058 | 0,00 | 0,00 | NE | 0,9973 |
| Investigations | Neutrophil count decreased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0945 | 0,00 | 0,00 | NE | |
| Investigations | Weight increased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Investigations | Weight increased | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Investigations | White blood cell count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | 0,9970 |
| Investigations | White blood cell count decreased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,0425 |
| Metabolism and nutrition disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,0936 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Decreased appetite | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Metabolism and nutrition disorders | Decreased appetite | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Metabolism and nutrition disorders | Hypophosphataemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | 0,9963 |
| Metabolism and nutrition disorders | Hypophosphataemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Metabolism and nutrition disorders | Type 2 diabetes mellitus | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3391 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Musculoskeletal and connective tissue disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,1113 |
| Musculoskeletal and connective tissue disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| Musculoskeletal and connective tissue disorders | Myalgia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Musculoskeletal and connective tissue disorders | Myalgia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9964 |
| Musculoskeletal and connective tissue disorders | Pain in extremity | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9967 |
| Respiratory, thoracic and mediastinal disorders | | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1414 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Asthma | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Respiratory, thoracic and mediastinal disorders | Asthma | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Respiratory, thoracic and mediastinal disorders | Cough | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Cough | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Skin and subcutaneous tissue disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9979 |
| Skin and subcutaneous tissue disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Rash | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | 0,9965 |
| Skin and subcutaneous tissue disorders | Rash | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | 0,9964 |
| Skin and subcutaneous tissue disorders | Rash maculo-papular | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,2609 |
| Vascular disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |
| Vascular disorders | Embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | 0,9965 |
| Vascular disorders | Embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | |
| Vascular disorders | Essential hypertension | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | NE |
| Vascular disorders | Essential hypertension | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Vascular disorders | Lymphoedema | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Vascular disorders | Lymphoedema | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR3AE_SE_26JUN2023_40336.xls
26JAN2024 16:44

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: All

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1430 | 0,00 | 0,00 | NE | | NE |
| Blood and lymphatic system disorders | Neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1430 | 0,00 | 0,00 | NE | | NE |
| Cardiac disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,2883 | 0,31 | 0,03 | 3,01 | | NE |
| Investigations | Blood creatine phosphokinase increased | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Investigations | Neutrophil count decreased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0739 | 0,00 | 0,00 | NE | | NE |
| Metabolism and nutrition disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR4AE_SE_26JUN2023_40336.xls
26JAN2024 16:48

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 1 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, Neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 2 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 3 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Acute myocardial infarction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 4 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Investigations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 5 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Investigations, Blood creatine phosphokinase increased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 6 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Investigations, Neutrophil count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 7 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 8 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**
Metabolism and nutrition disorders, Hypertriglyceridaemia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 9 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 10 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Uterine prolapse




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 11 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 12 of 13

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pulmonary embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ../data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTGR4AE_SE_26JUN2023_40336.pdf
26JAN2024 14:02

Page 13 of 13

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Sex

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9979 |
| Blood and lymphatic system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2471 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9979 |
| Blood and lymphatic system disorders | Neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2471 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1949 | 0,00 | 0,00 | NE | | 0,2514 |
| Investigations | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,8382 | 0,75 | 0,05 | 11,99 | | |
| Investigations | Blood creatine phosphokinase increased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Investigations | Blood creatine phosphokinase increased | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1949 | 0,00 | 0,00 | NE | | 0,9974 |
| Investigations | Neutrophil count decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR4AE_SE_26JUN2023_40336.xls
26JAN2024 16:48

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Age

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9965 |
| Blood and lymphatic system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9965 |
| Blood and lymphatic system disorders | Neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,4782 | 0,43 | 0,04 | 4,75 | | 0,4727 |
| Investigations | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Investigations | Blood creatine phosphokinase increased | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Investigations | Blood creatine phosphokinase increased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Neutrophil count decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1274 | 0,00 | 0,00 | NE | | 0,9974 |
| Investigations | Neutrophil count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Respiratory, thoracic and mediastinal disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR4AE_SE_26JUN2023_40336.xls
26JAN2024 16:48

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Geographic region

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | Neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,5335 | 0,47 | 0,04 | 5,23 | | 0,7023 |
| Investigations | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Investigations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood creatine phosphokinase increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Investigations | Blood creatine phosphokinase increased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Blood creatine phosphokinase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Neutrophil count decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1471 | 0,00 | 0,00 | NE | | 1,0000 |
| Investigations | Neutrophil count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Reproductive system and breast disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR4AE_SE_26JUN2023_40336.xls
26JAN2024 16:48

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 4 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Baseline ECOG

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9969 |
| Blood and lymphatic system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1723 | 0,00 | 0,00 | NE | | |
| Blood and lymphatic system disorders | Neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9969 |
| Blood and lymphatic system disorders | Neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1723 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,4583 | 0,41 | 0,04 | 4,58 | | 0,4555 |
| Investigations | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Investigations | Blood creatine phosphokinase increased | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9964 |
| Investigations | Blood creatine phosphokinase increased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Neutrophil count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1175 | 0,00 | 0,00 | NE | | 0,9974 |
| Investigations | Neutrophil count decreased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Metabolism and nutrition disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR4AE_SE_26JUN2023_40336.xls
26JAN2024 16:48

**POPULATION: Safety Population**
**ENDPOINT: Time to First Grade 5 Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Null Report: No results could be derived for this output.

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTGR5AE_SE_26JUN2023_40336.xls
26JAN2024 16:51

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.2 Unerwünschte Ereignisse UE nach Systemorganklassen (SOC) und Preferred Terms (PT)**

**4.1.2.3 Patienten mit schwerwiegenden unerwünschten Ereignissen (SUE)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: All

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Blood and lymphatic system disorders | Febrile neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Cardiac disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0376 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Abdominal pain | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Colitis | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Epigastric discomfort | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Ileus paralytic | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Nausea | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1433 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Pancreatitis acute | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Regurgitation | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Gastrointestinal disorders | Vomiting | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| General disorders and administration site conditions | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| General disorders and administration site conditions | Fatigue | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3017 | 0,00 | 0,00 | NE | | NE |
| Infections and infestations | | n/a | 128 | 100,0 | 11 | 8,6 | 117 | 91,4 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,6967 | 0,67 | 0,09 | 5,15 | | NE |
| Infections and infestations | Appendicitis | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,9276 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Influenza | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Lower respiratory tract infection | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,6628 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Pneumonia | n/a | 128 | 100,0 | 3 | 2,3 | 125 | 97,7 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3192 | 0,09 | 0,00 | 12,49 | | NE |
| Infections and infestations | Pneumonia viral | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Urinary tract infection | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3036 | 0,00 | 0,00 | NE | | NE |
| Infections and infestations | Urosepsis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Investigations | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1447 | 0,00 | 0,00 | NE | | NE |
| Investigations | Neutrophil count decreased | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1447 | 0,00 | 0,00 | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Reproductive system and breast disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | NE | NE | NE | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,5958 | 1,89 | 0,17 | 20,89 | | NE |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0,0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | NE |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3052 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |
| Vascular disorders | Embolism | n/a | 128 | 100,0 | 0 | 0,0 | 128 | 100,0 | 120 | 100,0 | 1 | 0,8 | 119 | 99,2 | 0,3010 | 0,00 | 0,00 | NE | | NE |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTSAE_SE_26JUN2023_40336.xls
26JAN2024 16:58

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Blood and lymphatic system disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 1 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Blood and lymphatic system disorders, Febrile neutropenia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 2 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Cardiac disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 3 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Cardiac disorders, Acute myocardial infarction




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 4 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 5 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Abdominal pain




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 6 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Colitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 7 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Epigastric discomfort




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 8 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Gastrointestinal disorders, Gastritis erosive




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 9 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Gastrointestinal disorders, Ileus paralytic




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 10 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Nausea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 11 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Pancreatitis acute




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 12 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Regurgitation




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 13 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Gastrointestinal disorders, Vomiting




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 14 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 15 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

General disorders and administration site conditions, Fatigue




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 16 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Infections and infestations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 111 | 110 | 106 | 102 | 76 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 17 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Infections and infestations, Appendicitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 115 | 115 | 111 | 108 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 18 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Infections and infestations, Influenza




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 19 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Infections and infestations, Lower respiratory tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 20 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Infections and infestations, Pneumonia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 114 | 113 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 21 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Infections and infestations, Pneumonia viral




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 22 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urinary tract infection




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 23 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Infections and infestations, Urosepsis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 24 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Investigations, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 25 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Investigations, Neutrophil count decreased




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 26 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Neoplasms benign, malignant and unspecified (incl cysts and polyps), All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 27 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Neoplasms benign, malignant and unspecified (incl cysts and polyps), Bladder cancer




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 28 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Reproductive system and breast disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 29 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Benign prostatic hyperplasia




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 30 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Reproductive system and breast disorders, Uterine prolapse




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 31 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 32 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Respiratory, thoracic and mediastinal disorders, Dyspnoea




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 33 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pneumonitis




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 34 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**

Respiratory, thoracic and mediastinal disorders, Pulmonary embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 35 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Vascular disorders, All




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 36 of 37

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**STUDY: BO40336**
Vascular disorders, Embolism




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..tudies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km_soc.sas
Output: ..36/data_analysis/ACE_INTERIM_2023/prod/output/g_km_soc_TTSAE_SE_26JUN2023_40336.pdf
26JAN2024 14:09

Page 37 of 37

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Sex

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Blood and lymphatic system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Blood and lymphatic system disorders | Febrile neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | | 0,0928 |
| Gastrointestinal disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Abdominal pain | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Gastrointestinal disorders | Abdominal pain | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Colitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Gastrointestinal disorders | Colitis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Gastrointestinal disorders | Epigastric discomfort | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Ileus paralytic | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Ileus paralytic | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9952 |
| Gastrointestinal disorders | Nausea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3583 | 0,00 | 0,00 | NE | | 0,9963 |
| Gastrointestinal disorders | Pancreatitis acute | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Gastrointestinal disorders | Regurgitation | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Vomiting | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| Gastrointestinal disorders | Vomiting | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| General disorders and administration site conditions | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Fatigue | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9966 |
| General disorders and administration site conditions | Fatigue | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,7309 | 1,55 | 0,12 | 19,32 | | 0,9647 |
| Infections and infestations | | Female | 74 | 57,8 | 7 | 9,5 | 67 | 90,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Appendicitis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,8897 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Influenza | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9966 |
| Infections and infestations | Influenza | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,6456 | >999.99 | 0,00 | NE | | 0,9970 |
| Infections and infestations | Lower respiratory tract infection | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9968 |
| Infections and infestations | Pneumonia | Female | 74 | 57,8 | 3 | 4,1 | 71 | 95,9 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Pneumonia viral | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Pneumonia viral | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Urinary tract infection | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3628 | 0,00 | 0,00 | NE | | 0,9963 |
| Infections and infestations | Urinary tract infection | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9979 |
| Investigations | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9979 |
| Investigations | Neutrophil count decreased | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,8971 | 1,20 | 0,08 | 19,19 | | 0,3775 |
| Respiratory, thoracic and mediastinal disorders | | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Male | 54 | 42,2 | 1 | 1,9 | 53 | 98,1 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | 0,2763 | >999.99 | 0,00 | NE | | 0,9966 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Vascular disorders | | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 1 | 1,6 | 63 | 98,4 | 0,3598 | 0,00 | 0,00 | NE | | 0,9963 |
| Vascular disorders | Embolism | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTSAE_SE_26JUN2023_40336.xls
26JAN2024 16:58

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Age

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Blood and lymphatic system disorders | Febrile neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 4 | 4,6 | 83 | 95,4 | 0,0297 | 0,00 | 0,00 | NE | | 0,9959 |
| Gastrointestinal disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Abdominal pain | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Abdominal pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Colitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2861 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Epigastric discomfort | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Ileus paralytic | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Ileus paralytic | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9955 |
| Gastrointestinal disorders | Nausea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Pancreatitis acute | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Regurgitation | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| Gastrointestinal disorders | Vomiting | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| General disorders and administration site conditions | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9968 |
| General disorders and administration site conditions | Fatigue | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3103 | >999.99 | 0,00 | NE | | 0,0349 |
| Infections and infestations | | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,1970 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Appendicitis | < 65 | 101 | 78,9 | 4 | 4,0 | 97 | 96,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | NE |
| Infections and infestations | Appendicitis | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Infections and infestations | Influenza | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,6613 | >999.99 | 0,00 | NE | | 0,9958 |
| Infections and infestations | Lower respiratory tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,9199 | >999.99 | 0,00 | NE | | 0,0461 |
| Infections and infestations | Pneumonia | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Pneumonia viral | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Pneumonia viral | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urinary tract infection | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9969 |
| Infections and infestations | Urinary tract infection | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3657 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urosepsis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9965 |
| Investigations | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 1 | 1,1 | 86 | 98,9 | 0,2813 | 0,00 | 0,00 | NE | | 0,9965 |
| Investigations | Neutrophil count decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,3635 |
| Respiratory, thoracic and mediastinal disorders | | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,8807 | 1,24 | 0,08 | 19,76 | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | 0,3534 | >999.99 | 0,00 | NE | | 0,9967 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Vascular disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| Vascular disorders | Embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0,0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| Vascular disorders | Embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3630 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTSAE_SE_26JUN2023_40336.xls
26JAN2024 16:58

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Geographic region

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Blood and lymphatic system disorders | Febrile neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Cardiac disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0727 | 0,00 | 0,00 | NE | | 0,8186 |
| Gastrointestinal disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Abdominal pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Abdominal pain | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Abdominal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Colitis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Colitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3033 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Epigastric discomfort | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Ileus paralytic | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Gastrointestinal disorders | Ileus paralytic | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Ileus paralytic | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Nausea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Gastrointestinal disorders | Pancreatitis acute | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Regurgitation | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Regurgitation | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Gastrointestinal disorders | Vomiting | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Vomiting | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| General disorders and administration site conditions | Fatigue | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| General disorders and administration site conditions | Fatigue | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | Asia Pacific | 73 | 57,0 | 9 | 12,3 | 64 | 87,7 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 0,0580 |
| Infections and infestations | | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,2521 | 0,24 | 0,02 | 3,15 | | |
| Infections and infestations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Appendicitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Infections and infestations | Appendicitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Infections and infestations | Influenza | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Lower respiratory tract infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Infections and infestations | Lower respiratory tract infection | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,6514 | >999.99 | 0,00 | NE | | |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Infections and infestations | Lower respiratory tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia | Asia Pacific | 73 | 57,0 | 3 | 4,1 | 70 | 95,9 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 0,1047 |
| Infections and infestations | Pneumonia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Pneumonia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia viral | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Infections and infestations | Pneumonia viral | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia viral | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urinary tract infection | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Infections and infestations | Urinary tract infection | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urinary tract infection | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urosepsis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Investigations | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Investigations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Investigations | Neutrophil count decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3037 | 0,00 | 0,00 | NE | | 1,0000 |
| Investigations | Neutrophil count decreased | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Reproductive system and breast disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 1,0000 | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 0,5828 |
| Respiratory, thoracic and mediastinal disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,9426 | 0,90 | 0,06 | 14,44 | | |
| Respiratory, thoracic and mediastinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,2996 | 0,00 | 0,00 | NE | | 1,0000 |
| Vascular disorders | Embolism | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0,0 | 47 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTSAE_SE_26JUN2023_40336.xls
26JAN2024 16:58

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to First Serious Adverse Event**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis (Safety)**

Name: Baseline ECOG

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Blood and lymphatic system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Blood and lymphatic system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Blood and lymphatic system disorders | Febrile neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Blood and lymphatic system disorders | Febrile neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Cardiac disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Cardiac disorders | Acute myocardial infarction | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Cardiac disorders | Acute myocardial infarction | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Gastrointestinal disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,8604 |
| Gastrointestinal disorders | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Abdominal pain | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Gastrointestinal disorders | Abdominal pain | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Colitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Gastrointestinal disorders | Colitis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Epigastric discomfort | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Gastrointestinal disorders | Epigastric discomfort | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Gastritis erosive | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Gastrointestinal disorders | Gastritis erosive | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Gastrointestinal disorders | Ileus paralytic | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| Gastrointestinal disorders | Ileus paralytic | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | |
| Gastrointestinal disorders | Nausea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9979 |
| Gastrointestinal disorders | Nausea | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Pancreatitis acute | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Gastrointestinal disorders | Pancreatitis acute | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Regurgitation | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Gastrointestinal disorders | Regurgitation | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Gastrointestinal disorders | Vomiting | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2733 | 0,00 | 0,00 | NE | | 0,9965 |
| Gastrointestinal disorders | Vomiting | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| General disorders and administration site conditions | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| General disorders and administration site conditions | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| General disorders and administration site conditions | Fatigue | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| General disorders and administration site conditions | Fatigue | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Infections and infestations | | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | | 0,1374 |
| Infections and infestations | | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,6384 | 0,58 | 0,06 | 5,92 | | |
| Infections and infestations | Appendicitis | 0 | 72 | 56,3 | 3 | 4,2 | 69 | 95,8 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Appendicitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Influenza | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Infections and infestations | Influenza | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Infections and infestations | Lower respiratory tract infection | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,6897 | >999.99 | 0,00 | NE | | 0,9969 |
| Infections and infestations | Lower respiratory tract infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Pneumonia | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9970 |
| Infections and infestations | Pneumonia | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3756 | 0,15 | 0,00 | 10,70 | | |
| Infections and infestations | Pneumonia viral | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Pneumonia viral | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Infections and infestations | Urinary tract infection | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9964 |
| Infections and infestations | Urinary tract infection | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3384 | 0,00 | 0,00 | NE | | |
| Infections and infestations | Urosepsis | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Infections and infestations | Urosepsis | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Investigations | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9979 |
| Investigations | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| Investigations | Neutrophil count decreased | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9979 |
| Investigations | Neutrophil count decreased | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |

## Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Reproductive system and breast disorders | | 0 | 72 | 56,3 | 2 | 2,8 | 70 | 97,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Benign prostatic hyperplasia | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Reproductive system and breast disorders | Uterine prolapse | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | NE |
| Reproductive system and breast disorders | Uterine prolapse | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,0400 |
| Respiratory, thoracic and mediastinal disorders | | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,1414 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |
| Vascular disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Vascular disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| Vascular disorders | Embolism | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,2678 | 0,00 | 0,00 | NE | | 0,9965 |
| Vascular disorders | Embolism | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_soc_sg2_TTSAE_SE_26JUN2023_40336.xls
26JAN2024 16:58

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.2 Unerwünschte Ereignisse UE nach Systemorganklassen (SOC) und Preferred Terms (PT)**

**4.1.2.4 Patienten mit Therapieabbruch aufgrund Unerwünschter Ereignisse (UE)**

Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Adverse Event leading to Treatment Discontinuation**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Dichotomous Analysis (Safety)**

Name: All

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Blood and lymphatic system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 2 | 1,7 |
| Blood and lymphatic system disorders | Anaemia | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Blood and lymphatic system disorders | Neutropenia | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| | | | | | | | | | | |
| Ear and labyrinth disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 3 | 2,5 |
| Ear and labyrinth disorders | Deafness | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Ear and labyrinth disorders | Tinnitus | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 2 | 1,7 |
| | | | | | | | | | | |
| Gastrointestinal disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 4 | 3,3 |
| Gastrointestinal disorders | Abdominal pain | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Gastrointestinal disorders | Nausea | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 4 | 3,3 |
| Gastrointestinal disorders | Regurgitation | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Gastrointestinal disorders | Vomiting | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 2 | 1,7 |
| | | | | | | | | | | |
| General disorders and administration site conditions | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 5 | 4,2 |
| General disorders and administration site conditions | Asthenia | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 3 | 2,5 |
| General disorders and administration site conditions | Fatigue | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 2 | 1,7 |
| | | | | | | | | | | |
| Infections and infestations | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Infections and infestations | Pneumonia | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| | | | | | | | | | | |
| Investigations | | n/a | 128 | 100,0 | 3 | 2,3 | 120 | 100,0 | 3 | 2,5 |
| Investigations | Alanine aminotransferase increased | n/a | 128 | 100,0 | 1 | 0,8 | 120 | 100,0 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | n/a | 128 | 100,0 | 1 | 0,8 | 120 | 100,0 | 0 | 0,0 |
| Investigations | Blood creatinine increased | n/a | 128 | 100,0 | 1 | 0,8 | 120 | 100,0 | 2 | 1,7 |
| Investigations | Creatinine renal clearance decreased | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Investigations | Liver function test increased | n/a | 128 | 100,0 | 1 | 0,8 | 120 | 100,0 | 0 | 0,0 |
| | | | | | | | | | | |
| Metabolism and nutrition disorders | | n/a | 128 | 100,0 | 1 | 0,8 | 120 | 100,0 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | n/a | 128 | 100,0 | 1 | 0,8 | 120 | 100,0 | 0 | 0,0 |
| | | | | | | | | | | |
| Nervous system disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Nervous system disorders | Neuropathy peripheral | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| | | | | | | | | | | |
| Renal and urinary disorders | | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 2 | 1,7 |
| Renal and urinary disorders | Renal failure | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| Renal and urinary disorders | Renal impairment | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |
| | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | n/a | 128 | 100,0 | 3 | 2,3 | 120 | 100,0 | 1 | 0,8 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | n/a | 128 | 100,0 | 3 | 2,3 | 120 | 100,0 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | n/a | 128 | 100,0 | 0 | 0,0 | 120 | 100,0 | 1 | 0,8 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_soc_descriptive.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_soc_descriptive_sg2_TTWDAE_SE_26JUN2023_40336.xls
26JAN2024 16:02

**POPULATION: Safety Population**
**ENDPOINT: Adverse Event leading to Treatment Discontinuation**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Dichotomous Analysis (Safety)**

Name: Sex

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Blood and lymphatic system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 2 | 3,1 |
| Blood and lymphatic system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| Blood and lymphatic system disorders | Anaemia | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Blood and lymphatic system disorders | Anaemia | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| Blood and lymphatic system disorders | Neutropenia | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Blood and lymphatic system disorders | Neutropenia | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| | | | | | | | | | | |
| Ear and labyrinth disorders | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Ear and labyrinth disorders | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 2 | 3,6 |
| Ear and labyrinth disorders | Deafness | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Ear and labyrinth disorders | Deafness | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| Ear and labyrinth disorders | Tinnitus | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Ear and labyrinth disorders | Tinnitus | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 2 | 3,6 |
| | | | | | | | | | | |
| Gastrointestinal disorders | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Gastrointestinal disorders | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 4 | 7,1 |
| Gastrointestinal disorders | Abdominal pain | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Gastrointestinal disorders | Abdominal pain | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| Gastrointestinal disorders | Nausea | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Gastrointestinal disorders | Nausea | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 4 | 7,1 |
| Gastrointestinal disorders | Regurgitation | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Gastrointestinal disorders | Regurgitation | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| Gastrointestinal disorders | Vomiting | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Gastrointestinal disorders | Vomiting | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 2 | 3,6 |
| | | | | | | | | | | |
| General disorders and administration site conditions | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 3 | 4,7 |
| General disorders and administration site conditions | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 2 | 3,6 |
| General disorders and administration site conditions | Asthenia | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 2 | 3,1 |
| General disorders and administration site conditions | Asthenia | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| General disorders and administration site conditions | Fatigue | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| General disorders and administration site conditions | Fatigue | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| | | | | | | | | | | |
| Infections and infestations | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Infections and infestations | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| Infections and infestations | Pneumonia | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Infections and infestations | Pneumonia | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| | | | | | | | | | | |
| Investigations | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 2 | 3,1 |
| Investigations | | Female | 74 | 57,8 | 3 | 4,1 | 56 | 46,7 | 1 | 1,8 |
| Investigations | Alanine aminotransferase increased | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Investigations | Alanine aminotransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 56 | 46,7 | 0 | 0,0 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Investigations | Aspartate aminotransferase increased | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | Female | 74 | 57,8 | 1 | 1,4 | 56 | 46,7 | 0 | 0,0 |
| Investigations | Blood creatinine increased | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 2 | 3,1 |
| Investigations | Blood creatinine increased | Female | 74 | 57,8 | 1 | 1,4 | 56 | 46,7 | 0 | 0,0 |
| Investigations | Creatinine renal clearance decreased | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Investigations | Creatinine renal clearance decreased | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| Investigations | Liver function test increased | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Investigations | Liver function test increased | Female | 74 | 57,8 | 1 | 1,4 | 56 | 46,7 | 0 | 0,0 |
| | | | | | | | | | | |
| Metabolism and nutrition disorders | | Male | 54 | 42,2 | 1 | 1,9 | 64 | 53,3 | 0 | 0,0 |
| Metabolism and nutrition disorders | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Male | 54 | 42,2 | 1 | 1,9 | 64 | 53,3 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| | | | | | | | | | | |
| Nervous system disorders | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Nervous system disorders | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| Nervous system disorders | Neuropathy peripheral | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Nervous system disorders | Neuropathy peripheral | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| | | | | | | | | | | |
| Renal and urinary disorders | | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Renal and urinary disorders | | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| Renal and urinary disorders | Renal failure | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 0 | 0,0 |
| Renal and urinary disorders | Renal failure | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 1 | 1,8 |
| Renal and urinary disorders | Renal impairment | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Renal and urinary disorders | Renal impairment | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Male | 54 | 42,2 | 1 | 1,9 | 64 | 53,3 | 1 | 1,6 |
| Respiratory, thoracic and mediastinal disorders | | Female | 74 | 57,8 | 2 | 2,7 | 56 | 46,7 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Male | 54 | 42,2 | 1 | 1,9 | 64 | 53,3 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Female | 74 | 57,8 | 2 | 2,7 | 56 | 46,7 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Male | 54 | 42,2 | 0 | 0,0 | 64 | 53,3 | 1 | 1,6 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Female | 74 | 57,8 | 0 | 0,0 | 56 | 46,7 | 0 | 0,0 |
| | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_soc_descriptive.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_soc_descriptive_sg2_TTWDAE_SE_26JUN2023_40336.xls
26JAN2024 16:02

Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Adverse Event leading to Treatment Discontinuation**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Dichotomous Analysis (Safety)**

Name: Age

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Blood and lymphatic system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Blood and lymphatic system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| Blood and lymphatic system disorders | Anaemia | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Blood and lymphatic system disorders | Anaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Blood and lymphatic system disorders | Neutropenia | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Blood and lymphatic system disorders | Neutropenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| | | | | | | | | | | |
| Ear and labyrinth disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 2 | 2,3 |
| Ear and labyrinth disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| Ear and labyrinth disorders | Deafness | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Ear and labyrinth disorders | Deafness | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| Ear and labyrinth disorders | Tinnitus | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 2 | 2,3 |
| Ear and labyrinth disorders | Tinnitus | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| | | | | | | | | | | |
| Gastrointestinal disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 4 | 4,6 |
| Gastrointestinal disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Gastrointestinal disorders | Abdominal pain | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Gastrointestinal disorders | Abdominal pain | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Gastrointestinal disorders | Nausea | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 4 | 4,6 |
| Gastrointestinal disorders | Nausea | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Gastrointestinal disorders | Regurgitation | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Gastrointestinal disorders | Regurgitation | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Gastrointestinal disorders | Vomiting | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 2 | 2,3 |
| Gastrointestinal disorders | Vomiting | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| | | | | | | | | | | |
| General disorders and administration site conditions | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 5 | 5,7 |
| General disorders and administration site conditions | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| General disorders and administration site conditions | Asthenia | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 3 | 3,4 |
| General disorders and administration site conditions | Asthenia | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| General disorders and administration site conditions | Fatigue | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 2 | 2,3 |
| General disorders and administration site conditions | Fatigue | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| | | | | | | | | | | |
| Infections and infestations | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Infections and infestations | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| Infections and infestations | Pneumonia | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Infections and infestations | Pneumonia | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| | | | | | | | | | | |
| Investigations | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 2 | 2,3 |
| Investigations | | >= 65 | 27 | 21,1 | 3 | 11,1 | 33 | 27,5 | 1 | 3,0 |
| Investigations | Alanine aminotransferase increased | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Investigations | Alanine aminotransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 33 | 27,5 | 0 | 0,0 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Investigations | Aspartate aminotransferase increased | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 33 | 27,5 | 0 | 0,0 |
| Investigations | Blood creatinine increased | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Investigations | Blood creatinine increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 33 | 27,5 | 1 | 3,0 |
| Investigations | Creatinine renal clearance decreased | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Investigations | Creatinine renal clearance decreased | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Investigations | Liver function test increased | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Investigations | Liver function test increased | >= 65 | 27 | 21,1 | 1 | 3,7 | 33 | 27,5 | 0 | 0,0 |
| | | | | | | | | | | |
| Metabolism and nutrition disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 87 | 72,5 | 0 | 0,0 |
| Metabolism and nutrition disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | < 65 | 101 | 78,9 | 1 | 1,0 | 87 | 72,5 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| | | | | | | | | | | |
| Nervous system disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Nervous system disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Nervous system disorders | Neuropathy peripheral | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Nervous system disorders | Neuropathy peripheral | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| | | | | | | | | | | |
| Renal and urinary disorders | | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Renal and urinary disorders | | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| Renal and urinary disorders | Renal failure | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 1 | 1,1 |
| Renal and urinary disorders | Renal failure | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 0 | 0,0 |
| Renal and urinary disorders | Renal impairment | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Renal and urinary disorders | Renal impairment | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | < 65 | 101 | 78,9 | 1 | 1,0 | 87 | 72,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | | >= 65 | 27 | 21,1 | 2 | 7,4 | 33 | 27,5 | 1 | 3,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | < 65 | 101 | 78,9 | 1 | 1,0 | 87 | 72,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | >= 65 | 27 | 21,1 | 2 | 7,4 | 33 | 27,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | < 65 | 101 | 78,9 | 0 | 0,0 | 87 | 72,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | >= 65 | 27 | 21,1 | 0 | 0,0 | 33 | 27,5 | 1 | 3,0 |
| | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_soc_descriptive.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_soc_descriptive_sg2_TTWDAE_SE_26JUN2023_40336.xls
26JAN2024 16:02

Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Adverse Event leading to Treatment Discontinuation**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Dichotomous Analysis (Safety)**

Name: Geographic region

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Blood and lymphatic system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Blood and lymphatic system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 2 | 4,3 |
| Blood and lymphatic system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Blood and lymphatic system disorders | Anaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Blood and lymphatic system disorders | Anaemia | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Blood and lymphatic system disorders | Anaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Blood and lymphatic system disorders | Neutropenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Blood and lymphatic system disorders | Neutropenia | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Blood and lymphatic system disorders | Neutropenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Ear and labyrinth disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Ear and labyrinth disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 3 | 6,4 |
| Ear and labyrinth disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Ear and labyrinth disorders | Deafness | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Ear and labyrinth disorders | Deafness | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Ear and labyrinth disorders | Deafness | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Ear and labyrinth disorders | Tinnitus | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Ear and labyrinth disorders | Tinnitus | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 2 | 4,3 |
| Ear and labyrinth disorders | Tinnitus | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Gastrointestinal disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 2 | 2,9 |
| Gastrointestinal disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 2 | 4,3 |
| Gastrointestinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Gastrointestinal disorders | Abdominal pain | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| Gastrointestinal disorders | Abdominal pain | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 0 | 0,0 |
| Gastrointestinal disorders | Abdominal pain | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Gastrointestinal disorders | Nausea | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 2 | 2,9 |
| Gastrointestinal disorders | Nausea | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 2 | 4,3 |
| Gastrointestinal disorders | Nausea | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Gastrointestinal disorders | Regurgitation | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| Gastrointestinal disorders | Regurgitation | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 0 | 0,0 |
| Gastrointestinal disorders | Regurgitation | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Gastrointestinal disorders | Vomiting | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| Gastrointestinal disorders | Vomiting | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Gastrointestinal disorders | Vomiting | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| General disorders and administration site conditions | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| General disorders and administration site conditions | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 4 | 8,5 |
| General disorders and administration site conditions | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| General disorders and administration site conditions | Asthenia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| General disorders and administration site conditions | Asthenia | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 3 | 6,4 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| General disorders and administration site conditions | Asthenia | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| General disorders and administration site conditions | Fatigue | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| General disorders and administration site conditions | Fatigue | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| General disorders and administration site conditions | Fatigue | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Infections and infestations | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Infections and infestations | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Infections and infestations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Infections and infestations | Pneumonia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Infections and infestations | Pneumonia | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Infections and infestations | Pneumonia | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Investigations | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 69 | 57,5 | 2 | 2,9 |
| Investigations | | Europe | 53 | 41,4 | 2 | 3,8 | 47 | 39,2 | 1 | 2,1 |
| Investigations | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Investigations | Alanine aminotransferase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Investigations | Alanine aminotransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 47 | 39,2 | 0 | 0,0 |
| Investigations | Alanine aminotransferase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | Europe | 53 | 41,4 | 1 | 1,9 | 47 | 39,2 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Investigations | Blood creatinine increased | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 69 | 57,5 | 1 | 1,4 |
| Investigations | Blood creatinine increased | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Investigations | Blood creatinine increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Investigations | Creatinine renal clearance decreased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| Investigations | Creatinine renal clearance decreased | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 0 | 0,0 |
| Investigations | Creatinine renal clearance decreased | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Investigations | Liver function test increased | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Investigations | Liver function test increased | Europe | 53 | 41,4 | 1 | 1,9 | 47 | 39,2 | 0 | 0,0 |
| Investigations | Liver function test increased | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Metabolism and nutrition disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Metabolism and nutrition disorders | | Europe | 53 | 41,4 | 1 | 1,9 | 47 | 39,2 | 0 | 0,0 |
| Metabolism and nutrition disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Europe | 53 | 41,4 | 1 | 1,9 | 47 | 39,2 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Nervous system disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Nervous system disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Nervous system disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Nervous system disorders | Neuropathy peripheral | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Nervous system disorders | Neuropathy peripheral | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Nervous system disorders | Neuropathy peripheral | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Renal and urinary disorders | | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 2 | 2,9 |
| Renal and urinary disorders | | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 0 | 0,0 |
| Renal and urinary disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Renal and urinary disorders | Renal failure | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| Renal and urinary disorders | Renal failure | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 0 | 0,0 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Renal and urinary disorders | Renal failure | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Renal and urinary disorders | Renal impairment | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 1 | 1,4 |
| Renal and urinary disorders | Renal impairment | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 0 | 0,0 |
| Renal and urinary disorders | Renal impairment | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 69 | 57,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | | Europe | 53 | 41,4 | 2 | 3,8 | 47 | 39,2 | 1 | 2,1 |
| Respiratory, thoracic and mediastinal disorders | | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 69 | 57,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Europe | 53 | 41,4 | 2 | 3,8 | 47 | 39,2 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 69 | 57,5 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Europe | 53 | 41,4 | 0 | 0,0 | 47 | 39,2 | 1 | 2,1 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | Rest of World | 2 | 1,6 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 |
| | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_soc_descriptive.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_soc_descriptive_sg2_TTWDAE_SE_26JUN2023_40336.xls
26JAN2024 16:02

**POPULATION: Safety Population**
**ENDPOINT: Adverse Event leading to Treatment Discontinuation**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Dichotomous Analysis (Safety)**

Name: Baseline ECOG

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Blood and lymphatic system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Blood and lymphatic system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Blood and lymphatic system disorders | Anaemia | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Blood and lymphatic system disorders | Anaemia | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Blood and lymphatic system disorders | Neutropenia | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Blood and lymphatic system disorders | Neutropenia | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| | | | | | | | | | | |
| Ear and labyrinth disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 2 | 3,3 |
| Ear and labyrinth disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Ear and labyrinth disorders | Deafness | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Ear and labyrinth disorders | Deafness | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Ear and labyrinth disorders | Tinnitus | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Ear and labyrinth disorders | Tinnitus | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| | | | | | | | | | | |
| Gastrointestinal disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 3 | 5,0 |
| Gastrointestinal disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Gastrointestinal disorders | Abdominal pain | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Gastrointestinal disorders | Abdominal pain | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Gastrointestinal disorders | Nausea | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 3 | 5,0 |
| Gastrointestinal disorders | Nausea | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Gastrointestinal disorders | Regurgitation | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Gastrointestinal disorders | Regurgitation | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Gastrointestinal disorders | Vomiting | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 2 | 3,3 |
| Gastrointestinal disorders | Vomiting | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| | | | | | | | | | | |
| General disorders and administration site conditions | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 2 | 3,3 |
| General disorders and administration site conditions | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 3 | 5,0 |
| General disorders and administration site conditions | Asthenia | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 2 | 3,3 |
| General disorders and administration site conditions | Asthenia | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| General disorders and administration site conditions | Fatigue | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| General disorders and administration site conditions | Fatigue | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 2 | 3,3 |
| | | | | | | | | | | |
| Infections and infestations | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Infections and infestations | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Infections and infestations | Pneumonia | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Infections and infestations | Pneumonia | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| | | | | | | | | | | |
| Investigations | | 0 | 72 | 56,3 | 2 | 2,8 | 60 | 50,0 | 1 | 1,7 |
| Investigations | | 1 | 56 | 43,8 | 1 | 1,8 | 60 | 50,0 | 2 | 3,3 |
| Investigations | Alanine aminotransferase increased | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 0 | 0,0 |
| Investigations | Alanine aminotransferase increased | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |

Post-hoc Analysen Studie ALINA

| | | | Alectinib (N=128) | | | | Platinum-Based Chemotherapy (N=120) | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Patients | | Patients with Event | | Patients | | Patients with Event | |
| MedDRA System Organ Class | MedDRA Preferred Term | Level | n | % | n | % | n | % | n | % |
| Investigations | Aspartate aminotransferase increased | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 0 | 0,0 |
| Investigations | Aspartate aminotransferase increased | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Investigations | Blood creatinine increased | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Investigations | Blood creatinine increased | 1 | 56 | 43,8 | 1 | 1,8 | 60 | 50,0 | 1 | 1,7 |
| Investigations | Creatinine renal clearance decreased | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Investigations | Creatinine renal clearance decreased | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Investigations | Liver function test increased | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 0 | 0,0 |
| Investigations | Liver function test increased | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| | | | | | | | | | | |
| Metabolism and nutrition disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 0 | 0,0 |
| Metabolism and nutrition disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 0 | 0,0 |
| Metabolism and nutrition disorders | Hypertriglyceridaemia | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| | | | | | | | | | | |
| Nervous system disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Nervous system disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Nervous system disorders | Neuropathy peripheral | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Nervous system disorders | Neuropathy peripheral | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| | | | | | | | | | | |
| Renal and urinary disorders | | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 2 | 3,3 |
| Renal and urinary disorders | | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Renal and urinary disorders | Renal failure | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Renal and urinary disorders | Renal failure | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| Renal and urinary disorders | Renal impairment | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Renal and urinary disorders | Renal impairment | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| | | | | | | | | | | |
| Respiratory, thoracic and mediastinal disorders | | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 1 | 1,7 |
| Respiratory, thoracic and mediastinal disorders | | 1 | 56 | 43,8 | 2 | 3,6 | 60 | 50,0 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 0 | 72 | 56,3 | 1 | 1,4 | 60 | 50,0 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis | 1 | 56 | 43,8 | 2 | 3,6 | 60 | 50,0 | 0 | 0,0 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 0 | 72 | 56,3 | 0 | 0,0 | 60 | 50,0 | 1 | 1,7 |
| Respiratory, thoracic and mediastinal disorders | Pulmonary embolism | 1 | 56 | 43,8 | 0 | 0,0 | 60 | 50,0 | 0 | 0,0 |
| | | | | | | | | | | |

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_soc_descriptive.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_soc_descriptive_sg2_TTWDAE_SE_26JUN2023_40336.xls
26JAN2024 16:02

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.1 Generelle Verträglichkeit**

**4.1.3 Ergebnis Unerwünschte Ereignisse (UE) (behoben/nicht behoben)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: All Patients**
**MODEL: --**
**STUDY: BO40336**
**Outcome of Adverse Events**

| | Alectinib (N=128) | | | | | | | | | | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Total | RECOVERED/RESOLVED | | RECOVERED/RESOLVED WITH SEQUELAE | | NOT RECOVERED/NOT RESOLVED | | FATAL | | RECOVERING/RESOLVING | | UNKNOWN | | MISSING | | Total | RECOVERED/RESOLVED | | RECOVERED/RESOLVED WITH SEQUELAE | | NOT RECOVERED/NOT RESOLVED | | FATAL | | RECOVERING/RESOLVING | | UNKNOWN | | MISSING | |
| Endpoint Grade | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Any AEs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 1685 | 1337 | 79,3 | 5 | 0,3 | 229 | 13,6 | 0 | 0,0 | 30 | 1,8 | 0 | 0,0 | 84 | 5,0 | 978 | 916 | 93,7 | 2 | 0,2 | 50 | 5,1 | 0 | 0,0 | 3 | 0,3 | 7 | 0,7 | 0 | 0,0 |
| Grade 1 | 1082 | 904 | 83,5 | 3 | 0,3 | 155 | 14,3 | 0 | 0,0 | 20 | 1,8 | 0 | 0,0 | 0 | 0,0 | 630 | 586 | 93,0 | 2 | 0,3 | 36 | 5,7 | 0 | 0,0 | 1 | 0,2 | 5 | 0,8 | 0 | 0,0 |
| Grade 2 | 333 | 253 | 76,0 | 2 | 0,6 | 69 | 20,7 | 0 | 0,0 | 9 | 2,7 | 0 | 0,0 | 0 | 0,0 | 281 | 265 | 94,3 | 0 | 0,0 | 13 | 4,6 | 0 | 0,0 | 1 | 0,4 | 2 | 0,7 | 0 | 0,0 |
| Grade 3 | 46 | 41 | 89,1 | 0 | 0,0 | 4 | 8,7 | 0 | 0,0 | 1 | 2,2 | 0 | 0,0 | 0 | 0,0 | 61 | 59 | 96,7 | 0 | 0,0 | 1 | 1,6 | 0 | 0,0 | 1 | 1,6 | 0 | 0,0 | 0 | 0,0 |
| Grade 4 | 4 | 3 | 75,0 | 0 | 0,0 | 1 | 25,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 6 | 6 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Missing | 220 | 136 | 61,8 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 84 | 38,2 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Any SAEs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 20 | 19 | 95,0 | 0 | 0,0 | 1 | 5,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 16 | 15 | 93,8 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 6,3 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 3 | 2 | 66,7 | 0 | 0,0 | 1 | 33,3 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 15 | 15 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 13 | 12 | 92,3 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 7,7 | 0 | 0,0 | 0 | 0,0 |
| Grade 4 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 3 | 3 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Any AESI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 916 | 772 | 84,3 | 3 | 0,3 | 122 | 13,3 | 0 | 0,0 | 19 | 2,1 | 0 | 0,0 | 0 | 0,0 | 660 | 627 | 95,0 | 2 | 0,3 | 25 | 3,8 | 0 | 0,0 | 0 | 0,0 | 6 | 0,9 | 0 | 0,0 |
| Grade 1 | 703 | 607 | 86,3 | 1 | 0,1 | 82 | 11,7 | 0 | 0,0 | 13 | 1,8 | 0 | 0,0 | 0 | 0,0 | 407 | 384 | 94,3 | 2 | 0,5 | 17 | 4,2 | 0 | 0,0 | 0 | 0,0 | 4 | 1,0 | 0 | 0,0 |
| Grade 2 | 187 | 141 | 75,4 | 2 | 1,1 | 38 | 20,3 | 0 | 0,0 | 6 | 3,2 | 0 | 0,0 | 0 | 0,0 | 199 | 189 | 95,0 | 0 | 0,0 | 8 | 4,0 | 0 | 0,0 | 0 | 0,0 | 2 | 1,0 | 0 | 0,0 |
| Grade 3 | 25 | 23 | 92,0 | 0 | 0,0 | 2 | 8,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 49 | 49 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 4 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 5 | 5 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |

Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_resolved.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_resolved_SE_26JUN2023_40336.xls
26JAN2024 11:52

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.2 Spezifische Verträglichkeit**

**4.2.1 Operationalisierung Unerwünschter Ereignisse von besonderem Interesse (AESI)**

**POPULATION: All Patients**
**ENDPOINT: --**
**MODEL: --**
**STUDY: BO40336**
**Definition of Adverse Events of Special Interest**

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| Gastrointestinal Tract Adverse Events | Custom AE grouping:Gastrointestinal tract AEs (SOC) | CUSTOM | | AEBODSYS | Gastrointestinal disorders |
| Hematological Abnormalities | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Agranulocytosis |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Anaemia macrocytic |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Anaemia neonatal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Aplasia pure red cell |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Aplastic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Aspiration bone marrow abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Basophil count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Biopsy bone marrow abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Differential white blood cell count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Eosinopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Eosinophil count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Erythroid maturation arrest |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Erythropenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Febrile neutropenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Full blood count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Full blood count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Granulocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Granulocytes abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Granulocytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Granulocytopenia neonatal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Haematocrit decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Haemoglobin abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Haemoglobin decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Hypoplastic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Leukopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Lymphocyte count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Lymphocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Lymphocytopenia neonatal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Lymphopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Megakaryocytes abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Megakaryocytes decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Microcytic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Monocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Monocytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome unclassifiable |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelofibrosis |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myeloid maturation arrest |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myeloid metaplasia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelosuppression |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutropenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutropenia neonatal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutrophil count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Normochromic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Normochromic normocytic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Normocytic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Pancytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Plasma cells absent |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Platelet count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Platelet count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Platelet disorder |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Platelet maturation arrest |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Platelet production decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Red blood cell count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Red blood cell count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Reticulocyte count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Reticulocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Reticulocytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Thrombocytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Thrombocytopenia neonatal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | White blood cell count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | White blood cell count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutropenic sepsis |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Haematocrit abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Erythropoiesis abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Panmyelopathy |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Granulocytes maturation arrest |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Leukopenia neonatal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myeloblast count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Metamyelocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Promyelocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | B-lymphocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | T-lymphocyte count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Idiopathic neutropenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Basophil percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Eosinophil percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutrophil percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myeloblast percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelocyte percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Monocyte percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Lymphocyte percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Congenital aplastic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Cyclic neutropenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Leukoerythroblastic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Febrile bone marrow aplasia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Scan bone marrow abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | B-lymphocyte abnormalities |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | T-lymphocyte count abnormal |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Bone marrow myelogram abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Band neutrophil count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Erythroblast count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Erythroblast count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Monoblast count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Plasmablast count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Bone marrow necrosis |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Bicytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Band neutrophil percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Platelet toxicity |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutropenic infection |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Reticulocyte percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Proerythroblast count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Proerythroblast count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Basophil count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Eosinophil count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Haematotoxicity |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Monocyte count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Neutrophil count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | White blood cell disorder |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Blood disorder |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Bone marrow disorder |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Plasma cell disorder |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Lymphocyte percentage abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | CD19 lymphocytes decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Plateletcrit decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Plateletcrit abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Bone marrow failure |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Cytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Radiation leukopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome transformation |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Pure white cell aplasia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Autoimmune aplastic anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | White blood cell analysis abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Bone marrow infiltration |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Basophilopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Acquired amegakaryocytic thrombocytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Primary myelofibrosis |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Foetal anaemia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Gelatinous transformation of the bone marrow |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | B-lymphocyte count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | CD19 lymphocyte count abnormal |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Mononuclear cell count decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Immune-mediated cytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Granulocyte percentage decreased |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Erythroid dysplasia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Radiation neutropenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Radiation thrombocytopenia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome with multilineage dysplasia |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome with excess blasts |
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome with ringed sideroblasts |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Haematopoietic cytopenias (SMQ) | SMQ | BROAD | AEDECOD | Myelodysplastic syndrome with single lineage dysplasia |
| Muscular Adverse Events, CPK Elevations | Custom AE grouping:Muscular AEs, CPK elevat.(HLGTs) | CUSTOM | | AEHLGT | Enzyme investigations NEC |
| | Custom AE grouping:Muscular AEs, CPK elevat.(HLGTs) | CUSTOM | | AEHLGT | Muscle disorders |
| | Custom AE grouping:Muscular AEs, CPK elevat.(HLGTs) | CUSTOM | | AEHLGT | Musculoskeletal and connective tissue disorders NEC |
| Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acute hepatic failure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Alanine aminotransferase abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Alanine aminotransferase increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Ammonia abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Ammonia increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Ascites |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Aspartate aminotransferase abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Aspartate aminotransferase increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Asterixis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Autoimmune hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Benign hepatic neoplasm |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Biliary cirrhosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Biliary fibrosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bilirubin conjugated increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Biopsy liver abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood bilirubin increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood bilirubin unconjugated increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood fibrinogen abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood fibrinogen decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood thrombin abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood thrombin decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood thromboplastin abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood thromboplastin decreased |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bromosulphthalein test abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cholestasis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Chronic hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor IX level decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor V level decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor VII level decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor X level decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coma hepatic |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gamma-glutamyltransferase abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gamma-glutamyltransferase increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Haemangioma of liver |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepaplastin abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepaplastin decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic adenoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic atrophy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cirrhosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cyst |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic encephalopathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic failure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic fibrosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic function abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic necrosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic neoplasm |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic pain |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic steatosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis acute |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis cholestatic |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis chronic active |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis chronic persistent |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis fulminant |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatitis toxic |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatoblastoma recurrent |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatocellular injury |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatomegaly |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatorenal failure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatorenal syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatosplenomegaly |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatotoxicity |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hyperammonaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hyperbilirubinaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypocoagulable state |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypoprothrombinaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Icterus index increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | International normalised ratio abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | International normalised ratio increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Ischaemic hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Jaundice |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Jaundice cholestatic |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Jaundice hepatocellular |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Kayser-Fleischer ring |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver disorder |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver function test abnormal |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver tenderness |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver transplant |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Lupoid hepatic cirrhosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Mixed hepatocellular cholangiocarcinoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Non-alcoholic fatty liver |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Oesophageal varices haemorrhage |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal hypertension |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Protein C decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Prothrombin level abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Prothrombin level decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Prothrombin time abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Prothrombin time prolonged |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Prothrombin time ratio increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Reye's syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Ultrasound liver abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cholaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cytolysis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Antithrombin III decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Oedema due to hepatic disease |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Urine bilirubin increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver carcinoma ruptured |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal hypertensive gastropathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Duodenal varices |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gastric varices |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Radiation hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Nodular regenerative hyperplasia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Protein S decreased |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypofibrinogenaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Thrombin time abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Guanase increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bile output decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bile output abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Thrombin time prolonged |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Protein S abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypercholia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatopulmonary syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Renal and liver transplant |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Focal nodular hyperplasia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver induration |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Foetor hepaticus |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Non-alcoholic steatohepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatocellular foamy cell syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cyst ruptured |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Perihepatic discomfort |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic haemangioma rupture |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Transaminases increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer metastatic |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Varices oesophageal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | X-ray hepatobiliary abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Subacute hepatic failure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic mass |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gastric varices haemorrhage |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Chronic hepatic failure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Ocular icterus |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Blood bilirubin abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypothrombinaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypothromboplastinaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer stage I |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer stage II |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer stage III |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer stage IV |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Galactose elimination capacity test abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Galactose elimination capacity test decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver-kidney microsomal antibody positive |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic enzyme decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic enzyme increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bilirubin excretion disorder |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Spontaneous bacterial peritonitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatobiliary neoplasm |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor IX level abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor V level abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor VII level abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Coagulation factor X level abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Prothrombin time ratio abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver scan abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatectomy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic lesion |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatobiliary disease |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatoblastoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver operation |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic enzyme abnormal |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Transaminases abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cryptogenic cirrhosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cholestatic pruritus |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic infiltration eosinophilic |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Graft versus host disease in liver |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Mitochondrial aspartate aminotransferase increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic calcification |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatobiliary scan abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic sequestration |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acute graft versus host disease in liver |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gastrooesophageal variceal haemorrhage prophylaxis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic encephalopathy prophylaxis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Mixed liver injury |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Molar ratio of total branched-chain amino acid to tyrosine |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver injury |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portopulmonary hypertension |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Retrograde portal vein flow |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic hydrothorax |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic angiosarcoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bilirubin conjugated abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Lupus hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Haemorrhagic hepatic cyst |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Splenic varices |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cholestatic liver injury |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hypertransaminasaemia |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Child-Pugh-Turcotte score increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic vascular resistance increased |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired protein S deficiency |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bacterascites |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Splenic varices haemorrhage |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal hypertensive enteropathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic artery flow decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acute yellow liver atrophy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Reynold's syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Allergic hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Diabetic hepatopathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Intestinal varices |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Chronic graft versus host disease in liver |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Drug-induced liver injury |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Varicose veins of abdominal wall |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gallbladder varices |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic cancer recurrent |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatocellular carcinoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatobiliary cancer |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatobiliary cancer in situ |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal vein dilatation |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Peripancreatic varices |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal vein cavernous transformation |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Biliary ascites |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Parenteral nutrition associated liver disease |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired antithrombin III deficiency |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal fibrosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hyperfibrinolysis |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver palpable |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gastric variceal injection |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Gastric variceal ligation |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic hypertrophy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Steatohepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver dialysis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Child-Pugh-Turcotte score abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic steato-fibrosis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Non-cirrhotic portal hypertension |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acute on chronic liver failure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bilirubin urine present |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Anti factor X activity abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Anti factor X activity increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Anti factor X activity decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver function test decreased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Liver function test increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cholangiosarcoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Benign hepatobiliary neoplasm |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Intestinal varices haemorrhage |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Computerised tomogram liver abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | White nipple sign |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Immune-mediated hepatitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal hypertensive colopathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic hamartoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatobiliary cyst |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Primary biliary cholangitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Alloimmune hepatitis |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Regenerative siderotic hepatic nodule |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired hepatocerebral degeneration |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Magnetic resonance proton density fat fraction measurement |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Cardiohepatic syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired factor VIII deficiency |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired factor XI deficiency |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired factor IX deficiency |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | AST/ALT ratio abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Sugiura procedure |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic venous pressure gradient increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic venous pressure gradient abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Immune-mediated cholangitis |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Immune-mediated hepatic disorder |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Congestive hepatopathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic hypoperfusion |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Flood syndrome |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Magnetic resonance imaging hepatobiliary abnormal |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic neuroendocrine tumour |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Acquired factor V deficiency |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic lipoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Hepatic sarcoma |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Anti-liver cytosol antibody type 1 positive |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Omental oedema |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Portal hypertensive biliopathy |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Bile acids increased |
| | Drug related hepatic disorders - comprehensive search (SMQ) | SMQ | NARROW | AEDECOD | Suspected drug-induced liver injury |
| Skin Disorders | (SOC) | CUSTOM | | AEBODSYS | Skin and subcutaneous tissue disorders |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| Abnormal Renal Function | Custom AE grouping:Renal and urinary disorders (SOC) | CUSTOM | | AEBODSYS | Renal and urinary disorders |
| | urinary tract investigations and urinalyses (HLGTs) | CUSTOM | | AEHLGT | Renal and urinary tract investigations and urinalyses |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Anuria |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Azotaemia |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Haemodialysis |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Nephropathy toxic |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Oliguria |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Peritoneal dialysis |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Renal failure |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Renal failure neonatal |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Renal impairment neonatal |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Neonatal anuria |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Haemofiltration |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Dialysis |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Renal impairment |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Continuous haemodiafiltration |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Acute kidney injury |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Acute phosphate nephropathy |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Prerenal failure |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Foetal renal impairment |
| | Acute renal failure (SMQ) | SMQ | NARROW | AEDECOD | Subacute kidney injury |
| Dysgeusia | Custom AE grouping:Dysgeusia (PT) | CUSTOM | | AEDECOD | Dysgeusia |
| | Custom AE grouping:Dysgeusia (PT) | CUSTOM | | AEDECOD | Hypogeusia |
| | Custom AE grouping:Dysgeusia (PT) | CUSTOM | | AEDECOD | Taste disorder |
| Oedema | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Eyelid oedema |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Face oedema |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Generalised oedema |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Joint swelling |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Lip swelling |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Oedema |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Oedema peripheral |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Periorbital oedema |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Swelling |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Swelling face |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Swelling of eyelid |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Peripheral swelling |
| | Custom AE grouping:Oedema (PT) | CUSTOM | | AEDECOD | Localised oedema |
| Bradycardia | Custom AE grouping:Bradycardia (PT) | CUSTOM | | AEDECOD | Bradycardia |
| | Custom AE grouping:Bradycardia (PT) | CUSTOM | | AEDECOD | Sinus bradycardia |
| Vision Disorders | (SOC) | CUSTOM | | AEBODSYS | Eye disorders |
| Interstitial Lung Disease | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Alveolar proteinosis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Alveolitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Bronchiolitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Eosinophilia myalgia syndrome |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Eosinophilic pneumonia |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Idiopathic pulmonary fibrosis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Interstitial lung disease |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Lung infiltration |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Obliterative bronchiolitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pneumonitis |

| Adverse Event of Special Interest | Grouping Definition Name | Grouping Definition Type | Scope | Variable on which Grouping is Based* | Grouping Def. Clause Dictionary Term |
|---|---|---|---|---|---|
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Progressive massive fibrosis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pulmonary fibrosis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pulmonary vasculitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Radiation alveolitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Radiation fibrosis - lung |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Radiation pneumonitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Alveolitis necrotising |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Transfusion-related acute lung injury |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Eosinophilic pneumonia acute |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Eosinophilic pneumonia chronic |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pulmonary necrosis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Diffuse alveolar damage |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pulmonary radiation injury |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pulmonary toxicity |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Idiopathic pneumonia syndrome |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Acute interstitial pneumonitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Necrotising bronchiolitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Alveolar lung disease |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Combined pulmonary fibrosis and emphysema |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Eosinophilic granulomatosis with polyangiitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Idiopathic interstitial pneumonia |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Small airways disease |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Autoimmune lung disease |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Lung opacity |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Hypersensitivity pneumonitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Bronchiolitis obliterans syndrome |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Pleuroparenchymal fibroelastosis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Probable e-cigarette or vaping product use associated lung injury |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Confirmed e-cigarette or vaping product use associated lung injury |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Immune-mediated lung disease |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Rheumatoid arthritis-associated interstitial lung disease |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Radiation bronchitis |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Chronic graft versus host disease in lung |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Low lung compliance |
| | Interstitial lung disease (SMQ) | SMQ | NARROW | AEDECOD | Interstitial lung abnormality |

Investigator text for AEs encoded using MedDRA version 26.0.
* AEBODSYS = SOC, AEDECOD = PT and AEHLGT = HLGT.
Clinical cut-off: 26JUN2023

Program: ..dies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/l_aesi_def.sas
Output: ..7/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/l_aesi_def_26JUN2023_40336.xls
14JUN2024 10:29

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.2 Spezifische Verträglichkeit**

**4.2.2 Unerwünschte Ereignisse von besonderem Interesse (AESI)**

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Gastrointestinal Tract Adverse Events**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 87 | 68,0 | 41 | 32,0 | 120 | 100,0 | 95 | 79,2 | 25 | 20,8 | <.0001 | 0,42 | 0,31 | 0,58 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 33 | 61,1 | 21 | 38,9 | 64 | 53,3 | 51 | 79,7 | 13 | 20,3 | <.0001 | 0,36 | 0,23 | 0,58 | | 0,3811 |
| | Female | 74 | 57,8 | 54 | 73,0 | 20 | 27,0 | 56 | 46,7 | 44 | 78,6 | 12 | 21,4 | 0,0005 | 0,47 | 0,30 | 0,72 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 67 | 66,3 | 34 | 33,7 | 87 | 72,5 | 73 | 83,9 | 14 | 16,1 | <.0001 | 0,34 | 0,23 | 0,49 | | 0,0224 |
| | >= 65 | 27 | 21,1 | 20 | 74,1 | 7 | 25,9 | 33 | 27,5 | 22 | 66,7 | 11 | 33,3 | 0,5426 | 0,82 | 0,44 | 1,54 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 50 | 68,5 | 23 | 31,5 | 69 | 57,5 | 56 | 81,2 | 13 | 18,8 | <.0001 | 0,36 | 0,24 | 0,56 | | 0,3514 |
| | Europe | 53 | 41,4 | 35 | 66,0 | 18 | 34,0 | 47 | 39,2 | 35 | 74,5 | 12 | 25,5 | 0,0062 | 0,50 | 0,30 | 0,83 | | |
| | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 4 | 100,0 | 0 | 0,0 | 0,5521 | 1,88 | 0,23 | 15,47 | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 53 | 73,6 | 19 | 26,4 | 60 | 50,0 | 51 | 85,0 | 9 | 15,0 | <.0001 | 0,40 | 0,27 | 0,61 | | 0,8381 |
| | 1 | 56 | 43,8 | 34 | 60,7 | 22 | 39,3 | 60 | 50,0 | 44 | 73,3 | 16 | 26,7 | 0,0002 | 0,39 | 0,24 | 0,65 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes1_SE_26JUN2023_40336.xls
26JAN2024 17:17

**POPULATION: Safety Population**
**ENDPOINT: Time to Gastrointestinal Tract Adverse Events**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 53 | 45 | 41 | 38 | 36 | 23 |
| Platinum-Based Chemotherapy | 120 | 4 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 3 | 4 | 4 | 5 | 7 | 18 |
| Platinum-Based Chemotherapy | 0 | 21 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes1_SE_26JUN2023_40336.pdf
26JAN2024 13:53

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Gastrointestinal Tract Adverse Events, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 9 | 7,5 | 111 | 92,5 | 0,0591 | 0,30 | 0,08 | 1,13 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 4 | 6,3 | 60 | 93,8 | 0,5309 | 0,59 | 0,11 | 3,19 | | 0,1487 |
| | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 5 | 8,9 | 51 | 91,1 | 0,0434 | 0,15 | 0,02 | 1,27 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 3 | 3,0 | 98 | 97,0 | 87 | 72,5 | 7 | 8,0 | 80 | 92,0 | 0,0522 | 0,24 | 0,05 | 1,15 | | 0,6704 |
| | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 2 | 6,1 | 31 | 93,9 | 0,6877 | 0,61 | 0,06 | 6,78 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 4 | 5,8 | 65 | 94,2 | 0,1520 | 0,23 | 0,03 | 2,06 | | 0,8103 |
| | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,1804 | 0,34 | 0,07 | 1,77 | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 5 | 8,3 | 55 | 91,7 | 0,3107 | 0,48 | 0,12 | 2,03 | | 0,0816 |
| | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 4 | 6,7 | 56 | 93,3 | 0,0514 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes135_SE_26JUN2023_40336.xls
26JAN2024 18:33

**POPULATION: Safety Population**
**ENDPOINT: Time to Gastrointestinal Tract Adverse Events, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 115 | 115 | 111 | 109 | 81 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 10 | 10 | 13 | 15 | 43 |
| Platinum-Based Chemotherapy | 0 | 95 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes135_SE_26JUN2023_40336.pdf
26JAN2024 15:00

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Gastrointestinal Tract Adverse Events, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0376 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1922 | 0,00 | 0,00 | NE | | 0,0928 |
| | Female | 74 | 57,8 | 0 | 0,0 | 74 | 100,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,1025 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 4 | 4,6 | 83 | 95,4 | 0,0297 | 0,00 | 0,00 | NE | | 0,9959 |
| | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 3 | 4,3 | 66 | 95,7 | 0,0727 | 0,00 | 0,00 | NE | | 0,8186 |
| | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2883 | 0,00 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1198 | 0,00 | 0,00 | NE | | 0,8604 |
| | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1701 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes1s_SE_26JUN2023_40336.xls
26JAN2024 17:55

**POPULATION: Safety Population**
**ENDPOINT: Time to Gastrointestinal Tract Adverse Events, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes1s_SE_26JUN2023_40336.pdf
26JAN2024 14:26

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Hematological Abnormalities**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 34 | 26,6 | 94 | 73,4 | 120 | 100,0 | 56 | 46,7 | 64 | 53,3 | <.0001 | 0,27 | 0,16 | 0,45 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 7 | 13,0 | 47 | 87,0 | 64 | 53,3 | 31 | 48,4 | 33 | 51,6 | <.0001 | 0,11 | 0,04 | 0,31 | | 0,0045 |
| | Female | 74 | 57,8 | 27 | 36,5 | 47 | 63,5 | 56 | 46,7 | 25 | 44,6 | 31 | 55,4 | 0,0066 | 0,43 | 0,23 | 0,80 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 27 | 26,7 | 74 | 73,3 | 87 | 72,5 | 37 | 42,5 | 50 | 57,5 | 0,0001 | 0,34 | 0,19 | 0,60 | | 0,3149 |
| | >= 65 | 27 | 21,1 | 7 | 25,9 | 20 | 74,1 | 33 | 27,5 | 19 | 57,6 | 14 | 42,4 | 0,0002 | 0,13 | 0,04 | 0,45 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 25 | 34,2 | 48 | 65,8 | 69 | 57,5 | 29 | 42,0 | 40 | 58,0 | 0,0046 | 0,42 | 0,23 | 0,78 | | 0,0403 |
| | Europe | 53 | 41,4 | 9 | 17,0 | 44 | 83,0 | 47 | 39,2 | 25 | 53,2 | 22 | 46,8 | <.0001 | 0,13 | 0,05 | 0,35 | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 13 | 18,1 | 59 | 81,9 | 60 | 50,0 | 27 | 45,0 | 33 | 55,0 | <.0001 | 0,14 | 0,06 | 0,34 | | 0,0498 |
| | 1 | 56 | 43,8 | 21 | 37,5 | 35 | 62,5 | 60 | 50,0 | 29 | 48,3 | 31 | 51,7 | 0,0116 | 0,45 | 0,24 | 0,85 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes2_SE_26JUN2023_40336.xls
26JAN2024 17:18

**POPULATION: Safety Population**
**ENDPOINT: Time to Hematological Abnormalities**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 100 | 89 | 87 | 85 | 80 | 65 |
| Platinum-Based Chemotherapy | 120 | 2 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 11 | 11 | 13 | 15 | 29 |
| Platinum-Based Chemotherapy | 0 | 62 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes2_SE_26JUN2023_40336.pdf
26JAN2024 13:55

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Hematological Abnormalities, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 25 | 20,8 | 95 | 79,2 | <.0001 | 0,03 | 0,00 | 0,25 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 17 | 26,6 | 47 | 73,4 | <.0001 | 0,00 | 0,00 | NE | | 0,1878 |
| | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 8 | 14,3 | 48 | 85,7 | 0,0039 | 0,09 | 0,01 | 0,71 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 1 | 1,0 | 100 | 99,0 | 87 | 72,5 | 15 | 17,2 | 72 | 82,8 | <.0001 | 0,05 | 0,01 | 0,40 | | 0,3620 |
| | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 10 | 30,3 | 23 | 69,7 | 0,0021 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 13 | 18,8 | 56 | 81,2 | 0,0005 | 0,07 | 0,01 | 0,50 | | 0,5170 |
| | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 10 | 21,3 | 37 | 78,7 | 0,0004 | 0,00 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 2 | 50,0 | 2 | 50,0 | 0,2807 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 13 | 21,7 | 47 | 78,3 | <.0001 | 0,00 | 0,00 | NE | | 0,1894 |
| | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 12 | 20,0 | 48 | 80,0 | 0,0019 | 0,08 | 0,01 | 0,62 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes235_SE_26JUN2023_40336.xls
26JAN2024 18:34

**POPULATION: Safety Population**
**ENDPOINT: Time to Hematological Abnormalities, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 83 |
| Platinum-Based Chemotherapy | 120 | 12 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 83 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes235_SE_26JUN2023_40336.pdf
26JAN2024 15:01

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Hematological Abnormalities, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,0731 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,1928 | 0,00 | 0,00 | NE | | 0,9974 |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2503 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,1265 | 0,00 | 0,00 | NE | | 0,9974 |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,3711 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,1443 | 0,00 | 0,00 | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,2971 | 0,00 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,1175 | 0,00 | 0,00 | NE | | 0,9974 |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,3340 | 0,00 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes2s_SE_26JUN2023_40336.xls
26JAN2024 17:56

**POPULATION: Safety Population**
**ENDPOINT: Time to Hematological Abnormalities, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes2s_SE_26JUN2023_40336.pdf
26JAN2024 14:27

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Muscular Adverse Events, CPK Elevations**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 92 | 71,9 | 36 | 28,1 | 120 | 100,0 | 12 | 10,0 | 108 | 90,0 | <.0001 | 11,10 | 6,00 | 20,50 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 39 | 72,2 | 15 | 27,8 | 64 | 53,3 | 8 | 12,5 | 56 | 87,5 | <.0001 | 8,29 | 3,81 | 18,05 | | 0,3499 |
| | Female | 74 | 57,8 | 53 | 71,6 | 21 | 28,4 | 56 | 46,7 | 4 | 7,1 | 52 | 92,9 | <.0001 | 16,35 | 5,81 | 45,97 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 73 | 72,3 | 28 | 27,7 | 87 | 72,5 | 11 | 12,6 | 76 | 87,4 | <.0001 | 8,79 | 4,60 | 16,79 | | 0,1184 |
| | >= 65 | 27 | 21,1 | 19 | 70,4 | 8 | 29,6 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | <.0001 | 34,64 | 4,54 | 264,09 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 57 | 78,1 | 16 | 21,9 | 69 | 57,5 | 7 | 10,1 | 62 | 89,9 | <.0001 | 12,87 | 5,76 | 28,78 | | 0,9174 |
| | Europe | 53 | 41,4 | 33 | 62,3 | 20 | 37,7 | 47 | 39,2 | 4 | 8,5 | 43 | 91,5 | <.0001 | 10,26 | 3,59 | 29,34 | | |
| | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 0,2072 | 4,22 | 0,37 | 47,51 | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 48 | 66,7 | 24 | 33,3 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | <.0001 | 10,00 | 4,22 | 23,68 | | 0,7353 |
| | 1 | 56 | 43,8 | 44 | 78,6 | 12 | 21,4 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | <.0001 | 12,69 | 5,28 | 30,48 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes3_SE_26JUN2023_40336.xls
26JAN2024 17:21

**POPULATION: Safety Population**
**ENDPOINT: Time to Muscular Adverse Events, CPK Elevations**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 38 | 34 | 32 | 31 | 28 | 20 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 7 | 7 | 8 | 9 | 16 |
| Platinum-Based Chemotherapy | 0 | 92 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes3_SE_26JUN2023_40336.pdf
26JAN2024 13:56

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Muscular Adverse Events, CPK Elevations, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 8 | 6,3 | 120 | 93,8 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,1064 | 3,39 | 0,70 | 16,33 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,4971 | 1,84 | 0,31 | 11,02 | | 0,1916 |
| | Female | 74 | 57,8 | 4 | 5,4 | 70 | 94,6 | 56 | 46,7 | 0 | 0,0 | 56 | 100,0 | 0,0787 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 6 | 5,9 | 95 | 94,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,3294 | 2,22 | 0,43 | 11,43 | | 0,2427 |
| | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,1148 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 5 | 6,8 | 68 | 93,2 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0275 | >999.99 | 0,00 | NE | | 0,1803 |
| | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,9191 | 0,90 | 0,13 | 6,41 | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0875 | 5,23 | 0,63 | 43,50 | | 0,5867 |
| | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,9560 | 1,08 | 0,07 | 17,29 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes335_SE_26JUN2023_40336.xls
26JAN2024 18:36

**POPULATION: Safety Population**
**ENDPOINT: Time to Muscular Adverse Events, CPK Elevations, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 114 | 109 | 108 | 105 | 104 | 77 |
| Platinum-Based Chemotherapy | 120 | 18 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 16 | 43 |
| Platinum-Based Chemotherapy | 0 | 100 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes335_SE_26JUN2023_40336.pdf
26JAN2024 15:02

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Muscular Adverse Events, CPK Elevations, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes3s_SE_26JUN2023_40336.xls
26JAN2024 17:58

**POPULATION: Safety Population**
**ENDPOINT: Time to Muscular Adverse Events, CPK Elevations, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes3s_SE_26JUN2023_40336.pdf
26JAN2024 14:28

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 78 | 60,9 | 50 | 39,1 | 120 | 100,0 | 16 | 13,3 | 104 | 86,7 | <.0001 | 4,95 | 2,85 | 8,60 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 33 | 61,1 | 21 | 38,9 | 64 | 53,3 | 8 | 12,5 | 56 | 87,5 | <.0001 | 4,94 | 2,23 | 10,97 | | 0,8849 |
| | Female | 74 | 57,8 | 45 | 60,8 | 29 | 39,2 | 56 | 46,7 | 8 | 14,3 | 48 | 85,7 | <.0001 | 4,91 | 2,27 | 10,63 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 63 | 62,4 | 38 | 37,6 | 87 | 72,5 | 12 | 13,8 | 75 | 86,2 | <.0001 | 4,76 | 2,53 | 8,98 | | 0,9159 |
| | >= 65 | 27 | 21,1 | 15 | 55,6 | 12 | 44,4 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,0012 | 5,44 | 1,75 | 16,93 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 51 | 69,9 | 22 | 30,1 | 69 | 57,5 | 11 | 15,9 | 58 | 84,1 | <.0001 | 4,54 | 2,32 | 8,90 | | 0,2438 |
| | Europe | 53 | 41,4 | 25 | 47,2 | 28 | 52,8 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,0004 | 4,92 | 1,85 | 13,12 | | |
| | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,0177 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 38 | 52,8 | 34 | 47,2 | 60 | 50,0 | 6 | 10,0 | 54 | 90,0 | <.0001 | 5,45 | 2,27 | 13,11 | | 0,9477 |
| | 1 | 56 | 43,8 | 40 | 71,4 | 16 | 28,6 | 60 | 50,0 | 10 | 16,7 | 50 | 83,3 | <.0001 | 5,07 | 2,47 | 10,42 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes4_SE_26JUN2023_40336.xls
26JAN2024 17:23

**POPULATION: Safety Population**
**ENDPOINT: Time to Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 58 | 50 | 44 | 42 | 40 | 30 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 8 | 8 | 9 | 10 | 20 |
| Platinum-Based Chemotherapy | 0 | 89 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes4_SE_26JUN2023_40336.pdf
26JAN2024 13:57

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 6 | 4,7 | 122 | 95,3 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,0291 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | 0,0272 | >999.99 | 0,00 | NE | | 0,9966 |
| | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,3876 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | | 0,9966 |
| | >= 65 | 27 | 21,1 | 4 | 14,8 | 23 | 85,2 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | 0,0511 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 1 | 1,4 | 72 | 98,6 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | 0,3309 | >999.99 | 0,00 | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | 0,0985 | >999.99 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 4 | 5,6 | 68 | 94,4 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,1127 | >999.99 | 0,00 | NE | | 0,9966 |
| | 1 | 56 | 43,8 | 2 | 3,6 | 54 | 96,4 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,1415 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes435_SE_26JUN2023_40336.xls
26JAN2024 18:38

**POPULATION: Safety Population**
**ENDPOINT: Time to Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 113 | 113 | 110 | 108 | 81 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 9 | 9 | 12 | 14 | 41 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes435_SE_26JUN2023_40336.pdf
26JAN2024 15:04

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes4s_SE_26JUN2023_40336.xls
26JAN2024 17:59

**POPULATION: Safety Population**
**ENDPOINT: Time to Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes4s_SE_26JUN2023_40336.pdf
26JAN2024 14:30

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Skin Disorders**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 50 | 39,1 | 78 | 60,9 | 120 | 100,0 | 22 | 18,3 | 98 | 81,7 | 0,2166 | 1,40 | 0,82 | 2,41 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 20 | 37,0 | 34 | 63,0 | 64 | 53,3 | 7 | 10,9 | 57 | 89,1 | 0,1540 | 1,96 | 0,76 | 5,05 | | 0,1015 |
| | Female | 74 | 57,8 | 30 | 40,5 | 44 | 59,5 | 56 | 46,7 | 15 | 26,8 | 41 | 73,2 | 0,8905 | 1,05 | 0,54 | 2,03 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 39 | 38,6 | 62 | 61,4 | 87 | 72,5 | 17 | 19,5 | 70 | 80,5 | 0,3065 | 1,37 | 0,75 | 2,52 | | 0,4993 |
| | >= 65 | 27 | 21,1 | 11 | 40,7 | 16 | 59,3 | 33 | 27,5 | 5 | 15,2 | 28 | 84,8 | 0,5353 | 1,45 | 0,44 | 4,79 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 33 | 45,2 | 40 | 54,8 | 69 | 57,5 | 13 | 18,8 | 56 | 81,2 | 0,0582 | 1,90 | 0,97 | 3,74 | | 0,0791 |
| | Europe | 53 | 41,4 | 15 | 28,3 | 38 | 71,7 | 47 | 39,2 | 9 | 19,1 | 38 | 80,9 | 0,4347 | 0,68 | 0,26 | 1,78 | | |
| | Rest of World | 2 | 1,6 | 2 | 100,0 | 0 | 0,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 34 | 47,2 | 38 | 52,8 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,0436 | 2,18 | 1,00 | 4,72 | | 0,0525 |
| | 1 | 56 | 43,8 | 16 | 28,6 | 40 | 71,4 | 60 | 50,0 | 13 | 21,7 | 47 | 78,3 | 0,6083 | 0,81 | 0,35 | 1,83 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes5_SE_26JUN2023_40336.xls
26JAN2024 17:24

**POPULATION: Safety Population**
**ENDPOINT: Time to Skin Disorders**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 89 | 75 | 70 | 66 | 63 | 45 |
| Platinum-Based Chemotherapy | 120 | 13 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 34 |
| Platinum-Based Chemotherapy | 0 | 85 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes5_SE_26JUN2023_40336.pdf
26JAN2024 13:59

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Skin Disorders, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 2 | 1,6 | 126 | 98,4 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,1701 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9968 |
| | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,2170 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | 0,1882 | >999.99 | 0,00 | NE | | 0,9971 |
| | >= 65 | 27 | 21,1 | 0 | 0,0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | 0,1677 | >999.99 | 0,00 | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 0 | 0,0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,3613 | >999.99 | 0,00 | NE | | 0,9979 |
| | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes535_SE_26JUN2023_40336.xls
26JAN2024 18:39

**POPULATION: Safety Population**
**ENDPOINT: Time to Skin Disorders, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 119 | 114 | 114 | 111 | 109 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes535_SE_26JUN2023_40336.pdf
26JAN2024 15:05

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Skin Disorders, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes5s_SE_26JUN2023_40336.xls
26JAN2024 18:01

**POPULATION: Safety Population**
**ENDPOINT: Time to Skin Disorders, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes5s_SE_26JUN2023_40336.pdf
26JAN2024 14:31

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Abnormal Renal Function**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 27 | 21,1 | 101 | 78,9 | 120 | 100,0 | 17 | 14,2 | 103 | 85,8 | 0,9449 | 1,02 | 0,53 | 1,96 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 14 | 25,9 | 40 | 74,1 | 64 | 53,3 | 9 | 14,1 | 55 | 85,9 | 0,8460 | 1,10 | 0,43 | 2,78 | | 0,4894 |
| | Female | 74 | 57,8 | 13 | 17,6 | 61 | 82,4 | 56 | 46,7 | 8 | 14,3 | 48 | 85,7 | 0,9328 | 0,96 | 0,38 | 2,41 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 18 | 17,8 | 83 | 82,2 | 87 | 72,5 | 13 | 14,9 | 74 | 85,1 | 0,4791 | 0,75 | 0,34 | 1,65 | | 0,1514 |
| | >= 65 | 27 | 21,1 | 9 | 33,3 | 18 | 66,7 | 33 | 27,5 | 4 | 12,1 | 29 | 87,9 | 0,1806 | 2,26 | 0,66 | 7,67 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 18 | 24,7 | 55 | 75,3 | 69 | 57,5 | 12 | 17,4 | 57 | 82,6 | 0,7831 | 0,89 | 0,40 | 1,99 | | 0,3158 |
| | Europe | 53 | 41,4 | 8 | 15,1 | 45 | 84,9 | 47 | 39,2 | 5 | 10,6 | 42 | 89,4 | 0,9077 | 1,07 | 0,33 | 3,47 | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 10 | 13,9 | 62 | 86,1 | 60 | 50,0 | 8 | 13,3 | 52 | 86,7 | 0,5155 | 0,71 | 0,26 | 1,98 | | 0,2449 |
| | 1 | 56 | 43,8 | 17 | 30,4 | 39 | 69,6 | 60 | 50,0 | 9 | 15,0 | 51 | 85,0 | 0,4482 | 1,39 | 0,59 | 3,29 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes6_SE_26JUN2023_40336.xls
26JAN2024 17:26

**POPULATION: Safety Population**
**ENDPOINT: Time to Abnormal Renal Function**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 103 | 97 | 94 | 91 | 89 | 72 |
| Platinum-Based Chemotherapy | 120 | 16 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 9 | 9 | 11 | 12 | 29 |
| Platinum-Based Chemotherapy | 0 | 87 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes6_SE_26JUN2023_40336.pdf
26JAN2024 14:00

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Abnormal Renal Function, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,3294 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,3788 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | 0,2636 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | 0,3375 | >999.99 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,3669 | >999.99 | 0,00 | NE | | 0,9963 |
| | 1 | 56 | 43,8 | 0 | 0,0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes635_SE_26JUN2023_40336.xls
26JAN2024 18:41

**POPULATION: Safety Population**
**ENDPOINT: Time to Abnormal Renal Function, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 120 | 115 | 115 | 112 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes635_SE_26JUN2023_40336.pdf
26JAN2024 15:06

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Abnormal Renal Function, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes6s_SE_26JUN2023_40336.xls
26JAN2024 18:03

**POPULATION: Safety Population**
**ENDPOINT: Time to Abnormal Renal Function, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes6s_SE_26JUN2023_40336.pdf
26JAN2024 14:32

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Dysgeusia**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 17 | 13,3 | 111 | 86,7 | 120 | 100,0 | 4 | 3,3 | 116 | 96,7 | 0,0116 | 3,76 | 1,25 | 11,32 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 4 | 7,4 | 50 | 92,6 | 64 | 53,3 | 3 | 4,7 | 61 | 95,3 | 0,8173 | 1,21 | 0,24 | 5,98 | | 0,1094 |
| | Female | 74 | 57,8 | 13 | 17,6 | 61 | 82,4 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,0065 | 9,99 | 1,30 | 76,90 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 14 | 13,9 | 87 | 86,1 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,0191 | 4,01 | 1,14 | 14,06 | | 0,9272 |
| | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 1 | 3,0 | 32 | 97,0 | 0,4302 | 2,54 | 0,23 | 28,02 | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 8 | 11,0 | 65 | 89,0 | 69 | 57,5 | 2 | 2,9 | 67 | 97,1 | 0,0985 | 3,47 | 0,72 | 16,72 | | 0,7261 |
| | Europe | 53 | 41,4 | 8 | 15,1 | 45 | 84,9 | 47 | 39,2 | 1 | 2,1 | 46 | 97,9 | 0,0231 | 7,73 | 0,96 | 62,09 | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 1 | 25,0 | 3 | 75,0 | 1,0000 | 1,00 | 0,05 | 18,91 | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 14 | 19,4 | 58 | 80,6 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,0038 | 11,05 | 1,44 | 85,03 | | 0,0399 |
| | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 3 | 5,0 | 57 | 95,0 | 0,9222 | 1,08 | 0,22 | 5,37 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes7_SE_26JUN2023_40336.xls
26JAN2024 17:28

**POPULATION: Safety Population**
**ENDPOINT: Time to Dysgeusia**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 107 | 101 | 101 | 97 | 95 | 70 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 41 |
| Platinum-Based Chemotherapy | 0 | 97 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes7_SE_26JUN2023_40336.pdf
26JAN2024 14:01

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Dysgeusia, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes735_SE_26JUN2023_40336.xls
26JAN2024 18:42

**POPULATION: Safety Population**
**ENDPOINT: Time to Dysgeusia, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes735_SE_26JUN2023_40336.pdf
26JAN2024 15:08

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Dysgeusia, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes7s_SE_26JUN2023_40336.xls
26JAN2024 18:04

**POPULATION: Safety Population**
**ENDPOINT: Time to Dysgeusia, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes7s_SE_26JUN2023_40336.pdf
26JAN2024 14:34

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Oedema**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 20 | 15,6 | 108 | 84,4 | 120 | 100,0 | 2 | 1,7 | 118 | 98,3 | 0,0034 | 6,78 | 1,54 | 29,85 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 3 | 5,6 | 51 | 94,4 | 64 | 53,3 | 0 | 0,0 | 64 | 100,0 | NE | NE | NE | NE | | 0,3600 |
| | Female | 74 | 57,8 | 17 | 23,0 | 57 | 77,0 | 56 | 46,7 | 2 | 3,6 | 54 | 96,4 | 0,0103 | 5,60 | 1,27 | 24,67 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 14 | 13,9 | 87 | 86,1 | 87 | 72,5 | 2 | 2,3 | 85 | 97,7 | 0,0583 | 3,94 | 0,85 | 18,26 | | 0,1617 |
| | >= 65 | 27 | 21,1 | 6 | 22,2 | 21 | 77,8 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | 0,0110 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 10 | 13,7 | 63 | 86,3 | 69 | 57,5 | 0 | 0,0 | 69 | 100,0 | 0,0049 | >999.99 | 0,00 | NE | | 0,1810 |
| | Europe | 53 | 41,4 | 9 | 17,0 | 44 | 83,0 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,3282 | 2,22 | 0,43 | 11,47 | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 11 | 15,3 | 61 | 84,7 | 60 | 50,0 | 0 | 0,0 | 60 | 100,0 | 0,0137 | >999.99 | 0,00 | NE | | 0,1134 |
| | 1 | 56 | 43,8 | 9 | 16,1 | 47 | 83,9 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,0717 | 3,84 | 0,79 | 18,53 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes8_SE_26JUN2023_40336.xls
26JAN2024 17:29

**POPULATION: Safety Population**
**ENDPOINT: Time to Oedema**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 108 | 101 | 98 | 94 | 92 | 69 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 39 |
| Platinum-Based Chemotherapy | 0 | 99 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes8_SE_26JUN2023_40336.pdf
26JAN2024 14:03

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Oedema, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes835_SE_26JUN2023_40336.xls
26JAN2024 18:44

**POPULATION: Safety Population**
**ENDPOINT: Time to Oedema, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes835_SE_26JUN2023_40336.pdf
26JAN2024 15:09

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Oedema, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes8s_SE_26JUN2023_40336.xls
26JAN2024 18:06

**POPULATION: Safety Population**
**ENDPOINT: Time to Oedema, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes8s_SE_26JUN2023_40336.pdf
26JAN2024 14:35

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Bradycardia**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 15 | 11,7 | 113 | 88,3 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,0054 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 7 | 13,0 | 47 | 87,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | 0,0273 | >999.99 | 0,00 | NE | | 0,9974 |
| | Female | 74 | 57,8 | 8 | 10,8 | 66 | 89,2 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,0778 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 14 | 13,9 | 87 | 86,1 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | 0,0074 | >999.99 | 0,00 | NE | | 0,9974 |
| | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 11 | 15,1 | 62 | 84,9 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | 0,0153 | >999.99 | 0,00 | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 3 | 5,7 | 50 | 94,3 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | 0,1573 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 6 | 8,3 | 66 | 91,7 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,0650 | >999.99 | 0,00 | NE | | 0,9975 |
| | 1 | 56 | 43,8 | 9 | 16,1 | 47 | 83,9 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,0345 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes9_SE_26JUN2023_40336.xls
26JAN2024 17:31

**POPULATION: Safety Population**
**ENDPOINT: Time to Bradycardia**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 113 | 105 | 103 | 99 | 96 | 73 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 40 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..BO40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes9_SE_26JUN2023_40336.pdf
26JAN2024 14:04

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Bradycardia, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes935_SE_26JUN2023_40336.xls
26JAN2024 18:46

**POPULATION: Safety Population**
**ENDPOINT: Time to Bradycardia, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes935_SE_26JUN2023_40336.pdf
26JAN2024 15:10

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Bradycardia, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes9s_SE_26JUN2023_40336.xls
26JAN2024 18:08

**POPULATION: Safety Population**
**ENDPOINT: Time to Bradycardia, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes9s_SE_26JUN2023_40336.pdf
26JAN2024 14:37

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Vision Disorders**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 12 | 9,4 | 116 | 90,6 | 120 | 100,0 | 3 | 2,5 | 117 | 97,5 | 0,7130 | 1,32 | 0,30 | 5,76 | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 2 | 3,1 | 62 | 96,9 | 0,2888 | 0,23 | 0,01 | 3,76 | | 0,1669 |
| | Female | 74 | 57,8 | 10 | 13,5 | 64 | 86,5 | 56 | 46,7 | 1 | 1,8 | 55 | 98,2 | 0,2795 | 3,14 | 0,35 | 28,14 | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 9 | 8,9 | 92 | 91,1 | 87 | 72,5 | 3 | 3,4 | 84 | 96,6 | 0,7904 | 1,22 | 0,28 | 5,33 | | 0,1414 |
| | >= 65 | 27 | 21,1 | 3 | 11,1 | 24 | 88,9 | 33 | 27,5 | 0 | 0,0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 7 | 9,6 | 66 | 90,4 | 69 | 57,5 | 1 | 1,4 | 68 | 98,6 | 0,3112 | 3,02 | 0,32 | 28,35 | | 0,3978 |
| | Europe | 53 | 41,4 | 4 | 7,5 | 49 | 92,5 | 47 | 39,2 | 2 | 4,3 | 45 | 95,7 | 0,4974 | 0,45 | 0,04 | 4,91 | | |
| | Rest of World | 2 | 1,6 | 1 | 50,0 | 1 | 50,0 | 4 | 3,3 | 0 | 0,0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 7 | 9,7 | 65 | 90,3 | 60 | 50,0 | 2 | 3,3 | 58 | 96,7 | 0,9126 | 0,90 | 0,14 | 5,93 | | 0,6128 |
| | 1 | 56 | 43,8 | 5 | 8,9 | 51 | 91,1 | 60 | 50,0 | 1 | 1,7 | 59 | 98,3 | 0,5091 | 2,20 | 0,20 | 24,25 | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes10_SE_26JUN2023_40336.xls
26JAN2024 17:33

**POPULATION: Safety Population**
**ENDPOINT: Time to Vision Disorders**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 117 | 110 | 108 | 102 | 99 | 74 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 42 |
| Platinum-Based Chemotherapy | 0 | 98 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes10_SE_26JUN2023_40336.pdf
26JAN2024 14:05

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Vision Disorders, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes1035_SE_26JUN2023_40336.xls
26JAN2024 18:48

**POPULATION: Safety Population**
**ENDPOINT: Time to Vision Disorders, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes1035_SE_26JUN2023_40336.pdf
26JAN2024 15:12

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Vision Disorders, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 0 | 0 | 128 | 100,0 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | NE |
| | Female | 74 | 57,8 | 0 | 0 | 74 | 100,0 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | NE |
| | >= 65 | 27 | 21,1 | 0 | 0 | 27 | 100,0 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | NE |
| | Europe | 53 | 41,4 | 0 | 0 | 53 | 100,0 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | NE | NE | NE | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | NE |
| | 1 | 56 | 43,8 | 0 | 0 | 56 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes10s_SE_26JUN2023_40336.xls
26JAN2024 18:10

**POPULATION: Safety Population**
**ENDPOINT: Time to Vision Disorders, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 7 | 12 | 12 | 15 | 17 | 45 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes10s_SE_26JUN2023_40336.pdf
26JAN2024 14:38

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Interstitial Lung Disease**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 4 | 3,1 | 124 | 96,9 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,1712 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 2 | 3,7 | 52 | 96,3 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | 1,0000 | NE | NE | NE | | 0,9979 |
| | Female | 74 | 57,8 | 2 | 2,7 | 72 | 97,3 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,2202 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 2 | 2,0 | 99 | 98,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | 1,0000 | NE | NE | NE | | 0,9979 |
| | >= 65 | 27 | 21,1 | 2 | 7,4 | 25 | 92,6 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | 0,1190 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 2 | 2,7 | 71 | 97,3 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | 0,3350 | >999.99 | 0,00 | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 2 | 3,8 | 51 | 96,2 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 1 | 1,4 | 71 | 98,6 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 1,0000 | NE | NE | NE | | 0,9965 |
| | 1 | 56 | 43,8 | 3 | 5,4 | 53 | 94,6 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,1411 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes11_SE_26JUN2023_40336.xls
26JAN2024 17:35

**POPULATION: Safety Population**
**ENDPOINT: Time to Interstitial Lung Disease**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 110 | 82 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 5 | 9 | 9 | 12 | 14 | 42 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..O40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes11_SE_26JUN2023_40336.pdf
26JAN2024 14:07

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Interstitial Lung Disease, Grade 3-5**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes1135_SE_26JUN2023_40336.xls
26JAN2024 18:49

**POPULATION: Safety Population**
**ENDPOINT: Time to Interstitial Lung Disease, Grade 3-5**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..0336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes1135_SE_26JUN2023_40336.pdf
26JAN2024 15:13

## Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: Time to Interstitial Lung Disease, Serious AE**
**MODEL: Unstratified analysis**
**STUDY: BO40336**
**Time to Event Analysis by Subgroups (Safety)**

| | | Alectinib (N=128) | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | Alectinib vs. Platinum-Based Chemotherapy | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Patients | | Patients with Event | | Censored | | Patients | | Patients with Event | | Censored | | log-rank | Hazard Ratio | | | | Interaction Test |
| Name | Level | n | % | n | % | n | % | n | % | n | % | n | % | p-value | Hazard Ratio | 95% Lower CL | 95% Upper CL | | p-value (likelihood ratio) |
| All | n/a | 128 | 100,0 | 1 | 0,8 | 127 | 99,2 | 120 | 100,0 | 0 | 0 | 120 | 100,0 | 0,3329 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Sex | Male | 54 | 42,2 | 0 | 0,0 | 54 | 100,0 | 64 | 53,3 | 0 | 0 | 64 | 100,0 | NE | NE | NE | NE | | 0,9963 |
| | Female | 74 | 57,8 | 1 | 1,4 | 73 | 98,6 | 56 | 46,7 | 0 | 0 | 56 | 100,0 | 0,3843 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Age | < 65 | 101 | 78,9 | 0 | 0,0 | 101 | 100,0 | 87 | 72,5 | 0 | 0 | 87 | 100,0 | NE | NE | NE | NE | | 0,9971 |
| | >= 65 | 27 | 21,1 | 1 | 3,7 | 26 | 96,3 | 33 | 27,5 | 0 | 0 | 33 | 100,0 | 0,2689 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Geographic region | Asia Pacific | 73 | 57,0 | 0 | 0,0 | 73 | 100,0 | 69 | 57,5 | 0 | 0 | 69 | 100,0 | NE | NE | NE | NE | | 1,0000 |
| | Europe | 53 | 41,4 | 1 | 1,9 | 52 | 98,1 | 47 | 39,2 | 0 | 0 | 47 | 100,0 | 0,3463 | >999.99 | 0,00 | NE | | |
| | Rest of World | 2 | 1,6 | 0 | 0,0 | 2 | 100,0 | 4 | 3,3 | 0 | 0 | 4 | 100,0 | NE | NE | NE | NE | | |
| | | | | | | | | | | | | | | | | | | | |
| Baseline ECOG | 0 | 72 | 56,3 | 0 | 0,0 | 72 | 100,0 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | NE | NE | NE | NE | | 0,9965 |
| | 1 | 56 | 43,8 | 1 | 1,8 | 55 | 98,2 | 60 | 50,0 | 0 | 0 | 60 | 100,0 | 0,3006 | >999.99 | 0,00 | NE | | |
| | | | | | | | | | | | | | | | | | | | |

Test for interaction based on Likelihood-Ratio test for interaction with treatment effect
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_tte_sg2_aes11s_SE_26JUN2023_40336.xls
26JAN2024 18:11

**POPULATION: Safety Population**
**ENDPOINT: Time to Interstitial Lung Disease, Serious AE**
**STUDY: BO40336**




| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Patients at risk | | | | | | | |
| Alectinib | 128 | 121 | 116 | 116 | 113 | 111 | 83 |
| Platinum-Based Chemotherapy | 120 | 19 | NE | NE | NE | NE | NE |
| Patients censored | | | | | | | |
| Alectinib | 0 | 6 | 11 | 11 | 14 | 16 | 44 |
| Platinum-Based Chemotherapy | 0 | 101 | NE | NE | NE | NE | NE |

Clinical cut-off: 26JUN2023

Program: ..al_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/g_km.sas
Output: ..40336/data_analysis/ACE_INTERIM_2023/prod/output/g_km_aes11s_SE_26JUN2023_40336.pdf
26JAN2024 14:40

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**4 Verträglichkeit**

**4.2 Spezifische Verträglichkeit**

**4.2.3 Ergebnis Unerwünschter Ereignisse von Besonderem Interesse (AESI) (behoben/nicht behoben)**

# Post-hoc Analysen Studie ALINA

**POPULATION: Safety Population**
**ENDPOINT: All Patients**
**MODEL: --**
**STUDY: BO40336**
**Outcome of Adverse Events of Special Interest**

| | Alectinib (N=128) | | | | | | | | | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Total | RECOVERED/RESOLVED | | RECOVERED/RESOLVED WITH SEQUELAE | | NOT RECOVERED/NOT RESOLVED | | FATAL | | RECOVERING/RESOLVING | | UNKNOWN | | MISSING | | Total | RECOVERED/RESOLVED | | RECOVERED/RESOLVED WITH SEQUELAE | | NOT RECOVERED/NOT RESOLVED | | FATAL | | RECOVERING/RESOLVING | | UNKNOWN | | MISSING | |
| Endpoint Grade | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Gastrointestinal Tract Adverse Events | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 157 | 132 | 84,1 | 0 | 0,0 | 24 | 15,3 | 0 | 0,0 | 1 | 0,6 | 0 | 0,0 | 0 | 0,0 | 324 | 318 | 98,1 | 2 | 0,6 | 3 | 0,9 | 0 | 0,0 | 0 | 0,0 | 1 | 0,3 | 0 | 0,0 |
| Grade 1 | 120 | 103 | 85,8 | 0 | 0,0 | 16 | 13,3 | 0 | 0,0 | 1 | 0,8 | 0 | 0,0 | 0 | 0,0 | 222 | 216 | 97,3 | 2 | 0,9 | 3 | 1,4 | 0 | 0,0 | 0 | 0,0 | 1 | 0,5 | 0 | 0,0 |
| Grade 2 | 33 | 25 | 75,8 | 0 | 0,0 | 8 | 24,2 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 88 | 88 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 4 | 4 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 14 | 14 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Gastrointestinal Tract Adverse Events | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 8 | 8 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 8 | 8 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Hematological Abnormalities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 65 | 53 | 81,5 | 0 | 0,0 | 10 | 15,4 | 0 | 0,0 | 2 | 3,1 | 0 | 0,0 | 0 | 0,0 | 206 | 196 | 95,1 | 0 | 0,0 | 7 | 3,4 | 0 | 0,0 | 0 | 0,0 | 3 | 1,5 | 0 | 0,0 |
| Grade 1 | 42 | 37 | 88,1 | 0 | 0,0 | 3 | 7,1 | 0 | 0,0 | 2 | 4,8 | 0 | 0,0 | 0 | 0,0 | 80 | 78 | 97,5 | 0 | 0,0 | 1 | 1,3 | 0 | 0,0 | 0 | 0,0 | 1 | 1,3 | 0 | 0,0 |
| Grade 2 | 22 | 15 | 68,2 | 0 | 0,0 | 7 | 31,8 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 88 | 80 | 90,9 | 0 | 0,0 | 6 | 6,8 | 0 | 0,0 | 0 | 0,0 | 2 | 2,3 | 0 | 0,0 |
| Grade 3 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 33 | 33 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 4 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 5 | 5 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Hematological Abnormalities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 3 | 3 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 4 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Muscular Adverse Events or CPK Elevations | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 213 | 183 | 85,9 | 1 | 0,5 | 23 | 10,8 | 0 | 0,0 | 6 | 2,8 | 0 | 0,0 | 0 | 0,0 | 29 | 23 | 79,3 | 0 | 0,0 | 5 | 17,2 | 0 | 0,0 | 0 | 0,0 | 1 | 3,4 | 0 | 0,0 |
| Grade 1 | 169 | 145 | 85,8 | 1 | 0,6 | 19 | 11,2 | 0 | 0,0 | 4 | 2,4 | 0 | 0,0 | 0 | 0,0 | 25 | 19 | 76,0 | 0 | 0,0 | 5 | 20,0 | 0 | 0,0 | 0 | 0,0 | 1 | 4,0 | 0 | 0,0 |
| Grade 2 | 35 | 30 | 85,7 | 0 | 0,0 | 3 | 8,6 | 0 | 0,0 | 2 | 5,7 | 0 | 0,0 | 0 | 0,0 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 8 | 7 | 87,5 | 0 | 0,0 | 1 | 12,5 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 4 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Muscular Adverse Events or CPK Elevations | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 258 | 227 | 88,0 | 2 | 0,8 | 25 | 9,7 | 0 | 0,0 | 4 | 1,6 | 0 | 0,0 | 0 | 0,0 | 31 | 26 | 83,9 | 0 | 0,0 | 5 | 16,1 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 189 | 171 | 90,5 | 0 | 0,0 | 15 | 7,9 | 0 | 0,0 | 3 | 1,6 | 0 | 0,0 | 0 | 0,0 | 29 | 24 | 82,8 | 0 | 0,0 | 5 | 17,2 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 61 | 49 | 80,3 | 2 | 3,3 | 9 | 14,8 | 0 | 0,0 | 1 | 1,6 | 0 | 0,0 | 0 | 0,0 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 8 | 7 | 87,5 | 0 | 0,0 | 1 | 12,5 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Hepatocellular or Cholestatic Damage AEs or Abnormal Liver Function Tests | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Skin Disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 71 | 55 | 77,5 | 0 | 0,0 | 15 | 21,1 | 0 | 0,0 | 1 | 1,4 | 0 | 0,0 | 0 | 0,0 | 33 | 33 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 55 | 42 | 76,4 | 0 | 0,0 | 13 | 23,6 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 21 | 21 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 14 | 11 | 78,6 | 0 | 0,0 | 2 | 14,3 | 0 | 0,0 | 1 | 7,1 | 0 | 0,0 | 0 | 0,0 | 12 | 12 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Skin Disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Abnormal Renal Function | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 60 | 49 | 81,7 | 0 | 0,0 | 10 | 16,7 | 0 | 0,0 | 1 | 1,7 | 0 | 0,0 | 0 | 0,0 | 23 | 17 | 73,9 | 0 | 0,0 | 5 | 21,7 | 0 | 0,0 | 0 | 0,0 | 1 | 4,3 | 0 | 0,0 |
| Grade 1 | 48 | 43 | 89,6 | 0 | 0,0 | 5 | 10,4 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 18 | 14 | 77,8 | 0 | 0,0 | 3 | 16,7 | 0 | 0,0 | 0 | 0,0 | 1 | 5,6 | 0 | 0,0 |
| Grade 2 | 11 | 5 | 45,5 | 0 | 0,0 | 5 | 45,5 | 0 | 0,0 | 1 | 9,1 | 0 | 0,0 | 0 | 0,0 | 5 | 3 | 60,0 | 0 | 0,0 | 2 | 40,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Abnormal Renal Function | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Dysgeusia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 22 | 20 | 90,9 | 0 | 0,0 | 2 | 9,1 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 5 | 5 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 19 | 18 | 94,7 | 0 | 0,0 | 1 | 5,3 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 5 | 5 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 3 | 2 | 66,7 | 0 | 0,0 | 1 | 33,3 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Dysgeusia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Oedema | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 29 | 26 | 89,7 | 0 | 0,0 | 2 | 6,9 | 0 | 0,0 | 1 | 3,4 | 0 | 0,0 | 0 | 0,0 | 6 | 6 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 29 | 26 | 89,7 | 0 | 0,0 | 2 | 6,9 | 0 | 0,0 | 1 | 3,4 | 0 | 0,0 | 0 | 0,0 | 4 | 4 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Oedema | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |

# Post-hoc Analysen Studie ALINA

| | Alectinib (N=128) | | | | | | | | | | | | | | | Platinum-Based Chemotherapy (N=120) | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Total | RECOVERED/RESOLVED | | RECOVERED/RESOLVED WITH SEQUELAE | | NOT RECOVERED/NOT RESOLVED | | FATAL | | RECOVERING/RESOLVING | | UNKNOWN | | MISSING | | Total | RECOVERED/RESOLVED | | RECOVERED/RESOLVED WITH SEQUELAE | | NOT RECOVERED/NOT RESOLVED | | FATAL | | RECOVERING/RESOLVING | | UNKNOWN | | MISSING | |
| Endpoint<br>Grade | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Bradycardia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 19 | 10 | 52,6 | 0 | 0,0 | 8 | 42,1 | 0 | 0,0 | 1 | 5,3 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 15 | 9 | 60,0 | 0 | 0,0 | 5 | 33,3 | 0 | 0,0 | 1 | 6,7 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 4 | 1 | 25,0 | 0 | 0,0 | 3 | 75,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Bradycardia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Vision Disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 18 | 13 | 72,2 | 0 | 0,0 | 3 | 16,7 | 0 | 0,0 | 2 | 11,1 | 0 | 0,0 | 0 | 0,0 | 3 | 3 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 16 | 12 | 75,0 | 0 | 0,0 | 3 | 18,8 | 0 | 0,0 | 1 | 6,3 | 0 | 0,0 | 0 | 0,0 | 3 | 3 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 2 | 1 | 50,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 50,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Vision Disorders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Interstitial Lung Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 4 | 4 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 1 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 2 | 2 | 2 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Serious Interstitial Lung Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| All | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Grade 3 | 1 | 1 | 100,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |

Clinical cut-off: 26JUN2023

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_resolved.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ae_resolved_aesi_SE_26JUN2023_40336.xls
26JAN2024 11:53

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.1 Anzahl Zentren, Länder, Regionen**

# Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: --**
**MODEL: Descriptive**
**STUDY: BO40336**
**Number of Centers/Countries/Geographical Regions with <10, >=10 patients per arm (ITT Population)**

| | Center | | | | Country | | | | Geographical region | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | n | % | n of patients randomized | % randomized patients | n | % | n of patients randomized | % randomized patients | n | % | n of patients randomized | % randomized patients |
| Overall | 113 | 100,0 | 257 | 100,0 | 26 | 100,0 | 257 | 100,0 | 3 | 100,0 | 257 | 100,0 |
| with <10 patients per arm | 113 | 100,0 | 257 | 100,0 | 23 | 88,5 | 128 | 49,8 | 1 | 33,3 | 6 | 2,3 |
| with >=10 patients per arm | 0 | NE | NE | NE | 3 | 11,5 | 129 | 50,2 | 2 | 66,7 | 251 | 97,7 |

' <10 patients category' if at least one treatment arm has <10 patients. ' >=10 patients ' category if all treatment arms have >=10 patients.
Geographical regions: Europe, Asia-Pacific, Rest of World
'n': Number of centers '%': Percent of centers compared to overall number of centers
'n of patients randomized': Number of patients randomized in the corresponding category (e.g .Number of patients randomized in centers with <10 pts per arm)
'% randomized patients': Percent of randomized patients compared to overall number of randomized patients (e.g . % of randomized patients in centers with <10 patients per arm compared to overall number of randomized patients)
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_center.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_center_IT_26JUN2023_40336.xls
29JAN2024 16:32

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.2 Listung Carboplatin-haltigen Therapien**

**POPULATION: Intent-To-Treat Population, Carboplatin Patients**
**STUDY: BO40336**
**Listing of Carboplatin-containing Regimen**

Treatment: Platinum-Based Chemotherapy (N=14)

| Center/ Patient ID | Time of Switch from Cisplatin to Carboplatin | Cycle of Switch | Total Carboplatin Dose [AUC] | Number of Carboplatin Cycles |
|---|---|---|---|---|
| 309562/10033 | | | 20 | 4 |
| 309918/10081 | WEEK 6 | 3 | 10 | 2 |
| 310221/10223 | WEEK 6 | 3 | 10 | 2 |
| 310460/10043 | WEEK 6 | 3 | 10 | 2 |
| 310782/10045 | WEEK 6 | 3 | 12 | 2 |
| 311144/10172 | WEEK 3 | 2 | 15 | 3 |
| 311222/10146 | WEEK 6 | 3 | 5 | 1 |
| 315612/10164 | WEEK 6 | 3 | 5 | 1 |
| 316511/10092 | WEEK 3 | 2 | 15 | 3 |
| 316938/10119 | WEEK 3 | 2 | 15 | 3 |
| 328387/10161 | WEEK 6 | 3 | 10 | 2 |
| 328387/10162 | WEEK 3 | 2 | 10 | 2 |
| 334964/10216 | WEEK 6 | 3 | 8,28 | 2 |
| 334964/10227 | WEEK 3 | 2 | 14,33 | 3 |

Clinical cut-off: 26JUN2023

Program: ..studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/l_carbo.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/l_carbo_CARBO_IT_26JUN2023_40336.xls
29JAN2024 16:42

**POPULATION: Safety Population, Carboplatin Patients**
**STUDY: BO40336**
**Listing of Carboplatin-containing Regimen**

Treatment: Platinum-Based Chemotherapy (N=14)

| Center/ Patient ID | Time of Switch from Cisplatin to Carboplatin | Cycle of Switch | Total Carboplatin Dose [AUC] | Number of Carboplatin Cycles |
|---|---|---|---|---|
| 309562/10033 | | | 20 | 4 |
| 309918/10081 | WEEK 6 | 3 | 10 | 2 |
| 310221/10223 | WEEK 6 | 3 | 10 | 2 |
| 310460/10043 | WEEK 6 | 3 | 10 | 2 |
| 310782/10045 | WEEK 6 | 3 | 12 | 2 |
| 311144/10172 | WEEK 3 | 2 | 15 | 3 |
| 311222/10146 | WEEK 6 | 3 | 5 | 1 |
| 315612/10164 | WEEK 6 | 3 | 5 | 1 |
| 316511/10092 | WEEK 3 | 2 | 15 | 3 |
| 316938/10119 | WEEK 3 | 2 | 15 | 3 |
| 328387/10161 | WEEK 6 | 3 | 10 | 2 |
| 328387/10162 | WEEK 3 | 2 | 10 | 2 |
| 334964/10216 | WEEK 6 | 3 | 8,28 | 2 |
| 334964/10227 | WEEK 3 | 2 | 14,33 | 3 |

Clinical cut-off: 26JUN2023

Program: ..studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/l_carbo.sas
Output: ..336/data_analysis/ACE_INTERIM_2023/prod/output/l_carbo_CARBO_SE_26JUN2023_40336.xls
29JAN2024 16:42

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.3 Nachfolgende Antikrebs-Therapien**

**POPULATION: Patients with disease recurrence**
**ENDPOINT: --**
**MODEL: Descriptive**
**STUDY: BO40336**
**Number of patients with post recurrence subsequent therapy**

| Number of patients with disease recurrence, n(%) | Alectinib (n=15) | Platinum-Based Chemotherapy (n=49) |
|---|---|---|
| Patients with any subsequent therapy | 13 (86.7) | 43 (87.8) |
| | | |
| Systemic therapy | 13 (86.7) | 38 (77.6) |
| ALK TKI | 7 (46.7) | 37 (75.5) |
| Alectinib | 4 (26.7) | 29 (59.2) |
| Brigatinib | 4 (26.7) | 4 ( 8.2) |
| Crizotinib | 0 | 4 ( 8.2) |
| Lorlatinib | 0 | 2 ( 4.1) |
| Ceritinib | 0 | 1 ( 2.0) |
| Chemotherapy | 6 (40.0) | 2 ( 4.1) |
| Immunotherapy | 1 ( 6.7) | 1 ( 2.0) |
| Other anticancer therapy | 1 ( 6.7) | 1 ( 2.0) |
| Radiotherapy | 5 (33.3) | 9 (18.4) |
| Surgery | 1 ( 6.7) | 3 ( 6.1) |
| | | |

Includes any subsequent therapy reported on or after date of earliest contributing event to disease recurrence.
Patients may have received more than one subsequent anticancer therapy.
Clinical cut-off: 26JUN2023

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.4 Behandlungsabbruch unter Angabe von Gründen**

**POPULATION: Safety Population**
**ENDPOINT: --**
**MODEL: Descriptive**
**STUDY: BO40336**
**Patients who Discontinued Treatment including Reason**

| | Alectinib (N=128) | Platinum-Based Chemotherapy (N=120) | All Patients (N=248) |
|---|---|---|---|
| Received Treatment | 128 ( 100%) | 120 ( 100%) | 248 ( 100%) |
| | | | |
| Treatment Discontinuation Reason | | | |
| All | 18 (14.1%) | 12 (10.0%) | 30 (12.1%) |
| Adverse Event | 7 ( 5.5%) | 6 ( 5.0%) | 13 ( 5.2%) |
| Protocol Deviation | 2 ( 1.6%) | 1 ( 0.8%) | 3 ( 1.2%) |
| Withdrawal by Subject | 1 ( 0.8%) | 3 ( 2.5%) | 4 ( 1.6%) |
| Physician Decision | 0 | 1 ( 0.8%) | 1 ( 0.4%) |
| Disease Recurrence | 8 ( 6.3%) | 0 | 8 ( 3.2%) |
| Other | 0 | 1 ( 0.8%) | 1 ( 0.4%) |
| | | | |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_ds_trt.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ds_trt_SE_26JUN2023_40336.xls
29JAN2024 16:41

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.5 Studienabbruch unter Angabe von Gründen**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: --**
**MODEL: Descriptive**
**STUDY: BO40336**
**Patients who Discontinued Study including Reason**

| | Alectinib (N=130) | Platinum-Based Chemotherapy (N=127) | All Patients (N=257) |
|---|---|---|---|
| Received Treatment | 128 (98.5%) | 120 (94.5%) | 248 (96.5%) |
| | | | |
| Discontinued Study | 7 ( 5.4%) | 16 (12.6%) | 23 ( 8.9%) |
| Death | 2 ( 1.5%) | 5 ( 3.9%) | 7 ( 2.7%) |
| Treatment received | 2 ( 1.5%) | 5 ( 3.9%) | 7 ( 2.7%) |
| Protocol Deviation | 0 | 1 ( 0.8%) | 1 ( 0.4%) |
| Lost to Follow-Up | 0 | 1 ( 0.8%) | 1 ( 0.4%) |
| Withdrawal by Subject | 5 ( 3.8%) | 9 ( 7.1%) | 14 ( 5.4%) |
| | | | |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_ds_study.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_ds_study_IT_26JUN2023_40336.xls
29JAN2024 16:40

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.6 Beobachtungsdauern**

Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Overall Survival, Follow-up Efficacy (OS) [Months]**
**MODEL: Descriptive**
**STUDY: BO40336**
**Duration of Follow Up, Efficacy**

| | Alectinib (N=130) | Platinum-Based Chemotherapy (N=127) |
|---|---|---|
| n | 130 | 127 |
| Median | 27,79 | 28,42 |
| | | |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_fu3.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_fu3_FUEFFOS_OS_IT_26JUN2023_40336.xls
29JAN2024 16:39

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Disease Free Survival, Follow-up Follow Up, Efficacy (DFS) [Months]**
**MODEL: Descriptive**
**STUDY: BO40336**
**Duration of Follow Up, Efficacy**

| | Alectinib (N=130) | Platinum-Based Chemotherapy (N=127) |
|---|---|---|
| n | 130 | 127 |
| Median | 29,95 | 23,46 |
| | | |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_fu3.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_fu3_FUEFFDFS_DFS_IT_26JUN2023_40336.xls
29JAN2024 16:40

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)**
**ENDPOINT: Follow-up last PRO assessment for EQ-5D-5L (VAS) [Months]**
**MODEL: Descriptive**
**STUDY: BO40336**

| | Alectinib (N=126) | Platinum-Based Chemotherapy (N=119) |
|---|---|---|
| n | 126 | 119 |
| Median | 22,18 | 22,11 |
| | | |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_fu.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_fu_FUVAS_VASEVAL_IT_26JUN2023_40336.xls
03JUN2024 16:23

**POPULATION: Intent-To-Treat Population, PRO-Evaluable for SF36v2**
**ENDPOINT: Follow-up last PRO assessment for SF36v2 [Months]**
**MODEL: Descriptive**
**STUDY: BO40336**

| | Alectinib (N=125) | Platinum-Based Chemotherapy (N=119) |
|---|---|---|
| n | 125 | 119 |
| Median | 22,18 | 22,11 |
| | | |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_fu.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_fu_FUSF36_SF36EVAL_IT_26JUN2023_40336.xls
03JUN2024 16:25

**POPULATION: Safety Population**
**ENDPOINT: Safety Follow-up at 28 Days and 49 Days Time Window [Months]**
**MODEL: Descriptive**
**STUDY: BO40336**

| | Alectinib (N=128) | Platinum-Based Chemotherapy (N=120) |
|---|---|---|
| n | 128 | 120 |
| Median | 24,84 | 3,71 |
| | | |

Safety Follow-Up Duration was calculated as min(Datacut Date, Death Date, Lost to Follow Up Date, Withdrawal of Consent Date, Study Discontinuation Date, (Date of Last Dose of Study Treatment + 28 Days or Date of Last Cycle of Chemotherapy + 28 Days in Arm B) - Treatment Start Date.
Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_fu.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_fu_AER28_SE_26JUN2023_40336.xls
29JAN2024 16:38

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.7 Todesfälle unter Angabe von Gründen**

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Death**
**MODEL: Descriptive**
**STUDY: BO40336**
**Deaths and Primary Reason for Death**

| | Alectinib (N=130) | | Platinum-Based Chemotherapy (N=127) | |
|---|---|---|---|---|
| | n | % | n | % |
| All Deaths | 2 | 1,5 | 5 | 3,9 |
| Progressive Disease | 1 | 0,8 | 1 | 0,8 |
| Disease Recurrence | 1 | 0,8 | 1 | 0,8 |
| COVID-19 | 0 | NE | 1 | 0,8 |
| Bilateral Pneumonia | 0 | NE | 1 | 0,8 |
| Unknown | 0 | NE | 1 | 0,8 |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_death.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_death_IT_26JUN2023_40336.xls
29JAN2024 16:36

**POPULATION: Safety Population**
**ENDPOINT: Death**
**MODEL: Descriptive**
**STUDY: BO40336**
**Deaths and Primary Reason for Death**

| | Alectinib (N=128) | | Platinum-Based Chemotherapy (N=120) | |
|---|---|---|---|---|
| | n | % | n | % |
| All Deaths | 2 | 1,6 | 5 | 4,2 |
| Progressive Disease | 1 | 0,8 | 1 | 0,8 |
| Disease Recurrence | 1 | 0,8 | 1 | 0,8 |
| COVID-19 | 0 | NE | 1 | 0,8 |
| Bilateral Pneumonia | 0 | NE | 1 | 0,8 |
| Unknown | 0 | NE | 1 | 0,8 |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_death.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_death_SE_26JUN2023_40336.xls
29JAN2024 16:36

Post-hoc Analysen Studie ALINA

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Death(Single Component of DFS)**
**MODEL: Descriptive**
**STUDY: BO40336**
**Deaths and Primary Reason for Death**

| | Alectinib (N=130) | | Platinum-Based Chemotherapy (N=127) | |
|---|---|---|---|---|
| | n | % | n | % |
| All Deaths | 0 | NE | 1 | 0,8 |
| Bilateral Pneumonia | 0 | NE | 1 | 0,8 |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_death.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_death_DFS_IT_26JUN2023_40336.xls
29JAN2024 16:34

**POPULATION: Safety Population**
**ENDPOINT: Death(Single Component of DFS)**
**MODEL: Descriptive**
**STUDY: BO40336**
**Deaths and Primary Reason for Death**

| | Alectinib (N=128) | | Platinum-Based Chemotherapy (N=120) | |
|---|---|---|---|---|
| | n | % | n | % |
| All Deaths | 0 | NE | 1 | 0,8 |
| Bilateral Pneumonia | 0 | NE | 1 | 0,8 |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_death.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_death_DFS_SE_26JUN2023_40336.xls
29JAN2024 16:33

**POPULATION: Intent-To-Treat Population**
**ENDPOINT: Death(Single Component of DFSCNS)**
**MODEL: Descriptive**
**STUDY: BO40336**
**Deaths and Primary Reason for Death**

| | Alectinib (N=130) | | Platinum-Based Chemotherapy (N=127) | |
|---|---|---|---|---|
| | n | % | n | % |
| All Deaths | 1 | 0,8 | 4 | 3,1 |
| Progressive Disease | 1 | 0,8 | 1 | 0,8 |
| Disease Recurrence | 0 | NE | 1 | 0,8 |
| COVID-19 | 0 | NE | 1 | 0,8 |
| Bilateral Pneumonia | 0 | NE | 1 | 0,8 |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_death.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_death_DFSCNS_IT_26JUN2023_40336.xls
29JAN2024 16:35

**POPULATION: Safety Population**
**ENDPOINT: Death(Single Component of DFSCNS)**
**MODEL: Descriptive**
**STUDY: BO40336**
**Deaths and Primary Reason for Death**

| | Alectinib (N=128) | | Platinum-Based Chemotherapy (N=120) | |
|---|---|---|---|---|
| | n | % | n | % |
| All Deaths | 1 | 0,8 | 4 | 3,3 |
| Progressive Disease | 1 | 0,8 | 1 | 0,8 |
| Disease Recurrence | 0 | NE | 1 | 0,8 |
| COVID-19 | 0 | NE | 1 | 0,8 |
| Bilateral Pneumonia | 0 | NE | 1 | 0,8 |

Clinical cut-off: 26JUN2023

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_Base/prod/program/t_death.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/ACE_INTERIM_2023/prod/output/t_death_DFSCNS_SE_26JUN2023_40336.xls
29JAN2024 16:34

**Anhang 4-G – Analysen Studie ALINA; Zulassungsdatenschnitt vom 26. Juni 2023**

**5 Sonstige Analysen**

**5.8 Re-Staging nach UICC V8**

Lung Cancer History, Intent-to-Treat Patients
Protocol: BO40336
Snapshot Date: 03AUG2023, Clinical Data Cut-off Date: 26JUN2023.

| | Alectinib (N=130) | Chemotherapy (N=127) | All Patients (N=257) |
|---|---|---|---|
| **Initial diagnosis staging per AJCC 7th edition (eCRF)** | | | |
| n | 130 | 127 | 257 |
| Stage IB | 17 (13.1%) | 9 ( 7.1%) | 26 (10.1%) |
| Stage IIA | 38 (29.2%) | 42 (33.1%) | 80 (31.1%) |
| Stage IIB | 5 ( 3.8%) | 5 ( 3.9%) | 10 ( 3.9%) |
| Stage IIIA | 70 (53.8%) | 71 (55.9%) | 141 (54.9%) |
| **Initial diagnosis staging per AJCC 7th edition (IxRS)** | | | |
| n | 130 | 127 | 257 |
| Stage IB | 14 (10.8%) | 12 ( 9.4%) | 26 (10.1%) |
| Stage II | 47 (36.2%) | 45 (35.4%) | 92 (35.8%) |
| Stage IIIA | 69 (53.1%) | 70 (55.1%) | 139 (54.1%) |
| **Initial diagnosis staging per AJCC 8th edition** | | | |
| n | 130 | 127 | 257 |
| Stage IB | 6 ( 4.6%) | 5 ( 3.9%) | 11 ( 4.3%) |
| Stage IIA | 11 ( 8.5%) | 4 ( 3.1%) | 15 ( 5.8%) |
| Stage IIB | 40 (30.8%) | 44 (34.6%) | 84 (32.7%) |
| Stage IIIA | 66 (50.8%) | 68 (53.5%) | 134 (52.1%) |
| Stage IIIB | 7 ( 5.4%) | 6 ( 4.7%) | 13 ( 5.1%) |
| **Initial diagnosis staging per AJCC 8th edition (Grouped)** | | | |
| n | 130 | 127 | 257 |
| Stage IB | 6 ( 4.6%) | 5 ( 3.9%) | 11 ( 4.3%) |
| Stage II | 51 (39.2%) | 48 (37.8%) | 99 (38.5%) |
| Stage IIIA | 66 (50.8%) | 68 (53.5%) | 134 (52.1%) |
| Stage IIIB | 7 ( 5.4%) | 6 ( 4.7%) | 13 ( 5.1%) |

Program: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/INTERIM_2023_HA/prod/
program/t_mh_lung_v8.sas
Output: root/clinical_studies/RO5424802/CDT30127/BO40336/data_analysis/INTERIM_2023_HA/prod/
output/t_mh_lung_v8_IT_26JUN2023_40336.out
10JAN2024 9:39